[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fvt9OtAplLnNNFwtROhQBeyYhjf2b_f3WRZs3p3wv954":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":84,"rows":91},"Gilead Sciences",[4],681,false,63,210,253259,99,19,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"HIV Infections",71,{"name":18,"count":19},"Hepatitis C Virus Infection",46,{"name":21,"count":22},"HIV-1 Infection",32,{"name":24,"count":25},"Chronic Hepatitis B",30,{"name":27,"count":28},"Hepatitis C",23,{"name":30,"count":31},"Cystic Fibrosis",22,{"name":33,"count":34},"HIV-1-infection",20,{"name":36,"count":12},"Chronic Lymphocytic Leukemia",[38,43,48,53,58,62,67,71,76,80],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT01651403","Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection","2017-08-07","Tenofovir DF",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT02842086","Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F\u002FTAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection","2019-01-31","F\u002FTAF",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04150068","Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","2020-10-05","Oral Lenacapavir",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04454437","Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments","2021-08-06","Sacituzumab Govitecan-hziy",{"nctId":59,"briefTitle":60,"date":61,"intervention":57},"NCT05089734","Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","2023-11-29",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05052996","Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV","2023-12-19","ISL",{"nctId":68,"briefTitle":69,"date":70,"intervention":52},"NCT04994509","Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine\u002FTenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection","2024-05-27",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05729568","A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","2024-07-02","Teropavimab",{"nctId":77,"briefTitle":78,"date":79,"intervention":52},"NCT04925752","Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection","2024-08-21",{"nctId":81,"briefTitle":82,"date":83,"intervention":57},"NCT03964727","Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","2025-01-15",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,370,486,628,708,743,902,928,946,964,1224,1334,1432,1512,1591,1644,1683,1717,1796,1846,1894,1945,1975,2005,2035,2074,2128,2169,2195,2217,2245,2267,2289,2311,2409,2521,2555,2618,2644,2666,2704,2726,2748,2770,2788,2806,2824,2842,2860,2878,2896,2914,2932,2950,2968,2986,3004,3022,3040,3058,3076,3094,3112,3130,3148,3182,3243,3269,3374,3407,3435,3457,3479,3497,3515,3533,3551,3576,3594,3612,3630,3648,3666,3689,3707,3733,3751,3769,3791,3809,3832,3850,3873,3891,3915,3933,3951,4021,4039,4057,4585,4747,4827,4937,5006,5070,5128,5185,5229,5259,5289,5326,5365,5391,5432,5459,5481,5499,5517,5539,5557,5581,5599,5621,5639,5657,5675,5693,5711,5729,5747,5765,5783,5801,5823,5845,5863,5887,5987,6175,6266,6320,6409,6451,6493,6574,6642,6720,6795,6833,6903,6972,7013,7070,7104,7134,7164,7215,7274,7304,7346,7379,7411,7446,7481,7511,7541,7585,7615,7651,7677,7703,7729,7768,7794,7820,7846,7872,7899,7921,7943,7965,7987,8009,8031,8053,8075,8097,8121,8143,8165,8195,8217,8239,8261,8283,8305,8327,8349,8381,8411,8446,8468,8490,8512,8538,8560,8578,8596,8614,8632,8650,8668,8686,8704,8722,8745,8763,8785,8803,8821,8839,8857,8875,8893,8917,8935,8958,8976,8994,9012,9030,9048,9066,9084,9102,9120,9138,9160,9178,9196,9214,9232,9250,9268,9291,9309,9327,9345,9414,9489,9559,9623,9672,9728,9781,9836,9879,9909,9939,9969,10017,10057,10092,10134,10167,10236,10285,10311,10345,10376,10410,10436,10472,10498,10536,10562,10588,10622,10648,10670,10692,10727,10749,10776,10798,10820,10842,10864,10886,10908,10934,10962,10984,11006,11035,11057,11079,11108,11130,11159,11184,11206,11228,11250,11272,11297,11325,11343,11361,11383,11401,11419,11437,11455,11473,11498,11516,11534,11559,11581,11599,11617,11635,11653,11671,11689,11716,11734,11752,11775,11793,11811,11832,11850,11872,11890,11908,11929,11951,11972,11990,12008,12033,12051,12069,12094,12112,12130,12148,12166,12189,12207,12225,12246,12270,12288,12306,12324,12342,12360,12378,12396,12414,12432,12450,12468,12486,12504,12522,12540,12558,12581,12599,12617,12635,12653,12676,12698,12716,12734,12752,12770,12788,12806,12832,12850,12868,12891,12909,12927,12948,12969,12994,13012,13033,13058,13076,13094,13112,13130,13153,13175,13193,13211,13229,13247,13265,13283,13325,13363,13392,13416,13443,13475,13505,13527,13558,13590,13608,13626,13644,13666,13684,13706,13724,13745,13767,13785,13809,13831,13853,13871,13889,13907,13925,13943,13964,13982,14000,14018,14043,14061,14084,14106,14124,14154,14172,14190,14208,14226,14244,14262,14280,14298,14316,14337,14359,14377,14395,14413,14431,14454,14472,14490,14508,14529,14552,14570,14588,14606,14627,14645,14663,14684,14706,14724,14742,14764,14785,14809,14832,14855,14873,14894,14912,14942,14960,14978,14996,15014,15032,15055,15073,15096,15310,15510,15700,15830,15931,16040,16134,16208,16278,16332,16398,16449,16504,16536,16566,16594,16616,16639,16657,16675,16698,16716,16734,16756,16774,16792,16810,16831,16853,16871,16894],{"intervention":93,"totalTrials":28,"cells":94},"B\u002FF\u002FTAF",{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":148,"PHASE3":182,"PHASE4":333,"NA":359},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":147,"soonestReadout":132},[100,115,127,137],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":110},"NCT05585307","Study of Novel Antiretrovirals in Participants With HIV-1","COMPLETED",[86],"2024-02-17","2024-03-18","2022-10-26",49,[33],[111,93,112,113,112,114,112],"Bavtavirine","Standard of Care","GS-1720","GS-6212",{"nctId":116,"briefTitle":117,"status":103,"phases":118,"primaryCompletion":119,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":124},"NCT03739866","Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults",[86],"2019-11-14","2020-06-15","2018-11-26",53,[21],[125,93,126],"Lenacapavir","TAF",{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":136},"NCT07055451","Study of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide in Newborns Exposed to HIV","ACTIVE_NOT_RECRUITING",[86],"2028-03","2025-08-12",16,[33],[93],{"nctId":138,"briefTitle":139,"status":103,"phases":140,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":146},"NCT03960645","Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B\u002FF\u002FTAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters",[86],"2022-07-21","2022-08-18","2019-06-28",62,[33],[93],1,{"trials":149,"activeCount":147,"soonestReadout":65},[150,162,175],{"nctId":151,"briefTitle":152,"status":103,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":159},"NCT04143594","Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV",[87],"2021-10-05","2023-09-19","2019-11-22",183,[33],[52,47,160,126,161,93],"Subcutaneous Lenacapavir","BIC",{"nctId":163,"briefTitle":164,"status":103,"phases":165,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":171},"NCT02397694","Safety and Efficacy of Bictegravir + Emtricitabine\u002FTenofovir Alafenamide Versus Dolutegravir + Emtricitabine\u002FTenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",[87],"2015-11-30","2019-02-27","2015-03-23",98,[21],[161,47,172,173,174,93],"DTG","BIC Placebo","DTG Placebo",{"nctId":63,"briefTitle":64,"status":130,"phases":176,"primaryCompletion":65,"completion":132,"start":154,"enrollment":177,"conditions":178,"interventions":179},[87],142,[21],[66,180,93,181],"LEN","ISL\u002FLEN FDC",{"trials":183,"activeCount":332,"soonestReadout":326},[184,196,208,219,233,244,256,269,279,288,297,312,322],{"nctId":185,"briefTitle":186,"status":103,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":193},"NCT02607956","Study to Evaluate the Safety and Efficacy of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide Versus Dolutegravir + Emtricitabine\u002FTenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",[88],"2017-05-12","2021-07-05","2015-11-11",657,[21],[172,47,93,174,194,195],"F\u002FTAF Placebo","B\u002FF\u002FTAF Placebo",{"nctId":197,"briefTitle":198,"status":103,"phases":199,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":205},"NCT03631732","Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide (B\u002FF\u002FTAF), in Virologically-Suppressed, HIV-1 Infected African American Participants",[88],"2019-08-12","2020-08-19","2018-08-28",496,[21],[93,206,207],"NRTIs","Third Agent",{"nctId":209,"briefTitle":210,"status":103,"phases":211,"primaryCompletion":212,"completion":213,"start":190,"enrollment":214,"conditions":215,"interventions":216},"NCT02603120","Safety and Efficacy of Switching From Dolutegravir and ABC\u002F3TC or ABC\u002FDTG\u002F3TC to B\u002FF\u002FTAF in HIV-1 Infected Adults Who Are Virologically Suppressed",[88],"2017-05-09","2019-10-23",567,[21],[217,93,218,195],"ABC\u002FDTG\u002F3TC","ABC\u002FDTG\u002F3TC Placebo",{"nctId":220,"briefTitle":221,"status":103,"phases":222,"primaryCompletion":223,"completion":121,"start":224,"enrollment":225,"conditions":226,"interventions":227},"NCT02652624","Safety and Efficacy of Switching to a FDC of B\u002FF\u002FTAF From E\u002FC\u002FF\u002FTAF, E\u002FC\u002FF\u002FTDF, or ATV+RTV+FTC\u002FTDF in Virologically Suppressed HIV-1 Infected Women",[88],"2017-10-09","2016-02-19",472,[21],[228,229,230,231,232,93],"E\u002FC\u002FF\u002FTAF","E\u002FC\u002FF\u002FTDF","ATV","RTV","FTC\u002FTDF",{"nctId":234,"briefTitle":235,"status":130,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":242},"NCT06333808","Study to Compare Bictegravir\u002FLenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy",[88],"2025-10-27","2029-12","2024-03-25",577,[33],[243,125,93],"Bictegravir",{"nctId":245,"briefTitle":246,"status":103,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},"NCT03547908","Safety and Efficacy of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide Versus Dolutegravir + Emtricitabine\u002FTenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults",[88],"2022-02-25","2024-03-07","2018-05-30",244,[253],"HIV-1\u002FHBV Co-Infection",[93,172,255],"F\u002FTDF",{"nctId":257,"briefTitle":258,"status":130,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":265},"NCT06630286","Study to Compare an Oral Weekly Islatravir\u002FLenacapavir Regimen With Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide in Virologically Suppressed People With HIV-1",[88],"2026-04-17","2030-08","2024-10-09",609,[33],[266,93,267,268],"ISL\u002FLEN","PTM B\u002FF\u002FTAF","PTM ISL\u002FLEN",{"nctId":270,"briefTitle":271,"status":103,"phases":272,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":278},"NCT03405935","Study to Evaluate Switching From an E\u002FC\u002FF\u002FTAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B\u002FF\u002FTAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years",[88],"2018-11-20","2020-05-29","2018-03-01",86,[21],[93],{"nctId":280,"briefTitle":281,"status":103,"phases":282,"primaryCompletion":283,"completion":284,"start":285,"enrollment":214,"conditions":286,"interventions":287},"NCT03110380","Switching to a Fixed Dose Combination of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide (B\u002FF\u002FTAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed",[88],"2018-12-04","2021-02-10","2017-06-12",[33],[93,47,172,174,194,195],{"nctId":289,"briefTitle":290,"status":103,"phases":291,"primaryCompletion":212,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":296},"NCT02607930","Study to Evaluate the Safety and Efficacy of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide Versus Abacavir\u002FDolutegravir\u002FLamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",[88],"2021-07-02","2015-11-13",631,[21],[217,93,218,195],{"nctId":298,"briefTitle":299,"status":103,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":306},"NCT02603107","Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine\u002FTenofovir or Abacavir\u002FLamivudine to Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults",[88],"2017-05-15","2019-12-23","2015-11-20",578,[21],[231,230,307,308,309,310,232,311,93],"DRV","COBI","ATV\u002Fco","DRV\u002Fco","ABC\u002F3TC",{"nctId":313,"briefTitle":314,"status":103,"phases":315,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":321},"NCT02600819","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E\u002FC\u002FF\u002FTAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis",[88],"2017-09-29","2019-10-15","2015-12-14",55,[21],[228,93],{"nctId":323,"briefTitle":324,"status":130,"phases":325,"primaryCompletion":326,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":331},"NCT02881320","Study of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1",[87,88],"2025-03-24","2026-11","2016-09-21",177,[21],[93,93,93,93,93,93],3,{"trials":334,"activeCount":147,"soonestReadout":350},[335,345],{"nctId":336,"briefTitle":337,"status":103,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":344},"NCT06104306","Study of B\u002FF\u002FTAF in Participants Switching From CAB + RPV to B\u002FF\u002FTAF for HIV-1 Infection (EMPOWER)",[89],"2025-01-29","2025-04-23","2023-12-13",33,[33],[93],{"nctId":346,"briefTitle":347,"status":348,"phases":349,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":354},"NCT06337032","A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","RECRUITING",[89],"2034-03","2024-08-27",350,[33],[47,47,47,47,47,47,228,228,355,355,355,93,93,93,93,93,356,357,230,307,358],"Cobicistat","3rd ARV Agent","Nucleos","Lopinavir Boosted with ritonavir",{"trials":360,"activeCount":97},[361],{"nctId":362,"briefTitle":363,"status":103,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":369},"NCT03580668","Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir\u002F Emtricitabine\u002FTenofovir Alafenamide",[],"2024-06-03","2018-11-13",201,[33],[93],{"intervention":47,"totalTrials":371,"cells":372},12,{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":387,"PHASE4":478,"NA":484},{"trials":374,"activeCount":97},[],{"trials":376,"activeCount":97},[],{"trials":378,"activeCount":97},[379,383],{"nctId":151,"briefTitle":152,"status":103,"phases":380,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":381,"interventions":382},[87],[33],[52,47,160,126,161,93],{"nctId":163,"briefTitle":164,"status":103,"phases":384,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":385,"interventions":386},[87],[21],[161,47,172,173,174,93],{"trials":388,"activeCount":477,"soonestReadout":46},[389,393,402,414,426,439,447,457,461],{"nctId":185,"briefTitle":186,"status":103,"phases":390,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":391,"interventions":392},[88],[21],[172,47,93,174,194,195],{"nctId":44,"briefTitle":45,"status":130,"phases":394,"primaryCompletion":46,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":400},[88],"2026-07","2016-09-02",5399,[399],"Pre-Exposure Prophylaxis of HIV-1 Infection",[47,255,194,401],"F\u002FTDF Placebo",{"nctId":403,"briefTitle":404,"status":103,"phases":405,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":411},"NCT02121795","Switch Study to Evaluate F\u002FTAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC\u002FTDF",[88],"2015-08-12","2019-03-01","2014-05-06",668,[21],[232,47,412,413,194],"Allowed third antiretroviral agent","FTC\u002FTDF Placebo",{"nctId":68,"briefTitle":69,"status":130,"phases":415,"primaryCompletion":70,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":421},[88],"2028-01","2021-08-30",5368,[420],"Pre-Exposure Prophylaxis of HIV Infection",[52,422,47,255,423,424,425],"Subcutaneous","PTM Oral LEN","PTM F\u002FTAF","PTM F\u002FTDF",{"nctId":427,"briefTitle":428,"status":103,"phases":429,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":436},"NCT02285114","Study To Evaluate Emtricitabine\u002FTenofovir Alafenamide (F\u002FTAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside\u002FNucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen",[87,88],"2019-11-04","2024-12-11","2015-01-20",41,[435],"HIV-1",[47,437,438],"3rd ARV agent","Boosted PIs",{"nctId":77,"briefTitle":78,"status":130,"phases":440,"primaryCompletion":79,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":445},[88],"2028-08","2021-06-28",3292,[420],[52,255,446,425,423,47],"Sub-cutaneous",{"nctId":448,"briefTitle":449,"status":103,"phases":450,"primaryCompletion":451,"completion":452,"start":453,"enrollment":214,"conditions":454,"interventions":455},"NCT02469246","Switch Study to Evaluate F\u002FTAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC\u002F3TC",[88],"2017-12-11","2019-03-13","2015-06-29",[21],[47,311,456,194,437],"ABC\u002F3TC Placebo",{"nctId":280,"briefTitle":281,"status":103,"phases":458,"primaryCompletion":283,"completion":284,"start":285,"enrollment":214,"conditions":459,"interventions":460},[88],[33],[93,47,172,174,194,195],{"nctId":462,"briefTitle":463,"status":130,"phases":464,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT02016924","Study of Cobicistat-Boosted Atazanavir (ATV\u002Fco), Cobicistat-Boosted Darunavir (DRV\u002Fco) and Emtricitabine\u002FTenofovir Alafenamide (F\u002FTAF) in Children With HIV",[87,88],"2025-06-13","2027-03","2014-01-16",133,[470,15],"Acquired Immune Deficiency Syndrome (AIDS)",[230,307,355,472,47,473,474,475,476],"BR","LPV\u002Fr","Third Unboosted Drug","Cobicistat TOS","F\u002FTAF TOS",4,{"trials":479,"activeCount":147,"soonestReadout":350},[480],{"nctId":346,"briefTitle":347,"status":348,"phases":481,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":482,"interventions":483},[89],[33],[47,47,47,47,47,47,228,228,355,355,355,93,93,93,93,93,356,357,230,307,358],{"trials":485,"activeCount":97},[],{"intervention":230,"totalTrials":487,"cells":488},13,{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":526,"PHASE4":606,"NA":626},{"trials":490,"activeCount":97},[],{"trials":492,"activeCount":97},[],{"trials":494,"activeCount":97},[495,514],{"nctId":496,"briefTitle":497,"status":103,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":505},"NCT01565889","Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV\u002FHCV Co-infected Patients.",[86,87],"2013-08","2013-11","2012-03",52,[27,504],"HIV",[506,507,508,509,230,510,232,307,511,512,513],"SOF","EFV\u002FFTC\u002FTDF","EFV","ZDV\u002F3TC","Ritonavir","RAL","PEG","RBV",{"nctId":515,"briefTitle":516,"status":103,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":523},"NCT00892437","Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine\u002FTenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",[87],"2009-12","2015-01","2009-05",85,[21],[308,231,230,232,524,525],"COBI placebo","RTV placebo",{"trials":527,"activeCount":147,"soonestReadout":465},[528,540,544,557,569,579,589,593,602],{"nctId":529,"briefTitle":530,"status":103,"phases":531,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":538},"NCT01363011","Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment",[88],"2013-01","2015-02","2011-05",106,[537,15],"Acquired Immunodeficiency Syndrome",[229,308,230,307,539],"NRTI",{"nctId":220,"briefTitle":221,"status":103,"phases":541,"primaryCompletion":223,"completion":121,"start":224,"enrollment":225,"conditions":542,"interventions":543},[88],[21],[228,229,230,231,232,93],{"nctId":545,"briefTitle":546,"status":103,"phases":547,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":552,"interventions":553},"NCT01705574","Safety and Efficacy of E\u002FC\u002FF\u002FTDF Versus RTV-Boosted ATV Plus FTC\u002FTDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women",[88],"2015-02-09","2018-09-06","2012-10-24",583,[537,15],[229,230,231,232,554,555,556,413,228],"E\u002FC\u002FF\u002FTDF Placebo","ATV Placebo","RTV Placebo",{"nctId":558,"briefTitle":559,"status":103,"phases":560,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":566},"NCT01106586","Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",[88],"2011-09","2014-09","2010-04",708,[504,15],[567,230,510,232,568,555,556,413],"Stribild","Stribild Placebo",{"nctId":570,"briefTitle":571,"status":103,"phases":572,"primaryCompletion":573,"completion":574,"start":575,"enrollment":319,"conditions":576,"interventions":577},"NCT01967940","Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",[88],"2015-05-21","2017-07-31","2013-10-25",[504,15,537],[126,228,578,230],"Current failing ARV regimen",{"nctId":580,"briefTitle":581,"status":103,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":588},"NCT01815736","Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants",[88],"2015-03-16","2020-04-01","2013-03-27",1443,[504,15],[228,229,507,231,230,232,308],{"nctId":462,"briefTitle":463,"status":130,"phases":590,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":591,"interventions":592},[87,88],[470,15],[230,307,355,472,47,473,474,475,476],{"nctId":594,"briefTitle":595,"status":103,"phases":596,"primaryCompletion":597,"completion":598,"start":563,"enrollment":599,"conditions":600,"interventions":601},"NCT01108510","Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine\u002FTenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",[88],"2011-11","2015-04",698,[504,15],[308,231,230,232,524,525],{"nctId":298,"briefTitle":299,"status":103,"phases":603,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":604,"interventions":605},[88],[21],[231,230,307,308,309,310,232,311,93],{"trials":607,"activeCount":147,"soonestReadout":350},[608,622],{"nctId":609,"briefTitle":610,"status":103,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":617},"NCT02246998","Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir\u002FLamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults",[89],"2016-01-20","2016-02-17","2014-12-15",72,[21],[618,619,620,231,230,311,621],"STB","TVD","ATR","Iohexol",{"nctId":346,"briefTitle":347,"status":348,"phases":623,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":624,"interventions":625},[89],[33],[47,47,47,47,47,47,228,228,355,355,355,93,93,93,93,93,356,357,230,307,358],{"trials":627,"activeCount":97},[],{"intervention":307,"totalTrials":629,"cells":630},9,{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":666,"PHASE4":700,"NA":706},{"trials":632,"activeCount":97},[],{"trials":634,"activeCount":97},[],{"trials":636,"activeCount":97},[637,650,662],{"nctId":638,"briefTitle":639,"status":103,"phases":640,"primaryCompletion":532,"completion":641,"start":642,"enrollment":643,"conditions":644,"interventions":645},"NCT01565850","D\u002FC\u002FF\u002FTAF Versus COBI-boosted DRV Plus FTC\u002FTDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults",[87],"2014-02","2012-04",153,[537,15],[646,307,308,232,647,648,649,413],"D\u002FC\u002FF\u002FTAF","D\u002FC\u002FF\u002FTAF Placebo","DRV Placebo","COBI Placebo",{"nctId":651,"briefTitle":652,"status":653,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":659},"NCT03472326","Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus","TERMINATED",[87],"2019-12-09","2018-04-03",21,[33],[660,161,126,661,307,231],"GS-9131","ARV regimen",{"nctId":496,"briefTitle":497,"status":103,"phases":663,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":664,"interventions":665},[86,87],[27,504],[506,507,508,509,230,510,232,307,511,512,513],{"trials":667,"activeCount":147,"soonestReadout":465},[668,672,676,680,691],{"nctId":529,"briefTitle":530,"status":103,"phases":669,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":670,"interventions":671},[88],[537,15],[229,308,230,307,539],{"nctId":462,"briefTitle":463,"status":130,"phases":673,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":674,"interventions":675},[87,88],[470,15],[230,307,355,472,47,473,474,475,476],{"nctId":298,"briefTitle":299,"status":103,"phases":677,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":678,"interventions":679},[88],[21],[231,230,307,308,309,310,232,311,93],{"nctId":681,"briefTitle":682,"status":103,"phases":683,"primaryCompletion":684,"completion":685,"start":686,"enrollment":687,"conditions":688,"interventions":689},"NCT01968551","Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir Alafenamide (E\u002FC\u002FF\u002FTAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults",[88],"2015-07-21","2016-07-09","2013-09-03",158,[435,15,537],[228,307,690],"Baseline DRV- containing ARV regimen",{"nctId":692,"briefTitle":693,"status":103,"phases":694,"primaryCompletion":695,"completion":696,"start":561,"enrollment":697,"conditions":698,"interventions":699},"NCT01440569","Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults",[88],"2012-08","2015-10",314,[537,15],[308,307,206],{"trials":701,"activeCount":147,"soonestReadout":350},[702],{"nctId":346,"briefTitle":347,"status":348,"phases":703,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":704,"interventions":705},[89],[33],[47,47,47,47,47,47,228,228,355,355,355,93,93,93,93,93,356,357,230,307,358],{"trials":707,"activeCount":97},[],{"intervention":355,"totalTrials":332,"cells":709},{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":727,"PHASE3":729,"PHASE4":735,"NA":741},{"trials":711,"activeCount":97},[],{"trials":713,"activeCount":97},[714],{"nctId":715,"briefTitle":716,"status":653,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":723},"NCT05458102","Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels",[86],"2023-05-01","2022-08-19",18,[722],"Human Immunodeficiency Virus Type 1 (HIV-1) Infection",[724,355,725,726],"Vesatolimod","Voriconazole","Rifabutin",{"trials":728,"activeCount":97},[],{"trials":730,"activeCount":147,"soonestReadout":465},[731],{"nctId":462,"briefTitle":463,"status":130,"phases":732,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":733,"interventions":734},[87,88],[470,15],[230,307,355,472,47,473,474,475,476],{"trials":736,"activeCount":147,"soonestReadout":350},[737],{"nctId":346,"briefTitle":347,"status":348,"phases":738,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":739,"interventions":740},[89],[33],[47,47,47,47,47,47,228,228,355,355,355,93,93,93,93,93,356,357,230,307,358],{"trials":742,"activeCount":97},[],{"intervention":228,"totalTrials":720,"cells":744},{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":762,"PHASE4":894,"NA":900},{"trials":746,"activeCount":97},[],{"trials":748,"activeCount":97},[],{"trials":750,"activeCount":97},[751],{"nctId":752,"briefTitle":753,"status":103,"phases":754,"primaryCompletion":755,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":760},"NCT01497899","Safety and Efficacy of E\u002FC\u002FF\u002FTAF (Genvoya®) Versus E\u002FC\u002FF\u002FTDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",[87],"2012-10-17","2016-08-22","2011-12-28",279,[537,15],[229,761,228,554],"E\u002FC\u002FF\u002FTAF Placebo",{"trials":763,"activeCount":97},[764,768,772,786,798,802,812,822,833,837,847,856,865,869,873,883],{"nctId":220,"briefTitle":221,"status":103,"phases":765,"primaryCompletion":223,"completion":121,"start":224,"enrollment":225,"conditions":766,"interventions":767},[88],[21],[228,229,230,231,232,93],{"nctId":545,"briefTitle":546,"status":103,"phases":769,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":770,"interventions":771},[88],[537,15],[229,230,231,232,554,555,556,413,228],{"nctId":773,"briefTitle":774,"status":103,"phases":775,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":781},"NCT02616783","Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002F Tenofovir Alafenamide (E\u002FC\u002FF\u002FTAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years",[88],"2018-02-21","2018-03-21","2015-12-22",167,[21],[228,782,783,232,784,785],"TDF","FTC","3TC","Third agent",{"nctId":787,"briefTitle":788,"status":103,"phases":789,"primaryCompletion":790,"completion":316,"start":791,"enrollment":792,"conditions":793,"interventions":795},"NCT02707601","Efficacy, Safety, and Tolerability of Ledipasvir\u002FSofosbuvir (LDV\u002FSOF) Treatment for HIV\u002FHCV Co-infected Participants Who Switch to Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir Alafenamide (E\u002FC\u002FF\u002FTAF) or Emtricitabine\u002FRilpivirine\u002FTenofovir Alafenamide (F\u002FR\u002FTAF) Prior to LDV\u002FSOF HCV Treatment",[88],"2017-09-14","2016-04-01",150,[21,794],"HCV Infection",[228,796,797],"F\u002FR\u002FTAF","LDV\u002FSOF",{"nctId":570,"briefTitle":571,"status":103,"phases":799,"primaryCompletion":573,"completion":574,"start":575,"enrollment":319,"conditions":800,"interventions":801},[88],[504,15,537],[126,228,578,230],{"nctId":803,"briefTitle":804,"status":103,"phases":805,"primaryCompletion":806,"completion":807,"start":808,"enrollment":809,"conditions":810,"interventions":811},"NCT01780506","Study to Evaluate the Safety and Efficacy of E\u002FC\u002FF\u002FTAF (Genvoya®) Versus E\u002FC\u002FF\u002FTDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",[88],"2014-08-26","2017-09-06","2012-12-26",872,[504,15],[228,229,554,761],{"nctId":813,"briefTitle":814,"status":103,"phases":815,"primaryCompletion":816,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":821},"NCT02616029","Study to Evaluate Switching to Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir Alafenamide (E\u002FC\u002FF\u002FTAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V\u002FM184I",[88],"2018-10-11","2019-07-11","2015-12-17",66,[21],[228],{"nctId":823,"briefTitle":824,"status":103,"phases":825,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":832},"NCT02071082","Efficacy and Safety of E\u002FC\u002FF\u002FTAF (Genvoya®) in HIV-1\u002FHepatitis B Co-infected Adults",[88],"2015-01-23","2016-10-26","2014-02-25",79,[504,831],"HBV",[228],{"nctId":580,"briefTitle":581,"status":103,"phases":834,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":835,"interventions":836},[88],[504,15],[228,229,507,231,230,232,308],{"nctId":838,"briefTitle":839,"status":103,"phases":840,"primaryCompletion":841,"completion":842,"start":843,"enrollment":844,"conditions":845,"interventions":846},"NCT01854775","Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir Alafenamide (E\u002FC\u002FF\u002FTAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children",[87,88],"2020-05-11","2025-06-18","2013-05-06",129,[470,15],[228,228],{"nctId":848,"briefTitle":849,"status":103,"phases":850,"primaryCompletion":851,"completion":852,"start":585,"enrollment":853,"conditions":854,"interventions":855},"NCT01818596","Open-label Safety Study of E\u002FC\u002FF\u002FTAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment",[88],"2014-07-31","2018-07-18",252,[504,15],[228],{"nctId":857,"briefTitle":858,"status":103,"phases":859,"primaryCompletion":860,"completion":861,"start":862,"enrollment":809,"conditions":863,"interventions":864},"NCT01797445","Study to Evaluate the Safety and Efficacy of E\u002FC\u002FF\u002FTAF Versus E\u002FC\u002FF\u002FTDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",[88],"2014-09-19","2018-10-03","2013-03-12",[504,15],[228,229,554,761],{"nctId":313,"briefTitle":314,"status":103,"phases":866,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":867,"interventions":868},[88],[21],[228,93],{"nctId":681,"briefTitle":682,"status":103,"phases":870,"primaryCompletion":684,"completion":685,"start":686,"enrollment":687,"conditions":871,"interventions":872},[88],[435,15,537],[228,307,690],{"nctId":874,"briefTitle":875,"status":103,"phases":876,"primaryCompletion":877,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":882},"NCT02276612","Efficacy and Safety of Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir Alafenamide in HIV-1 Infected Adolescents",[87,88],"2016-11-10","2017-10-23","2014-12-03",60,[504],[228],{"nctId":884,"briefTitle":885,"status":103,"phases":886,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":891,"interventions":892},"NCT02605954","Safety and Efficacy of Switching From Regimens of ABC\u002F3TC + a 3rd Agent to E\u002FC\u002FF\u002FTAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults",[88],"2017-06-14","2018-01-24","2015-11-18",275,[21],[228,311,893],"Third Antiretroviral Agent",{"trials":895,"activeCount":147,"soonestReadout":350},[896],{"nctId":346,"briefTitle":347,"status":348,"phases":897,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":898,"interventions":899},[89],[33],[47,47,47,47,47,47,228,228,355,355,355,93,93,93,93,93,356,357,230,307,358],{"trials":901,"activeCount":97},[],{"intervention":437,"totalTrials":332,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":920,"NA":926},{"trials":905,"activeCount":97},[],{"trials":907,"activeCount":97},[],{"trials":909,"activeCount":97},[],{"trials":911,"activeCount":97},[912,916],{"nctId":427,"briefTitle":428,"status":103,"phases":913,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":914,"interventions":915},[87,88],[435],[47,437,438],{"nctId":448,"briefTitle":449,"status":103,"phases":917,"primaryCompletion":451,"completion":452,"start":453,"enrollment":214,"conditions":918,"interventions":919},[88],[21],[47,311,456,194,437],{"trials":921,"activeCount":147,"soonestReadout":350},[922],{"nctId":346,"briefTitle":347,"status":348,"phases":923,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":924,"interventions":925},[89],[33],[47,47,47,47,47,47,228,228,355,355,355,93,93,93,93,93,356,357,230,307,358],{"trials":927,"activeCount":97},[],{"intervention":357,"totalTrials":147,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":938,"NA":944},{"trials":931,"activeCount":97},[],{"trials":933,"activeCount":97},[],{"trials":935,"activeCount":97},[],{"trials":937,"activeCount":97},[],{"trials":939,"activeCount":147,"soonestReadout":350},[940],{"nctId":346,"briefTitle":347,"status":348,"phases":941,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":942,"interventions":943},[89],[33],[47,47,47,47,47,47,228,228,355,355,355,93,93,93,93,93,356,357,230,307,358],{"trials":945,"activeCount":97},[],{"intervention":358,"totalTrials":147,"cells":947},{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":954,"PHASE4":956,"NA":962},{"trials":949,"activeCount":97},[],{"trials":951,"activeCount":97},[],{"trials":953,"activeCount":97},[],{"trials":955,"activeCount":97},[],{"trials":957,"activeCount":147,"soonestReadout":350},[958],{"nctId":346,"briefTitle":347,"status":348,"phases":959,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":960,"interventions":961},[89],[33],[47,47,47,47,47,47,228,228,355,355,355,93,93,93,93,93,356,357,230,307,358],{"trials":963,"activeCount":97},[],{"intervention":57,"totalTrials":657,"cells":965},{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":994,"PHASE3":1123,"PHASE4":1220,"NA":1222},{"trials":967,"activeCount":97},[],{"trials":969,"activeCount":993,"soonestReadout":974},[970,980],{"nctId":971,"briefTitle":972,"status":348,"phases":973,"primaryCompletion":974,"completion":974,"start":975,"enrollment":25,"conditions":976,"interventions":979},"NCT04617522","Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment",[86],"2026-12","2021-04-06",[977,978],"Advanced or Metastatic Solid Tumor","Liver Failure",[57],{"nctId":981,"briefTitle":982,"status":130,"phases":983,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":989},"NCT05006794","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies",[86],"2029-03","2021-09-15",145,[988],"Solid Malignancies",[990,991,992],"zamzetoclax","Docetaxel","sacituzumab govitecan-hziy",2,{"trials":995,"activeCount":1122,"soonestReadout":56},[996,1002,1015,1039,1052,1060,1069,1078,1093,1105],{"nctId":81,"briefTitle":82,"status":130,"phases":997,"primaryCompletion":83,"completion":974,"start":317,"enrollment":998,"conditions":999,"interventions":1001},[87],227,[1000],"Metastatic Solid Tumor",[57],{"nctId":1003,"briefTitle":1004,"status":130,"phases":1005,"primaryCompletion":1006,"completion":1006,"start":1007,"enrollment":1008,"conditions":1009,"interventions":1011},"NCT05186974","Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)",[87],"2026-09","2022-05-30",193,[1010],"Non-small Cell Lung Cancer",[57,1012,1013,1014],"Pembrolizumab","Carboplatin","Cisplatin",{"nctId":1016,"briefTitle":1017,"status":103,"phases":1018,"primaryCompletion":407,"completion":1019,"start":1020,"enrollment":1021,"conditions":1022,"interventions":1038},"NCT01631552","Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer",[86,87],"2020-08-13","2012-12-17",515,[1023,1024,1025,1010,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,1037],"Gastric Adenocarcinoma","Esophageal Cancer","Hepatocellular Carcinoma","Small Cell Lung Cancer","Ovarian Epithelial Cancer","Carcinoma Breast Stage IV","Hormone-refractory Prostate Cancer","Head and Neck Cancers- Squamous Cell","Renal Cell Cancer","Urinary Bladder Neoplasms","Cervical Cancer","Endometrial Cancer","Glioblastoma Multiforme","Triple Negative Breast Cancer","Pancreatic Cancer",[57],{"nctId":1040,"briefTitle":1041,"status":653,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1048},"NCT04958785","Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer",[87],"2024-10-08","2021-12-14",92,[1047],"Triple-Negative Breast Cancer",[1049,1050,1051,57],"Magrolimab","Nab-Paclitaxel","Paclitaxel",{"nctId":54,"briefTitle":55,"status":130,"phases":1053,"primaryCompletion":56,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1059},[87],"2027-12","2020-10-23",80,[1058],"Metastatic Triple-negative Breast Cancer",[57],{"nctId":1061,"briefTitle":1062,"status":130,"phases":1063,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":122,"conditions":1066,"interventions":1068},"NCT05119907","Study of Sacituzumab Govitecan in Patients With Solid Tumor",[87],"2026-10","2021-10-12",[1067],"Solid Tumor",[57],{"nctId":1070,"briefTitle":1071,"status":348,"phases":1072,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":1075,"conditions":1076,"interventions":1077},"NCT06926920","A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer",[86,87],"2028-06","2025-04-30",100,[1036],[57],{"nctId":1079,"briefTitle":1080,"status":348,"phases":1081,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":1085,"interventions":1087},"NCT03547973","Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread",[87],"2030-04","2018-08-13",827,[1086],"Metastatic Urothelial Cancer",[57,1012,1014,1088,1089,1013,1090,1091,1092],"Avelumab","Zimberelimab","Gemcitabine","Domvanalimab","Enfortumab Vedotin",{"nctId":1094,"briefTitle":1095,"status":130,"phases":1096,"primaryCompletion":1097,"completion":1097,"start":1098,"enrollment":1099,"conditions":1100,"interventions":1104},"NCT05101096","Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors",[86,87],"2026-05","2021-10-20",135,[1101,1102,1103,1086],"Advanced Solid Tumor","Metastatic Triple-Negative Breast Cancer","HR+\u002FHER2- Metastatic Breast Cancer",[57],{"nctId":1106,"briefTitle":1107,"status":130,"phases":1108,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1116},"NCT05633667","Study of Novel Treatment Combinations in Patients With Lung Cancer",[87],"2029-09","2023-03-16",192,[1113,1114,1115],"Lung Cancer","Advanced or Metastatic Non-Small-Cell Lung Cancer","Resectable Non-Small-Cell Lung Cancer",[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],"Sacituzumab govitecan-hziy","Etrumadenant","Pemetrexed","Nab-paclitaxel","Nivolumab",8,{"trials":1124,"activeCount":1219,"soonestReadout":61},[1125,1136,1149,1159,1169,1179,1187,1198,1208],{"nctId":1126,"briefTitle":1127,"status":130,"phases":1128,"primaryCompletion":1129,"completion":1129,"start":1130,"enrollment":1131,"conditions":1132,"interventions":1134},"NCT05382299","Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",[88],"2028-07","2022-07-20",623,[1036,1133],"PD-L1 Negative",[57,1051,1135,1090,1013],"nab-Paclitaxel",{"nctId":1137,"briefTitle":1138,"status":103,"phases":1139,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1145},"NCT03901339","Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+\u002FHER2- Metastatic Breast Cancer",[88],"2023-10-20","2019-05-08",543,[1144],"Metastatic Breast Cancer",[57,1146,1147,1090,1148],"Eribulin","Capecitabine","Vinorelbine",{"nctId":1150,"briefTitle":1151,"status":130,"phases":1152,"primaryCompletion":974,"completion":974,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1156},"NCT04639986","Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+\u002FHER2- Metastatic Breast Cancer (MBC)",[88],"2020-11-23",331,[1144],[57,1157,1158,1090,1148],"Eribulin Mesylate","Capecitabine Oral Product",{"nctId":1160,"briefTitle":1161,"status":348,"phases":1162,"primaryCompletion":1163,"completion":1164,"start":1165,"enrollment":1166,"conditions":1167,"interventions":1168},"NCT05633654","Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05\u002FAFT-65 OptimICE-RD\u002FGBG 119\u002FNSABP B-63)",[88],"2027-06","2031-08","2022-12-12",1514,[1036],[1117,1012,1147],{"nctId":1170,"briefTitle":1171,"status":130,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1178},"NCT05382286","Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",[88],"2027-02","2022-07-25",443,[1036,1177],"PD-L1 Positive",[57,1012,1051,1135,1090,1013],{"nctId":59,"briefTitle":60,"status":130,"phases":1180,"primaryCompletion":61,"completion":1181,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1186},[88],"2027-01","2021-11-17",603,[1185],"Non-Small Cell Lung Cancer",[57,991],{"nctId":1188,"briefTitle":1189,"status":103,"phases":1190,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1194,"interventions":1196},"NCT04527991","Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread",[88],"2025-07-04","2021-01-13",711,[1195],"Locally Advanced or Metastatic Unresectable Urothelial Cancer",[57,1051,991,1197],"Vinflunine",{"nctId":1199,"briefTitle":1200,"status":130,"phases":1201,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1206},"NCT06486441","Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01\u002FGOG-3104\u002FENGOT-en26)",[88],"2029-06","2024-08-28",640,[1034],[1117,1207,1051],"Doxorubicin",{"nctId":1209,"briefTitle":1210,"status":130,"phases":1211,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1218},"NCT05840211","Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive\u002FHuman Epidermal Growth Factor Receptor 2 Negative (HR+\u002FHER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy",[88],"2028-04","2023-05-08",654,[1216,1217],"Locally Advanced or Unresectable Metastatic Breast Cancer","Stage IV Breast Cancer",[57,1051,1120,1147],7,{"trials":1221,"activeCount":97},[],{"trials":1223,"activeCount":97},[],{"intervention":1089,"totalTrials":1225,"cells":1226},11,{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1280,"PHASE3":1319,"PHASE4":1330,"NA":1332},{"trials":1228,"activeCount":97},[],{"trials":1230,"activeCount":477,"soonestReadout":395},[1231,1240,1251,1261,1270],{"nctId":1232,"briefTitle":1233,"status":130,"phases":1234,"primaryCompletion":395,"completion":395,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1238},"NCT05840224","Study of GS-4528 in Adults With Solid Tumors",[86],"2023-05-11",182,[1067],[1239,1089],"GS-4528",{"nctId":1241,"briefTitle":1242,"status":653,"phases":1243,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":487,"conditions":1246,"interventions":1248},"NCT04747470","Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors",[86],"2022-11-07","2021-03-25",[1247],"Advanced Solid Tumors",[1249,1089,1014,1013,1250,991],"GS-3583","5-Fluorouracil",{"nctId":1252,"briefTitle":1253,"status":130,"phases":1254,"primaryCompletion":974,"completion":974,"start":1255,"enrollment":1256,"conditions":1257,"interventions":1259},"NCT06082960","Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors",[86],"2023-10-09",45,[1258],"Solid Tumors",[1260,1089],"GS-9911",{"nctId":1262,"briefTitle":1263,"status":348,"phases":1264,"primaryCompletion":1073,"completion":1073,"start":1265,"enrollment":1266,"conditions":1267,"interventions":1268},"NCT06532565","Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors",[86],"2024-07-26",154,[1247],[1269,1089],"GS-2121",{"nctId":1271,"briefTitle":1272,"status":348,"phases":1273,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1276,"conditions":1277,"interventions":1278},"NCT05007782","Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors",[86],"2028-12","2021-08-18",416,[1101],[1279,1089],"Denikitug",{"trials":1281,"activeCount":477,"soonestReadout":1307},[1282,1292,1303,1311,1315],{"nctId":1283,"briefTitle":1284,"status":653,"phases":1285,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1008,"conditions":1288,"interventions":1290},"NCT04854499","Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma",[87],"2024-10-02","2021-09-07",[1289],"Head and Neck Squamous Cell Carcinoma",[1049,1012,991,1291,1014,1013,1089],"5-FU",{"nctId":1293,"briefTitle":1294,"status":130,"phases":1295,"primaryCompletion":1054,"completion":1054,"start":1296,"enrollment":1297,"conditions":1298,"interventions":1300},"NCT05676931","Study With Various Immunotherapy Treatments in Participants With Lung Cancer",[87],"2023-02-21",400,[1299],"Advanced Non-Small Cell Lung Cancer",[1091,1301,1089,991,1302],"Quemliclustat","Platinum-Based Doublet",{"nctId":1304,"briefTitle":1305,"status":130,"phases":1306,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1075,"conditions":1309,"interventions":1310},"NCT06727565","Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01",[87],"2026-08","2025-02-18",[1289],[1091,1089,1051,1013],{"nctId":1079,"briefTitle":1080,"status":348,"phases":1312,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":1313,"interventions":1314},[87],[1086],[57,1012,1014,1088,1089,1013,1090,1091,1092],{"nctId":1106,"briefTitle":1107,"status":130,"phases":1316,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1317,"interventions":1318},[87],[1113,1114,1115],[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],{"trials":1320,"activeCount":147,"soonestReadout":1073},[1321],{"nctId":1322,"briefTitle":1323,"status":130,"phases":1324,"primaryCompletion":1073,"completion":1325,"start":1326,"enrollment":1327,"conditions":1328,"interventions":1329},"NCT05502237","Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer",[88],"2029-01","2022-10-12",1021,[1010],[1089,1091,1012,1013,1014,1051,1120,1119],{"trials":1331,"activeCount":97},[],{"trials":1333,"activeCount":97},[],{"intervention":125,"totalTrials":1335,"cells":1336},10,{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1345,"PHASE3":1382,"PHASE4":1417,"NA":1419},{"trials":1338,"activeCount":97},[],{"trials":1340,"activeCount":97},[1341],{"nctId":116,"briefTitle":117,"status":103,"phases":1342,"primaryCompletion":119,"completion":120,"start":121,"enrollment":122,"conditions":1343,"interventions":1344},[86],[21],[125,93,126],{"trials":1346,"activeCount":477,"soonestReadout":74},[1347,1357,1366,1375],{"nctId":1348,"briefTitle":1349,"status":130,"phases":1350,"primaryCompletion":1097,"completion":1351,"start":1352,"enrollment":1353,"conditions":1354,"interventions":1355},"NCT06513312","Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)",[87],"2028-11","2024-10-07",268,[420],[125,125,1356],"Emtricitabine\u002Ftenofovir disoproxil fumarate",{"nctId":72,"briefTitle":73,"status":130,"phases":1358,"primaryCompletion":74,"completion":1359,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1363},[87],"2030-12","2023-05-15",83,[21],[75,1364,125,125,1365],"Zinlirvimab","Antiretroviral Therapy",{"nctId":1367,"briefTitle":1368,"status":130,"phases":1369,"primaryCompletion":395,"completion":416,"start":1370,"enrollment":1371,"conditions":1372,"interventions":1373},"NCT06101329","Study of Lenacapavir and Emtricitabine\u002FTenofovir Disoproxil Fumarate (F\u002FTDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)",[87],"2023-11-17",253,[420],[125,125,1374],"Emtricitabine\u002FTenofovir Disoproxil Fumarate",{"nctId":1376,"briefTitle":1377,"status":130,"phases":1378,"primaryCompletion":416,"completion":416,"start":341,"enrollment":1379,"conditions":1380,"interventions":1381},"NCT06101342","Study of Lenacapavir and Emtricitabine\u002FTenofovir Disoproxil Fumarate (F\u002FTDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)",[87],181,[420],[125,125,1356],{"trials":1383,"activeCount":477,"soonestReadout":1392},[1384,1388,1399,1408],{"nctId":234,"briefTitle":235,"status":130,"phases":1385,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":1386,"interventions":1387},[88],[33],[243,125,93],{"nctId":1389,"briefTitle":1390,"status":130,"phases":1391,"primaryCompletion":1392,"completion":1129,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1396},"NCT05502341","Study to Compare Bictegravir\u002FLenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen",[87,88],"2025-09-29","2022-08-16",689,[33],[243,125,1397,1398],"BIC\u002FLEN FDC","Stable Baseline Regimen",{"nctId":1400,"briefTitle":1401,"status":348,"phases":1402,"primaryCompletion":1403,"completion":1403,"start":1404,"enrollment":352,"conditions":1405,"interventions":1407},"NCT07047716","Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)",[88],"2028-09","2025-07-22",[1406],"HIV Pre-exposure Prophylaxis",[125,125],{"nctId":1409,"briefTitle":1410,"status":348,"phases":1411,"primaryCompletion":1412,"completion":441,"start":1413,"enrollment":1414,"conditions":1415,"interventions":1416},"NCT06532656","Study of Bictegravir\u002FLenacapavir in Children and Adolescents With HIV-1",[87,88],"2028-02","2024-11-20",75,[33],[125,1397],{"trials":1418,"activeCount":97},[],{"trials":1420,"activeCount":147,"soonestReadout":1212},[1421],{"nctId":1422,"briefTitle":1423,"status":348,"phases":1424,"primaryCompletion":1212,"completion":1425,"start":1426,"enrollment":1427,"conditions":1428,"interventions":1429},"NCT07473778","Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention",[],"2029-04","2026-03-17",3000,[15],[125,1356,1430,1431,125],"Emtricitabine\u002Ftenofovir alafenamide","Cabotegravir",{"intervention":1051,"totalTrials":1225,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1455,"PHASE3":1481,"PHASE4":1508,"NA":1510},{"trials":1435,"activeCount":97},[],{"trials":1437,"activeCount":97},[1438],{"nctId":1439,"briefTitle":1440,"status":103,"phases":1441,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":1445,"interventions":1449},"NCT01803282","Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors",[86],"2019-04-23","2013-03-29",236,[1037,1010,1446,1447,1448],"Esophagogastric Cancer","Colorectal Cancer","Breast Cancer",[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],"Andecaliximab","Leucovorin","Oxaliplatin","Bevacizumab","Irinotecan",{"trials":1456,"activeCount":332,"soonestReadout":1307},[1457,1461,1465,1477],{"nctId":1304,"briefTitle":1305,"status":130,"phases":1458,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1075,"conditions":1459,"interventions":1460},[87],[1289],[1091,1089,1051,1013],{"nctId":1040,"briefTitle":1041,"status":653,"phases":1462,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":1045,"conditions":1463,"interventions":1464},[87],[1047],[1049,1050,1051,57],{"nctId":1466,"briefTitle":1467,"status":348,"phases":1468,"primaryCompletion":1469,"completion":1469,"start":1097,"enrollment":1470,"conditions":1471,"interventions":1475},"NCT07546812","Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas",[87],"2030-01",120,[1472,1473,1474,1023],"HER2-negative","Gastroesophageal Junction","Esophageal Adenocarcinoma",[1279,1121,1476,1051],"Ramucirumab",{"nctId":1106,"briefTitle":1107,"status":130,"phases":1478,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1479,"interventions":1480},[87],[1113,1114,1115],[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],{"trials":1482,"activeCount":1507,"soonestReadout":1173},[1483,1487,1491,1495,1499,1503],{"nctId":1126,"briefTitle":1127,"status":130,"phases":1484,"primaryCompletion":1129,"completion":1129,"start":1130,"enrollment":1131,"conditions":1485,"interventions":1486},[88],[1036,1133],[57,1051,1135,1090,1013],{"nctId":1170,"briefTitle":1171,"status":130,"phases":1488,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1489,"interventions":1490},[88],[1036,1177],[57,1012,1051,1135,1090,1013],{"nctId":1188,"briefTitle":1189,"status":103,"phases":1492,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1493,"interventions":1494},[88],[1195],[57,1051,991,1197],{"nctId":1322,"briefTitle":1323,"status":130,"phases":1496,"primaryCompletion":1073,"completion":1325,"start":1326,"enrollment":1327,"conditions":1497,"interventions":1498},[88],[1010],[1089,1091,1012,1013,1014,1051,1120,1119],{"nctId":1199,"briefTitle":1200,"status":130,"phases":1500,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1501,"interventions":1502},[88],[1034],[1117,1207,1051],{"nctId":1209,"briefTitle":1210,"status":130,"phases":1504,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":1214,"conditions":1505,"interventions":1506},[88],[1216,1217],[57,1051,1120,1147],5,{"trials":1509,"activeCount":97},[],{"trials":1511,"activeCount":97},[],{"intervention":1013,"totalTrials":371,"cells":1513},{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1542,"PHASE3":1573,"PHASE4":1587,"NA":1589},{"trials":1515,"activeCount":97},[],{"trials":1517,"activeCount":97},[1518,1522,1526],{"nctId":1241,"briefTitle":1242,"status":653,"phases":1519,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":487,"conditions":1520,"interventions":1521},[86],[1247],[1249,1089,1014,1013,1250,991],{"nctId":1439,"briefTitle":1440,"status":103,"phases":1523,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":1524,"interventions":1525},[86],[1037,1010,1446,1447,1448],[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],{"nctId":1527,"briefTitle":1528,"status":1529,"phases":1530,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":97,"conditions":1534,"interventions":1537},"NCT03349346","Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents","WITHDRAWN",[86],"2021-02","2026-02","2019-06",[1535,1536],"Diffuse Large B-Cell Lymphoma","Mediastinal B-cell Lymphoma",[1538,1539,1540,1013,1541],"Idelalisib","Rituximab","Ifosfamide","Etoposide",{"trials":1543,"activeCount":477,"soonestReadout":1307},[1544,1548,1552,1561,1565,1569],{"nctId":1283,"briefTitle":1284,"status":653,"phases":1545,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1008,"conditions":1546,"interventions":1547},[87],[1289],[1049,1012,991,1291,1014,1013,1089],{"nctId":1003,"briefTitle":1004,"status":130,"phases":1549,"primaryCompletion":1006,"completion":1006,"start":1007,"enrollment":1008,"conditions":1550,"interventions":1551},[87],[1010],[57,1012,1013,1014],{"nctId":1553,"briefTitle":1554,"status":653,"phases":1555,"primaryCompletion":1556,"completion":1556,"start":1557,"enrollment":34,"conditions":1558,"interventions":1559},"NCT00650949","Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma",[86,87],"2011-06","2009-11",[1035],[1560,1013],"CYT997",{"nctId":1304,"briefTitle":1305,"status":130,"phases":1562,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1075,"conditions":1563,"interventions":1564},[87],[1289],[1091,1089,1051,1013],{"nctId":1079,"briefTitle":1080,"status":348,"phases":1566,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":1567,"interventions":1568},[87],[1086],[57,1012,1014,1088,1089,1013,1090,1091,1092],{"nctId":1106,"briefTitle":1107,"status":130,"phases":1570,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1571,"interventions":1572},[87],[1113,1114,1115],[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],{"trials":1574,"activeCount":332,"soonestReadout":1173},[1575,1579,1583],{"nctId":1126,"briefTitle":1127,"status":130,"phases":1576,"primaryCompletion":1129,"completion":1129,"start":1130,"enrollment":1131,"conditions":1577,"interventions":1578},[88],[1036,1133],[57,1051,1135,1090,1013],{"nctId":1170,"briefTitle":1171,"status":130,"phases":1580,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1581,"interventions":1582},[88],[1036,1177],[57,1012,1051,1135,1090,1013],{"nctId":1322,"briefTitle":1323,"status":130,"phases":1584,"primaryCompletion":1073,"completion":1325,"start":1326,"enrollment":1327,"conditions":1585,"interventions":1586},[88],[1010],[1089,1091,1012,1013,1014,1051,1120,1119],{"trials":1588,"activeCount":97},[],{"trials":1590,"activeCount":97},[],{"intervention":1120,"totalTrials":1122,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1612,"PHASE3":1622,"PHASE4":1640,"NA":1642},{"trials":1594,"activeCount":97},[],{"trials":1596,"activeCount":97},[1597,1601],{"nctId":1439,"briefTitle":1440,"status":103,"phases":1598,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":1599,"interventions":1600},[86],[1037,1010,1446,1447,1448],[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],{"nctId":1602,"briefTitle":1603,"status":653,"phases":1604,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":134,"conditions":1607,"interventions":1610},"NCT02468557","Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma",[86],"2016-04-27","2015-07-30",[1608,1609],"Previously Untreated Pancreatic Ductal Adenocarcinoma","Relapsed\u002FRefractory Pancreatic Ductal Adenocarcinoma",[1538,1120,1611],"mFOLFOX6",{"trials":1613,"activeCount":147,"soonestReadout":1109},[1614,1618],{"nctId":1040,"briefTitle":1041,"status":653,"phases":1615,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":1045,"conditions":1616,"interventions":1617},[87],[1047],[1049,1050,1051,57],{"nctId":1106,"briefTitle":1107,"status":130,"phases":1619,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1620,"interventions":1621},[87],[1113,1114,1115],[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],{"trials":1623,"activeCount":477,"soonestReadout":1173},[1624,1628,1632,1636],{"nctId":1126,"briefTitle":1127,"status":130,"phases":1625,"primaryCompletion":1129,"completion":1129,"start":1130,"enrollment":1131,"conditions":1626,"interventions":1627},[88],[1036,1133],[57,1051,1135,1090,1013],{"nctId":1170,"briefTitle":1171,"status":130,"phases":1629,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1630,"interventions":1631},[88],[1036,1177],[57,1012,1051,1135,1090,1013],{"nctId":1322,"briefTitle":1323,"status":130,"phases":1633,"primaryCompletion":1073,"completion":1325,"start":1326,"enrollment":1327,"conditions":1634,"interventions":1635},[88],[1010],[1089,1091,1012,1013,1014,1051,1120,1119],{"nctId":1209,"briefTitle":1210,"status":130,"phases":1637,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":1214,"conditions":1638,"interventions":1639},[88],[1216,1217],[57,1051,1120,1147],{"trials":1641,"activeCount":97},[],{"trials":1643,"activeCount":97},[],{"intervention":1012,"totalTrials":1645,"cells":1646},6,{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1665,"PHASE4":1679,"NA":1681},{"trials":1648,"activeCount":97},[],{"trials":1650,"activeCount":97},[],{"trials":1652,"activeCount":993,"soonestReadout":1006},[1653,1657,1661],{"nctId":1283,"briefTitle":1284,"status":653,"phases":1654,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1008,"conditions":1655,"interventions":1656},[87],[1289],[1049,1012,991,1291,1014,1013,1089],{"nctId":1003,"briefTitle":1004,"status":130,"phases":1658,"primaryCompletion":1006,"completion":1006,"start":1007,"enrollment":1008,"conditions":1659,"interventions":1660},[87],[1010],[57,1012,1013,1014],{"nctId":1079,"briefTitle":1080,"status":348,"phases":1662,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":1663,"interventions":1664},[87],[1086],[57,1012,1014,1088,1089,1013,1090,1091,1092],{"trials":1666,"activeCount":332,"soonestReadout":1173},[1667,1671,1675],{"nctId":1160,"briefTitle":1161,"status":348,"phases":1668,"primaryCompletion":1163,"completion":1164,"start":1165,"enrollment":1166,"conditions":1669,"interventions":1670},[88],[1036],[1117,1012,1147],{"nctId":1170,"briefTitle":1171,"status":130,"phases":1672,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1673,"interventions":1674},[88],[1036,1177],[57,1012,1051,1135,1090,1013],{"nctId":1322,"briefTitle":1323,"status":130,"phases":1676,"primaryCompletion":1073,"completion":1325,"start":1326,"enrollment":1327,"conditions":1677,"interventions":1678},[88],[1010],[1089,1091,1012,1013,1014,1051,1120,1119],{"trials":1680,"activeCount":97},[],{"trials":1682,"activeCount":97},[],{"intervention":1091,"totalTrials":1507,"cells":1684},{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1707,"PHASE4":1713,"NA":1715},{"trials":1686,"activeCount":97},[],{"trials":1688,"activeCount":97},[],{"trials":1690,"activeCount":477,"soonestReadout":1307},[1691,1695,1699,1703],{"nctId":1293,"briefTitle":1294,"status":130,"phases":1692,"primaryCompletion":1054,"completion":1054,"start":1296,"enrollment":1297,"conditions":1693,"interventions":1694},[87],[1299],[1091,1301,1089,991,1302],{"nctId":1304,"briefTitle":1305,"status":130,"phases":1696,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1075,"conditions":1697,"interventions":1698},[87],[1289],[1091,1089,1051,1013],{"nctId":1079,"briefTitle":1080,"status":348,"phases":1700,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":1701,"interventions":1702},[87],[1086],[57,1012,1014,1088,1089,1013,1090,1091,1092],{"nctId":1106,"briefTitle":1107,"status":130,"phases":1704,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1705,"interventions":1706},[87],[1113,1114,1115],[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],{"trials":1708,"activeCount":147,"soonestReadout":1073},[1709],{"nctId":1322,"briefTitle":1323,"status":130,"phases":1710,"primaryCompletion":1073,"completion":1325,"start":1326,"enrollment":1327,"conditions":1711,"interventions":1712},[88],[1010],[1089,1091,1012,1013,1014,1051,1120,1119],{"trials":1714,"activeCount":97},[],{"trials":1716,"activeCount":97},[],{"intervention":1090,"totalTrials":1335,"cells":1718},{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1727,"PHASE3":1752,"PHASE4":1792,"NA":1794},{"trials":1720,"activeCount":97},[],{"trials":1722,"activeCount":97},[1723],{"nctId":1439,"briefTitle":1440,"status":103,"phases":1724,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":1725,"interventions":1726},[86],[1037,1010,1446,1447,1448],[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],{"trials":1728,"activeCount":147,"soonestReadout":1082},[1729,1738,1748],{"nctId":1730,"briefTitle":1731,"status":103,"phases":1732,"primaryCompletion":1733,"completion":533,"start":597,"enrollment":1734,"conditions":1735,"interventions":1736},"NCT01472198","A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma",[87],"2013-10",250,[1037],[1737,1090],"Simtuzumab",{"nctId":1739,"briefTitle":1740,"status":653,"phases":1741,"primaryCompletion":239,"completion":239,"start":1742,"enrollment":1743,"conditions":1744,"interventions":1746},"NCT02953509","Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed\u002FRefractory B-cell Non-Hodgkin's Lymphoma",[86,87],"2016-11-21",178,[1745],"Non Hodgkin Lymphoma",[1049,1539,1090,1452,1747],"Allopurinol",{"nctId":1079,"briefTitle":1080,"status":348,"phases":1749,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":1750,"interventions":1751},[87],[1086],[57,1012,1014,1088,1089,1013,1090,1091,1092],{"trials":1753,"activeCount":332,"soonestReadout":974},[1754,1765,1769,1773,1777,1788],{"nctId":1755,"briefTitle":1756,"status":103,"phases":1757,"primaryCompletion":1758,"completion":1759,"start":1760,"enrollment":1761,"conditions":1762,"interventions":1763},"NCT02574455","Trial of Sacituzumab Govitecan in Participants With Refractory\u002FRelapsed Metastatic Triple-Negative Breast Cancer (TNBC)",[88],"2020-03-30","2020-12-08","2017-11-07",529,[1448],[1764,1146,1147,1090,1148],"Sacituzumab govitecan",{"nctId":1126,"briefTitle":1127,"status":130,"phases":1766,"primaryCompletion":1129,"completion":1129,"start":1130,"enrollment":1131,"conditions":1767,"interventions":1768},[88],[1036,1133],[57,1051,1135,1090,1013],{"nctId":1137,"briefTitle":1138,"status":103,"phases":1770,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":1771,"interventions":1772},[88],[1144],[57,1146,1147,1090,1148],{"nctId":1150,"briefTitle":1151,"status":130,"phases":1774,"primaryCompletion":974,"completion":974,"start":1153,"enrollment":1154,"conditions":1775,"interventions":1776},[88],[1144],[57,1157,1158,1090,1148],{"nctId":1778,"briefTitle":1779,"status":653,"phases":1780,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":1783,"conditions":1784,"interventions":1786},"NCT01956812","Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer",[88],"2016-11","2013-12",334,[1785,1037],"Metastatic Pancreatic Cancer",[1787,1090],"IMMU-107",{"nctId":1170,"briefTitle":1171,"status":130,"phases":1789,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1790,"interventions":1791},[88],[1036,1177],[57,1012,1051,1135,1090,1013],{"trials":1793,"activeCount":97},[],{"trials":1795,"activeCount":97},[],{"intervention":991,"totalTrials":1122,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1810,"PHASE3":1832,"PHASE4":1842,"NA":1844},{"trials":1799,"activeCount":97},[],{"trials":1801,"activeCount":147,"soonestReadout":984},[1802,1806],{"nctId":1241,"briefTitle":1242,"status":653,"phases":1803,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":487,"conditions":1804,"interventions":1805},[86],[1247],[1249,1089,1014,1013,1250,991],{"nctId":981,"briefTitle":982,"status":130,"phases":1807,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":1808,"interventions":1809},[86],[988],[990,991,992],{"trials":1811,"activeCount":993,"soonestReadout":1054},[1812,1816,1824,1828],{"nctId":1283,"briefTitle":1284,"status":653,"phases":1813,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1008,"conditions":1814,"interventions":1815},[87],[1289],[1049,1012,991,1291,1014,1013,1089],{"nctId":1817,"briefTitle":1818,"status":653,"phases":1819,"primaryCompletion":1820,"completion":1820,"start":1821,"enrollment":535,"conditions":1822,"interventions":1823},"NCT04827576","Study of Magrolimab in Patients With Solid Tumors",[87],"2024-10-01","2021-10-01",[1067],[1049,991],{"nctId":1293,"briefTitle":1294,"status":130,"phases":1825,"primaryCompletion":1054,"completion":1054,"start":1296,"enrollment":1297,"conditions":1826,"interventions":1827},[87],[1299],[1091,1301,1089,991,1302],{"nctId":1106,"briefTitle":1107,"status":130,"phases":1829,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1830,"interventions":1831},[87],[1113,1114,1115],[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],{"trials":1833,"activeCount":147,"soonestReadout":61},[1834,1838],{"nctId":59,"briefTitle":60,"status":130,"phases":1835,"primaryCompletion":61,"completion":1181,"start":1182,"enrollment":1183,"conditions":1836,"interventions":1837},[88],[1185],[57,991],{"nctId":1188,"briefTitle":1189,"status":103,"phases":1839,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1840,"interventions":1841},[88],[1195],[57,1051,991,1197],{"trials":1843,"activeCount":97},[],{"trials":1845,"activeCount":97},[],{"intervention":1014,"totalTrials":1219,"cells":1847},{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1866,"PHASE3":1884,"PHASE4":1890,"NA":1892},{"trials":1849,"activeCount":97},[],{"trials":1851,"activeCount":97},[1852,1856],{"nctId":1241,"briefTitle":1242,"status":653,"phases":1853,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":487,"conditions":1854,"interventions":1855},[86],[1247],[1249,1089,1014,1013,1250,991],{"nctId":1857,"briefTitle":1858,"status":653,"phases":1859,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":1862,"conditions":1863,"interventions":1864},"NCT02862535","Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma",[86],"2019-10-25","2016-09-20",36,[1023],[1450,1865,1014,1452,1121],"S-1",{"trials":1867,"activeCount":332,"soonestReadout":1006},[1868,1872,1876,1880],{"nctId":1283,"briefTitle":1284,"status":653,"phases":1869,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1008,"conditions":1870,"interventions":1871},[87],[1289],[1049,1012,991,1291,1014,1013,1089],{"nctId":1003,"briefTitle":1004,"status":130,"phases":1873,"primaryCompletion":1006,"completion":1006,"start":1007,"enrollment":1008,"conditions":1874,"interventions":1875},[87],[1010],[57,1012,1013,1014],{"nctId":1079,"briefTitle":1080,"status":348,"phases":1877,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":1878,"interventions":1879},[87],[1086],[57,1012,1014,1088,1089,1013,1090,1091,1092],{"nctId":1106,"briefTitle":1107,"status":130,"phases":1881,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1882,"interventions":1883},[87],[1113,1114,1115],[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],{"trials":1885,"activeCount":147,"soonestReadout":1073},[1886],{"nctId":1322,"briefTitle":1323,"status":130,"phases":1887,"primaryCompletion":1073,"completion":1325,"start":1326,"enrollment":1327,"conditions":1888,"interventions":1889},[88],[1010],[1089,1091,1012,1013,1014,1051,1120,1119],{"trials":1891,"activeCount":97},[],{"trials":1893,"activeCount":97},[],{"intervention":52,"totalTrials":1645,"cells":1895},{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1909,"PHASE3":1924,"PHASE4":1941,"NA":1943},{"trials":1897,"activeCount":97},[],{"trials":1899,"activeCount":97},[1900],{"nctId":1901,"briefTitle":1902,"status":103,"phases":1903,"primaryCompletion":1904,"completion":1905,"start":1906,"enrollment":22,"conditions":1907,"interventions":1908},"NCT04811040","Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection",[86],"2022-06-09","2023-10-26","2021-04-08",[21],[52,160,75,1364],{"trials":1910,"activeCount":147,"soonestReadout":466},[1911,1915],{"nctId":151,"briefTitle":152,"status":103,"phases":1912,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":1913,"interventions":1914},[87],[33],[52,47,160,126,161,93],{"nctId":1916,"briefTitle":1917,"status":348,"phases":1918,"primaryCompletion":466,"completion":1919,"start":1920,"enrollment":371,"conditions":1921,"interventions":1922},"NCT06749054","Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children",[87],"2027-09","2025-03-26",[33],[52,160,1923],"Optimized Background Regimen",{"trials":1925,"activeCount":332,"soonestReadout":51},[1926,1933,1937],{"nctId":49,"briefTitle":50,"status":130,"phases":1927,"primaryCompletion":51,"completion":1181,"start":1928,"enrollment":615,"conditions":1929,"interventions":1930},[87,88],"2019-11-21",[33],[52,1931,160,1932,1923],"Oral Lenacapavir Placebo","Failing ARV Regimen",{"nctId":68,"briefTitle":69,"status":130,"phases":1934,"primaryCompletion":70,"completion":416,"start":417,"enrollment":418,"conditions":1935,"interventions":1936},[88],[420],[52,422,47,255,423,424,425],{"nctId":77,"briefTitle":78,"status":130,"phases":1938,"primaryCompletion":79,"completion":441,"start":442,"enrollment":443,"conditions":1939,"interventions":1940},[88],[420],[52,255,446,425,423,47],{"trials":1942,"activeCount":97},[],{"trials":1944,"activeCount":97},[],{"intervention":255,"totalTrials":477,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1971,"NA":1973},{"trials":1948,"activeCount":97},[],{"trials":1950,"activeCount":97},[],{"trials":1952,"activeCount":97},[],{"trials":1954,"activeCount":332,"soonestReadout":46},[1955,1959,1963,1967],{"nctId":44,"briefTitle":45,"status":130,"phases":1956,"primaryCompletion":46,"completion":395,"start":396,"enrollment":397,"conditions":1957,"interventions":1958},[88],[399],[47,255,194,401],{"nctId":68,"briefTitle":69,"status":130,"phases":1960,"primaryCompletion":70,"completion":416,"start":417,"enrollment":418,"conditions":1961,"interventions":1962},[88],[420],[52,422,47,255,423,424,425],{"nctId":77,"briefTitle":78,"status":130,"phases":1964,"primaryCompletion":79,"completion":441,"start":442,"enrollment":443,"conditions":1965,"interventions":1966},[88],[420],[52,255,446,425,423,47],{"nctId":245,"briefTitle":246,"status":103,"phases":1968,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":1969,"interventions":1970},[88],[253],[93,172,255],{"trials":1972,"activeCount":97},[],{"trials":1974,"activeCount":97},[],{"intervention":160,"totalTrials":477,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1985,"PHASE3":1995,"PHASE4":2001,"NA":2003},{"trials":1978,"activeCount":97},[],{"trials":1980,"activeCount":97},[1981],{"nctId":1901,"briefTitle":1902,"status":103,"phases":1982,"primaryCompletion":1904,"completion":1905,"start":1906,"enrollment":22,"conditions":1983,"interventions":1984},[86],[21],[52,160,75,1364],{"trials":1986,"activeCount":147,"soonestReadout":466},[1987,1991],{"nctId":151,"briefTitle":152,"status":103,"phases":1988,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":1989,"interventions":1990},[87],[33],[52,47,160,126,161,93],{"nctId":1916,"briefTitle":1917,"status":348,"phases":1992,"primaryCompletion":466,"completion":1919,"start":1920,"enrollment":371,"conditions":1993,"interventions":1994},[87],[33],[52,160,1923],{"trials":1996,"activeCount":147,"soonestReadout":51},[1997],{"nctId":49,"briefTitle":50,"status":130,"phases":1998,"primaryCompletion":51,"completion":1181,"start":1928,"enrollment":615,"conditions":1999,"interventions":2000},[87,88],[33],[52,1931,160,1932,1923],{"trials":2002,"activeCount":97},[],{"trials":2004,"activeCount":97},[],{"intervention":1147,"totalTrials":477,"cells":2006},{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2013,"PHASE4":2031,"NA":2033},{"trials":2008,"activeCount":97},[],{"trials":2010,"activeCount":97},[],{"trials":2012,"activeCount":97},[],{"trials":2014,"activeCount":993,"soonestReadout":1163},[2015,2019,2023,2027],{"nctId":1755,"briefTitle":1756,"status":103,"phases":2016,"primaryCompletion":1758,"completion":1759,"start":1760,"enrollment":1761,"conditions":2017,"interventions":2018},[88],[1448],[1764,1146,1147,1090,1148],{"nctId":1137,"briefTitle":1138,"status":103,"phases":2020,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":2021,"interventions":2022},[88],[1144],[57,1146,1147,1090,1148],{"nctId":1160,"briefTitle":1161,"status":348,"phases":2024,"primaryCompletion":1163,"completion":1164,"start":1165,"enrollment":1166,"conditions":2025,"interventions":2026},[88],[1036],[1117,1012,1147],{"nctId":1209,"briefTitle":1210,"status":130,"phases":2028,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":1214,"conditions":2029,"interventions":2030},[88],[1216,1217],[57,1051,1120,1147],{"trials":2032,"activeCount":97},[],{"trials":2034,"activeCount":97},[],{"intervention":243,"totalTrials":477,"cells":2036},{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2058,"PHASE3":2060,"PHASE4":2070,"NA":2072},{"trials":2038,"activeCount":97},[],{"trials":2040,"activeCount":97},[2041,2049],{"nctId":2042,"briefTitle":2043,"status":103,"phases":2044,"primaryCompletion":826,"completion":2045,"start":2046,"enrollment":28,"conditions":2047,"interventions":2048},"NCT02275065","Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants",[86],"2015-01-29","2014-10-24",[21],[243],{"nctId":2050,"briefTitle":2051,"status":103,"phases":2052,"primaryCompletion":2053,"completion":2054,"start":2055,"enrollment":12,"conditions":2056,"interventions":2057},"NCT02400307","Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function",[86],"2015-07-06","2015-07-13","2015-04-17",[504],[243],{"trials":2059,"activeCount":97},[],{"trials":2061,"activeCount":993,"soonestReadout":1392},[2062,2066],{"nctId":234,"briefTitle":235,"status":130,"phases":2063,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":2064,"interventions":2065},[88],[33],[243,125,93],{"nctId":1389,"briefTitle":1390,"status":130,"phases":2067,"primaryCompletion":1392,"completion":1129,"start":1393,"enrollment":1394,"conditions":2068,"interventions":2069},[87,88],[33],[243,125,1397,1398],{"trials":2071,"activeCount":97},[],{"trials":2073,"activeCount":97},[],{"intervention":2075,"totalTrials":477,"cells":2076},"Seladelpar 10 mg",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2083,"PHASE4":2124,"NA":2126},{"trials":2078,"activeCount":97},[],{"trials":2080,"activeCount":97},[],{"trials":2082,"activeCount":97},[],{"trials":2084,"activeCount":993,"soonestReadout":2089},[2085,2095,2106,2116],{"nctId":2086,"briefTitle":2087,"status":130,"phases":2088,"primaryCompletion":2089,"completion":2089,"start":2090,"enrollment":2091,"conditions":2092,"interventions":2094},"NCT06060665","Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)",[88],"2026-06","2023-09-05",90,[2093],"Primary Biliary Cholangitis",[2075],{"nctId":2096,"briefTitle":2097,"status":103,"phases":2098,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":2101,"conditions":2102,"interventions":2103},"NCT03602560","ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)",[88],"2020-02-16","2018-10-01",265,[2093],[2104,2105],"seladelpar 5-10 mg","seladelpar 10 mg",{"nctId":2107,"briefTitle":2108,"status":130,"phases":2109,"primaryCompletion":1351,"completion":1274,"start":2110,"enrollment":2111,"conditions":2112,"interventions":2114},"NCT03301506","Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)",[88],"2017-12-12",340,[2113],"Primary Biliary Cirrhosis",[2115,2075],"Seladelpar 5 mg",{"nctId":2117,"briefTitle":2118,"status":103,"phases":2119,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":1008,"conditions":2122,"interventions":2123},"NCT04620733","RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)",[88],"2023-08-11","2021-04-21",[2093],[2075,2115],{"trials":2125,"activeCount":97},[],{"trials":2127,"activeCount":97},[],{"intervention":2129,"totalTrials":332,"cells":2130},"Sacituzumab Govitecan",{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2144,"PHASE3":2146,"PHASE4":2165,"NA":2167},{"trials":2132,"activeCount":97},[],{"trials":2134,"activeCount":147,"soonestReadout":1403},[2135],{"nctId":2136,"briefTitle":2137,"status":348,"phases":2138,"primaryCompletion":1403,"completion":1403,"start":2139,"enrollment":2140,"conditions":2141,"interventions":2142},"NCT06167317","Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors",[86],"2024-01-09",278,[1247],[2143,2129],"GS-0201",{"trials":2145,"activeCount":97},[],{"trials":2147,"activeCount":147,"soonestReadout":2156},[2148,2152],{"nctId":1755,"briefTitle":1756,"status":103,"phases":2149,"primaryCompletion":1758,"completion":1759,"start":1760,"enrollment":1761,"conditions":2150,"interventions":2151},[88],[1448],[1764,1146,1147,1090,1148],{"nctId":2153,"briefTitle":2154,"status":348,"phases":2155,"primaryCompletion":2156,"completion":2156,"start":2157,"enrollment":2158,"conditions":2159,"interventions":2161},"NCT06801834","Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer",[88],"2029-10","2025-04-04",695,[2160],"Extensive Stage Small Cell Lung Cancer (ES-SCLC)",[2129,2162,2163,2164],"Topotecan","Amrubicin","Lurbinectedin",{"trials":2166,"activeCount":97},[],{"trials":2168,"activeCount":97},[],{"intervention":1119,"totalTrials":332,"cells":2170},{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2179,"PHASE3":2185,"PHASE4":2191,"NA":2193},{"trials":2172,"activeCount":97},[],{"trials":2174,"activeCount":97},[2175],{"nctId":1439,"briefTitle":1440,"status":103,"phases":2176,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":2177,"interventions":2178},[86],[1037,1010,1446,1447,1448],[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],{"trials":2180,"activeCount":147,"soonestReadout":1109},[2181],{"nctId":1106,"briefTitle":1107,"status":130,"phases":2182,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":2183,"interventions":2184},[87],[1113,1114,1115],[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],{"trials":2186,"activeCount":147,"soonestReadout":1073},[2187],{"nctId":1322,"briefTitle":1323,"status":130,"phases":2188,"primaryCompletion":1073,"completion":1325,"start":1326,"enrollment":1327,"conditions":2189,"interventions":2190},[88],[1010],[1089,1091,1012,1013,1014,1051,1120,1119],{"trials":2192,"activeCount":97},[],{"trials":2194,"activeCount":97},[],{"intervention":1923,"totalTrials":993,"cells":2196},{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2201,"PHASE3":2207,"PHASE4":2213,"NA":2215},{"trials":2198,"activeCount":97},[],{"trials":2200,"activeCount":97},[],{"trials":2202,"activeCount":147,"soonestReadout":466},[2203],{"nctId":1916,"briefTitle":1917,"status":348,"phases":2204,"primaryCompletion":466,"completion":1919,"start":1920,"enrollment":371,"conditions":2205,"interventions":2206},[87],[33],[52,160,1923],{"trials":2208,"activeCount":147,"soonestReadout":51},[2209],{"nctId":49,"briefTitle":50,"status":130,"phases":2210,"primaryCompletion":51,"completion":1181,"start":1928,"enrollment":615,"conditions":2211,"interventions":2212},[87,88],[33],[52,1931,160,1932,1923],{"trials":2214,"activeCount":97},[],{"trials":2216,"activeCount":97},[],{"intervention":266,"totalTrials":993,"cells":2218},{"EARLY_PHASE1":2219,"PHASE1":2221,"PHASE2":2223,"PHASE3":2225,"PHASE4":2241,"NA":2243},{"trials":2220,"activeCount":97},[],{"trials":2222,"activeCount":97},[],{"trials":2224,"activeCount":97},[],{"trials":2226,"activeCount":993,"soonestReadout":260},[2227,2237],{"nctId":2228,"briefTitle":2229,"status":130,"phases":2230,"primaryCompletion":2231,"completion":261,"start":1043,"enrollment":2232,"conditions":2233,"interventions":2235},"NCT06630299","Study to Compare an Oral Weekly Islatravir\u002FLenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1",[88],"2026-04-23",600,[2234],"HIV-1-Infection",[266,2236],"Antiretroviral Combinations",{"nctId":257,"briefTitle":258,"status":130,"phases":2238,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":2239,"interventions":2240},[88],[33],[266,93,267,268],{"trials":2242,"activeCount":97},[],{"trials":2244,"activeCount":97},[],{"intervention":423,"totalTrials":993,"cells":2246},{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2253,"PHASE4":2263,"NA":2265},{"trials":2248,"activeCount":97},[],{"trials":2250,"activeCount":97},[],{"trials":2252,"activeCount":97},[],{"trials":2254,"activeCount":993,"soonestReadout":70},[2255,2259],{"nctId":68,"briefTitle":69,"status":130,"phases":2256,"primaryCompletion":70,"completion":416,"start":417,"enrollment":418,"conditions":2257,"interventions":2258},[88],[420],[52,422,47,255,423,424,425],{"nctId":77,"briefTitle":78,"status":130,"phases":2260,"primaryCompletion":79,"completion":441,"start":442,"enrollment":443,"conditions":2261,"interventions":2262},[88],[420],[52,255,446,425,423,47],{"trials":2264,"activeCount":97},[],{"trials":2266,"activeCount":97},[],{"intervention":425,"totalTrials":993,"cells":2268},{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2285,"NA":2287},{"trials":2270,"activeCount":97},[],{"trials":2272,"activeCount":97},[],{"trials":2274,"activeCount":97},[],{"trials":2276,"activeCount":993,"soonestReadout":70},[2277,2281],{"nctId":68,"briefTitle":69,"status":130,"phases":2278,"primaryCompletion":70,"completion":416,"start":417,"enrollment":418,"conditions":2279,"interventions":2280},[88],[420],[52,422,47,255,423,424,425],{"nctId":77,"briefTitle":78,"status":130,"phases":2282,"primaryCompletion":79,"completion":441,"start":442,"enrollment":443,"conditions":2283,"interventions":2284},[88],[420],[52,255,446,425,423,47],{"trials":2286,"activeCount":97},[],{"trials":2288,"activeCount":97},[],{"intervention":1397,"totalTrials":993,"cells":2290},{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2295,"PHASE3":2297,"PHASE4":2307,"NA":2309},{"trials":2292,"activeCount":97},[],{"trials":2294,"activeCount":97},[],{"trials":2296,"activeCount":97},[],{"trials":2298,"activeCount":993,"soonestReadout":1392},[2299,2303],{"nctId":1389,"briefTitle":1390,"status":130,"phases":2300,"primaryCompletion":1392,"completion":1129,"start":1393,"enrollment":1394,"conditions":2301,"interventions":2302},[87,88],[33],[243,125,1397,1398],{"nctId":1409,"briefTitle":1410,"status":348,"phases":2304,"primaryCompletion":1412,"completion":441,"start":1413,"enrollment":1414,"conditions":2305,"interventions":2306},[87,88],[33],[125,1397],{"trials":2308,"activeCount":97},[],{"trials":2310,"activeCount":97},[],{"intervention":42,"totalTrials":629,"cells":2312},{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2317,"PHASE3":2366,"PHASE4":2396,"NA":2407},{"trials":2314,"activeCount":97},[],{"trials":2316,"activeCount":97},[],{"trials":2318,"activeCount":97},[2319,2328,2336,2347,2357],{"nctId":2320,"briefTitle":2321,"status":103,"phases":2322,"primaryCompletion":2323,"completion":2323,"start":2324,"enrollment":25,"conditions":2325,"interventions":2326},"NCT00036634","A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients",[86,87],"2003-02","2002-03",[15],[42,2327],"Tenofovir alafenamide",{"nctId":2329,"briefTitle":2330,"status":103,"phases":2331,"primaryCompletion":1782,"completion":1782,"start":2332,"enrollment":25,"conditions":2333,"interventions":2335},"NCT01334567","Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan",[87],"2010-08",[2334],"Hepatitis B",[42],{"nctId":2337,"briefTitle":2338,"status":103,"phases":2339,"primaryCompletion":2340,"completion":2341,"start":2323,"enrollment":1075,"conditions":2342,"interventions":2344},"NCT00647946","Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue",[87],"2004-10","2006-02",[2343],"Lipodystrophy",[2345,2346],"tenofovir DF","abacavir 300mg twice daily",{"nctId":2348,"briefTitle":2349,"status":103,"phases":2350,"primaryCompletion":2351,"completion":2352,"start":2353,"enrollment":535,"conditions":2354,"interventions":2355},"NCT00307489","Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil",[87],"2008-01","2010-10","2006-03",[24],[2345,2356],"emtricitabine \u002Ftenofovir DF",{"nctId":2358,"briefTitle":2359,"status":103,"phases":2360,"primaryCompletion":2361,"completion":695,"start":2362,"enrollment":2363,"conditions":2364,"interventions":2365},"NCT00507507","A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)",[87],"2012-02","2007-09",126,[24],[42,783],{"trials":2367,"activeCount":147,"soonestReadout":41},[2368,2375,2384],{"nctId":39,"briefTitle":40,"status":130,"phases":2369,"primaryCompletion":41,"completion":2370,"start":2371,"enrollment":2091,"conditions":2372,"interventions":2373},[88],"2027-07","2012-12-06",[24],[42,2374],"TDF Placebo",{"nctId":2376,"briefTitle":2377,"status":103,"phases":2378,"primaryCompletion":2379,"completion":1782,"start":2380,"enrollment":2381,"conditions":2382,"interventions":2383},"NCT00352053","Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy",[88],"2008-09","2006-06",87,[15],[42],{"nctId":2385,"briefTitle":2386,"status":103,"phases":2387,"primaryCompletion":2388,"completion":2389,"start":2390,"enrollment":2391,"conditions":2392,"interventions":2393},"NCT00528957","Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children",[88],"2009-04-06","2017-08-16","2006-12-28",97,[15],[42,2394,2395],"Zidovudine","Stavudine",{"trials":2397,"activeCount":97},[2398],{"nctId":2399,"briefTitle":2400,"status":653,"phases":2401,"primaryCompletion":2402,"completion":2403,"start":2404,"enrollment":25,"conditions":2405,"interventions":2406},"NCT02479880","Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection",[89],"2018-02-28","2018-04-11","2015-07-03",[2334],[42],{"trials":2408,"activeCount":97},[],{"intervention":2374,"totalTrials":1335,"cells":2410},{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2431,"PHASE4":2517,"NA":2519},{"trials":2412,"activeCount":97},[],{"trials":2414,"activeCount":97},[],{"trials":2416,"activeCount":97},[2417],{"nctId":2418,"briefTitle":2419,"status":103,"phases":2420,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2423,"conditions":2424,"interventions":2425},"NCT00298363","Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)\u002FTDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.",[87],"2011-04","2006-04",112,[24],[2426,1356,2427,2428,2429,2430],"Tenofovir disoproxil fumarate","Entecavir","TDF placebo","FTC\u002FTDF placebo","ETV placebo",{"trials":2432,"activeCount":147,"soonestReadout":41},[2433,2445,2457,2464,2468,2477,2488,2499,2509],{"nctId":2434,"briefTitle":2435,"status":103,"phases":2436,"primaryCompletion":2437,"completion":2438,"start":2439,"enrollment":2440,"conditions":2441,"interventions":2442},"NCT00116805","A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B",[88],"2007-05","2016-01","2005-06",266,[24],[782,2443,2428,2444,232],"ADV","ADV placebo",{"nctId":2446,"briefTitle":2447,"status":103,"phases":2448,"primaryCompletion":2449,"completion":2450,"start":2451,"enrollment":2452,"conditions":2453,"interventions":2455},"NCT01940341","Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen",[88],"2015-09-30","2022-08-31","2013-09-12",426,[2454],"HBeAg-negative Chronic Hepatitis B",[126,782,2456,2374],"TAF Placebo",{"nctId":2458,"briefTitle":2459,"status":103,"phases":2460,"primaryCompletion":597,"completion":533,"start":2379,"enrollment":2461,"conditions":2462,"interventions":2463},"NCT00737568","Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine\u002FTenofovir DF in Subjects Resistant to Lamivudine",[88],280,[2334],[782,232,2374,413],{"nctId":39,"briefTitle":40,"status":130,"phases":2465,"primaryCompletion":41,"completion":2370,"start":2371,"enrollment":2091,"conditions":2466,"interventions":2467},[88],[24],[42,2374],{"nctId":2469,"briefTitle":2470,"status":103,"phases":2471,"primaryCompletion":2472,"completion":2438,"start":2473,"enrollment":2474,"conditions":2475,"interventions":2476},"NCT00117676","A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B",[88],"2007-04","2005-02",382,[24],[782,2443,2428,2444,232],{"nctId":2478,"briefTitle":2479,"status":103,"phases":2480,"primaryCompletion":2481,"completion":2482,"start":2483,"enrollment":2484,"conditions":2485,"interventions":2487},"NCT01940471","Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen",[88],"2015-11-16","2022-10-13","2013-09-11",875,[2486],"HBeAg-positive Chronic Hepatitis B",[126,782,2456,2374],{"nctId":2489,"briefTitle":2490,"status":103,"phases":2491,"primaryCompletion":2492,"completion":2493,"start":2494,"enrollment":2495,"conditions":2496,"interventions":2498},"NCT02836236","Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)",[88],"2017-04-05","2023-09-18","2015-06-19",155,[831,2497],"Chronic HBV Infection",[126,782,2456,2374],{"nctId":2500,"briefTitle":2501,"status":103,"phases":2502,"primaryCompletion":2503,"completion":2504,"start":2505,"enrollment":2506,"conditions":2507,"interventions":2508},"NCT02979613","Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed",[88],"2018-09-10","2020-01-30","2016-12-29",490,[24],[126,782,2456,2374],{"nctId":2510,"briefTitle":2511,"status":103,"phases":2512,"primaryCompletion":2513,"completion":2514,"start":2494,"enrollment":1379,"conditions":2515,"interventions":2516},"NCT02836249","Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)",[88],"2017-03-21","2023-08-31",[831,2497],[126,782,2456,2374],{"trials":2518,"activeCount":97},[],{"trials":2520,"activeCount":97},[],{"intervention":194,"totalTrials":1507,"cells":2522},{"EARLY_PHASE1":2523,"PHASE1":2525,"PHASE2":2527,"PHASE3":2529,"PHASE4":2551,"NA":2553},{"trials":2524,"activeCount":97},[],{"trials":2526,"activeCount":97},[],{"trials":2528,"activeCount":97},[],{"trials":2530,"activeCount":147,"soonestReadout":46},[2531,2535,2539,2543,2547],{"nctId":185,"briefTitle":186,"status":103,"phases":2532,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":2533,"interventions":2534},[88],[21],[172,47,93,174,194,195],{"nctId":44,"briefTitle":45,"status":130,"phases":2536,"primaryCompletion":46,"completion":395,"start":396,"enrollment":397,"conditions":2537,"interventions":2538},[88],[399],[47,255,194,401],{"nctId":403,"briefTitle":404,"status":103,"phases":2540,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":2541,"interventions":2542},[88],[21],[232,47,412,413,194],{"nctId":448,"briefTitle":449,"status":103,"phases":2544,"primaryCompletion":451,"completion":452,"start":453,"enrollment":214,"conditions":2545,"interventions":2546},[88],[21],[47,311,456,194,437],{"nctId":280,"briefTitle":281,"status":103,"phases":2548,"primaryCompletion":283,"completion":284,"start":285,"enrollment":214,"conditions":2549,"interventions":2550},[88],[33],[93,47,172,174,194,195],{"trials":2552,"activeCount":97},[],{"trials":2554,"activeCount":97},[],{"intervention":2556,"totalTrials":1507,"cells":2557},"Seladelpar",{"EARLY_PHASE1":2558,"PHASE1":2560,"PHASE2":2583,"PHASE3":2604,"PHASE4":2614,"NA":2616},{"trials":2559,"activeCount":97},[],{"trials":2561,"activeCount":97},[2562,2572],{"nctId":2563,"briefTitle":2564,"status":103,"phases":2565,"primaryCompletion":2566,"completion":2566,"start":2567,"enrollment":22,"conditions":2568,"interventions":2570},"NCT03369002","Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects",[86],"2018-05-15","2017-11-27",[2569],"Hepatic Impairment",[2571],"seladelpar",{"nctId":2573,"briefTitle":2574,"status":103,"phases":2575,"primaryCompletion":2576,"completion":2577,"start":2578,"enrollment":2579,"conditions":2580,"interventions":2582},"NCT04950764","An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)",[86],"2025-02-24","2025-02-27","2021-11-16",24,[2093,2581,2569],"Compensated Cirrhosis",[2556],{"trials":2584,"activeCount":97},[2585,2594],{"nctId":2586,"briefTitle":2587,"status":653,"phases":2588,"primaryCompletion":2589,"completion":2589,"start":2590,"enrollment":147,"conditions":2591,"interventions":2593},"NCT04024813","A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC",[87],"2020-01-09","2019-11-12",[2592],"Primary Sclerosing Cholangitis",[2556],{"nctId":2595,"briefTitle":2596,"status":653,"phases":2597,"primaryCompletion":1141,"completion":2598,"start":2599,"enrollment":1379,"conditions":2600,"interventions":2602},"NCT03551522","A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)",[87],"2020-08-10","2018-04-30",[2601],"NASH - Nonalcoholic Steatohepatitis",[2556,2603],"Placebos",{"trials":2605,"activeCount":147,"soonestReadout":261},[2606],{"nctId":2607,"briefTitle":2608,"status":348,"phases":2609,"primaryCompletion":261,"completion":261,"start":2610,"enrollment":2611,"conditions":2612,"interventions":2613},"NCT06051617","Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis",[88],"2023-09-07",318,[2093],[2556],{"trials":2615,"activeCount":97},[],{"trials":2617,"activeCount":97},[],{"intervention":1148,"totalTrials":332,"cells":2619},{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2626,"PHASE4":2640,"NA":2642},{"trials":2621,"activeCount":97},[],{"trials":2623,"activeCount":97},[],{"trials":2625,"activeCount":97},[],{"trials":2627,"activeCount":147,"soonestReadout":974},[2628,2632,2636],{"nctId":1755,"briefTitle":1756,"status":103,"phases":2629,"primaryCompletion":1758,"completion":1759,"start":1760,"enrollment":1761,"conditions":2630,"interventions":2631},[88],[1448],[1764,1146,1147,1090,1148],{"nctId":1137,"briefTitle":1138,"status":103,"phases":2633,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":2634,"interventions":2635},[88],[1144],[57,1146,1147,1090,1148],{"nctId":1150,"briefTitle":1151,"status":130,"phases":2637,"primaryCompletion":974,"completion":974,"start":1153,"enrollment":1154,"conditions":2638,"interventions":2639},[88],[1144],[57,1157,1158,1090,1148],{"trials":2641,"activeCount":97},[],{"trials":2643,"activeCount":97},[],{"intervention":2115,"totalTrials":993,"cells":2645},{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2650,"PHASE3":2652,"PHASE4":2662,"NA":2664},{"trials":2647,"activeCount":97},[],{"trials":2649,"activeCount":97},[],{"trials":2651,"activeCount":97},[],{"trials":2653,"activeCount":147,"soonestReadout":1351},[2654,2658],{"nctId":2107,"briefTitle":2108,"status":130,"phases":2655,"primaryCompletion":1351,"completion":1274,"start":2110,"enrollment":2111,"conditions":2656,"interventions":2657},[88],[2113],[2115,2075],{"nctId":2117,"briefTitle":2118,"status":103,"phases":2659,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":1008,"conditions":2660,"interventions":2661},[88],[2093],[2075,2115],{"trials":2663,"activeCount":97},[],{"trials":2665,"activeCount":97},[],{"intervention":2667,"totalTrials":993,"cells":2668},"lepetegravir",{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2673,"PHASE3":2675,"PHASE4":2700,"NA":2702},{"trials":2670,"activeCount":97},[],{"trials":2672,"activeCount":97},[],{"trials":2674,"activeCount":97},[],{"trials":2676,"activeCount":147,"soonestReadout":416},[2677,2689],{"nctId":2678,"briefTitle":2679,"status":653,"phases":2680,"primaryCompletion":2681,"completion":2681,"start":2682,"enrollment":2683,"conditions":2684,"interventions":2685},"NCT06613685","Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated",[87,88],"2026-03-16","2024-10-21",73,[33],[2667,2686,2687,2688],"lenacapavir pacfosacil","Bictegravir\u002Femtricitabine\u002Ftenofovir alafenamide","lepetegravir\u002Flenacapavir pacfosacil FDC",{"nctId":2690,"briefTitle":2691,"status":130,"phases":2692,"primaryCompletion":416,"completion":1202,"start":2693,"enrollment":2694,"conditions":2695,"interventions":2696},"NCT06544733","Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed",[87,88],"2024-08-20",675,[2234],[2697,2698,2687,2699],"Lepetegravir","Lenacapavir pacfosacil","Lepetegravir\u002FLenacapavir pacfosacil FDC",{"trials":2701,"activeCount":97},[],{"trials":2703,"activeCount":97},[],{"intervention":2686,"totalTrials":993,"cells":2705},{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2712,"PHASE4":2722,"NA":2724},{"trials":2707,"activeCount":97},[],{"trials":2709,"activeCount":97},[],{"trials":2711,"activeCount":97},[],{"trials":2713,"activeCount":147,"soonestReadout":416},[2714,2718],{"nctId":2678,"briefTitle":2679,"status":653,"phases":2715,"primaryCompletion":2681,"completion":2681,"start":2682,"enrollment":2683,"conditions":2716,"interventions":2717},[87,88],[33],[2667,2686,2687,2688],{"nctId":2690,"briefTitle":2691,"status":130,"phases":2719,"primaryCompletion":416,"completion":1202,"start":2693,"enrollment":2694,"conditions":2720,"interventions":2721},[87,88],[2234],[2697,2698,2687,2699],{"trials":2723,"activeCount":97},[],{"trials":2725,"activeCount":97},[],{"intervention":2687,"totalTrials":993,"cells":2727},{"EARLY_PHASE1":2728,"PHASE1":2730,"PHASE2":2732,"PHASE3":2734,"PHASE4":2744,"NA":2746},{"trials":2729,"activeCount":97},[],{"trials":2731,"activeCount":97},[],{"trials":2733,"activeCount":97},[],{"trials":2735,"activeCount":147,"soonestReadout":416},[2736,2740],{"nctId":2678,"briefTitle":2679,"status":653,"phases":2737,"primaryCompletion":2681,"completion":2681,"start":2682,"enrollment":2683,"conditions":2738,"interventions":2739},[87,88],[33],[2667,2686,2687,2688],{"nctId":2690,"briefTitle":2691,"status":130,"phases":2741,"primaryCompletion":416,"completion":1202,"start":2693,"enrollment":2694,"conditions":2742,"interventions":2743},[87,88],[2234],[2697,2698,2687,2699],{"trials":2745,"activeCount":97},[],{"trials":2747,"activeCount":97},[],{"intervention":2688,"totalTrials":993,"cells":2749},{"EARLY_PHASE1":2750,"PHASE1":2752,"PHASE2":2754,"PHASE3":2756,"PHASE4":2766,"NA":2768},{"trials":2751,"activeCount":97},[],{"trials":2753,"activeCount":97},[],{"trials":2755,"activeCount":97},[],{"trials":2757,"activeCount":147,"soonestReadout":416},[2758,2762],{"nctId":2678,"briefTitle":2679,"status":653,"phases":2759,"primaryCompletion":2681,"completion":2681,"start":2682,"enrollment":2683,"conditions":2760,"interventions":2761},[87,88],[33],[2667,2686,2687,2688],{"nctId":2690,"briefTitle":2691,"status":130,"phases":2763,"primaryCompletion":416,"completion":1202,"start":2693,"enrollment":2694,"conditions":2764,"interventions":2765},[87,88],[2234],[2697,2698,2687,2699],{"trials":2767,"activeCount":97},[],{"trials":2769,"activeCount":97},[],{"intervention":401,"totalTrials":147,"cells":2771},{"EARLY_PHASE1":2772,"PHASE1":2774,"PHASE2":2776,"PHASE3":2778,"PHASE4":2784,"NA":2786},{"trials":2773,"activeCount":97},[],{"trials":2775,"activeCount":97},[],{"trials":2777,"activeCount":97},[],{"trials":2779,"activeCount":147,"soonestReadout":46},[2780],{"nctId":44,"briefTitle":45,"status":130,"phases":2781,"primaryCompletion":46,"completion":395,"start":396,"enrollment":397,"conditions":2782,"interventions":2783},[88],[399],[47,255,194,401],{"trials":2785,"activeCount":97},[],{"trials":2787,"activeCount":97},[],{"intervention":2236,"totalTrials":147,"cells":2789},{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2794,"PHASE3":2796,"PHASE4":2802,"NA":2804},{"trials":2791,"activeCount":97},[],{"trials":2793,"activeCount":97},[],{"trials":2795,"activeCount":97},[],{"trials":2797,"activeCount":147,"soonestReadout":2231},[2798],{"nctId":2228,"briefTitle":2229,"status":130,"phases":2799,"primaryCompletion":2231,"completion":261,"start":1043,"enrollment":2232,"conditions":2800,"interventions":2801},[88],[2234],[266,2236],{"trials":2803,"activeCount":97},[],{"trials":2805,"activeCount":97},[],{"intervention":1157,"totalTrials":147,"cells":2807},{"EARLY_PHASE1":2808,"PHASE1":2810,"PHASE2":2812,"PHASE3":2814,"PHASE4":2820,"NA":2822},{"trials":2809,"activeCount":97},[],{"trials":2811,"activeCount":97},[],{"trials":2813,"activeCount":97},[],{"trials":2815,"activeCount":147,"soonestReadout":974},[2816],{"nctId":1150,"briefTitle":1151,"status":130,"phases":2817,"primaryCompletion":974,"completion":974,"start":1153,"enrollment":1154,"conditions":2818,"interventions":2819},[88],[1144],[57,1157,1158,1090,1148],{"trials":2821,"activeCount":97},[],{"trials":2823,"activeCount":97},[],{"intervention":1158,"totalTrials":147,"cells":2825},{"EARLY_PHASE1":2826,"PHASE1":2828,"PHASE2":2830,"PHASE3":2832,"PHASE4":2838,"NA":2840},{"trials":2827,"activeCount":97},[],{"trials":2829,"activeCount":97},[],{"trials":2831,"activeCount":97},[],{"trials":2833,"activeCount":147,"soonestReadout":974},[2834],{"nctId":1150,"briefTitle":1151,"status":130,"phases":2835,"primaryCompletion":974,"completion":974,"start":1153,"enrollment":1154,"conditions":2836,"interventions":2837},[88],[1144],[57,1157,1158,1090,1148],{"trials":2839,"activeCount":97},[],{"trials":2841,"activeCount":97},[],{"intervention":1931,"totalTrials":147,"cells":2843},{"EARLY_PHASE1":2844,"PHASE1":2846,"PHASE2":2848,"PHASE3":2850,"PHASE4":2856,"NA":2858},{"trials":2845,"activeCount":97},[],{"trials":2847,"activeCount":97},[],{"trials":2849,"activeCount":97},[],{"trials":2851,"activeCount":147,"soonestReadout":51},[2852],{"nctId":49,"briefTitle":50,"status":130,"phases":2853,"primaryCompletion":51,"completion":1181,"start":1928,"enrollment":615,"conditions":2854,"interventions":2855},[87,88],[33],[52,1931,160,1932,1923],{"trials":2857,"activeCount":97},[],{"trials":2859,"activeCount":97},[],{"intervention":1932,"totalTrials":147,"cells":2861},{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2866,"PHASE3":2868,"PHASE4":2874,"NA":2876},{"trials":2863,"activeCount":97},[],{"trials":2865,"activeCount":97},[],{"trials":2867,"activeCount":97},[],{"trials":2869,"activeCount":147,"soonestReadout":51},[2870],{"nctId":49,"briefTitle":50,"status":130,"phases":2871,"primaryCompletion":51,"completion":1181,"start":1928,"enrollment":615,"conditions":2872,"interventions":2873},[87,88],[33],[52,1931,160,1932,1923],{"trials":2875,"activeCount":97},[],{"trials":2877,"activeCount":97},[],{"intervention":422,"totalTrials":147,"cells":2879},{"EARLY_PHASE1":2880,"PHASE1":2882,"PHASE2":2884,"PHASE3":2886,"PHASE4":2892,"NA":2894},{"trials":2881,"activeCount":97},[],{"trials":2883,"activeCount":97},[],{"trials":2885,"activeCount":97},[],{"trials":2887,"activeCount":147,"soonestReadout":70},[2888],{"nctId":68,"briefTitle":69,"status":130,"phases":2889,"primaryCompletion":70,"completion":416,"start":417,"enrollment":418,"conditions":2890,"interventions":2891},[88],[420],[52,422,47,255,423,424,425],{"trials":2893,"activeCount":97},[],{"trials":2895,"activeCount":97},[],{"intervention":424,"totalTrials":147,"cells":2897},{"EARLY_PHASE1":2898,"PHASE1":2900,"PHASE2":2902,"PHASE3":2904,"PHASE4":2910,"NA":2912},{"trials":2899,"activeCount":97},[],{"trials":2901,"activeCount":97},[],{"trials":2903,"activeCount":97},[],{"trials":2905,"activeCount":147,"soonestReadout":70},[2906],{"nctId":68,"briefTitle":69,"status":130,"phases":2907,"primaryCompletion":70,"completion":416,"start":417,"enrollment":418,"conditions":2908,"interventions":2909},[88],[420],[52,422,47,255,423,424,425],{"trials":2911,"activeCount":97},[],{"trials":2913,"activeCount":97},[],{"intervention":446,"totalTrials":147,"cells":2915},{"EARLY_PHASE1":2916,"PHASE1":2918,"PHASE2":2920,"PHASE3":2922,"PHASE4":2928,"NA":2930},{"trials":2917,"activeCount":97},[],{"trials":2919,"activeCount":97},[],{"trials":2921,"activeCount":97},[],{"trials":2923,"activeCount":147,"soonestReadout":79},[2924],{"nctId":77,"briefTitle":78,"status":130,"phases":2925,"primaryCompletion":79,"completion":441,"start":442,"enrollment":443,"conditions":2926,"interventions":2927},[88],[420],[52,255,446,425,423,47],{"trials":2929,"activeCount":97},[],{"trials":2931,"activeCount":97},[],{"intervention":267,"totalTrials":147,"cells":2933},{"EARLY_PHASE1":2934,"PHASE1":2936,"PHASE2":2938,"PHASE3":2940,"PHASE4":2946,"NA":2948},{"trials":2935,"activeCount":97},[],{"trials":2937,"activeCount":97},[],{"trials":2939,"activeCount":97},[],{"trials":2941,"activeCount":147,"soonestReadout":260},[2942],{"nctId":257,"briefTitle":258,"status":130,"phases":2943,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":2944,"interventions":2945},[88],[33],[266,93,267,268],{"trials":2947,"activeCount":97},[],{"trials":2949,"activeCount":97},[],{"intervention":268,"totalTrials":147,"cells":2951},{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2956,"PHASE3":2958,"PHASE4":2964,"NA":2966},{"trials":2953,"activeCount":97},[],{"trials":2955,"activeCount":97},[],{"trials":2957,"activeCount":97},[],{"trials":2959,"activeCount":147,"soonestReadout":260},[2960],{"nctId":257,"briefTitle":258,"status":130,"phases":2961,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":2962,"interventions":2963},[88],[33],[266,93,267,268],{"trials":2965,"activeCount":97},[],{"trials":2967,"activeCount":97},[],{"intervention":1398,"totalTrials":147,"cells":2969},{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2974,"PHASE3":2976,"PHASE4":2982,"NA":2984},{"trials":2971,"activeCount":97},[],{"trials":2973,"activeCount":97},[],{"trials":2975,"activeCount":97},[],{"trials":2977,"activeCount":147,"soonestReadout":1392},[2978],{"nctId":1389,"briefTitle":1390,"status":130,"phases":2979,"primaryCompletion":1392,"completion":1129,"start":1393,"enrollment":1394,"conditions":2980,"interventions":2981},[87,88],[33],[243,125,1397,1398],{"trials":2983,"activeCount":97},[],{"trials":2985,"activeCount":97},[],{"intervention":472,"totalTrials":147,"cells":2987},{"EARLY_PHASE1":2988,"PHASE1":2990,"PHASE2":2992,"PHASE3":2994,"PHASE4":3000,"NA":3002},{"trials":2989,"activeCount":97},[],{"trials":2991,"activeCount":97},[],{"trials":2993,"activeCount":97},[],{"trials":2995,"activeCount":147,"soonestReadout":465},[2996],{"nctId":462,"briefTitle":463,"status":130,"phases":2997,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":2998,"interventions":2999},[87,88],[470,15],[230,307,355,472,47,473,474,475,476],{"trials":3001,"activeCount":97},[],{"trials":3003,"activeCount":97},[],{"intervention":473,"totalTrials":147,"cells":3005},{"EARLY_PHASE1":3006,"PHASE1":3008,"PHASE2":3010,"PHASE3":3012,"PHASE4":3018,"NA":3020},{"trials":3007,"activeCount":97},[],{"trials":3009,"activeCount":97},[],{"trials":3011,"activeCount":97},[],{"trials":3013,"activeCount":147,"soonestReadout":465},[3014],{"nctId":462,"briefTitle":463,"status":130,"phases":3015,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":3016,"interventions":3017},[87,88],[470,15],[230,307,355,472,47,473,474,475,476],{"trials":3019,"activeCount":97},[],{"trials":3021,"activeCount":97},[],{"intervention":474,"totalTrials":147,"cells":3023},{"EARLY_PHASE1":3024,"PHASE1":3026,"PHASE2":3028,"PHASE3":3030,"PHASE4":3036,"NA":3038},{"trials":3025,"activeCount":97},[],{"trials":3027,"activeCount":97},[],{"trials":3029,"activeCount":97},[],{"trials":3031,"activeCount":147,"soonestReadout":465},[3032],{"nctId":462,"briefTitle":463,"status":130,"phases":3033,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":3034,"interventions":3035},[87,88],[470,15],[230,307,355,472,47,473,474,475,476],{"trials":3037,"activeCount":97},[],{"trials":3039,"activeCount":97},[],{"intervention":475,"totalTrials":147,"cells":3041},{"EARLY_PHASE1":3042,"PHASE1":3044,"PHASE2":3046,"PHASE3":3048,"PHASE4":3054,"NA":3056},{"trials":3043,"activeCount":97},[],{"trials":3045,"activeCount":97},[],{"trials":3047,"activeCount":97},[],{"trials":3049,"activeCount":147,"soonestReadout":465},[3050],{"nctId":462,"briefTitle":463,"status":130,"phases":3051,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":3052,"interventions":3053},[87,88],[470,15],[230,307,355,472,47,473,474,475,476],{"trials":3055,"activeCount":97},[],{"trials":3057,"activeCount":97},[],{"intervention":476,"totalTrials":147,"cells":3059},{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3064,"PHASE3":3066,"PHASE4":3072,"NA":3074},{"trials":3061,"activeCount":97},[],{"trials":3063,"activeCount":97},[],{"trials":3065,"activeCount":97},[],{"trials":3067,"activeCount":147,"soonestReadout":465},[3068],{"nctId":462,"briefTitle":463,"status":130,"phases":3069,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":3070,"interventions":3071},[87,88],[470,15],[230,307,355,472,47,473,474,475,476],{"trials":3073,"activeCount":97},[],{"trials":3075,"activeCount":97},[],{"intervention":1207,"totalTrials":147,"cells":3077},{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3084,"PHASE4":3090,"NA":3092},{"trials":3079,"activeCount":97},[],{"trials":3081,"activeCount":97},[],{"trials":3083,"activeCount":97},[],{"trials":3085,"activeCount":147,"soonestReadout":1202},[3086],{"nctId":1199,"briefTitle":1200,"status":130,"phases":3087,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":3088,"interventions":3089},[88],[1034],[1117,1207,1051],{"trials":3091,"activeCount":97},[],{"trials":3093,"activeCount":97},[],{"intervention":2162,"totalTrials":147,"cells":3095},{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3100,"PHASE3":3102,"PHASE4":3108,"NA":3110},{"trials":3097,"activeCount":97},[],{"trials":3099,"activeCount":97},[],{"trials":3101,"activeCount":97},[],{"trials":3103,"activeCount":147,"soonestReadout":2156},[3104],{"nctId":2153,"briefTitle":2154,"status":348,"phases":3105,"primaryCompletion":2156,"completion":2156,"start":2157,"enrollment":2158,"conditions":3106,"interventions":3107},[88],[2160],[2129,2162,2163,2164],{"trials":3109,"activeCount":97},[],{"trials":3111,"activeCount":97},[],{"intervention":2163,"totalTrials":147,"cells":3113},{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3120,"PHASE4":3126,"NA":3128},{"trials":3115,"activeCount":97},[],{"trials":3117,"activeCount":97},[],{"trials":3119,"activeCount":97},[],{"trials":3121,"activeCount":147,"soonestReadout":2156},[3122],{"nctId":2153,"briefTitle":2154,"status":348,"phases":3123,"primaryCompletion":2156,"completion":2156,"start":2157,"enrollment":2158,"conditions":3124,"interventions":3125},[88],[2160],[2129,2162,2163,2164],{"trials":3127,"activeCount":97},[],{"trials":3129,"activeCount":97},[],{"intervention":2164,"totalTrials":147,"cells":3131},{"EARLY_PHASE1":3132,"PHASE1":3134,"PHASE2":3136,"PHASE3":3138,"PHASE4":3144,"NA":3146},{"trials":3133,"activeCount":97},[],{"trials":3135,"activeCount":97},[],{"trials":3137,"activeCount":97},[],{"trials":3139,"activeCount":147,"soonestReadout":2156},[3140],{"nctId":2153,"briefTitle":2154,"status":348,"phases":3141,"primaryCompletion":2156,"completion":2156,"start":2157,"enrollment":2158,"conditions":3142,"interventions":3143},[88],[2160],[2129,2162,2163,2164],{"trials":3145,"activeCount":97},[],{"trials":3147,"activeCount":97},[],{"intervention":1356,"totalTrials":1507,"cells":3149},{"EARLY_PHASE1":3150,"PHASE1":3152,"PHASE2":3154,"PHASE3":3172,"PHASE4":3174,"NA":3176},{"trials":3151,"activeCount":97},[],{"trials":3153,"activeCount":97},[],{"trials":3155,"activeCount":332,"soonestReadout":1097},[3156,3160,3164,3168],{"nctId":1348,"briefTitle":1349,"status":130,"phases":3157,"primaryCompletion":1097,"completion":1351,"start":1352,"enrollment":1353,"conditions":3158,"interventions":3159},[87],[420],[125,125,1356],{"nctId":2418,"briefTitle":2419,"status":103,"phases":3161,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2423,"conditions":3162,"interventions":3163},[87],[24],[2426,1356,2427,2428,2429,2430],{"nctId":1367,"briefTitle":1368,"status":130,"phases":3165,"primaryCompletion":395,"completion":416,"start":1370,"enrollment":1371,"conditions":3166,"interventions":3167},[87],[420],[125,125,1374],{"nctId":1376,"briefTitle":1377,"status":130,"phases":3169,"primaryCompletion":416,"completion":416,"start":341,"enrollment":1379,"conditions":3170,"interventions":3171},[87],[420],[125,125,1356],{"trials":3173,"activeCount":97},[],{"trials":3175,"activeCount":97},[],{"trials":3177,"activeCount":147,"soonestReadout":1212},[3178],{"nctId":1422,"briefTitle":1423,"status":348,"phases":3179,"primaryCompletion":1212,"completion":1425,"start":1426,"enrollment":1427,"conditions":3180,"interventions":3181},[],[15],[125,1356,1430,1431,125],{"intervention":1121,"totalTrials":1645,"cells":3183},{"EARLY_PHASE1":3184,"PHASE1":3186,"PHASE2":3192,"PHASE3":3237,"PHASE4":3239,"NA":3241},{"trials":3185,"activeCount":97},[],{"trials":3187,"activeCount":97},[3188],{"nctId":1857,"briefTitle":1858,"status":653,"phases":3189,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":1862,"conditions":3190,"interventions":3191},[86],[1023],[1450,1865,1014,1452,1121],{"trials":3193,"activeCount":332,"soonestReadout":1274},[3194,3205,3216,3229,3233],{"nctId":3195,"briefTitle":3196,"status":3197,"phases":3198,"primaryCompletion":1274,"completion":1274,"start":3199,"enrollment":3200,"conditions":3201,"interventions":3203},"NCT07527858","Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","NOT_YET_RECRUITING",[87],"2026-04",170,[3202],"Advanced Microsatellite Stable Colorectal Cancer",[1279,1121,1453,3204],"Trifluridine-Tipiracil",{"nctId":3206,"briefTitle":3207,"status":103,"phases":3208,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":3213,"interventions":3215},"NCT02864381","Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma",[87],"2017-11-08","2019-08-23","2016-09-01",144,[1023,3214],"Gastroesophageal Junction Adenocarcinoma",[1450,1121],{"nctId":3217,"briefTitle":3218,"status":103,"phases":3219,"primaryCompletion":3220,"completion":3221,"start":3222,"enrollment":3223,"conditions":3224,"interventions":3225},"NCT04891770","Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)",[87],"2024-01-23","2024-07-19","2021-08-14",103,[24],[3226,3227,1121,3228],"Tenofovir Alafenamide","VIR-2218","Selgantolimod",{"nctId":1466,"briefTitle":1467,"status":348,"phases":3230,"primaryCompletion":1469,"completion":1469,"start":1097,"enrollment":1470,"conditions":3231,"interventions":3232},[87],[1472,1473,1474,1023],[1279,1121,1476,1051],{"nctId":1106,"briefTitle":1107,"status":130,"phases":3234,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":3235,"interventions":3236},[87],[1113,1114,1115],[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],{"trials":3238,"activeCount":97},[],{"trials":3240,"activeCount":97},[],{"trials":3242,"activeCount":97},[],{"intervention":1279,"totalTrials":332,"cells":3244},{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3253,"PHASE3":3263,"PHASE4":3265,"NA":3267},{"trials":3246,"activeCount":97},[],{"trials":3248,"activeCount":147,"soonestReadout":1274},[3249],{"nctId":1271,"briefTitle":1272,"status":348,"phases":3250,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1276,"conditions":3251,"interventions":3252},[86],[1101],[1279,1089],{"trials":3254,"activeCount":993,"soonestReadout":1274},[3255,3259],{"nctId":3195,"briefTitle":3196,"status":3197,"phases":3256,"primaryCompletion":1274,"completion":1274,"start":3199,"enrollment":3200,"conditions":3257,"interventions":3258},[87],[3202],[1279,1121,1453,3204],{"nctId":1466,"briefTitle":1467,"status":348,"phases":3260,"primaryCompletion":1469,"completion":1469,"start":1097,"enrollment":1470,"conditions":3261,"interventions":3262},[87],[1472,1473,1474,1023],[1279,1121,1476,1051],{"trials":3264,"activeCount":97},[],{"trials":3266,"activeCount":97},[],{"trials":3268,"activeCount":97},[],{"intervention":126,"totalTrials":3270,"cells":3271},15,{"EARLY_PHASE1":3272,"PHASE1":3274,"PHASE2":3288,"PHASE3":3344,"PHASE4":3370,"NA":3372},{"trials":3273,"activeCount":97},[],{"trials":3275,"activeCount":97},[3276,3284],{"nctId":3277,"briefTitle":3278,"status":103,"phases":3279,"primaryCompletion":2055,"completion":2055,"start":3280,"enrollment":34,"conditions":3281,"interventions":3283},"NCT02296853","Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment",[86],"2014-12-22",[3282],"Hepatitis B Virus",[126],{"nctId":116,"briefTitle":117,"status":103,"phases":3285,"primaryCompletion":119,"completion":120,"start":121,"enrollment":122,"conditions":3286,"interventions":3287},[86],[21],[125,93,126],{"trials":3289,"activeCount":147,"soonestReadout":1006},[3290,3294,3303,3313,3323,3329,3340],{"nctId":151,"briefTitle":152,"status":103,"phases":3291,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":3292,"interventions":3293},[87],[33],[52,47,160,126,161,93],{"nctId":3295,"briefTitle":3296,"status":103,"phases":3297,"primaryCompletion":3298,"completion":3299,"start":202,"enrollment":3300,"conditions":3301,"interventions":3302},"NCT03615066","Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment",[87],"2019-12-12","2021-04-12",67,[24],[3228,126],{"nctId":3304,"briefTitle":3305,"status":653,"phases":3306,"primaryCompletion":3307,"completion":3308,"start":2402,"enrollment":3309,"conditions":3310,"interventions":3311},"NCT03434353","Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)",[87],"2020-01-20","2021-01-26",123,[24],[3312,126],"Inarigivir Soproxil",{"nctId":3314,"briefTitle":3315,"status":103,"phases":3316,"primaryCompletion":3317,"completion":3318,"start":3319,"enrollment":3320,"conditions":3321,"interventions":3322},"NCT03180619","Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and\u002For Other Oral Antiviral Treatment (OAV)",[87],"2019-03-27","2020-09-04","2017-06-29",124,[24],[126],{"nctId":3324,"briefTitle":3325,"status":348,"phases":3326,"primaryCompletion":1006,"completion":2156,"start":1781,"enrollment":792,"conditions":3327,"interventions":3328},"NCT02932150","Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection",[87],[24],[126],{"nctId":3330,"briefTitle":3331,"status":103,"phases":3332,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":3336,"conditions":3337,"interventions":3338},"NCT02862548","Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant",[87],"2018-02-08","2021-05-05","2016-09-16",51,[24],[126,782,3339],"Other approved antivirals",{"nctId":651,"briefTitle":652,"status":653,"phases":3341,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":3342,"interventions":3343},[87],[33],[660,161,126,661,307,231],{"trials":3345,"activeCount":97},[3346,3350,3354,3358,3362,3366],{"nctId":2446,"briefTitle":2447,"status":103,"phases":3347,"primaryCompletion":2449,"completion":2450,"start":2451,"enrollment":2452,"conditions":3348,"interventions":3349},[88],[2454],[126,782,2456,2374],{"nctId":570,"briefTitle":571,"status":103,"phases":3351,"primaryCompletion":573,"completion":574,"start":575,"enrollment":319,"conditions":3352,"interventions":3353},[88],[504,15,537],[126,228,578,230],{"nctId":2478,"briefTitle":2479,"status":103,"phases":3355,"primaryCompletion":2481,"completion":2482,"start":2483,"enrollment":2484,"conditions":3356,"interventions":3357},[88],[2486],[126,782,2456,2374],{"nctId":2489,"briefTitle":2490,"status":103,"phases":3359,"primaryCompletion":2492,"completion":2493,"start":2494,"enrollment":2495,"conditions":3360,"interventions":3361},[88],[831,2497],[126,782,2456,2374],{"nctId":2500,"briefTitle":2501,"status":103,"phases":3363,"primaryCompletion":2503,"completion":2504,"start":2505,"enrollment":2506,"conditions":3364,"interventions":3365},[88],[24],[126,782,2456,2374],{"nctId":2510,"briefTitle":2511,"status":103,"phases":3367,"primaryCompletion":2513,"completion":2514,"start":2494,"enrollment":1379,"conditions":3368,"interventions":3369},[88],[831,2497],[126,782,2456,2374],{"trials":3371,"activeCount":97},[],{"trials":3373,"activeCount":97},[],{"intervention":1453,"totalTrials":332,"cells":3375},{"EARLY_PHASE1":3376,"PHASE1":3378,"PHASE2":3384,"PHASE3":3401,"PHASE4":3403,"NA":3405},{"trials":3377,"activeCount":97},[],{"trials":3379,"activeCount":97},[3380],{"nctId":1439,"briefTitle":1440,"status":103,"phases":3381,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":3382,"interventions":3383},[86],[1037,1010,1446,1447,1448],[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],{"trials":3385,"activeCount":147,"soonestReadout":1274},[3386,3397],{"nctId":3387,"briefTitle":3388,"status":653,"phases":3389,"primaryCompletion":3390,"completion":3390,"start":3391,"enrollment":3392,"conditions":3393,"interventions":3395},"NCT05330429","Study of Magrolimab Given Together With FOLFIRI\u002FBevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)",[87],"2024-06-26","2022-07-08",77,[3394],"Metastatic Colorectal Cancer",[1049,1453,1454,3396,1451],"Fluorouracil",{"nctId":3195,"briefTitle":3196,"status":3197,"phases":3398,"primaryCompletion":1274,"completion":1274,"start":3199,"enrollment":3200,"conditions":3399,"interventions":3400},[87],[3202],[1279,1121,1453,3204],{"trials":3402,"activeCount":97},[],{"trials":3404,"activeCount":97},[],{"trials":3406,"activeCount":97},[],{"intervention":1088,"totalTrials":993,"cells":3408},{"EARLY_PHASE1":3409,"PHASE1":3411,"PHASE2":3423,"PHASE3":3429,"PHASE4":3431,"NA":3433},{"trials":3410,"activeCount":97},[],{"trials":3412,"activeCount":97},[3413],{"nctId":3414,"briefTitle":3415,"status":103,"phases":3416,"primaryCompletion":3417,"completion":3417,"start":3418,"enrollment":3419,"conditions":3420,"interventions":3422},"NCT03558139","Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy",[86],"2020-12-03","2018-05-23",34,[3421],"Ovarian Cancer",[1049,1088],{"trials":3424,"activeCount":147,"soonestReadout":1082},[3425],{"nctId":1079,"briefTitle":1080,"status":348,"phases":3426,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":3427,"interventions":3428},[87],[1086],[57,1012,1014,1088,1089,1013,1090,1091,1092],{"trials":3430,"activeCount":97},[],{"trials":3432,"activeCount":97},[],{"trials":3434,"activeCount":97},[],{"intervention":75,"totalTrials":993,"cells":3436},{"EARLY_PHASE1":3437,"PHASE1":3439,"PHASE2":3445,"PHASE3":3451,"PHASE4":3453,"NA":3455},{"trials":3438,"activeCount":97},[],{"trials":3440,"activeCount":97},[3441],{"nctId":1901,"briefTitle":1902,"status":103,"phases":3442,"primaryCompletion":1904,"completion":1905,"start":1906,"enrollment":22,"conditions":3443,"interventions":3444},[86],[21],[52,160,75,1364],{"trials":3446,"activeCount":147,"soonestReadout":74},[3447],{"nctId":72,"briefTitle":73,"status":130,"phases":3448,"primaryCompletion":74,"completion":1359,"start":1360,"enrollment":1361,"conditions":3449,"interventions":3450},[87],[21],[75,1364,125,125,1365],{"trials":3452,"activeCount":97},[],{"trials":3454,"activeCount":97},[],{"trials":3456,"activeCount":97},[],{"intervention":1364,"totalTrials":993,"cells":3458},{"EARLY_PHASE1":3459,"PHASE1":3461,"PHASE2":3467,"PHASE3":3473,"PHASE4":3475,"NA":3477},{"trials":3460,"activeCount":97},[],{"trials":3462,"activeCount":97},[3463],{"nctId":1901,"briefTitle":1902,"status":103,"phases":3464,"primaryCompletion":1904,"completion":1905,"start":1906,"enrollment":22,"conditions":3465,"interventions":3466},[86],[21],[52,160,75,1364],{"trials":3468,"activeCount":147,"soonestReadout":74},[3469],{"nctId":72,"briefTitle":73,"status":130,"phases":3470,"primaryCompletion":74,"completion":1359,"start":1360,"enrollment":1361,"conditions":3471,"interventions":3472},[87],[21],[75,1364,125,125,1365],{"trials":3474,"activeCount":97},[],{"trials":3476,"activeCount":97},[],{"trials":3478,"activeCount":97},[],{"intervention":1365,"totalTrials":147,"cells":3480},{"EARLY_PHASE1":3481,"PHASE1":3483,"PHASE2":3485,"PHASE3":3491,"PHASE4":3493,"NA":3495},{"trials":3482,"activeCount":97},[],{"trials":3484,"activeCount":97},[],{"trials":3486,"activeCount":147,"soonestReadout":74},[3487],{"nctId":72,"briefTitle":73,"status":130,"phases":3488,"primaryCompletion":74,"completion":1359,"start":1360,"enrollment":1361,"conditions":3489,"interventions":3490},[87],[21],[75,1364,125,125,1365],{"trials":3492,"activeCount":97},[],{"trials":3494,"activeCount":97},[],{"trials":3496,"activeCount":97},[],{"intervention":1301,"totalTrials":147,"cells":3498},{"EARLY_PHASE1":3499,"PHASE1":3501,"PHASE2":3503,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3500,"activeCount":97},[],{"trials":3502,"activeCount":97},[],{"trials":3504,"activeCount":147,"soonestReadout":1054},[3505],{"nctId":1293,"briefTitle":1294,"status":130,"phases":3506,"primaryCompletion":1054,"completion":1054,"start":1296,"enrollment":1297,"conditions":3507,"interventions":3508},[87],[1299],[1091,1301,1089,991,1302],{"trials":3510,"activeCount":97},[],{"trials":3512,"activeCount":97},[],{"trials":3514,"activeCount":97},[],{"intervention":1302,"totalTrials":147,"cells":3516},{"EARLY_PHASE1":3517,"PHASE1":3519,"PHASE2":3521,"PHASE3":3527,"PHASE4":3529,"NA":3531},{"trials":3518,"activeCount":97},[],{"trials":3520,"activeCount":97},[],{"trials":3522,"activeCount":147,"soonestReadout":1054},[3523],{"nctId":1293,"briefTitle":1294,"status":130,"phases":3524,"primaryCompletion":1054,"completion":1054,"start":1296,"enrollment":1297,"conditions":3525,"interventions":3526},[87],[1299],[1091,1301,1089,991,1302],{"trials":3528,"activeCount":97},[],{"trials":3530,"activeCount":97},[],{"trials":3532,"activeCount":97},[],{"intervention":3204,"totalTrials":147,"cells":3534},{"EARLY_PHASE1":3535,"PHASE1":3537,"PHASE2":3539,"PHASE3":3545,"PHASE4":3547,"NA":3549},{"trials":3536,"activeCount":97},[],{"trials":3538,"activeCount":97},[],{"trials":3540,"activeCount":147,"soonestReadout":1274},[3541],{"nctId":3195,"briefTitle":3196,"status":3197,"phases":3542,"primaryCompletion":1274,"completion":1274,"start":3199,"enrollment":3200,"conditions":3543,"interventions":3544},[87],[3202],[1279,1121,1453,3204],{"trials":3546,"activeCount":97},[],{"trials":3548,"activeCount":97},[],{"trials":3550,"activeCount":97},[],{"intervention":3552,"totalTrials":147,"cells":3553},"emvistegrast",{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3558,"PHASE3":3570,"PHASE4":3572,"NA":3574},{"trials":3555,"activeCount":97},[],{"trials":3557,"activeCount":97},[],{"trials":3559,"activeCount":147,"soonestReadout":3564},[3560],{"nctId":3561,"briefTitle":3562,"status":130,"phases":3563,"primaryCompletion":3564,"completion":1212,"start":3565,"enrollment":3566,"conditions":3567,"interventions":3569},"NCT06290934","Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis",[87],"2026-03-04","2024-03-27",228,[3568],"Ulcerative Colitis",[3552],{"trials":3571,"activeCount":97},[],{"trials":3573,"activeCount":97},[],{"trials":3575,"activeCount":97},[],{"intervention":66,"totalTrials":147,"cells":3577},{"EARLY_PHASE1":3578,"PHASE1":3580,"PHASE2":3582,"PHASE3":3588,"PHASE4":3590,"NA":3592},{"trials":3579,"activeCount":97},[],{"trials":3581,"activeCount":97},[],{"trials":3583,"activeCount":147,"soonestReadout":65},[3584],{"nctId":63,"briefTitle":64,"status":130,"phases":3585,"primaryCompletion":65,"completion":132,"start":154,"enrollment":177,"conditions":3586,"interventions":3587},[87],[21],[66,180,93,181],{"trials":3589,"activeCount":97},[],{"trials":3591,"activeCount":97},[],{"trials":3593,"activeCount":97},[],{"intervention":180,"totalTrials":147,"cells":3595},{"EARLY_PHASE1":3596,"PHASE1":3598,"PHASE2":3600,"PHASE3":3606,"PHASE4":3608,"NA":3610},{"trials":3597,"activeCount":97},[],{"trials":3599,"activeCount":97},[],{"trials":3601,"activeCount":147,"soonestReadout":65},[3602],{"nctId":63,"briefTitle":64,"status":130,"phases":3603,"primaryCompletion":65,"completion":132,"start":154,"enrollment":177,"conditions":3604,"interventions":3605},[87],[21],[66,180,93,181],{"trials":3607,"activeCount":97},[],{"trials":3609,"activeCount":97},[],{"trials":3611,"activeCount":97},[],{"intervention":181,"totalTrials":147,"cells":3613},{"EARLY_PHASE1":3614,"PHASE1":3616,"PHASE2":3618,"PHASE3":3624,"PHASE4":3626,"NA":3628},{"trials":3615,"activeCount":97},[],{"trials":3617,"activeCount":97},[],{"trials":3619,"activeCount":147,"soonestReadout":65},[3620],{"nctId":63,"briefTitle":64,"status":130,"phases":3621,"primaryCompletion":65,"completion":132,"start":154,"enrollment":177,"conditions":3622,"interventions":3623},[87],[21],[66,180,93,181],{"trials":3625,"activeCount":97},[],{"trials":3627,"activeCount":97},[],{"trials":3629,"activeCount":97},[],{"intervention":1476,"totalTrials":147,"cells":3631},{"EARLY_PHASE1":3632,"PHASE1":3634,"PHASE2":3636,"PHASE3":3642,"PHASE4":3644,"NA":3646},{"trials":3633,"activeCount":97},[],{"trials":3635,"activeCount":97},[],{"trials":3637,"activeCount":147,"soonestReadout":1469},[3638],{"nctId":1466,"briefTitle":1467,"status":348,"phases":3639,"primaryCompletion":1469,"completion":1469,"start":1097,"enrollment":1470,"conditions":3640,"interventions":3641},[87],[1472,1473,1474,1023],[1279,1121,1476,1051],{"trials":3643,"activeCount":97},[],{"trials":3645,"activeCount":97},[],{"trials":3647,"activeCount":97},[],{"intervention":1092,"totalTrials":147,"cells":3649},{"EARLY_PHASE1":3650,"PHASE1":3652,"PHASE2":3654,"PHASE3":3660,"PHASE4":3662,"NA":3664},{"trials":3651,"activeCount":97},[],{"trials":3653,"activeCount":97},[],{"trials":3655,"activeCount":147,"soonestReadout":1082},[3656],{"nctId":1079,"briefTitle":1080,"status":348,"phases":3657,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":3658,"interventions":3659},[87],[1086],[57,1012,1014,1088,1089,1013,1090,1091,1092],{"trials":3661,"activeCount":97},[],{"trials":3663,"activeCount":97},[],{"trials":3665,"activeCount":97},[],{"intervention":3667,"totalTrials":147,"cells":3668},"Tilpisertib Fosmecarbil",{"EARLY_PHASE1":3669,"PHASE1":3671,"PHASE2":3673,"PHASE3":3683,"PHASE4":3685,"NA":3687},{"trials":3670,"activeCount":97},[],{"trials":3672,"activeCount":97},[],{"trials":3674,"activeCount":147,"soonestReadout":1181},[3675],{"nctId":3676,"briefTitle":3677,"status":348,"phases":3678,"primaryCompletion":1181,"completion":1412,"start":3679,"enrollment":3680,"conditions":3681,"interventions":3682},"NCT06029972","Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis",[87],"2023-12-05",176,[3568],[3667],{"trials":3684,"activeCount":97},[],{"trials":3686,"activeCount":97},[],{"trials":3688,"activeCount":97},[],{"intervention":1118,"totalTrials":147,"cells":3690},{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3695,"PHASE3":3701,"PHASE4":3703,"NA":3705},{"trials":3692,"activeCount":97},[],{"trials":3694,"activeCount":97},[],{"trials":3696,"activeCount":147,"soonestReadout":1109},[3697],{"nctId":1106,"briefTitle":1107,"status":130,"phases":3698,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":3699,"interventions":3700},[87],[1113,1114,1115],[1089,1091,1117,1118,1013,1014,1119,1051,1120,991,1121],{"trials":3702,"activeCount":97},[],{"trials":3704,"activeCount":97},[],{"trials":3706,"activeCount":97},[],{"intervention":3708,"totalTrials":147,"cells":3709},"GS-4321",{"EARLY_PHASE1":3710,"PHASE1":3712,"PHASE2":3714,"PHASE3":3727,"PHASE4":3729,"NA":3731},{"trials":3711,"activeCount":97},[],{"trials":3713,"activeCount":97},[],{"trials":3715,"activeCount":147,"soonestReadout":3720},[3716],{"nctId":3717,"briefTitle":3718,"status":348,"phases":3719,"primaryCompletion":3720,"completion":3720,"start":3721,"enrollment":3722,"conditions":3723,"interventions":3725},"NCT07096193","Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus",[86,87],"2029-02","2025-07-31",107,[3724],"Chronic Hepatitis Delta",[3708,3726,3708],"GS-4321 Placebo",{"trials":3728,"activeCount":97},[],{"trials":3730,"activeCount":97},[],{"trials":3732,"activeCount":97},[],{"intervention":3726,"totalTrials":147,"cells":3734},{"EARLY_PHASE1":3735,"PHASE1":3737,"PHASE2":3739,"PHASE3":3745,"PHASE4":3747,"NA":3749},{"trials":3736,"activeCount":97},[],{"trials":3738,"activeCount":97},[],{"trials":3740,"activeCount":147,"soonestReadout":3720},[3741],{"nctId":3717,"briefTitle":3718,"status":348,"phases":3742,"primaryCompletion":3720,"completion":3720,"start":3721,"enrollment":3722,"conditions":3743,"interventions":3744},[86,87],[3724],[3708,3726,3708],{"trials":3746,"activeCount":97},[],{"trials":3748,"activeCount":97},[],{"trials":3750,"activeCount":97},[],{"intervention":1239,"totalTrials":147,"cells":3752},{"EARLY_PHASE1":3753,"PHASE1":3755,"PHASE2":3761,"PHASE3":3763,"PHASE4":3765,"NA":3767},{"trials":3754,"activeCount":97},[],{"trials":3756,"activeCount":147,"soonestReadout":395},[3757],{"nctId":1232,"briefTitle":1233,"status":130,"phases":3758,"primaryCompletion":395,"completion":395,"start":1235,"enrollment":1236,"conditions":3759,"interventions":3760},[86],[1067],[1239,1089],{"trials":3762,"activeCount":97},[],{"trials":3764,"activeCount":97},[],{"trials":3766,"activeCount":97},[],{"trials":3768,"activeCount":97},[],{"intervention":3770,"totalTrials":147,"cells":3771},"GS-2426",{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3783,"PHASE3":3785,"PHASE4":3787,"NA":3789},{"trials":3773,"activeCount":97},[],{"trials":3775,"activeCount":147,"soonestReadout":1325},[3776],{"nctId":3777,"briefTitle":3778,"status":3197,"phases":3779,"primaryCompletion":1325,"completion":1325,"start":1097,"enrollment":3780,"conditions":3781,"interventions":3782},"NCT07601243","Study of GS-2426 in Participants With Advanced Solid Tumors",[86],174,[1247],[3770],{"trials":3784,"activeCount":97},[],{"trials":3786,"activeCount":97},[],{"trials":3788,"activeCount":97},[],{"trials":3790,"activeCount":97},[],{"intervention":1260,"totalTrials":147,"cells":3792},{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3801,"PHASE3":3803,"PHASE4":3805,"NA":3807},{"trials":3794,"activeCount":97},[],{"trials":3796,"activeCount":147,"soonestReadout":974},[3797],{"nctId":1252,"briefTitle":1253,"status":130,"phases":3798,"primaryCompletion":974,"completion":974,"start":1255,"enrollment":1256,"conditions":3799,"interventions":3800},[86],[1258],[1260,1089],{"trials":3802,"activeCount":97},[],{"trials":3804,"activeCount":97},[],{"trials":3806,"activeCount":97},[],{"trials":3808,"activeCount":97},[],{"intervention":3810,"totalTrials":147,"cells":3811},"GS-5319",{"EARLY_PHASE1":3812,"PHASE1":3814,"PHASE2":3824,"PHASE3":3826,"PHASE4":3828,"NA":3830},{"trials":3813,"activeCount":97},[],{"trials":3815,"activeCount":147,"soonestReadout":3820},[3816],{"nctId":3817,"briefTitle":3818,"status":348,"phases":3819,"primaryCompletion":3820,"completion":3820,"start":3821,"enrollment":1743,"conditions":3822,"interventions":3823},"NCT07128303","Study of GS-5319 in Adults With Solid Tumors",[86],"2028-05","2025-08-28",[1101],[3810],{"trials":3825,"activeCount":97},[],{"trials":3827,"activeCount":97},[],{"trials":3829,"activeCount":97},[],{"trials":3831,"activeCount":97},[],{"intervention":2143,"totalTrials":147,"cells":3833},{"EARLY_PHASE1":3834,"PHASE1":3836,"PHASE2":3842,"PHASE3":3844,"PHASE4":3846,"NA":3848},{"trials":3835,"activeCount":97},[],{"trials":3837,"activeCount":147,"soonestReadout":1403},[3838],{"nctId":2136,"briefTitle":2137,"status":348,"phases":3839,"primaryCompletion":1403,"completion":1403,"start":2139,"enrollment":2140,"conditions":3840,"interventions":3841},[86],[1247],[2143,2129],{"trials":3843,"activeCount":97},[],{"trials":3845,"activeCount":97},[],{"trials":3847,"activeCount":97},[],{"trials":3849,"activeCount":97},[],{"intervention":3851,"totalTrials":147,"cells":3852},"GS-0151",{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3865,"PHASE3":3867,"PHASE4":3869,"NA":3871},{"trials":3854,"activeCount":97},[],{"trials":3856,"activeCount":147,"soonestReadout":466},[3857],{"nctId":3858,"briefTitle":3859,"status":348,"phases":3860,"primaryCompletion":466,"completion":466,"start":3861,"enrollment":1414,"conditions":3862,"interventions":3864},"NCT06902519","Study of GS-0151 in Participants With Rheumatoid Arthritis",[86],"2025-05-14",[3863],"Rheumatoid Arthritis",[3851],{"trials":3866,"activeCount":97},[],{"trials":3868,"activeCount":97},[],{"trials":3870,"activeCount":97},[],{"trials":3872,"activeCount":97},[],{"intervention":990,"totalTrials":147,"cells":3874},{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3883,"PHASE3":3885,"PHASE4":3887,"NA":3889},{"trials":3876,"activeCount":97},[],{"trials":3878,"activeCount":147,"soonestReadout":984},[3879],{"nctId":981,"briefTitle":982,"status":130,"phases":3880,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":3881,"interventions":3882},[86],[988],[990,991,992],{"trials":3884,"activeCount":97},[],{"trials":3886,"activeCount":97},[],{"trials":3888,"activeCount":97},[],{"trials":3890,"activeCount":97},[],{"intervention":3892,"totalTrials":147,"cells":3893},"GS-4571",{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3907,"PHASE3":3909,"PHASE4":3911,"NA":3913},{"trials":3895,"activeCount":97},[],{"trials":3897,"activeCount":147,"soonestReadout":395},[3898],{"nctId":3899,"briefTitle":3900,"status":348,"phases":3901,"primaryCompletion":395,"completion":395,"start":1203,"enrollment":3902,"conditions":3903,"interventions":3905},"NCT06562907","Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)",[86],134,[3904],"Weight Management",[3892,3906],"Omeprazole",{"trials":3908,"activeCount":97},[],{"trials":3910,"activeCount":97},[],{"trials":3912,"activeCount":97},[],{"trials":3914,"activeCount":97},[],{"intervention":3906,"totalTrials":147,"cells":3916},{"EARLY_PHASE1":3917,"PHASE1":3919,"PHASE2":3925,"PHASE3":3927,"PHASE4":3929,"NA":3931},{"trials":3918,"activeCount":97},[],{"trials":3920,"activeCount":147,"soonestReadout":395},[3921],{"nctId":3899,"briefTitle":3900,"status":348,"phases":3922,"primaryCompletion":395,"completion":395,"start":1203,"enrollment":3902,"conditions":3923,"interventions":3924},[86],[3904],[3892,3906],{"trials":3926,"activeCount":97},[],{"trials":3928,"activeCount":97},[],{"trials":3930,"activeCount":97},[],{"trials":3932,"activeCount":97},[],{"intervention":1269,"totalTrials":147,"cells":3934},{"EARLY_PHASE1":3935,"PHASE1":3937,"PHASE2":3943,"PHASE3":3945,"PHASE4":3947,"NA":3949},{"trials":3936,"activeCount":97},[],{"trials":3938,"activeCount":147,"soonestReadout":1073},[3939],{"nctId":1262,"briefTitle":1263,"status":348,"phases":3940,"primaryCompletion":1073,"completion":1073,"start":1265,"enrollment":1266,"conditions":3941,"interventions":3942},[86],[1247],[1269,1089],{"trials":3944,"activeCount":97},[],{"trials":3946,"activeCount":97},[],{"trials":3948,"activeCount":97},[],{"trials":3950,"activeCount":97},[],{"intervention":3952,"totalTrials":1645,"cells":3953},"Bulevirtide",{"EARLY_PHASE1":3954,"PHASE1":3956,"PHASE2":3978,"PHASE3":3991,"PHASE4":4002,"NA":4004},{"trials":3955,"activeCount":97},[],{"trials":3957,"activeCount":97},[3958,3968],{"nctId":3959,"briefTitle":3960,"status":103,"phases":3961,"primaryCompletion":3962,"completion":3963,"start":3964,"enrollment":433,"conditions":3965,"interventions":3967},"NCT05760300","A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function",[86],"2024-07-18","2024-07-23","2023-03-15",[3966],"Chronic Hepatitis D Infection",[3952],{"nctId":3969,"briefTitle":3970,"status":103,"phases":3971,"primaryCompletion":3972,"completion":3973,"start":3964,"enrollment":3974,"conditions":3975,"interventions":3977},"NCT05765344","Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function",[86],"2025-01-10","2025-01-13",74,[2569,3976],"Healthy",[3952,3952],{"trials":3979,"activeCount":97},[3980],{"nctId":3981,"briefTitle":3982,"status":103,"phases":3983,"primaryCompletion":3984,"completion":3985,"start":3986,"enrollment":3987,"conditions":3988,"interventions":3989},"NCT03852433","Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)",[87],"2022-04-05","2022-09-28","2019-05-31",175,[3724],[3952,3990],"Peginterferon Alfa-2a",{"trials":3992,"activeCount":97},[3993],{"nctId":3994,"briefTitle":3995,"status":103,"phases":3996,"primaryCompletion":3997,"completion":3998,"start":3999,"enrollment":792,"conditions":4000,"interventions":4001},"NCT03852719","Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)",[88],"2020-11-26","2024-08-08","2019-04-17",[3724],[3952],{"trials":4003,"activeCount":97},[],{"trials":4005,"activeCount":147,"soonestReadout":1129},[4006,4013],{"nctId":4007,"briefTitle":4008,"status":130,"phases":4009,"primaryCompletion":1129,"completion":1129,"start":4010,"enrollment":3200,"conditions":4011,"interventions":4012},"NCT05718700","Study of Bulevirtide in Participants With Chronic Hepatitis D Infection",[],"2023-02-07",[3966],[3952],{"nctId":4014,"briefTitle":4015,"status":4016,"phases":4017,"conditions":4018,"interventions":4020},"NCT06780579","Expanded Access for Bulevirtide","AVAILABLE",[],[4019],"Chronic Hepatitis Delta Virus Infection",[3952],{"intervention":1430,"totalTrials":147,"cells":4022},{"EARLY_PHASE1":4023,"PHASE1":4025,"PHASE2":4027,"PHASE3":4029,"PHASE4":4031,"NA":4033},{"trials":4024,"activeCount":97},[],{"trials":4026,"activeCount":97},[],{"trials":4028,"activeCount":97},[],{"trials":4030,"activeCount":97},[],{"trials":4032,"activeCount":97},[],{"trials":4034,"activeCount":147,"soonestReadout":1212},[4035],{"nctId":1422,"briefTitle":1423,"status":348,"phases":4036,"primaryCompletion":1212,"completion":1425,"start":1426,"enrollment":1427,"conditions":4037,"interventions":4038},[],[15],[125,1356,1430,1431,125],{"intervention":1431,"totalTrials":147,"cells":4040},{"EARLY_PHASE1":4041,"PHASE1":4043,"PHASE2":4045,"PHASE3":4047,"PHASE4":4049,"NA":4051},{"trials":4042,"activeCount":97},[],{"trials":4044,"activeCount":97},[],{"trials":4046,"activeCount":97},[],{"trials":4048,"activeCount":97},[],{"trials":4050,"activeCount":97},[],{"trials":4052,"activeCount":147,"soonestReadout":1212},[4053],{"nctId":1422,"briefTitle":1423,"status":348,"phases":4054,"primaryCompletion":1212,"completion":1425,"start":1426,"enrollment":1427,"conditions":4055,"interventions":4056},[],[15],[125,1356,1430,1431,125],{"intervention":513,"totalTrials":4058,"cells":4059},61,{"EARLY_PHASE1":4060,"PHASE1":4062,"PHASE2":4064,"PHASE3":4353,"PHASE4":4574,"NA":4583},{"trials":4061,"activeCount":97},[],{"trials":4063,"activeCount":97},[],{"trials":4065,"activeCount":97},[4066,4076,4087,4096,4108,4120,4130,4140,4148,4157,4165,4172,4181,4192,4199,4208,4217,4227,4236,4244,4254,4263,4273,4280,4287,4296,4303,4310,4320,4324,4334,4345],{"nctId":4067,"briefTitle":4068,"status":103,"phases":4069,"primaryCompletion":4070,"completion":4070,"start":4071,"enrollment":4072,"conditions":4073,"interventions":4075},"NCT02120300","Efficacy and Safety of Ledipasvir\u002FSofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders",[87],"2015-08","2014-04",122,[4074],"Chronic HCV Infection",[797,506,513],{"nctId":4077,"briefTitle":4078,"status":103,"phases":4079,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":4083,"conditions":4084,"interventions":4085},"NCT01909804","Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection",[87],"2014-05","2014-08","2013-06",323,[27],[506,4086,513],"VEL",{"nctId":4088,"briefTitle":4089,"status":103,"phases":4090,"primaryCompletion":4071,"completion":4091,"start":1733,"enrollment":4092,"conditions":4093,"interventions":4094},"NCT01984294","Ledipasvir\u002FSofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection",[87],"2014-07",101,[4074],[797,513,4095],"GS-9669",{"nctId":4097,"briefTitle":4098,"status":103,"phases":4099,"primaryCompletion":4100,"completion":4101,"start":4102,"enrollment":4103,"conditions":4104,"interventions":4105},"NCT02378935","Safety and Efficacy of Voxilaprevir Plus Sofosbuvir\u002FVelpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection",[87],"2016-02-01","2016-04-12","2015-02-17",205,[18],[4106,4107,513],"VOX","SOF\u002FVEL",{"nctId":4109,"briefTitle":4110,"status":103,"phases":4111,"primaryCompletion":4112,"completion":4113,"start":561,"enrollment":4114,"conditions":4115,"interventions":4117},"NCT01435044","Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection",[87],"2013-04","2013-05",239,[4116],"Hepatitis C, Chronic",[4118,4119,513],"Sofosbuvir","GS-0938",{"nctId":4121,"briefTitle":4122,"status":103,"phases":4123,"primaryCompletion":4124,"completion":4125,"start":4126,"enrollment":108,"conditions":4127,"interventions":4128},"NCT02536313","Safety and Efficacy of Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen",[87],"2016-03-28","2016-06-28","2015-07-29",[18],[4129,513],"SOF\u002FVEL\u002FVOX",{"nctId":4131,"briefTitle":4132,"status":103,"phases":4133,"primaryCompletion":1782,"completion":4081,"start":4134,"enrollment":4135,"conditions":4136,"interventions":4139},"NCT01687270","Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant",[87],"2012-11",40,[4137,4138],"Recurrent Chronic Hepatitis C Virus","Post Liver Transplant",[4118,513],{"nctId":4141,"briefTitle":4142,"status":103,"phases":4143,"primaryCompletion":4144,"completion":4070,"start":4145,"enrollment":1783,"conditions":4146,"interventions":4147},"NCT02010255","Ledipasvir\u002FSofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant",[87],"2015-05","2014-01",[4074],[797,513],{"nctId":4149,"briefTitle":4150,"status":103,"phases":4151,"primaryCompletion":4152,"completion":4153,"start":4154,"enrollment":22,"conditions":4155,"interventions":4156},"NCT02994056","Evaluate the Efficacy and Safety of Sofosbuvir\u002FVelpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis",[87],"2018-09-25","2018-12-12","2017-01-23",[18],[4107,513],{"nctId":4158,"briefTitle":4159,"status":103,"phases":4160,"primaryCompletion":4161,"completion":2438,"start":598,"enrollment":4162,"conditions":4163,"interventions":4164},"NCT02413593","Safety and Efficacy of Ledipasvir\u002FSofosbuvir (LDV\u002FSOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection",[87],"2015-12",111,[18],[797,513],{"nctId":4166,"briefTitle":4167,"status":103,"phases":4168,"primaryCompletion":4080,"completion":4081,"start":4112,"enrollment":4169,"conditions":4170,"interventions":4171},"NCT01858766","Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection",[87],379,[27],[506,4086,513],{"nctId":4173,"briefTitle":4174,"status":103,"phases":4175,"primaryCompletion":4176,"completion":1782,"start":4177,"enrollment":4178,"conditions":4179,"interventions":4180},"NCT01808248","Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3",[87],"2013-09","2013-02",47,[27],[506,512,513],{"nctId":4182,"briefTitle":4183,"status":103,"phases":4184,"primaryCompletion":4185,"completion":4186,"start":4187,"enrollment":4188,"conditions":4189,"interventions":4191},"NCT02202980","Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection",[87],"2016-03-16","2016-05-09","2014-08-04",273,[4190],"Chronic Hepatitis C",[797,513,4107,4106],{"nctId":4193,"briefTitle":4194,"status":103,"phases":4195,"primaryCompletion":4081,"completion":4196,"start":1733,"enrollment":2495,"conditions":4197,"interventions":4198},"NCT01965535","Efficacy and Safety of Sofosbuvir\u002FLedipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection",[87],"2014-11",[794],[797,513],{"nctId":4200,"briefTitle":4201,"status":103,"phases":4202,"primaryCompletion":563,"completion":4203,"start":4204,"enrollment":4205,"conditions":4206,"interventions":4207},"NCT01054729","Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients",[87],"2011-08","2010-01",64,[27],[4118,512,513],{"nctId":4209,"briefTitle":4210,"status":103,"phases":4211,"primaryCompletion":4212,"completion":4144,"start":4112,"enrollment":4213,"conditions":4214,"interventions":4215},"NCT01826981","Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection",[87],"2015-03",359,[4190],[797,506,513,4216,4095,4086],"Peg-IFN",{"nctId":4218,"briefTitle":4219,"status":103,"phases":4220,"primaryCompletion":1733,"completion":1782,"start":4221,"enrollment":4222,"conditions":4223,"interventions":4225},"NCT01260350","Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3",[87],"2010-12",292,[4224],"Chronic Hepatitis C Infection",[506,513,512,4226,4095,797],"LDV",{"nctId":4228,"briefTitle":4229,"status":103,"phases":4230,"primaryCompletion":2421,"completion":4231,"start":2332,"enrollment":4232,"conditions":4233,"interventions":4235},"NCT01188772","Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients",[87],"2012-05",147,[4234],"Hepatitis C Virus",[4118,512,513],{"nctId":4237,"briefTitle":4238,"status":103,"phases":4239,"primaryCompletion":695,"completion":695,"start":4240,"enrollment":4241,"conditions":4242,"interventions":4243},"NCT01329978","Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6",[87],"2011-03",332,[4116],[4118,513,512],{"nctId":4245,"briefTitle":4246,"status":103,"phases":4247,"primaryCompletion":4248,"completion":4249,"start":4250,"enrollment":4251,"conditions":4252,"interventions":4253},"NCT02249182","Safety and Efficacy of Ledipasvir\u002FSofosbuvir Fixed Dose Combination +\u002F- Ribavirin in Adolescents and Children With Chronic HCV-Infection",[87],"2018-06-15","2018-08-24","2014-11-05",226,[18],[797,513],{"nctId":4255,"briefTitle":4256,"status":103,"phases":4257,"primaryCompletion":4258,"completion":4259,"start":4260,"enrollment":535,"conditions":4261,"interventions":4262},"NCT02175758","Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection",[87],"2018-06-21","2018-09-13","2014-07-07",[18],[506,513],{"nctId":4264,"briefTitle":4265,"status":103,"phases":4266,"primaryCompletion":4267,"completion":4268,"start":4269,"enrollment":4270,"conditions":4271,"interventions":4272},"NCT02781558","Efficacy and Safety of Sofosbuvir\u002FVelpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir\u002FVelpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis",[87],"2017-10-06","2017-10-27","2016-07-29",204,[18],[4107,513],{"nctId":4274,"briefTitle":4275,"status":103,"phases":4276,"primaryCompletion":500,"completion":641,"start":4277,"enrollment":880,"conditions":4278,"interventions":4279},"NCT01713283","Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection",[87],"2012-10",[4234],[506,513],{"nctId":4281,"briefTitle":4282,"status":103,"phases":4283,"primaryCompletion":533,"completion":533,"start":4091,"enrollment":4178,"conditions":4284,"interventions":4285},"NCT02226549","Ledipasvir\u002FSofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis",[87],[18],[797,4286,513],"VDV",{"nctId":4288,"briefTitle":4289,"status":653,"phases":4290,"primaryCompletion":4082,"completion":4082,"start":4203,"enrollment":4291,"conditions":4292,"interventions":4293},"NCT01384383","GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype",[87],248,[4190],[4294,4295,513,512],"GS-5885","GS-9451",{"nctId":4297,"briefTitle":4298,"status":103,"phases":4299,"primaryCompletion":519,"completion":4212,"start":4176,"enrollment":4300,"conditions":4301,"interventions":4302},"NCT01938430","Ledipasvir\u002FSofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant",[87],339,[4074],[797,513],{"nctId":4304,"briefTitle":4305,"status":103,"phases":4306,"primaryCompletion":4307,"completion":4307,"start":4091,"enrollment":1075,"conditions":4308,"interventions":4309},"NCT01987453","Ledipasvir\u002FSofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study",[87],"2015-11",[794],[797,513],{"nctId":4311,"briefTitle":4312,"status":103,"phases":4313,"primaryCompletion":4314,"completion":4315,"start":4316,"enrollment":4317,"conditions":4318,"interventions":4319},"NCT02300103","Efficacy And Safety Of Sofosbuvir\u002FVelpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study",[87],"2016-07-02","2016-09-15","2014-12-01",69,[18],[4107,513],{"nctId":496,"briefTitle":497,"status":103,"phases":4321,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":4322,"interventions":4323},[86,87],[27,504],[506,507,508,509,230,510,232,307,511,512,513],{"nctId":4325,"briefTitle":4326,"status":103,"phases":4327,"primaryCompletion":4328,"completion":4329,"start":4330,"enrollment":4331,"conditions":4332,"interventions":4333},"NCT01958281","Sofosbuvir Plus Ribavirin, or Ledipasvir\u002FSofosbuvir in Adults With HCV Infection and Renal Insufficiency",[87],"2017-07-18","2017-10-19","2013-10-07",38,[794],[506,513,797],{"nctId":4335,"briefTitle":4336,"status":103,"phases":4337,"primaryCompletion":519,"completion":696,"start":4338,"enrollment":4339,"conditions":4340,"interventions":4344},"NCT01687257","Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation",[87],"2012-07",50,[27,4341,4342,4343],"Cirrhosis","Portal Hypertension","With or Without Liver Decompensation",[506,513],{"nctId":4346,"briefTitle":4347,"status":103,"phases":4348,"primaryCompletion":4349,"completion":4145,"start":4277,"enrollment":1075,"conditions":4350,"interventions":4352},"NCT01726517","Safety and Efficacy of LDV\u002FSOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects",[87],"2013-07",[4351],"Chronic Hepatitis C Virus",[797,513],{"trials":4354,"activeCount":97},[4355,4363,4373,4381,4389,4395,4401,4409,4416,4425,4434,4441,4451,4458,4465,4471,4478,4485,4492,4502,4509,4519,4526,4534,4544,4551,4558,4565],{"nctId":4356,"briefTitle":4357,"status":103,"phases":4358,"primaryCompletion":500,"completion":641,"start":4338,"enrollment":4359,"conditions":4360,"interventions":4362},"NCT01667731","Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults",[88],224,[27,4361],"Human Immunodeficiency Virus",[506,513],{"nctId":4364,"briefTitle":4365,"status":103,"phases":4366,"primaryCompletion":4367,"completion":4368,"start":4369,"enrollment":4370,"conditions":4371,"interventions":4372},"NCT01625338","Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies",[88],"2014-10","2014-12","2012-06",534,[4190],[506,513,4216],{"nctId":4374,"briefTitle":4375,"status":103,"phases":4376,"primaryCompletion":4377,"completion":4378,"start":4101,"enrollment":4114,"conditions":4379,"interventions":4380},"NCT02738333","Ledipasvir\u002FSofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection",[88],"2017-02-14","2017-05-11",[18],[797,506,513],{"nctId":4382,"briefTitle":4383,"status":103,"phases":4384,"primaryCompletion":1733,"completion":4145,"start":4385,"enrollment":4386,"conditions":4387,"interventions":4388},"NCT01682720","Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection",[88],"2012-09",421,[27],[506,513],{"nctId":4390,"briefTitle":4391,"status":103,"phases":4392,"primaryCompletion":4070,"completion":4307,"start":4091,"enrollment":1353,"conditions":4393,"interventions":4394},"NCT02201901","Sofosbuvir\u002FVelpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis",[88],[18],[4107,513],{"nctId":4396,"briefTitle":4397,"status":103,"phases":4398,"primaryCompletion":4071,"completion":4091,"start":532,"enrollment":890,"conditions":4399,"interventions":4400},"NCT01783678","A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults",[88],[4190,4361],[4118,513],{"nctId":4402,"briefTitle":4403,"status":103,"phases":4404,"primaryCompletion":4405,"completion":4406,"start":4177,"enrollment":643,"conditions":4407,"interventions":4408},"NCT01910636","Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection",[88],"2014-03","2014-06",[27],[4118,513],{"nctId":4410,"briefTitle":4411,"status":103,"phases":4412,"primaryCompletion":4406,"completion":4081,"start":1733,"enrollment":4413,"conditions":4414,"interventions":4415},"NCT01975675","Efficacy and Safety of Sofosbuvir\u002FLedipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection",[88],341,[4074],[797,513],{"nctId":4417,"briefTitle":4418,"status":103,"phases":4419,"primaryCompletion":4420,"completion":4421,"start":4422,"enrollment":643,"conditions":4423,"interventions":4424},"NCT02472886","Safety and Efficacy of Ledipasvir\u002FSofosbuvir in Adults With Chronic HCV Infection",[88],"2016-03-30","2016-06-30","2015-06-17",[18],[797,513],{"nctId":4426,"briefTitle":4427,"status":103,"phases":4428,"primaryCompletion":4429,"completion":4430,"start":562,"enrollment":4431,"conditions":4432,"interventions":4433},"NCT02220998","Comparison of Sofosbuvir\u002FVelpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection",[88],"2015-07","2015-09",269,[18],[4107,506,513],{"nctId":4435,"briefTitle":4436,"status":103,"phases":4437,"primaryCompletion":4430,"completion":4307,"start":4405,"enrollment":4438,"conditions":4439,"interventions":4440},"NCT02074514","Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection",[88],117,[4074],[4118,513],{"nctId":4442,"briefTitle":4443,"status":103,"phases":4444,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":4448,"conditions":4449,"interventions":4450},"NCT02487030","Safety and Efficacy of Ledipasvir\u002FSofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection",[88],"2016-11-11","2017-02-04","2015-09-07",255,[18],[797,513],{"nctId":4452,"briefTitle":4453,"status":103,"phases":4454,"primaryCompletion":4177,"completion":4113,"start":4369,"enrollment":4455,"conditions":4456,"interventions":4457},"NCT01604850","Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)",[88],202,[4190],[506,513],{"nctId":4459,"briefTitle":4460,"status":103,"phases":4461,"primaryCompletion":4080,"completion":4081,"start":4462,"enrollment":3223,"conditions":4463,"interventions":4464},"NCT01838590","Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection",[88],"2013-03",[4234],[506,513],{"nctId":4466,"briefTitle":4467,"status":103,"phases":4468,"primaryCompletion":4134,"completion":4177,"start":501,"enrollment":2140,"conditions":4469,"interventions":4470},"NCT01542788","Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon",[88],[4190],[506,513],{"nctId":4472,"briefTitle":4473,"status":103,"phases":4474,"primaryCompletion":532,"completion":4112,"start":4369,"enrollment":4475,"conditions":4476,"interventions":4477},"NCT01641640","Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection",[88],328,[4190],[4118,513,512],{"nctId":4479,"briefTitle":4480,"status":653,"phases":4481,"primaryCompletion":2513,"completion":4482,"start":190,"enrollment":2381,"conditions":4483,"interventions":4484},"NCT02600351","Efficacy and Safety of Ledipasvir\u002FSofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies",[88],"2017-05-29",[18],[797,513],{"nctId":4486,"briefTitle":4487,"status":103,"phases":4488,"primaryCompletion":1782,"completion":4405,"start":4113,"enrollment":4489,"conditions":4490,"interventions":4491},"NCT01851330","Safety and Efficacy of Ledipasvir\u002FSofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)",[88],647,[4351],[797,513],{"nctId":4493,"briefTitle":4494,"status":103,"phases":4495,"primaryCompletion":4496,"completion":4497,"start":4498,"enrollment":4499,"conditions":4500,"interventions":4501},"NCT01962441","SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection",[88],"2015-01-07","2016-07-07","2013-09-24",601,[27],[506,513,4216],{"nctId":4503,"briefTitle":4504,"status":103,"phases":4505,"primaryCompletion":4430,"completion":4161,"start":4091,"enrollment":4506,"conditions":4507,"interventions":4508},"NCT02201953","Comparison of Sofosbuvir\u002FVelpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection",[88],558,[18],[4107,506,513],{"nctId":4510,"briefTitle":4511,"status":103,"phases":4512,"primaryCompletion":4513,"completion":4514,"start":4515,"enrollment":4516,"conditions":4517,"interventions":4518},"NCT02996682","Efficacy and Safety of Sofosbuvir\u002FVelpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis",[88],"2018-02-13","2018-05-08","2016-12-26",102,[18],[4107,513],{"nctId":4520,"briefTitle":4521,"status":103,"phases":4522,"primaryCompletion":4071,"completion":4406,"start":4082,"enrollment":4523,"conditions":4524,"interventions":4525},"NCT01896193","Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection",[88],127,[27],[506,513],{"nctId":4527,"briefTitle":4528,"status":103,"phases":4529,"primaryCompletion":532,"completion":4112,"start":4530,"enrollment":4531,"conditions":4532,"interventions":4533},"NCT01497366","Phase 3 Study of Sofosbuvir and Ribavirin",[88],"2011-12",527,[27],[4118,512,513],{"nctId":4535,"briefTitle":4536,"status":103,"phases":4537,"primaryCompletion":4538,"completion":4539,"start":4540,"enrollment":4541,"conditions":4542,"interventions":4543},"NCT02021643","Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection",[88],"2016-08-12","2016-11-03","2013-12-10",687,[4074],[4118,513,512],{"nctId":4545,"briefTitle":4546,"status":103,"phases":4547,"primaryCompletion":500,"completion":641,"start":532,"enrollment":4548,"conditions":4549,"interventions":4550},"NCT01768286","Safety and Efficacy of Ledipasvir\u002FSofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection",[88],441,[4351],[797,513],{"nctId":4552,"briefTitle":4553,"status":103,"phases":4554,"primaryCompletion":4405,"completion":4071,"start":4385,"enrollment":4555,"conditions":4556,"interventions":4557},"NCT01701401","Safety and Efficacy of Ledipasvir\u002FSofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV",[88],870,[4351],[797,513],{"nctId":4559,"briefTitle":4560,"status":103,"phases":4561,"primaryCompletion":4196,"completion":4161,"start":641,"enrollment":4562,"conditions":4563,"interventions":4564},"NCT02073656","Efficacy and Safety of Ledipasvir\u002FSofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection",[88],335,[4234,504],[797,513],{"nctId":4566,"briefTitle":4567,"status":103,"phases":4568,"primaryCompletion":4569,"completion":4570,"start":4571,"enrollment":4438,"conditions":4572,"interventions":4573},"NCT02822794","Sofosbuvir\u002FVelpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen",[88],"2017-06-02","2017-08-25","2016-07-25",[18],[4107,513],{"trials":4575,"activeCount":97},[4576],{"nctId":4577,"briefTitle":4578,"status":103,"phases":4579,"primaryCompletion":4580,"completion":4580,"start":4406,"enrollment":819,"conditions":4581,"interventions":4582},"NCT02128542","Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis",[89],"2015-06",[18],[4118,513],{"trials":4584,"activeCount":97},[],{"intervention":4586,"totalTrials":4587,"cells":4588},"Ranolazine",17,{"EARLY_PHASE1":4589,"PHASE1":4591,"PHASE2":4615,"PHASE3":4646,"PHASE4":4699,"NA":4745},{"trials":4590,"activeCount":97},[],{"trials":4592,"activeCount":97},[4593,4601,4608],{"nctId":4594,"briefTitle":4595,"status":103,"phases":4596,"primaryCompletion":501,"completion":501,"start":2361,"enrollment":2579,"conditions":4597,"interventions":4599},"NCT01546597","Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine",[86],[4598],"Type 2 Diabetes Mellitus",[4600,4586],"Metformin",{"nctId":4602,"briefTitle":4603,"status":103,"phases":4604,"primaryCompletion":501,"completion":501,"start":2361,"enrollment":4605,"conditions":4606,"interventions":4607},"NCT01546558","Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg",[86],25,[4598],[4600,4586],{"nctId":4609,"briefTitle":4610,"status":103,"phases":4611,"primaryCompletion":4176,"completion":4176,"start":4112,"enrollment":2579,"conditions":4612,"interventions":4613},"NCT01843127","A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.",[86],[4598],[4586,4614],"Exenatide",{"trials":4616,"activeCount":97},[4617,4629,4637],{"nctId":4618,"briefTitle":4619,"status":103,"phases":4620,"primaryCompletion":4621,"completion":4621,"start":4622,"enrollment":3902,"conditions":4623,"interventions":4625},"NCT01522651","Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation",[87],"2014-03-10","2012-01-24",[4624],"Atrial Fibrillation",[4586,4626,4627,4628],"Dronedarone","Ranolazine placebo","Dronedarone placebo",{"nctId":4630,"briefTitle":4631,"status":103,"phases":4632,"primaryCompletion":4633,"completion":4633,"start":563,"enrollment":34,"conditions":4634,"interventions":4636},"NCT01163734","Ranolazine in Diastolic Heart Failure",[87],"2011-02",[4635],"Diastolic Heart Failure",[4586],{"nctId":4638,"briefTitle":4639,"status":103,"phases":4640,"primaryCompletion":4641,"completion":4641,"start":4642,"enrollment":1056,"conditions":4643,"interventions":4645},"NCT01163721","Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy",[87],"2010-11","2010-06",[4644],"Diabetes Mellitus, Type 2",[4586],{"trials":4647,"activeCount":97},[4648,4655,4664,4673,4682,4689],{"nctId":4649,"briefTitle":4650,"status":103,"phases":4651,"primaryCompletion":1733,"completion":1733,"start":597,"enrollment":4652,"conditions":4653,"interventions":4654},"NCT01472185","Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus",[88],465,[4598],[4586],{"nctId":4656,"briefTitle":4657,"status":103,"phases":4658,"primaryCompletion":2473,"completion":2473,"start":4659,"enrollment":4660,"conditions":4661,"interventions":4663},"NCT00091429","Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine",[88],"2004-08",500,[4662],"Angina",[4586],{"nctId":4665,"briefTitle":4666,"status":103,"phases":4667,"primaryCompletion":4668,"completion":4668,"start":2340,"enrollment":4669,"conditions":4670,"interventions":4672},"NCT00099788","Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes",[88],"2007-02",6560,[4671],"Myocardial Ischemia",[4586],{"nctId":4674,"briefTitle":4675,"status":103,"phases":4676,"primaryCompletion":499,"completion":499,"start":4677,"enrollment":4678,"conditions":4679,"interventions":4680},"NCT01494987","Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus",[88],"2012-01",431,[4598],[4586,4681],"Glimepiride",{"nctId":4683,"briefTitle":4684,"status":103,"phases":4685,"primaryCompletion":4176,"completion":1733,"start":4369,"enrollment":4686,"conditions":4687,"interventions":4688},"NCT01555164","A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone",[88],442,[4598],[4586,4600],{"nctId":4690,"briefTitle":4691,"status":103,"phases":4692,"primaryCompletion":533,"completion":533,"start":4693,"enrollment":4694,"conditions":4695,"interventions":4698},"NCT01442038","Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)",[88],"2011-10",2651,[4696,4697],"Coronary Artery Disease","Angina Pectoris",[4586],{"trials":4700,"activeCount":97},[4701,4708,4715,4726,4736],{"nctId":4702,"briefTitle":4703,"status":1529,"phases":4704,"primaryCompletion":4277,"completion":4705,"start":534,"enrollment":97,"conditions":4706,"interventions":4707},"NCT01334203","A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)",[89],"2012-12",[4697,4696,4598],[4586],{"nctId":4709,"briefTitle":4710,"status":103,"phases":4711,"primaryCompletion":4277,"completion":4277,"start":561,"enrollment":4712,"conditions":4713,"interventions":4714},"NCT01425359","Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina",[89],949,[4697,4696,4598],[4586,4627],{"nctId":4716,"briefTitle":4717,"status":653,"phases":4718,"primaryCompletion":4719,"completion":4719,"start":4720,"enrollment":1507,"conditions":4721,"interventions":4725},"NCT00832572","Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy",[89],"2009-06","2009-01",[4696,4722,4723,4724],"Pain","Peripheral Nervous System Diseases","Polyneuropathy",[4586],{"nctId":4727,"briefTitle":4728,"status":103,"phases":4729,"primaryCompletion":4730,"completion":4730,"start":4731,"enrollment":4732,"conditions":4733,"interventions":4735},"NCT00644332","An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)",[89],"2011-01","2007-11",172,[4734],"Chronic Angina",[4586],{"nctId":4737,"briefTitle":4738,"status":103,"phases":4739,"primaryCompletion":4385,"completion":4385,"start":4740,"enrollment":4741,"conditions":4742,"interventions":4744},"NCT01221272","Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging",[89],"2010-09",81,[4743,4671],"Myocardial Perfusion Imaging",[4586],{"trials":4746,"activeCount":97},[],{"intervention":782,"totalTrials":487,"cells":4748},{"EARLY_PHASE1":4749,"PHASE1":4751,"PHASE2":4753,"PHASE3":4768,"PHASE4":4806,"NA":4825},{"trials":4750,"activeCount":97},[],{"trials":4752,"activeCount":97},[],{"trials":4754,"activeCount":97},[4755,4759],{"nctId":3330,"briefTitle":3331,"status":103,"phases":4756,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":3336,"conditions":4757,"interventions":4758},[87],[24],[126,782,3339],{"nctId":4760,"briefTitle":4761,"status":103,"phases":4762,"primaryCompletion":4763,"completion":4764,"start":4765,"enrollment":1111,"conditions":4766,"interventions":4767},"NCT02579382","Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated",[87],"2017-01-16","2019-05-03","2015-11-10",[24],[782,724],{"trials":4769,"activeCount":97},[4770,4774,4778,4782,4786,4790,4794,4798,4802],{"nctId":2434,"briefTitle":2435,"status":103,"phases":4771,"primaryCompletion":2437,"completion":2438,"start":2439,"enrollment":2440,"conditions":4772,"interventions":4773},[88],[24],[782,2443,2428,2444,232],{"nctId":773,"briefTitle":774,"status":103,"phases":4775,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":4776,"interventions":4777},[88],[21],[228,782,783,232,784,785],{"nctId":2446,"briefTitle":2447,"status":103,"phases":4779,"primaryCompletion":2449,"completion":2450,"start":2451,"enrollment":2452,"conditions":4780,"interventions":4781},[88],[2454],[126,782,2456,2374],{"nctId":2458,"briefTitle":2459,"status":103,"phases":4783,"primaryCompletion":597,"completion":533,"start":2379,"enrollment":2461,"conditions":4784,"interventions":4785},[88],[2334],[782,232,2374,413],{"nctId":2469,"briefTitle":2470,"status":103,"phases":4787,"primaryCompletion":2472,"completion":2438,"start":2473,"enrollment":2474,"conditions":4788,"interventions":4789},[88],[24],[782,2443,2428,2444,232],{"nctId":2478,"briefTitle":2479,"status":103,"phases":4791,"primaryCompletion":2481,"completion":2482,"start":2483,"enrollment":2484,"conditions":4792,"interventions":4793},[88],[2486],[126,782,2456,2374],{"nctId":2489,"briefTitle":2490,"status":103,"phases":4795,"primaryCompletion":2492,"completion":2493,"start":2494,"enrollment":2495,"conditions":4796,"interventions":4797},[88],[831,2497],[126,782,2456,2374],{"nctId":2500,"briefTitle":2501,"status":103,"phases":4799,"primaryCompletion":2503,"completion":2504,"start":2505,"enrollment":2506,"conditions":4800,"interventions":4801},[88],[24],[126,782,2456,2374],{"nctId":2510,"briefTitle":2511,"status":103,"phases":4803,"primaryCompletion":2513,"completion":2514,"start":2494,"enrollment":1379,"conditions":4804,"interventions":4805},[88],[831,2497],[126,782,2456,2374],{"trials":4807,"activeCount":97},[4808,4818],{"nctId":4809,"briefTitle":4810,"status":103,"phases":4811,"primaryCompletion":4812,"completion":4813,"start":4814,"enrollment":4815,"conditions":4816,"interventions":4817},"NCT01320943","Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB",[89],"2016-07-28","2016-08-23","2011-04-26",43,[24],[782],{"nctId":4819,"briefTitle":4820,"status":103,"phases":4821,"primaryCompletion":4081,"completion":4429,"start":2421,"enrollment":4822,"conditions":4823,"interventions":4824},"NCT01277601","Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B",[89],751,[24],[782,4216],{"trials":4826,"activeCount":97},[],{"intervention":4828,"totalTrials":1225,"cells":4829},"Ambrisentan",{"EARLY_PHASE1":4830,"PHASE1":4832,"PHASE2":4834,"PHASE3":4855,"PHASE4":4923,"NA":4935},{"trials":4831,"activeCount":97},[],{"trials":4833,"activeCount":97},[],{"trials":4835,"activeCount":97},[4836,4846],{"nctId":4837,"briefTitle":4838,"status":103,"phases":4839,"primaryCompletion":518,"completion":518,"start":4840,"enrollment":4841,"conditions":4842,"interventions":4844},"NCT00424021","Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension",[87],"2003-04",54,[4843],"Pulmonary Hypertension",[4845],"ambrisentan",{"nctId":4847,"briefTitle":4848,"status":103,"phases":4849,"primaryCompletion":4850,"completion":4851,"start":4852,"enrollment":1862,"conditions":4853,"interventions":4854},"NCT00423592","Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension",[87],"2006-01","2009-03","2005-05",[4843],[4845],{"trials":4856,"activeCount":97},[4857,4865,4873,4883,4892,4898,4906,4915],{"nctId":4858,"briefTitle":4859,"status":103,"phases":4860,"primaryCompletion":4861,"completion":520,"start":4862,"enrollment":4359,"conditions":4863,"interventions":4864},"NCT00380068","Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension",[88],"2008-07","2006-08",[4843],[4828],{"nctId":4866,"briefTitle":4867,"status":653,"phases":4868,"primaryCompletion":4633,"completion":4633,"start":4869,"enrollment":4135,"conditions":4870,"interventions":4872},"NCT00879229","ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis",[88],"2009-07",[4871,4843],"Idiopathic Pulmonary Fibrosis",[4828],{"nctId":4874,"briefTitle":4875,"status":103,"phases":4876,"completion":4877,"start":4878,"enrollment":4879,"conditions":4880,"interventions":4882},"NCT00423202","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.",[88],"2005-10","2003-12",186,[4881],"Pulmonary Arterial Hypertension",[4845],{"nctId":4884,"briefTitle":4885,"status":103,"phases":4886,"primaryCompletion":4887,"completion":4887,"start":4888,"enrollment":4889,"conditions":4890,"interventions":4891},"NCT00578786","A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)",[88],"2010-03","2004-02",383,[4881],[4845],{"nctId":4893,"briefTitle":4894,"status":103,"phases":4895,"completion":2341,"start":4878,"enrollment":4879,"conditions":4896,"interventions":4897},"NCT00423748","Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.",[88],[4881],[4845],{"nctId":4899,"briefTitle":4900,"status":653,"phases":4901,"primaryCompletion":4633,"completion":4633,"start":4902,"enrollment":4903,"conditions":4904,"interventions":4905},"NCT00768300","(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF",[88],"2008-12",494,[4871],[4828],{"nctId":4907,"briefTitle":4908,"status":103,"phases":4909,"primaryCompletion":4910,"completion":4910,"start":4911,"enrollment":4912,"conditions":4913,"interventions":4914},"NCT00777920","Study of Ambrisentan in Participants With Pulmonary Hypertension",[88],"2019-09-11","2008-11-17",140,[4843],[4828],{"nctId":4916,"briefTitle":4917,"status":103,"phases":4918,"primaryCompletion":2341,"completion":2341,"start":4919,"enrollment":4920,"conditions":4921,"interventions":4922},"NCT00091598","ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)",[88],"2004-01",372,[4843],[4828],{"trials":4924,"activeCount":97},[4925],{"nctId":4926,"briefTitle":4927,"status":103,"phases":4928,"primaryCompletion":4633,"completion":4929,"start":4930,"enrollment":4331,"conditions":4931,"interventions":4932},"NCT00617305","Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)",[89],"2011-07","2008-04",[4881],[4828,4933,4934],"Sildenafil","Tadalafil",{"trials":4936,"activeCount":97},[],{"intervention":231,"totalTrials":1225,"cells":4938},{"EARLY_PHASE1":4939,"PHASE1":4941,"PHASE2":4943,"PHASE3":4960,"PHASE4":4998,"NA":5004},{"trials":4940,"activeCount":97},[],{"trials":4942,"activeCount":97},[],{"trials":4944,"activeCount":97},[4945,4952,4956],{"nctId":4946,"briefTitle":4947,"status":103,"phases":4948,"primaryCompletion":4212,"completion":4212,"start":4668,"enrollment":1111,"conditions":4949,"interventions":4950},"NCT00445146","Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection",[87],[15],[4951,231,661],"EVG",{"nctId":651,"briefTitle":652,"status":653,"phases":4953,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":4954,"interventions":4955},[87],[33],[660,161,126,661,307,231],{"nctId":515,"briefTitle":516,"status":103,"phases":4957,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":4958,"interventions":4959},[87],[21],[308,231,230,232,524,525],{"trials":4961,"activeCount":97},[4962,4966,4970,4979,4986,4990,4994],{"nctId":220,"briefTitle":221,"status":103,"phases":4963,"primaryCompletion":223,"completion":121,"start":224,"enrollment":225,"conditions":4964,"interventions":4965},[88],[21],[228,229,230,231,232,93],{"nctId":545,"briefTitle":546,"status":103,"phases":4967,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":4968,"interventions":4969},[88],[537,15],[229,230,231,232,554,555,556,413,228],{"nctId":4971,"briefTitle":4972,"status":103,"phases":4973,"primaryCompletion":4677,"completion":4367,"start":4641,"enrollment":4974,"conditions":4975,"interventions":4976},"NCT01252940","Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine\u002FRilpivirine\u002FTenofovir DF",[88],482,[21],[4977,4978,231,206],"FTC\u002FRPV\u002FTDF","PI",{"nctId":4980,"briefTitle":4981,"status":103,"phases":4982,"primaryCompletion":500,"completion":4368,"start":597,"enrollment":4983,"conditions":4984,"interventions":4985},"NCT01475838","Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine\u002FTenofovir Fixed-Dose Combination to the Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",[88],438,[537,15],[4978,231,232,567],{"nctId":580,"briefTitle":581,"status":103,"phases":4987,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":4988,"interventions":4989},[88],[504,15],[228,229,507,231,230,232,308],{"nctId":594,"briefTitle":595,"status":103,"phases":4991,"primaryCompletion":597,"completion":598,"start":563,"enrollment":599,"conditions":4992,"interventions":4993},[88],[504,15],[308,231,230,232,524,525],{"nctId":298,"briefTitle":299,"status":103,"phases":4995,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":4996,"interventions":4997},[88],[21],[231,230,307,308,309,310,232,311,93],{"trials":4999,"activeCount":97},[5000],{"nctId":609,"briefTitle":610,"status":103,"phases":5001,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":5002,"interventions":5003},[89],[21],[618,619,620,231,230,311,621],{"trials":5005,"activeCount":97},[],{"intervention":5007,"totalTrials":1645,"cells":5008},"Truvada",{"EARLY_PHASE1":5009,"PHASE1":5011,"PHASE2":5013,"PHASE3":5015,"PHASE4":5017,"NA":5068},{"trials":5010,"activeCount":97},[],{"trials":5012,"activeCount":97},[],{"trials":5014,"activeCount":97},[],{"trials":5016,"activeCount":97},[],{"trials":5018,"activeCount":97},[5019,5028,5036,5045,5053,5061],{"nctId":5020,"briefTitle":5021,"status":103,"phases":5022,"completion":5023,"start":2340,"enrollment":502,"conditions":5024,"interventions":5025},"NCT00106379","Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients",[89],"2007-01",[15],[5007,5026,5027],"Emtriva","Viread",{"nctId":5029,"briefTitle":5030,"status":103,"phases":5031,"primaryCompletion":5023,"completion":5023,"start":5032,"enrollment":1075,"conditions":5033,"interventions":5034},"NCT00224445","Boosted Atazanavir and Truvada Given Once-Daily - BATON Study",[89],"2005-09",[15],[5007,5035,510],"Atazanavir",{"nctId":5037,"briefTitle":5038,"status":103,"phases":5039,"primaryCompletion":5040,"completion":2379,"start":5041,"enrollment":1056,"conditions":5042,"interventions":5043},"NCT00324649","Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada",[89],"2008-03","2006-05",[435],[5007,5044],"Zidovudine\u002Flamivudine",{"nctId":5046,"briefTitle":5047,"status":103,"phases":5048,"primaryCompletion":5049,"completion":5023,"start":5050,"enrollment":4339,"conditions":5051,"interventions":5052},"NCT00323687","SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada",[89],"2006-10","2004-09",[21],[5007],{"nctId":5054,"briefTitle":5055,"status":103,"phases":5056,"primaryCompletion":5057,"completion":5040,"start":5032,"enrollment":1045,"conditions":5058,"interventions":5059},"NCT00323492","TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada",[89],"2007-07",[15],[5007,5060],"Current HAART regimen",{"nctId":5062,"briefTitle":5063,"status":103,"phases":5064,"completion":2341,"start":5050,"enrollment":1297,"conditions":5065,"interventions":5066},"NCT00224458","Combination of Efavirenz and Truvada - COMET Study",[89],[15],[5007,5067],"efavirenz",{"trials":5069,"activeCount":97},[],{"intervention":5071,"totalTrials":1507,"cells":5072},"AmBisome",{"EARLY_PHASE1":5073,"PHASE1":5075,"PHASE2":5077,"PHASE3":5086,"PHASE4":5098,"NA":5126},{"trials":5074,"activeCount":97},[],{"trials":5076,"activeCount":97},[],{"trials":5078,"activeCount":97},[5079],{"nctId":5080,"briefTitle":5081,"status":103,"phases":5082,"primaryCompletion":4720,"completion":1557,"start":2380,"enrollment":3419,"conditions":5083,"interventions":5085},"NCT00326157","PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation",[87],[5084],"Fungus Diseases",[5071],{"trials":5087,"activeCount":97},[5088],{"nctId":5089,"briefTitle":5090,"status":103,"phases":5091,"completion":5092,"start":4840,"enrollment":5093,"conditions":5094,"interventions":5097},"NCT00158730","Study Safety\u002FEfficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment",[88],"2005-01",800,[5095,5096],"Invasive Aspergillosis","Other Fungal Infections",[5071],{"trials":5099,"activeCount":97},[5100,5109,5118],{"nctId":5101,"briefTitle":5102,"status":103,"phases":5103,"completion":5041,"start":5104,"enrollment":25,"conditions":5105,"interventions":5106},"NCT00334412","COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis",[89],"2004-03",[5095],[5107,5108],"Ambisome","caspofungin",{"nctId":5110,"briefTitle":5111,"status":103,"phases":5112,"primaryCompletion":4902,"completion":4720,"start":2437,"enrollment":5113,"conditions":5114,"interventions":5117},"NCT00670657","CRITIC - Treatment of Candidemia and Invasive Candidiasis",[89],39,[5115,5116],"Candidemia","Invasive Candidiasis",[5071],{"nctId":5119,"briefTitle":5120,"status":103,"phases":5121,"completion":2353,"start":5122,"enrollment":25,"conditions":5123,"interventions":5125},"NCT00362544","PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg\u002Fkg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia",[89],"2003-10",[5124],"Leukemia",[5107],{"trials":5127,"activeCount":97},[],{"intervention":5129,"totalTrials":1507,"cells":5130},"Efavirenz",{"EARLY_PHASE1":5131,"PHASE1":5133,"PHASE2":5135,"PHASE3":5154,"PHASE4":5168,"NA":5183},{"trials":5132,"activeCount":97},[],{"trials":5134,"activeCount":97},[],{"trials":5136,"activeCount":97},[5137,5146],{"nctId":5138,"briefTitle":5139,"status":103,"phases":5140,"enrollment":4605,"conditions":5141,"interventions":5142},"NCT00002419","Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment",[87],[15],[5143,5144,5129,5145],"Abacavir sulfate","Amprenavir","Adefovir dipivoxil",{"nctId":5147,"briefTitle":5148,"status":103,"phases":5149,"enrollment":4605,"conditions":5150,"interventions":5151},"NCT00002234","Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients",[87],[15],[5129,5145,5152,5153],"Lamivudine","Didanosine",{"trials":5155,"activeCount":97},[5156],{"nctId":5157,"briefTitle":5158,"status":103,"phases":5159,"primaryCompletion":2473,"completion":4719,"start":5160,"enrollment":5161,"conditions":5162,"interventions":5163},"NCT00112047","Tenofovir Disoproxil Fumarate\u002FEmtricitabine\u002FEfavirenz Versus Combivir\u002FEfavirenz in Antiretroviral-Naive HIV-1 Infected Subjects",[88],"2003-07",517,[15],[5164,5165,5129,232,5166,5167],"Emtricitabine","Tenofovir Disoproxil Fumarate","FTC\u002FTDF\u002FEFV","Lamivudine\u002Fzidovudine",{"trials":5169,"activeCount":97},[5170,5179],{"nctId":5171,"briefTitle":5172,"status":103,"phases":5173,"primaryCompletion":5174,"completion":2351,"start":5175,"enrollment":5176,"conditions":5177,"interventions":5178},"NCT00365612","Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients",[89],"2007-10","2006-07",300,[15],[5129],{"nctId":5062,"briefTitle":5063,"status":103,"phases":5180,"completion":2341,"start":5050,"enrollment":1297,"conditions":5181,"interventions":5182},[89],[15],[5007,5067],{"trials":5184,"activeCount":97},[],{"intervention":5164,"totalTrials":477,"cells":5186},{"EARLY_PHASE1":5187,"PHASE1":5189,"PHASE2":5191,"PHASE3":5209,"PHASE4":5215,"NA":5227},{"trials":5188,"activeCount":97},[],{"trials":5190,"activeCount":97},[],{"trials":5192,"activeCount":97},[5193,5201],{"nctId":5194,"briefTitle":5195,"status":103,"phases":5196,"primaryCompletion":5197,"completion":5197,"start":5198,"enrollment":134,"conditions":5199,"interventions":5200},"NCT00642291","An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects",[87],"2004-07","2002-11",[15],[5164,5164],{"nctId":5202,"briefTitle":5203,"status":103,"phases":5204,"primaryCompletion":5205,"completion":5205,"start":5206,"enrollment":4339,"conditions":5207,"interventions":5208},"NCT00743340","Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine",[87],"2017-02-13","2005-11-22",[21],[5164],{"trials":5210,"activeCount":97},[5211],{"nctId":5157,"briefTitle":5158,"status":103,"phases":5212,"primaryCompletion":2473,"completion":4719,"start":5160,"enrollment":5161,"conditions":5213,"interventions":5214},[88],[15],[5164,5165,5129,232,5166,5167],{"trials":5216,"activeCount":97},[5217],{"nctId":5218,"briefTitle":5219,"status":103,"phases":5220,"primaryCompletion":4240,"completion":2421,"start":4861,"enrollment":5221,"conditions":5222,"interventions":5224},"NCT00724711","Safety and Efficacy Study of Switching From Epzicom to Truvada",[89],312,[5223],"HIV Infection",[5225,5226],"emtricitabine","abacavir",{"trials":5228,"activeCount":97},[],{"intervention":4216,"totalTrials":477,"cells":5230},{"EARLY_PHASE1":5231,"PHASE1":5233,"PHASE2":5235,"PHASE3":5241,"PHASE4":5251,"NA":5257},{"trials":5232,"activeCount":97},[],{"trials":5234,"activeCount":97},[],{"trials":5236,"activeCount":97},[5237],{"nctId":4209,"briefTitle":4210,"status":103,"phases":5238,"primaryCompletion":4212,"completion":4144,"start":4112,"enrollment":4213,"conditions":5239,"interventions":5240},[87],[4190],[797,506,513,4216,4095,4086],{"trials":5242,"activeCount":97},[5243,5247],{"nctId":4364,"briefTitle":4365,"status":103,"phases":5244,"primaryCompletion":4367,"completion":4368,"start":4369,"enrollment":4370,"conditions":5245,"interventions":5246},[88],[4190],[506,513,4216],{"nctId":4493,"briefTitle":4494,"status":103,"phases":5248,"primaryCompletion":4496,"completion":4497,"start":4498,"enrollment":4499,"conditions":5249,"interventions":5250},[88],[27],[506,513,4216],{"trials":5252,"activeCount":97},[5253],{"nctId":4819,"briefTitle":4820,"status":103,"phases":5254,"primaryCompletion":4081,"completion":4429,"start":2421,"enrollment":4822,"conditions":5255,"interventions":5256},[89],[24],[782,4216],{"trials":5258,"activeCount":97},[],{"intervention":311,"totalTrials":477,"cells":5260},{"EARLY_PHASE1":5261,"PHASE1":5263,"PHASE2":5265,"PHASE3":5267,"PHASE4":5281,"NA":5287},{"trials":5262,"activeCount":97},[],{"trials":5264,"activeCount":97},[],{"trials":5266,"activeCount":97},[],{"trials":5268,"activeCount":97},[5269,5273,5277],{"nctId":448,"briefTitle":449,"status":103,"phases":5270,"primaryCompletion":451,"completion":452,"start":453,"enrollment":214,"conditions":5271,"interventions":5272},[88],[21],[47,311,456,194,437],{"nctId":298,"briefTitle":299,"status":103,"phases":5274,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":5275,"interventions":5276},[88],[21],[231,230,307,308,309,310,232,311,93],{"nctId":884,"briefTitle":885,"status":103,"phases":5278,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":5279,"interventions":5280},[88],[21],[228,311,893],{"trials":5282,"activeCount":97},[5283],{"nctId":609,"briefTitle":610,"status":103,"phases":5284,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":5285,"interventions":5286},[89],[21],[618,619,620,231,230,311,621],{"trials":5288,"activeCount":97},[],{"intervention":5027,"totalTrials":332,"cells":5290},{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5295,"PHASE3":5297,"PHASE4":5311,"NA":5324},{"trials":5292,"activeCount":97},[],{"trials":5294,"activeCount":97},[],{"trials":5296,"activeCount":97},[],{"trials":5298,"activeCount":97},[5299],{"nctId":5300,"briefTitle":5301,"status":103,"phases":5302,"primaryCompletion":5303,"completion":4082,"start":5304,"enrollment":5305,"conditions":5306,"interventions":5307},"NCT00158821","Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.",[88],"2001-12","2000-03",180,[15],[5027,5308,5309,5310],"Sustiva","Epivir","Zerit (Stavudine) Placebo",{"trials":5312,"activeCount":97},[5313,5317],{"nctId":5020,"briefTitle":5021,"status":103,"phases":5314,"completion":5023,"start":2340,"enrollment":502,"conditions":5315,"interventions":5316},[89],[15],[5007,5026,5027],{"nctId":5318,"briefTitle":5319,"status":103,"phases":5320,"completion":2380,"start":5321,"enrollment":880,"conditions":5322,"interventions":5323},"NCT00324688","Safety Study of Once a Day ART and Opiate Substitute.",[89],"2003-03",[15],[5027],{"trials":5325,"activeCount":97},[],{"intervention":5327,"totalTrials":332,"cells":5328},"Atripla",{"EARLY_PHASE1":5329,"PHASE1":5331,"PHASE2":5333,"PHASE3":5342,"PHASE4":5352,"NA":5363},{"trials":5330,"activeCount":97},[],{"trials":5332,"activeCount":97},[],{"trials":5334,"activeCount":97},[5335],{"nctId":5336,"briefTitle":5337,"status":103,"phases":5338,"primaryCompletion":1557,"completion":4176,"start":5339,"enrollment":16,"conditions":5340,"interventions":5341},"NCT00869557","Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",[87],"2009-04",[504,15],[567,5327],{"trials":5343,"activeCount":97},[5344],{"nctId":5345,"briefTitle":5346,"status":103,"phases":5347,"primaryCompletion":4203,"completion":562,"start":4887,"enrollment":5348,"conditions":5349,"interventions":5350},"NCT01095796","Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",[88],707,[504,15],[567,5327,568,5351],"Atripla Placebo",{"trials":5353,"activeCount":97},[5354],{"nctId":5355,"briefTitle":5356,"status":103,"phases":5357,"primaryCompletion":5358,"completion":4204,"start":5040,"enrollment":5359,"conditions":5360,"interventions":5361},"NCT00615810","ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial",[89],"2009-10",159,[15],[5327,5362],"Kivexa plus Sustiva",{"trials":5364,"activeCount":97},[],{"intervention":510,"totalTrials":332,"cells":5366},{"EARLY_PHASE1":5367,"PHASE1":5369,"PHASE2":5371,"PHASE3":5377,"PHASE4":5383,"NA":5389},{"trials":5368,"activeCount":97},[],{"trials":5370,"activeCount":97},[],{"trials":5372,"activeCount":97},[5373],{"nctId":496,"briefTitle":497,"status":103,"phases":5374,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":5375,"interventions":5376},[86,87],[27,504],[506,507,508,509,230,510,232,307,511,512,513],{"trials":5378,"activeCount":97},[5379],{"nctId":558,"briefTitle":559,"status":103,"phases":5380,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":5381,"interventions":5382},[88],[504,15],[567,230,510,232,568,555,556,413],{"trials":5384,"activeCount":97},[5385],{"nctId":5029,"briefTitle":5030,"status":103,"phases":5386,"primaryCompletion":5023,"completion":5023,"start":5032,"enrollment":1075,"conditions":5387,"interventions":5388},[89],[15],[5007,5035,510],{"trials":5390,"activeCount":97},[],{"intervention":5392,"totalTrials":332,"cells":5393},"Liposomal amphotericin B",{"EARLY_PHASE1":5394,"PHASE1":5396,"PHASE2":5398,"PHASE3":5400,"PHASE4":5410,"NA":5430},{"trials":5395,"activeCount":97},[],{"trials":5397,"activeCount":97},[],{"trials":5399,"activeCount":97},[],{"trials":5401,"activeCount":97},[5402],{"nctId":5403,"briefTitle":5404,"status":103,"phases":5405,"primaryCompletion":1782,"completion":4145,"start":2421,"enrollment":5406,"conditions":5407,"interventions":5409},"NCT01259713","Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia",[88],355,[5408],"Invasive Fungal Disease",[5392],{"trials":5411,"activeCount":97},[5412,5421],{"nctId":5413,"briefTitle":5414,"status":653,"phases":5415,"completion":2362,"start":5416,"enrollment":34,"conditions":5417,"interventions":5419},"NCT00386997","ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia",[89],"2006-11",[5418],"Fungal Infection",[5420],"liposomal amphotericin B",{"nctId":5422,"briefTitle":5423,"status":653,"phases":5424,"primaryCompletion":4930,"completion":5425,"start":5426,"enrollment":34,"conditions":5427,"interventions":5429},"NCT00421187","Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics",[89],"2008-05","2007-03",[5428],"Febrile Neutropenia",[5392,5392],{"trials":5431,"activeCount":97},[],{"intervention":5226,"totalTrials":993,"cells":5433},{"EARLY_PHASE1":5434,"PHASE1":5436,"PHASE2":5438,"PHASE3":5449,"PHASE4":5451,"NA":5457},{"trials":5435,"activeCount":97},[],{"trials":5437,"activeCount":97},[],{"trials":5439,"activeCount":97},[5440],{"nctId":5441,"briefTitle":5442,"status":103,"phases":5443,"completion":2340,"start":5444,"enrollment":1075,"conditions":5445,"interventions":5446},"NCT00270556","Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.",[87],"2003-01",[504],[5447,5448],"tenofovir disoproxil fumarate","Abacavir",{"trials":5450,"activeCount":97},[],{"trials":5452,"activeCount":97},[5453],{"nctId":5218,"briefTitle":5219,"status":103,"phases":5454,"primaryCompletion":4240,"completion":2421,"start":4861,"enrollment":5221,"conditions":5455,"interventions":5456},[89],[5223],[5225,5226],{"trials":5458,"activeCount":97},[],{"intervention":4627,"totalTrials":993,"cells":5460},{"EARLY_PHASE1":5461,"PHASE1":5463,"PHASE2":5465,"PHASE3":5471,"PHASE4":5473,"NA":5479},{"trials":5462,"activeCount":97},[],{"trials":5464,"activeCount":97},[],{"trials":5466,"activeCount":97},[5467],{"nctId":4618,"briefTitle":4619,"status":103,"phases":5468,"primaryCompletion":4621,"completion":4621,"start":4622,"enrollment":3902,"conditions":5469,"interventions":5470},[87],[4624],[4586,4626,4627,4628],{"trials":5472,"activeCount":97},[],{"trials":5474,"activeCount":97},[5475],{"nctId":4709,"briefTitle":4710,"status":103,"phases":5476,"primaryCompletion":4277,"completion":4277,"start":561,"enrollment":4712,"conditions":5477,"interventions":5478},[89],[4697,4696,4598],[4586,4627],{"trials":5480,"activeCount":97},[],{"intervention":5026,"totalTrials":147,"cells":5482},{"EARLY_PHASE1":5483,"PHASE1":5485,"PHASE2":5487,"PHASE3":5489,"PHASE4":5491,"NA":5497},{"trials":5484,"activeCount":97},[],{"trials":5486,"activeCount":97},[],{"trials":5488,"activeCount":97},[],{"trials":5490,"activeCount":97},[],{"trials":5492,"activeCount":97},[5493],{"nctId":5020,"briefTitle":5021,"status":103,"phases":5494,"completion":5023,"start":2340,"enrollment":502,"conditions":5495,"interventions":5496},[89],[15],[5007,5026,5027],{"trials":5498,"activeCount":97},[],{"intervention":5362,"totalTrials":147,"cells":5500},{"EARLY_PHASE1":5501,"PHASE1":5503,"PHASE2":5505,"PHASE3":5507,"PHASE4":5509,"NA":5515},{"trials":5502,"activeCount":97},[],{"trials":5504,"activeCount":97},[],{"trials":5506,"activeCount":97},[],{"trials":5508,"activeCount":97},[],{"trials":5510,"activeCount":97},[5511],{"nctId":5355,"briefTitle":5356,"status":103,"phases":5512,"primaryCompletion":5358,"completion":4204,"start":5040,"enrollment":5359,"conditions":5513,"interventions":5514},[89],[15],[5327,5362],{"trials":5516,"activeCount":97},[],{"intervention":5518,"totalTrials":147,"cells":5519},"EFV+TDF",{"EARLY_PHASE1":5520,"PHASE1":5522,"PHASE2":5524,"PHASE3":5526,"PHASE4":5528,"NA":5537},{"trials":5521,"activeCount":97},[],{"trials":5523,"activeCount":97},[],{"trials":5525,"activeCount":97},[],{"trials":5527,"activeCount":97},[],{"trials":5529,"activeCount":97},[5530],{"nctId":5531,"briefTitle":5532,"status":103,"phases":5533,"primaryCompletion":2439,"completion":5032,"start":5321,"enrollment":4912,"conditions":5534,"interventions":5535},"NCT00643968","Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial",[89],[15],[5518,5536],"EFV+3TC+TDF",{"trials":5538,"activeCount":97},[],{"intervention":5536,"totalTrials":147,"cells":5540},{"EARLY_PHASE1":5541,"PHASE1":5543,"PHASE2":5545,"PHASE3":5547,"PHASE4":5549,"NA":5555},{"trials":5542,"activeCount":97},[],{"trials":5544,"activeCount":97},[],{"trials":5546,"activeCount":97},[],{"trials":5548,"activeCount":97},[],{"trials":5550,"activeCount":97},[5551],{"nctId":5531,"briefTitle":5532,"status":103,"phases":5552,"primaryCompletion":2439,"completion":5032,"start":5321,"enrollment":4912,"conditions":5553,"interventions":5554},[89],[15],[5518,5536],{"trials":5556,"activeCount":97},[],{"intervention":5558,"totalTrials":147,"cells":5559},"Truvada + Kaletra",{"EARLY_PHASE1":5560,"PHASE1":5562,"PHASE2":5564,"PHASE3":5566,"PHASE4":5568,"NA":5579},{"trials":5561,"activeCount":97},[],{"trials":5563,"activeCount":97},[],{"trials":5565,"activeCount":97},[],{"trials":5567,"activeCount":97},[],{"trials":5569,"activeCount":97},[5570],{"nctId":5571,"briefTitle":5572,"status":103,"phases":5573,"primaryCompletion":5574,"completion":5358,"start":5575,"enrollment":521,"conditions":5576,"interventions":5577},"NCT00772902","ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial",[89],"2009-09","2008-10",[435],[5558,5578],"Kivexa + Kaletra",{"trials":5580,"activeCount":97},[],{"intervention":5578,"totalTrials":147,"cells":5582},{"EARLY_PHASE1":5583,"PHASE1":5585,"PHASE2":5587,"PHASE3":5589,"PHASE4":5591,"NA":5597},{"trials":5584,"activeCount":97},[],{"trials":5586,"activeCount":97},[],{"trials":5588,"activeCount":97},[],{"trials":5590,"activeCount":97},[],{"trials":5592,"activeCount":97},[5593],{"nctId":5571,"briefTitle":5572,"status":103,"phases":5594,"primaryCompletion":5574,"completion":5358,"start":5575,"enrollment":521,"conditions":5595,"interventions":5596},[89],[435],[5558,5578],{"trials":5598,"activeCount":97},[],{"intervention":5600,"totalTrials":147,"cells":5601},"Truvada (TDF+FTC) alone",{"EARLY_PHASE1":5602,"PHASE1":5604,"PHASE2":5606,"PHASE3":5608,"PHASE4":5610,"NA":5619},{"trials":5603,"activeCount":97},[],{"trials":5605,"activeCount":97},[],{"trials":5607,"activeCount":97},[],{"trials":5609,"activeCount":97},[],{"trials":5611,"activeCount":97},[5612],{"nctId":5613,"briefTitle":5614,"status":103,"phases":5615,"primaryCompletion":5425,"completion":5575,"start":5416,"enrollment":4339,"conditions":5616,"interventions":5617},"NCT00362687","GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance",[89],[15],[5600,5618],"FTC alone",{"trials":5620,"activeCount":97},[],{"intervention":5618,"totalTrials":147,"cells":5622},{"EARLY_PHASE1":5623,"PHASE1":5625,"PHASE2":5627,"PHASE3":5629,"PHASE4":5631,"NA":5637},{"trials":5624,"activeCount":97},[],{"trials":5626,"activeCount":97},[],{"trials":5628,"activeCount":97},[],{"trials":5630,"activeCount":97},[],{"trials":5632,"activeCount":97},[5633],{"nctId":5613,"briefTitle":5614,"status":103,"phases":5634,"primaryCompletion":5425,"completion":5575,"start":5416,"enrollment":4339,"conditions":5635,"interventions":5636},[89],[15],[5600,5618],{"trials":5638,"activeCount":97},[],{"intervention":4933,"totalTrials":147,"cells":5640},{"EARLY_PHASE1":5641,"PHASE1":5643,"PHASE2":5645,"PHASE3":5647,"PHASE4":5649,"NA":5655},{"trials":5642,"activeCount":97},[],{"trials":5644,"activeCount":97},[],{"trials":5646,"activeCount":97},[],{"trials":5648,"activeCount":97},[],{"trials":5650,"activeCount":97},[5651],{"nctId":4926,"briefTitle":4927,"status":103,"phases":5652,"primaryCompletion":4633,"completion":4929,"start":4930,"enrollment":4331,"conditions":5653,"interventions":5654},[89],[4881],[4828,4933,4934],{"trials":5656,"activeCount":97},[],{"intervention":4934,"totalTrials":147,"cells":5658},{"EARLY_PHASE1":5659,"PHASE1":5661,"PHASE2":5663,"PHASE3":5665,"PHASE4":5667,"NA":5673},{"trials":5660,"activeCount":97},[],{"trials":5662,"activeCount":97},[],{"trials":5664,"activeCount":97},[],{"trials":5666,"activeCount":97},[],{"trials":5668,"activeCount":97},[5669],{"nctId":4926,"briefTitle":4927,"status":103,"phases":5670,"primaryCompletion":4633,"completion":4929,"start":4930,"enrollment":4331,"conditions":5671,"interventions":5672},[89],[4881],[4828,4933,4934],{"trials":5674,"activeCount":97},[],{"intervention":618,"totalTrials":147,"cells":5676},{"EARLY_PHASE1":5677,"PHASE1":5679,"PHASE2":5681,"PHASE3":5683,"PHASE4":5685,"NA":5691},{"trials":5678,"activeCount":97},[],{"trials":5680,"activeCount":97},[],{"trials":5682,"activeCount":97},[],{"trials":5684,"activeCount":97},[],{"trials":5686,"activeCount":97},[5687],{"nctId":609,"briefTitle":610,"status":103,"phases":5688,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":5689,"interventions":5690},[89],[21],[618,619,620,231,230,311,621],{"trials":5692,"activeCount":97},[],{"intervention":619,"totalTrials":147,"cells":5694},{"EARLY_PHASE1":5695,"PHASE1":5697,"PHASE2":5699,"PHASE3":5701,"PHASE4":5703,"NA":5709},{"trials":5696,"activeCount":97},[],{"trials":5698,"activeCount":97},[],{"trials":5700,"activeCount":97},[],{"trials":5702,"activeCount":97},[],{"trials":5704,"activeCount":97},[5705],{"nctId":609,"briefTitle":610,"status":103,"phases":5706,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":5707,"interventions":5708},[89],[21],[618,619,620,231,230,311,621],{"trials":5710,"activeCount":97},[],{"intervention":620,"totalTrials":147,"cells":5712},{"EARLY_PHASE1":5713,"PHASE1":5715,"PHASE2":5717,"PHASE3":5719,"PHASE4":5721,"NA":5727},{"trials":5714,"activeCount":97},[],{"trials":5716,"activeCount":97},[],{"trials":5718,"activeCount":97},[],{"trials":5720,"activeCount":97},[],{"trials":5722,"activeCount":97},[5723],{"nctId":609,"briefTitle":610,"status":103,"phases":5724,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":5725,"interventions":5726},[89],[21],[618,619,620,231,230,311,621],{"trials":5728,"activeCount":97},[],{"intervention":621,"totalTrials":147,"cells":5730},{"EARLY_PHASE1":5731,"PHASE1":5733,"PHASE2":5735,"PHASE3":5737,"PHASE4":5739,"NA":5745},{"trials":5732,"activeCount":97},[],{"trials":5734,"activeCount":97},[],{"trials":5736,"activeCount":97},[],{"trials":5738,"activeCount":97},[],{"trials":5740,"activeCount":97},[5741],{"nctId":609,"briefTitle":610,"status":103,"phases":5742,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":5743,"interventions":5744},[89],[21],[618,619,620,231,230,311,621],{"trials":5746,"activeCount":97},[],{"intervention":5035,"totalTrials":147,"cells":5748},{"EARLY_PHASE1":5749,"PHASE1":5751,"PHASE2":5753,"PHASE3":5755,"PHASE4":5757,"NA":5763},{"trials":5750,"activeCount":97},[],{"trials":5752,"activeCount":97},[],{"trials":5754,"activeCount":97},[],{"trials":5756,"activeCount":97},[],{"trials":5758,"activeCount":97},[5759],{"nctId":5029,"briefTitle":5030,"status":103,"phases":5760,"primaryCompletion":5023,"completion":5023,"start":5032,"enrollment":1075,"conditions":5761,"interventions":5762},[89],[15],[5007,5035,510],{"trials":5764,"activeCount":97},[],{"intervention":5108,"totalTrials":147,"cells":5766},{"EARLY_PHASE1":5767,"PHASE1":5769,"PHASE2":5771,"PHASE3":5773,"PHASE4":5775,"NA":5781},{"trials":5768,"activeCount":97},[],{"trials":5770,"activeCount":97},[],{"trials":5772,"activeCount":97},[],{"trials":5774,"activeCount":97},[],{"trials":5776,"activeCount":97},[5777],{"nctId":5101,"briefTitle":5102,"status":103,"phases":5778,"completion":5041,"start":5104,"enrollment":25,"conditions":5779,"interventions":5780},[89],[5095],[5107,5108],{"trials":5782,"activeCount":97},[],{"intervention":5044,"totalTrials":147,"cells":5784},{"EARLY_PHASE1":5785,"PHASE1":5787,"PHASE2":5789,"PHASE3":5791,"PHASE4":5793,"NA":5799},{"trials":5786,"activeCount":97},[],{"trials":5788,"activeCount":97},[],{"trials":5790,"activeCount":97},[],{"trials":5792,"activeCount":97},[],{"trials":5794,"activeCount":97},[5795],{"nctId":5037,"briefTitle":5038,"status":103,"phases":5796,"primaryCompletion":5040,"completion":2379,"start":5041,"enrollment":1056,"conditions":5797,"interventions":5798},[89],[435],[5007,5044],{"trials":5800,"activeCount":97},[],{"intervention":5802,"totalTrials":147,"cells":5803},"Atripla (ATR) consisting of EFV 600 mg\u002FFTC 200 mg\u002FTDF 300 mg",{"EARLY_PHASE1":5804,"PHASE1":5806,"PHASE2":5808,"PHASE3":5810,"PHASE4":5812,"NA":5821},{"trials":5805,"activeCount":97},[],{"trials":5807,"activeCount":97},[],{"trials":5809,"activeCount":97},[],{"trials":5811,"activeCount":97},[],{"trials":5813,"activeCount":97},[5814],{"nctId":5815,"briefTitle":5816,"status":103,"phases":5817,"primaryCompletion":4641,"completion":4221,"start":4930,"enrollment":5818,"conditions":5819,"interventions":5820},"NCT00615745","ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla",[89],115,[15],[5802],{"trials":5822,"activeCount":97},[],{"intervention":5824,"totalTrials":147,"cells":5825},"Tenofovir DF placebo",{"EARLY_PHASE1":5826,"PHASE1":5828,"PHASE2":5830,"PHASE3":5832,"PHASE4":5834,"NA":5843},{"trials":5827,"activeCount":97},[],{"trials":5829,"activeCount":97},[],{"trials":5831,"activeCount":97},[],{"trials":5833,"activeCount":97},[],{"trials":5835,"activeCount":97},[5836],{"nctId":5837,"briefTitle":5838,"status":103,"phases":5839,"primaryCompletion":4731,"completion":5840,"start":5175,"enrollment":1122,"conditions":5841,"interventions":5842},"NCT00648817","Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers",[89],"2007-12",[15],[5165,5824],{"trials":5844,"activeCount":97},[],{"intervention":5060,"totalTrials":147,"cells":5846},{"EARLY_PHASE1":5847,"PHASE1":5849,"PHASE2":5851,"PHASE3":5853,"PHASE4":5855,"NA":5861},{"trials":5848,"activeCount":97},[],{"trials":5850,"activeCount":97},[],{"trials":5852,"activeCount":97},[],{"trials":5854,"activeCount":97},[],{"trials":5856,"activeCount":97},[5857],{"nctId":5054,"briefTitle":5055,"status":103,"phases":5858,"primaryCompletion":5057,"completion":5040,"start":5032,"enrollment":1045,"conditions":5859,"interventions":5860},[89],[15],[5007,5060],{"trials":5862,"activeCount":97},[],{"intervention":5864,"totalTrials":147,"cells":5865},"Sacituzumab Govitecan-hiy",{"EARLY_PHASE1":5866,"PHASE1":5868,"PHASE2":5870,"PHASE3":5872,"PHASE4":5874,"NA":5885},{"trials":5867,"activeCount":97},[],{"trials":5869,"activeCount":97},[],{"trials":5871,"activeCount":97},[],{"trials":5873,"activeCount":97},[],{"trials":5875,"activeCount":97},[5876],{"nctId":5877,"briefTitle":5878,"status":103,"phases":5879,"primaryCompletion":5880,"completion":5880,"start":5881,"enrollment":4605,"conditions":5882,"interventions":5884},"NCT04319198","Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy",[89],"2024-10-18","2020-08-04",[5883],"Metastatic Solid Tumors",[5864],{"trials":5886,"activeCount":97},[],{"intervention":232,"totalTrials":12,"cells":5888},{"EARLY_PHASE1":5889,"PHASE1":5891,"PHASE2":5893,"PHASE3":5921,"PHASE4":5983,"NA":5985},{"trials":5890,"activeCount":97},[],{"trials":5892,"activeCount":97},[],{"trials":5894,"activeCount":97},[5895,5902,5909,5913,5917],{"nctId":5896,"briefTitle":5897,"status":103,"phases":5898,"primaryCompletion":534,"completion":534,"start":2362,"enrollment":4135,"conditions":5899,"interventions":5900},"NCT00507689","Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant",[87],[24],[232,5901],"Hepatitis B Immunoglobulin",{"nctId":5903,"briefTitle":5904,"status":103,"phases":5905,"primaryCompletion":4307,"completion":4307,"start":5906,"enrollment":2579,"conditions":5907,"interventions":5908},"NCT00936715","Rollover Protocol Continued Access to Emtricitabine\u002FTenofovir Disoproxil Fumarate for Adults in United States",[87],"2009-08",[24],[232],{"nctId":638,"briefTitle":639,"status":103,"phases":5910,"primaryCompletion":532,"completion":641,"start":642,"enrollment":643,"conditions":5911,"interventions":5912},[87],[537,15],[646,307,308,232,647,648,649,413],{"nctId":496,"briefTitle":497,"status":103,"phases":5914,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":5915,"interventions":5916},[86,87],[27,504],[506,507,508,509,230,510,232,307,511,512,513],{"nctId":515,"briefTitle":516,"status":103,"phases":5918,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":5919,"interventions":5920},[87],[21],[308,231,230,232,524,525],{"trials":5922,"activeCount":97},[5923,5927,5931,5935,5939,5943,5947,5951,5955,5959,5963,5967,5971,5975],{"nctId":2434,"briefTitle":2435,"status":103,"phases":5924,"primaryCompletion":2437,"completion":2438,"start":2439,"enrollment":2440,"conditions":5925,"interventions":5926},[88],[24],[782,2443,2428,2444,232],{"nctId":403,"briefTitle":404,"status":103,"phases":5928,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":5929,"interventions":5930},[88],[21],[232,47,412,413,194],{"nctId":220,"briefTitle":221,"status":103,"phases":5932,"primaryCompletion":223,"completion":121,"start":224,"enrollment":225,"conditions":5933,"interventions":5934},[88],[21],[228,229,230,231,232,93],{"nctId":545,"briefTitle":546,"status":103,"phases":5936,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":5937,"interventions":5938},[88],[537,15],[229,230,231,232,554,555,556,413,228],{"nctId":773,"briefTitle":774,"status":103,"phases":5940,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":5941,"interventions":5942},[88],[21],[228,782,783,232,784,785],{"nctId":558,"briefTitle":559,"status":103,"phases":5944,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":5945,"interventions":5946},[88],[504,15],[567,230,510,232,568,555,556,413],{"nctId":4980,"briefTitle":4981,"status":103,"phases":5948,"primaryCompletion":500,"completion":4368,"start":597,"enrollment":4983,"conditions":5949,"interventions":5950},[88],[537,15],[4978,231,232,567],{"nctId":2458,"briefTitle":2459,"status":103,"phases":5952,"primaryCompletion":597,"completion":533,"start":2379,"enrollment":2461,"conditions":5953,"interventions":5954},[88],[2334],[782,232,2374,413],{"nctId":2469,"briefTitle":2470,"status":103,"phases":5956,"primaryCompletion":2472,"completion":2438,"start":2473,"enrollment":2474,"conditions":5957,"interventions":5958},[88],[24],[782,2443,2428,2444,232],{"nctId":580,"briefTitle":581,"status":103,"phases":5960,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":5961,"interventions":5962},[88],[504,15],[228,229,507,231,230,232,308],{"nctId":5157,"briefTitle":5158,"status":103,"phases":5964,"primaryCompletion":2473,"completion":4719,"start":5160,"enrollment":5161,"conditions":5965,"interventions":5966},[88],[15],[5164,5165,5129,232,5166,5167],{"nctId":594,"briefTitle":595,"status":103,"phases":5968,"primaryCompletion":597,"completion":598,"start":563,"enrollment":599,"conditions":5969,"interventions":5970},[88],[504,15],[308,231,230,232,524,525],{"nctId":298,"briefTitle":299,"status":103,"phases":5972,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":5973,"interventions":5974},[88],[21],[231,230,307,308,309,310,232,311,93],{"nctId":5976,"briefTitle":5977,"status":103,"phases":5978,"primaryCompletion":500,"completion":4368,"start":4530,"enrollment":5979,"conditions":5980,"interventions":5981},"NCT01495702","Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",[88],439,[537,15],[5982,232,567],"NNRTI",{"trials":5984,"activeCount":97},[],{"trials":5986,"activeCount":97},[],{"intervention":5988,"totalTrials":4587,"cells":5989},"Filgotinib",{"EARLY_PHASE1":5990,"PHASE1":5992,"PHASE2":6012,"PHASE3":6090,"PHASE4":6171,"NA":6173},{"trials":5991,"activeCount":97},[],{"trials":5993,"activeCount":97},[5994,6005],{"nctId":5995,"briefTitle":5996,"status":103,"phases":5997,"primaryCompletion":1192,"completion":1192,"start":5998,"enrollment":5999,"conditions":6000,"interventions":6001},"NCT04608344","Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants",[86],"2020-11-04",27,[3863],[6002,6003,6004,5988],"Atorvastatin","Pravastatin","Rosuvastatin",{"nctId":6006,"briefTitle":6007,"status":103,"phases":6008,"primaryCompletion":6009,"completion":6009,"start":656,"enrollment":34,"conditions":6010,"interventions":6011},"NCT03417778","Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function",[86],"2018-08-09",[3863],[5988],{"trials":6013,"activeCount":97},[6014,6026,6037,6047,6058,6068,6081],{"nctId":6015,"briefTitle":6016,"status":103,"phases":6017,"primaryCompletion":6018,"completion":6019,"start":328,"enrollment":1361,"conditions":6020,"interventions":6021},"NCT02885181","Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate",[87],"2017-08-22","2017-09-20",[3863],[6022,5988,6023,6024,6025],"GS-9876","GS-9876 placebo","Filgotinib placebo","Methotrexate",{"nctId":6027,"briefTitle":6028,"status":103,"phases":6029,"primaryCompletion":6030,"completion":6031,"start":6032,"enrollment":6033,"conditions":6034,"interventions":6036},"NCT03077412","Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease",[87],"2021-01-20","2021-02-17","2017-04-06",57,[6035],"Fistulizing Crohn's Disease",[5988],{"nctId":6038,"briefTitle":6039,"status":103,"phases":6040,"primaryCompletion":6041,"completion":6041,"start":6042,"enrollment":6043,"conditions":6044,"interventions":6046},"NCT03046056","Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)",[87],"2020-07-20","2017-04-11",78,[6045],"Small Bowel Crohn's Disease",[5988],{"nctId":6048,"briefTitle":6049,"status":653,"phases":6050,"primaryCompletion":6051,"completion":6052,"start":6053,"enrollment":3974,"conditions":6054,"interventions":6056},"NCT03207815","Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis",[87],"2020-12-29","2021-04-22","2017-07-26",[6055],"Noninfectious Uveitis",[5988,6057],"Prednisone",{"nctId":6059,"briefTitle":6060,"status":103,"phases":6061,"primaryCompletion":4764,"completion":6062,"start":4267,"enrollment":629,"conditions":6063,"interventions":6065},"NCT03285711","Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)",[87],"2020-02-03",[6064],"Lupus Membranous Nephropathy",[5988,6066,6024,6067],"Lanraplenib","Lanraplenib placebo",{"nctId":6069,"briefTitle":6070,"status":103,"phases":6071,"primaryCompletion":6072,"completion":6073,"start":6074,"enrollment":6075,"conditions":6076,"interventions":6078},"NCT03100942","Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome",[87],"2019-01-10","2019-10-02","2017-05-01",152,[6077],"Sjogren's Syndrome",[6066,5988,6079,6067,6024,6080],"Tirabrutinib","Tirabrutinib placebo",{"nctId":6082,"briefTitle":6083,"status":103,"phases":6084,"primaryCompletion":452,"completion":6085,"start":6086,"enrollment":4178,"conditions":6087,"interventions":6089},"NCT03134222","Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)",[87],"2019-12-18","2017-05-24",[6088],"Cutaneous Lupus Erythematosus",[6066,5988,6067,6024],{"trials":6091,"activeCount":97},[6092,6102,6112,6123,6133,6144,6154,6162],{"nctId":6093,"briefTitle":6094,"status":103,"phases":6095,"primaryCompletion":6096,"completion":6096,"start":6097,"enrollment":6098,"conditions":6099,"interventions":6100},"NCT02914522","Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis",[88],"2020-03-31","2016-11-14",1351,[3568],[5988,6101],"PTM filgotinib",{"nctId":6103,"briefTitle":6104,"status":103,"phases":6105,"primaryCompletion":6106,"completion":1141,"start":6107,"enrollment":6108,"conditions":6109,"interventions":6110},"NCT02886728","Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy",[88],"2018-10-05","2016-08-08",1252,[3863],[5988,6111],"MTX",{"nctId":6113,"briefTitle":6114,"status":103,"phases":6115,"primaryCompletion":6116,"completion":6117,"start":6118,"enrollment":6119,"conditions":6120,"interventions":6121},"NCT02873936","Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment",[88],"2018-03-20","2018-06-26","2016-07-27",449,[3863],[5988,6122],"csDMARDs",{"nctId":6124,"briefTitle":6125,"status":653,"phases":6126,"primaryCompletion":6127,"completion":6128,"start":6129,"enrollment":535,"conditions":6130,"interventions":6132},"NCT04115839","Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy",[88],"2021-01-04","2021-03-18","2019-11-13",[6131],"Psoriatic Arthritis",[5988],{"nctId":6134,"briefTitle":6135,"status":103,"phases":6136,"primaryCompletion":6137,"completion":6138,"start":6139,"enrollment":6140,"conditions":6141,"interventions":6142},"NCT02889796","Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",[88],"2018-07-04","2019-06-20","2016-08-30",1759,[3863],[5988,6143,6111],"Adalimumab",{"nctId":6145,"briefTitle":6146,"status":1529,"phases":6147,"primaryCompletion":6148,"completion":6149,"start":6150,"enrollment":97,"conditions":6151,"interventions":6153},"NCT04483687","Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy",[88],"2023-01","2024-09","2020-12",[6152],"Ankylosing Spondylitis",[5988],{"nctId":6155,"briefTitle":6156,"status":1529,"phases":6157,"primaryCompletion":6158,"completion":6159,"start":6150,"enrollment":97,"conditions":6160,"interventions":6161},"NCT04483700","Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy",[88],"2022-10","2024-06",[6152],[5988],{"nctId":6163,"briefTitle":6164,"status":653,"phases":6165,"primaryCompletion":6166,"completion":6167,"start":6168,"enrollment":3300,"conditions":6169,"interventions":6170},"NCT04115748","Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy",[88],"2021-01-19","2021-05-11","2019-12-03",[6131],[5988,6143],{"trials":6172,"activeCount":97},[],{"trials":6174,"activeCount":97},[],{"intervention":1450,"totalTrials":1335,"cells":6176},{"EARLY_PHASE1":6177,"PHASE1":6179,"PHASE2":6207,"PHASE3":6242,"PHASE4":6262,"NA":6264},{"trials":6178,"activeCount":97},[],{"trials":6180,"activeCount":97},[6181,6185,6194,6203],{"nctId":1857,"briefTitle":1858,"status":653,"phases":6182,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":1862,"conditions":6183,"interventions":6184},[86],[1023],[1450,1865,1014,1452,1121],{"nctId":6186,"briefTitle":6187,"status":103,"phases":6188,"primaryCompletion":6189,"completion":6190,"start":6191,"enrollment":3974,"conditions":6192,"interventions":6193},"NCT01831427","Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis",[86],"2015-01-05","2015-02-06","2013-03-28",[3568],[1450],{"nctId":6195,"briefTitle":6196,"status":103,"phases":6197,"primaryCompletion":6198,"completion":6198,"start":6199,"enrollment":1225,"conditions":6200,"interventions":6202},"NCT02077465","Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)",[86],"2014-10-27","2014-03-11",[6201],"Chronic Obstructive Pulmonary Disease",[1450],{"nctId":1439,"briefTitle":1440,"status":103,"phases":6204,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":6205,"interventions":6206},[86],[1037,1010,1446,1447,1448],[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],{"trials":6208,"activeCount":97},[6209,6220,6229,6238],{"nctId":6210,"briefTitle":6211,"status":653,"phases":6212,"primaryCompletion":6213,"completion":6214,"start":6215,"enrollment":6216,"conditions":6217,"interventions":6219},"NCT02405442","Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease",[87],"2016-11-30","2016-12-22","2015-04-30",187,[6218],"Crohn's Disease",[1450],{"nctId":6221,"briefTitle":6222,"status":653,"phases":6223,"primaryCompletion":6224,"completion":41,"start":6225,"enrollment":3270,"conditions":6226,"interventions":6227},"NCT02862574","Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis",[87],"2017-06-26","2016-12-15",[3863],[1450,6025,6228],"TNF Inhibitor",{"nctId":6230,"briefTitle":6231,"status":653,"phases":6232,"primaryCompletion":6233,"completion":6234,"start":6235,"enrollment":1645,"conditions":6236,"interventions":6237},"NCT02759562","Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis",[87],"2017-07-06","2017-07-21","2016-11-04",[30],[1450],{"nctId":3206,"briefTitle":3207,"status":103,"phases":6239,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":6240,"interventions":6241},[87],[1023,3214],[1450,1121],{"trials":6243,"activeCount":97},[6244,6252],{"nctId":6245,"briefTitle":6246,"status":653,"phases":6247,"primaryCompletion":6248,"completion":1781,"start":4430,"enrollment":6249,"conditions":6250,"interventions":6251},"NCT02520284","Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis",[87,88],"2016-09",165,[3568],[1450],{"nctId":6253,"briefTitle":6254,"status":103,"phases":6255,"primaryCompletion":6256,"completion":6256,"start":6257,"enrollment":6258,"conditions":6259,"interventions":6260},"NCT02545504","Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma",[88],"2019-05-15","2015-10-13",432,[1023],[1450,1451,6261,1452],"5-fluorouracil",{"trials":6263,"activeCount":97},[],{"trials":6265,"activeCount":97},[],{"intervention":512,"totalTrials":1335,"cells":6267},{"EARLY_PHASE1":6268,"PHASE1":6270,"PHASE2":6272,"PHASE3":6302,"PHASE4":6316,"NA":6318},{"trials":6269,"activeCount":97},[],{"trials":6271,"activeCount":97},[],{"trials":6273,"activeCount":97},[6274,6278,6282,6286,6290,6294,6298],{"nctId":4173,"briefTitle":4174,"status":103,"phases":6275,"primaryCompletion":4176,"completion":1782,"start":4177,"enrollment":4178,"conditions":6276,"interventions":6277},[87],[27],[506,512,513],{"nctId":4200,"briefTitle":4201,"status":103,"phases":6279,"primaryCompletion":563,"completion":4203,"start":4204,"enrollment":4205,"conditions":6280,"interventions":6281},[87],[27],[4118,512,513],{"nctId":4218,"briefTitle":4219,"status":103,"phases":6283,"primaryCompletion":1733,"completion":1782,"start":4221,"enrollment":4222,"conditions":6284,"interventions":6285},[87],[4224],[506,513,512,4226,4095,797],{"nctId":4228,"briefTitle":4229,"status":103,"phases":6287,"primaryCompletion":2421,"completion":4231,"start":2332,"enrollment":4232,"conditions":6288,"interventions":6289},[87],[4234],[4118,512,513],{"nctId":4237,"briefTitle":4238,"status":103,"phases":6291,"primaryCompletion":695,"completion":695,"start":4240,"enrollment":4241,"conditions":6292,"interventions":6293},[87],[4116],[4118,513,512],{"nctId":4288,"briefTitle":4289,"status":653,"phases":6295,"primaryCompletion":4082,"completion":4082,"start":4203,"enrollment":4291,"conditions":6296,"interventions":6297},[87],[4190],[4294,4295,513,512],{"nctId":496,"briefTitle":497,"status":103,"phases":6299,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":6300,"interventions":6301},[86,87],[27,504],[506,507,508,509,230,510,232,307,511,512,513],{"trials":6303,"activeCount":97},[6304,6308,6312],{"nctId":4472,"briefTitle":4473,"status":103,"phases":6305,"primaryCompletion":532,"completion":4112,"start":4369,"enrollment":4475,"conditions":6306,"interventions":6307},[88],[4190],[4118,513,512],{"nctId":4527,"briefTitle":4528,"status":103,"phases":6309,"primaryCompletion":532,"completion":4112,"start":4530,"enrollment":4531,"conditions":6310,"interventions":6311},[88],[27],[4118,512,513],{"nctId":4535,"briefTitle":4536,"status":103,"phases":6313,"primaryCompletion":4538,"completion":4539,"start":4540,"enrollment":4541,"conditions":6314,"interventions":6315},[88],[4074],[4118,513,512],{"trials":6317,"activeCount":97},[],{"trials":6319,"activeCount":97},[],{"intervention":6321,"totalTrials":1122,"cells":6322},"Cilofexor",{"EARLY_PHASE1":6323,"PHASE1":6325,"PHASE2":6352,"PHASE3":6394,"PHASE4":6405,"NA":6407},{"trials":6324,"activeCount":97},[],{"trials":6326,"activeCount":97},[6327,6335,6343],{"nctId":6328,"briefTitle":6329,"status":103,"phases":6330,"primaryCompletion":6331,"completion":6331,"start":612,"enrollment":1470,"conditions":6332,"interventions":6334},"NCT02654002","Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics",[86],"2016-07-14",[6333],"Nonalcoholic Steatohepatitis (NASH)",[6321],{"nctId":6336,"briefTitle":6337,"status":653,"phases":6338,"primaryCompletion":6339,"completion":6339,"start":6340,"enrollment":1225,"conditions":6341,"interventions":6342},"NCT04060147","Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis",[86],"2021-09-02","2019-10-17",[2592,2581],[6321],{"nctId":6344,"briefTitle":6345,"status":103,"phases":6346,"primaryCompletion":6347,"completion":6347,"start":6348,"enrollment":6033,"conditions":6349,"interventions":6351},"NCT02808312","Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function",[86],"2018-10-16","2016-07-13",[6333,6350],"Primary Sclerosing Cholangitis (PSC)",[6321],{"trials":6353,"activeCount":97},[6354,6362,6376,6386],{"nctId":6355,"briefTitle":6356,"status":103,"phases":6357,"primaryCompletion":2402,"completion":6358,"start":6359,"enrollment":502,"conditions":6360,"interventions":6361},"NCT02943460","Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis",[87],"2020-05-18","2016-11-29",[2592],[6321],{"nctId":6363,"briefTitle":6364,"status":103,"phases":6365,"primaryCompletion":6366,"completion":6367,"start":6368,"enrollment":6369,"conditions":6370,"interventions":6372},"NCT04971785","Study of Semaglutide, and Cilofexor\u002FFirsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)",[87],"2024-11-12","2024-12-09","2021-08-09",457,[6371],"Nonalcoholic Steatohepatitis",[6373,6321,6374,6375],"Semaglutide","PTM SEMA","PTM CILO\u002FFIR",{"nctId":6377,"briefTitle":6378,"status":103,"phases":6379,"primaryCompletion":6380,"completion":6380,"start":6381,"enrollment":6382,"conditions":6383,"interventions":6384},"NCT03987074","Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)",[87],"2020-07-13","2019-07-29",109,[6371],[6373,6385,6321],"Firsocostat",{"nctId":6387,"briefTitle":6388,"status":653,"phases":6389,"primaryCompletion":6390,"completion":6390,"start":6391,"enrollment":16,"conditions":6392,"interventions":6393},"NCT02943447","Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis",[87],"2019-09-04","2016-12-01",[2093],[6321],{"trials":6395,"activeCount":97},[6396],{"nctId":6397,"briefTitle":6398,"status":653,"phases":6399,"primaryCompletion":6400,"completion":6401,"start":3317,"enrollment":6402,"conditions":6403,"interventions":6404},"NCT03890120","Study of Cilofexor in Adults With Primary Sclerosing Cholangitis",[88],"2022-11-10","2022-12-23",419,[2592],[6321],{"trials":6406,"activeCount":97},[],{"trials":6408,"activeCount":97},[],{"intervention":229,"totalTrials":1219,"cells":6410},{"EARLY_PHASE1":6411,"PHASE1":6413,"PHASE2":6415,"PHASE3":6421,"PHASE4":6447,"NA":6449},{"trials":6412,"activeCount":97},[],{"trials":6414,"activeCount":97},[],{"trials":6416,"activeCount":97},[6417],{"nctId":752,"briefTitle":753,"status":103,"phases":6418,"primaryCompletion":755,"completion":756,"start":757,"enrollment":758,"conditions":6419,"interventions":6420},[87],[537,15],[229,761,228,554],{"trials":6422,"activeCount":97},[6423,6427,6431,6435,6439,6443],{"nctId":529,"briefTitle":530,"status":103,"phases":6424,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":6425,"interventions":6426},[88],[537,15],[229,308,230,307,539],{"nctId":220,"briefTitle":221,"status":103,"phases":6428,"primaryCompletion":223,"completion":121,"start":224,"enrollment":225,"conditions":6429,"interventions":6430},[88],[21],[228,229,230,231,232,93],{"nctId":545,"briefTitle":546,"status":103,"phases":6432,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":6433,"interventions":6434},[88],[537,15],[229,230,231,232,554,555,556,413,228],{"nctId":803,"briefTitle":804,"status":103,"phases":6436,"primaryCompletion":806,"completion":807,"start":808,"enrollment":809,"conditions":6437,"interventions":6438},[88],[504,15],[228,229,554,761],{"nctId":580,"briefTitle":581,"status":103,"phases":6440,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":6441,"interventions":6442},[88],[504,15],[228,229,507,231,230,232,308],{"nctId":857,"briefTitle":858,"status":103,"phases":6444,"primaryCompletion":860,"completion":861,"start":862,"enrollment":809,"conditions":6445,"interventions":6446},[88],[504,15],[228,229,554,761],{"trials":6448,"activeCount":97},[],{"trials":6450,"activeCount":97},[],{"intervention":308,"totalTrials":1219,"cells":6452},{"EARLY_PHASE1":6453,"PHASE1":6455,"PHASE2":6457,"PHASE3":6467,"PHASE4":6489,"NA":6491},{"trials":6454,"activeCount":97},[],{"trials":6456,"activeCount":97},[],{"trials":6458,"activeCount":97},[6459,6463],{"nctId":638,"briefTitle":639,"status":103,"phases":6460,"primaryCompletion":532,"completion":641,"start":642,"enrollment":643,"conditions":6461,"interventions":6462},[87],[537,15],[646,307,308,232,647,648,649,413],{"nctId":515,"briefTitle":516,"status":103,"phases":6464,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":6465,"interventions":6466},[87],[21],[308,231,230,232,524,525],{"trials":6468,"activeCount":97},[6469,6473,6477,6481,6485],{"nctId":529,"briefTitle":530,"status":103,"phases":6470,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":6471,"interventions":6472},[88],[537,15],[229,308,230,307,539],{"nctId":580,"briefTitle":581,"status":103,"phases":6474,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":6475,"interventions":6476},[88],[504,15],[228,229,507,231,230,232,308],{"nctId":594,"briefTitle":595,"status":103,"phases":6478,"primaryCompletion":597,"completion":598,"start":563,"enrollment":599,"conditions":6479,"interventions":6480},[88],[504,15],[308,231,230,232,524,525],{"nctId":298,"briefTitle":299,"status":103,"phases":6482,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":6483,"interventions":6484},[88],[21],[231,230,307,308,309,310,232,311,93],{"nctId":692,"briefTitle":693,"status":103,"phases":6486,"primaryCompletion":695,"completion":696,"start":561,"enrollment":697,"conditions":6487,"interventions":6488},[88],[537,15],[308,307,206],{"trials":6490,"activeCount":97},[],{"trials":6492,"activeCount":97},[],{"intervention":112,"totalTrials":1219,"cells":6494},{"EARLY_PHASE1":6495,"PHASE1":6497,"PHASE2":6533,"PHASE3":6535,"PHASE4":6570,"NA":6572},{"trials":6496,"activeCount":97},[],{"trials":6498,"activeCount":97},[6499,6503,6514,6523],{"nctId":101,"briefTitle":102,"status":103,"phases":6500,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":6501,"interventions":6502},[86],[33],[111,93,112,113,112,114,112],{"nctId":6504,"briefTitle":6505,"status":103,"phases":6506,"primaryCompletion":6507,"completion":6508,"start":6509,"enrollment":5999,"conditions":6510,"interventions":6511},"NCT07001319","Study of GS-3242 in Participants With HIV-1; Substudy-05",[86],"2026-03-03","2026-04-16","2025-05-29",[33],[6512,6513,112],"GS-3242","BVY",{"nctId":6515,"briefTitle":6516,"status":653,"phases":6517,"primaryCompletion":6518,"completion":6518,"start":6519,"enrollment":332,"conditions":6520,"interventions":6521},"NCT04809623","Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)",[86],"2022-10-18","2021-09-01",[6088],[6522,112],"Edecesertib",{"nctId":6524,"briefTitle":6525,"status":653,"phases":6526,"primaryCompletion":6527,"completion":6528,"start":6529,"enrollment":477,"conditions":6530,"interventions":6531},"NCT07115368","Study of GS-1219 in Participants With HIV-1",[86],"2025-09-19","2025-10-02","2025-08-11",[33],[6532,6513,112],"GS-1219",{"trials":6534,"activeCount":97},[],{"trials":6536,"activeCount":97},[6537,6549,6559],{"nctId":6538,"briefTitle":6539,"status":103,"phases":6540,"primaryCompletion":6541,"completion":6542,"start":6543,"enrollment":6544,"conditions":6545,"interventions":6547},"NCT04292899","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)",[88],"2020-04-09","2020-06-30","2020-03-06",4891,[6546],"COVID-19",[6548,112],"Remdesivir",{"nctId":6550,"briefTitle":6551,"status":103,"phases":6552,"primaryCompletion":6553,"completion":6554,"start":6555,"enrollment":6556,"conditions":6557,"interventions":6558},"NCT04292730","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",[88],"2020-04-29","2020-06-26","2020-03-15",1113,[6546],[6548,112],{"nctId":6560,"briefTitle":6561,"status":653,"phases":6562,"primaryCompletion":6563,"completion":6564,"start":6565,"enrollment":6566,"conditions":6567,"interventions":6568},"NCT04745351","Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)",[88],"2022-04-20","2022-05-24","2021-03-31",249,[6546],[6548,6569,112],"RDV Placebo",{"trials":6571,"activeCount":97},[],{"trials":6573,"activeCount":97},[],{"intervention":6575,"totalTrials":1219,"cells":6576},"AZLI",{"EARLY_PHASE1":6577,"PHASE1":6579,"PHASE2":6581,"PHASE3":6591,"PHASE4":6638,"NA":6640},{"trials":6578,"activeCount":97},[],{"trials":6580,"activeCount":97},[],{"trials":6582,"activeCount":97},[6583],{"nctId":6584,"briefTitle":6585,"status":103,"phases":6586,"primaryCompletion":5358,"completion":5358,"start":4902,"enrollment":6587,"conditions":6588,"interventions":6590},"NCT00805025","Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis",[87],89,[6589],"Bronchiectasis",[6575],{"trials":6592,"activeCount":97},[6593,6600,6606,6617,6623,6630],{"nctId":6594,"briefTitle":6595,"status":103,"phases":6596,"primaryCompletion":519,"completion":519,"start":4705,"enrollment":3722,"conditions":6597,"interventions":6598},"NCT01641822","Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF",[88],[30],[6575,6599],"Tobramycin inhalation solution",{"nctId":6601,"briefTitle":6602,"status":103,"phases":6603,"primaryCompletion":4462,"completion":4082,"start":2421,"enrollment":2440,"conditions":6604,"interventions":6605},"NCT01313624","Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis",[88],[6589],[6575],{"nctId":6607,"briefTitle":6608,"status":653,"phases":6609,"primaryCompletion":6610,"completion":6611,"start":6612,"enrollment":6613,"conditions":6614,"interventions":6616},"NCT03219164","Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria",[88],"2020-05-27","2021-09-23","2017-11-28",149,[6615,30],"Pseudomonas Aeruginosa Respiratory Tract Infection\u002FColonization",[6575],{"nctId":6618,"briefTitle":6602,"status":103,"phases":6619,"primaryCompletion":4112,"completion":4349,"start":2421,"enrollment":6620,"conditions":6621,"interventions":6622},"NCT01314716",[88],274,[6589],[6575],{"nctId":6624,"briefTitle":6625,"status":103,"phases":6626,"primaryCompletion":4112,"completion":4112,"start":4530,"enrollment":4058,"conditions":6627,"interventions":6629},"NCT01404234","Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways",[88],[30,6628],"Pseudomonas Aeruginosa",[6575],{"nctId":6631,"briefTitle":6632,"status":103,"phases":6633,"primaryCompletion":561,"completion":4677,"start":6634,"enrollment":4516,"conditions":6635,"interventions":6637},"NCT01059565","Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection",[88],"2010-02",[30,6636],"Burkholderia Infections",[6575],{"trials":6639,"activeCount":97},[],{"trials":6641,"activeCount":97},[],{"intervention":6643,"totalTrials":1645,"cells":6644},"Azacitidine",{"EARLY_PHASE1":6645,"PHASE1":6647,"PHASE2":6658,"PHASE3":6686,"PHASE4":6716,"NA":6718},{"trials":6646,"activeCount":97},[],{"trials":6648,"activeCount":97},[6649],{"nctId":6650,"briefTitle":6651,"status":653,"phases":6652,"primaryCompletion":2090,"completion":2090,"start":6653,"enrollment":6654,"conditions":6655,"interventions":6657},"NCT03248479","Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies",[86],"2017-09-08",258,[6656],"Hematological Malignancies",[1049,6643],{"trials":6659,"activeCount":97},[6660,6672],{"nctId":6661,"briefTitle":6662,"status":653,"phases":6663,"primaryCompletion":6664,"completion":6664,"start":442,"enrollment":4841,"conditions":6665,"interventions":6667},"NCT04778410","Study of Magrolimab Combinations in Participants With Myeloid Malignancies",[87],"2024-03-04",[6666],"Myeloid Malignancies",[1049,6643,6668,6669,1541,6670,6671],"Venetoclax","Mitoxantrone","Cytarabine","CC-486",{"nctId":6673,"briefTitle":6674,"status":653,"phases":6675,"primaryCompletion":6676,"completion":6677,"start":6678,"enrollment":6679,"conditions":6680,"interventions":6682},"NCT02343939","Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)",[86,87],"2018-09-04","2019-02-21","2015-07-01",148,[6681],"Acute Myeloid Leukemia",[6683,6684,6670,6685,6643],"Entospletinib","Daunorubicin","Decitabine",{"trials":6687,"activeCount":97},[6688,6697,6706],{"nctId":6689,"briefTitle":6690,"status":653,"phases":6691,"primaryCompletion":6692,"completion":6692,"start":6693,"enrollment":6694,"conditions":6695,"interventions":6696},"NCT05079230","Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia",[88],"2024-04-11","2022-07-07",378,[6681],[1049,6668,6643],{"nctId":6698,"briefTitle":6699,"status":653,"phases":6700,"primaryCompletion":239,"completion":239,"start":6701,"enrollment":6654,"conditions":6702,"interventions":6703},"NCT04778397","Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated",[88],"2021-07-01",[6681],[1049,6668,6643,6670,6684,6704,6705],"Idarubicin","Steroidal Eye Drops",{"nctId":6707,"briefTitle":6708,"status":653,"phases":6709,"primaryCompletion":6710,"completion":6710,"start":6711,"enrollment":6712,"conditions":6713,"interventions":6715},"NCT04313881","Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)",[88],"2023-09-13","2020-09-09",539,[6714],"Myelodysplastic Syndromes",[1049,6643],{"trials":6717,"activeCount":97},[],{"trials":6719,"activeCount":97},[],{"intervention":6721,"totalTrials":1645,"cells":6722},"SEL",{"EARLY_PHASE1":6723,"PHASE1":6725,"PHASE2":6727,"PHASE3":6772,"PHASE4":6791,"NA":6793},{"trials":6724,"activeCount":97},[],{"trials":6726,"activeCount":97},[],{"trials":6728,"activeCount":97},[6729,6740,6752,6762],{"nctId":6730,"briefTitle":6731,"status":103,"phases":6732,"primaryCompletion":6733,"completion":6734,"start":777,"enrollment":6735,"conditions":6736,"interventions":6737},"NCT03449446","Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)",[87],"2019-10-30","2019-11-19",395,[6371],[6721,6738,6739],"FIR","CILO",{"nctId":6741,"briefTitle":6742,"status":103,"phases":6743,"primaryCompletion":6744,"completion":6744,"start":6745,"enrollment":6746,"conditions":6747,"interventions":6749},"NCT02781584","Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)",[87],"2020-12-17","2016-06-13",220,[6333,6748],"Nonalcoholic Fatty Liver Disease (NAFLD)",[6721,6738,6739,6750,6751],"FENO","VAS",{"nctId":6753,"briefTitle":6754,"status":103,"phases":6755,"primaryCompletion":6756,"completion":6756,"start":6757,"enrollment":615,"conditions":6758,"interventions":6760},"NCT02466516","Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3",[87],"2016-10-11","2015-06-08",[6759],"Non-Alcoholic Steatohepatitis (NASH)",[6721,6761],"SIM",{"nctId":6763,"briefTitle":6764,"status":103,"phases":6765,"primaryCompletion":6766,"completion":6766,"start":6767,"enrollment":6768,"conditions":6769,"interventions":6771},"NCT04026165","Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease",[87],"2021-09-03","2019-07-24",384,[6770],"Diabetic Kidney Disease",[6721],{"trials":6773,"activeCount":97},[6774,6782],{"nctId":6775,"briefTitle":6776,"status":653,"phases":6777,"primaryCompletion":6778,"completion":6778,"start":5205,"enrollment":6779,"conditions":6780,"interventions":6781},"NCT03053050","Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis",[88],"2019-06-19",808,[6371],[6721],{"nctId":6783,"briefTitle":6784,"status":653,"phases":6785,"primaryCompletion":6786,"completion":6786,"start":6787,"enrollment":6788,"conditions":6789,"interventions":6790},"NCT03053063","Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)",[88],"2019-05-06","2017-01-30",883,[6371],[6721],{"trials":6792,"activeCount":97},[],{"trials":6794,"activeCount":97},[],{"intervention":413,"totalTrials":1645,"cells":6796},{"EARLY_PHASE1":6797,"PHASE1":6799,"PHASE2":6801,"PHASE3":6811,"PHASE4":6829,"NA":6831},{"trials":6798,"activeCount":97},[],{"trials":6800,"activeCount":97},[],{"trials":6802,"activeCount":97},[6803,6807],{"nctId":2418,"briefTitle":2419,"status":103,"phases":6804,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2423,"conditions":6805,"interventions":6806},[87],[24],[2426,1356,2427,2428,2429,2430],{"nctId":638,"briefTitle":639,"status":103,"phases":6808,"primaryCompletion":532,"completion":641,"start":642,"enrollment":643,"conditions":6809,"interventions":6810},[87],[537,15],[646,307,308,232,647,648,649,413],{"trials":6812,"activeCount":97},[6813,6817,6821,6825],{"nctId":403,"briefTitle":404,"status":103,"phases":6814,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":6815,"interventions":6816},[88],[21],[232,47,412,413,194],{"nctId":545,"briefTitle":546,"status":103,"phases":6818,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":6819,"interventions":6820},[88],[537,15],[229,230,231,232,554,555,556,413,228],{"nctId":558,"briefTitle":559,"status":103,"phases":6822,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":6823,"interventions":6824},[88],[504,15],[567,230,510,232,568,555,556,413],{"nctId":2458,"briefTitle":2459,"status":103,"phases":6826,"primaryCompletion":597,"completion":533,"start":2379,"enrollment":2461,"conditions":6827,"interventions":6828},[88],[2334],[782,232,2374,413],{"trials":6830,"activeCount":97},[],{"trials":6832,"activeCount":97},[],{"intervention":6834,"totalTrials":1645,"cells":6835},"Obeldesivir",{"EARLY_PHASE1":6836,"PHASE1":6838,"PHASE2":6840,"PHASE3":6871,"PHASE4":6899,"NA":6901},{"trials":6837,"activeCount":97},[],{"trials":6839,"activeCount":97},[],{"trials":6841,"activeCount":97},[6842,6852,6863],{"nctId":6843,"briefTitle":6844,"status":1529,"phases":6845,"primaryCompletion":6846,"completion":6846,"start":6846,"enrollment":97,"conditions":6847,"interventions":6850},"NCT06682234","Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease",[87],"2025-12",[6848,6849],"Filovirus Disease","Postexposure Prophylaxis for Filovirus Disease",[6851],"obeldesivir",{"nctId":6853,"briefTitle":6854,"status":653,"phases":6855,"primaryCompletion":6856,"completion":6857,"start":6858,"enrollment":792,"conditions":6859,"interventions":6861},"NCT06585150","Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection",[87],"2025-05-08","2025-06-09","2024-10-14",[6860],"RSV Infection",[6834,6862],"Obeldesivir Placebo",{"nctId":6864,"briefTitle":6865,"status":653,"phases":6866,"primaryCompletion":6867,"completion":6867,"start":6868,"enrollment":477,"conditions":6869,"interventions":6870},"NCT06784973","Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection",[87],"2025-04-16","2025-03-05",[6860],[6834,6862],{"trials":6872,"activeCount":97},[6873,6882,6891],{"nctId":6874,"briefTitle":6875,"status":103,"phases":6876,"primaryCompletion":6877,"completion":3220,"start":6878,"enrollment":6879,"conditions":6880,"interventions":6881},"NCT05715528","Study of Obeldesivir in Nonhospitalized Participants With COVID-19",[88],"2023-11-28","2023-02-08",2011,[6546],[6834,6862],{"nctId":6883,"briefTitle":6884,"status":653,"phases":6885,"primaryCompletion":6886,"completion":6886,"start":6887,"enrollment":6888,"conditions":6889,"interventions":6890},"NCT05603143","Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness",[88],"2023-11-07","2022-11-05",468,[6546],[6834,6862],{"nctId":6892,"briefTitle":6893,"status":653,"phases":6894,"primaryCompletion":6895,"completion":6895,"start":6896,"enrollment":332,"conditions":6897,"interventions":6898},"NCT05996744","Study of Obeldesivir in Children and Adolescents With COVID-19",[87,88],"2024-02-23","2023-12-26",[6546],[6834],{"trials":6900,"activeCount":97},[],{"trials":6902,"activeCount":97},[],{"intervention":6904,"totalTrials":1645,"cells":6905},"Eleclazine",{"EARLY_PHASE1":6906,"PHASE1":6908,"PHASE2":6934,"PHASE3":6945,"PHASE4":6968,"NA":6970},{"trials":6907,"activeCount":97},[],{"trials":6909,"activeCount":97},[6910,6919,6925],{"nctId":6911,"briefTitle":6912,"status":103,"phases":6913,"primaryCompletion":6914,"completion":6914,"start":6915,"enrollment":108,"conditions":6916,"interventions":6918},"NCT02412098","Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function",[86],"2016-04-22","2015-03-19",[6917],"Long QT Syndrome",[6904],{"nctId":6920,"briefTitle":6921,"status":103,"phases":6922,"primaryCompletion":4161,"completion":4161,"start":4144,"enrollment":319,"conditions":6923,"interventions":6924},"NCT02441829","Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function",[86],[6917],[6904],{"nctId":6926,"briefTitle":6927,"status":103,"phases":6928,"primaryCompletion":6929,"completion":6745,"start":6930,"enrollment":487,"conditions":6931,"interventions":6933},"NCT02365506","Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome",[86],"2016-05-13","2015-07-20",[6932],"LQT2 Syndrome",[6904],{"trials":6935,"activeCount":97},[6936],{"nctId":6937,"briefTitle":6938,"status":103,"phases":6939,"primaryCompletion":6248,"completion":6940,"start":562,"enrollment":6941,"conditions":6942,"interventions":6944},"NCT02104583","Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator",[87],"2016-10",313,[6943],"Ventricular Arrhythmia",[6904],{"trials":6946,"activeCount":97},[6947,6958],{"nctId":6948,"briefTitle":6949,"status":653,"phases":6950,"primaryCompletion":6951,"completion":6952,"start":6953,"enrollment":433,"conditions":6954,"interventions":6956},"NCT02300558","Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3",[88],"2016-12-12","2017-02-15","2014-12-17",[6955],"Long QT Syndrome Type 3",[6904,6957],"Eleclazine placebo",{"nctId":6959,"briefTitle":6960,"status":653,"phases":6961,"primaryCompletion":6962,"completion":6963,"start":6964,"enrollment":4732,"conditions":6965,"interventions":6967},"NCT02291237","Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy",[87,88],"2017-01-20","2017-02-17","2015-02-05",[6966],"Hypertrophic Cardiomyopathy",[6904],{"trials":6969,"activeCount":97},[],{"trials":6971,"activeCount":97},[],{"intervention":567,"totalTrials":1645,"cells":6973},{"EARLY_PHASE1":6974,"PHASE1":6976,"PHASE2":6978,"PHASE3":6984,"PHASE4":7009,"NA":7011},{"trials":6975,"activeCount":97},[],{"trials":6977,"activeCount":97},[],{"trials":6979,"activeCount":97},[6980],{"nctId":5336,"briefTitle":5337,"status":103,"phases":6981,"primaryCompletion":1557,"completion":4176,"start":5339,"enrollment":16,"conditions":6982,"interventions":6983},[87],[504,15],[567,5327],{"trials":6985,"activeCount":97},[6986,6990,6994,6998,7005],{"nctId":5345,"briefTitle":5346,"status":103,"phases":6987,"primaryCompletion":4203,"completion":562,"start":4887,"enrollment":5348,"conditions":6988,"interventions":6989},[88],[504,15],[567,5327,568,5351],{"nctId":558,"briefTitle":559,"status":103,"phases":6991,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":6992,"interventions":6993},[88],[504,15],[567,230,510,232,568,555,556,413],{"nctId":4980,"briefTitle":4981,"status":103,"phases":6995,"primaryCompletion":500,"completion":4368,"start":597,"enrollment":4983,"conditions":6996,"interventions":6997},[88],[537,15],[4978,231,232,567],{"nctId":6999,"briefTitle":7000,"status":103,"phases":7001,"primaryCompletion":4134,"completion":4349,"start":4677,"enrollment":7002,"conditions":7003,"interventions":7004},"NCT01533259","Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine\u002FTenofovir DF Fixed-Dose Combination to the Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",[88],48,[537,15],[567],{"nctId":5976,"briefTitle":5977,"status":103,"phases":7006,"primaryCompletion":500,"completion":4368,"start":4530,"enrollment":5979,"conditions":7007,"interventions":7008},[88],[537,15],[5982,232,567],{"trials":7010,"activeCount":97},[],{"trials":7012,"activeCount":97},[],{"intervention":7014,"totalTrials":1507,"cells":7015},"Darusentan",{"EARLY_PHASE1":7016,"PHASE1":7018,"PHASE2":7020,"PHASE3":7032,"PHASE4":7066,"NA":7068},{"trials":7017,"activeCount":97},[],{"trials":7019,"activeCount":97},[],{"trials":7021,"activeCount":97},[7022],{"nctId":7023,"briefTitle":7024,"status":103,"phases":7025,"completion":7026,"start":7027,"conditions":7028,"interventions":7030},"NCT00364026","A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs",[87],"2005-07","2004-06",[7029],"Hypertension",[7031],"darusentan",{"trials":7033,"activeCount":97},[7034,7043,7052,7059],{"nctId":7035,"briefTitle":7036,"status":653,"phases":7037,"primaryCompletion":6634,"completion":7038,"start":2437,"enrollment":7039,"conditions":7040,"interventions":7041},"NCT00389675","DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension",[88],"2010-05",661,[7029],[7014,7042],"Guanfacine",{"nctId":7044,"briefTitle":7045,"status":103,"phases":7046,"primaryCompletion":5906,"completion":5906,"start":7047,"enrollment":7048,"conditions":7049,"interventions":7050},"NCT00389779","DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension",[88],"2006-09",849,[7029],[7014,7042,7051],"Darusentan Placebo",{"nctId":7053,"briefTitle":7054,"status":103,"phases":7055,"primaryCompletion":4720,"completion":4720,"start":2380,"enrollment":7056,"conditions":7057,"interventions":7058},"NCT00330369","DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension",[88],352,[7029],[7014,7051],{"nctId":7060,"briefTitle":7061,"status":653,"phases":7062,"primaryCompletion":6634,"completion":563,"start":7047,"enrollment":7063,"conditions":7064,"interventions":7065},"NCT00353574","DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension",[88],282,[7029],[7014],{"trials":7067,"activeCount":97},[],{"trials":7069,"activeCount":97},[],{"intervention":2456,"totalTrials":1507,"cells":7071},{"EARLY_PHASE1":7072,"PHASE1":7074,"PHASE2":7076,"PHASE3":7078,"PHASE4":7100,"NA":7102},{"trials":7073,"activeCount":97},[],{"trials":7075,"activeCount":97},[],{"trials":7077,"activeCount":97},[],{"trials":7079,"activeCount":97},[7080,7084,7088,7092,7096],{"nctId":2446,"briefTitle":2447,"status":103,"phases":7081,"primaryCompletion":2449,"completion":2450,"start":2451,"enrollment":2452,"conditions":7082,"interventions":7083},[88],[2454],[126,782,2456,2374],{"nctId":2478,"briefTitle":2479,"status":103,"phases":7085,"primaryCompletion":2481,"completion":2482,"start":2483,"enrollment":2484,"conditions":7086,"interventions":7087},[88],[2486],[126,782,2456,2374],{"nctId":2489,"briefTitle":2490,"status":103,"phases":7089,"primaryCompletion":2492,"completion":2493,"start":2494,"enrollment":2495,"conditions":7090,"interventions":7091},[88],[831,2497],[126,782,2456,2374],{"nctId":2500,"briefTitle":2501,"status":103,"phases":7093,"primaryCompletion":2503,"completion":2504,"start":2505,"enrollment":2506,"conditions":7094,"interventions":7095},[88],[24],[126,782,2456,2374],{"nctId":2510,"briefTitle":2511,"status":103,"phases":7097,"primaryCompletion":2513,"completion":2514,"start":2494,"enrollment":1379,"conditions":7098,"interventions":7099},[88],[831,2497],[126,782,2456,2374],{"trials":7101,"activeCount":97},[],{"trials":7103,"activeCount":97},[],{"intervention":172,"totalTrials":477,"cells":7105},{"EARLY_PHASE1":7106,"PHASE1":7108,"PHASE2":7110,"PHASE3":7116,"PHASE4":7130,"NA":7132},{"trials":7107,"activeCount":97},[],{"trials":7109,"activeCount":97},[],{"trials":7111,"activeCount":97},[7112],{"nctId":163,"briefTitle":164,"status":103,"phases":7113,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":7114,"interventions":7115},[87],[21],[161,47,172,173,174,93],{"trials":7117,"activeCount":97},[7118,7122,7126],{"nctId":185,"briefTitle":186,"status":103,"phases":7119,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":7120,"interventions":7121},[88],[21],[172,47,93,174,194,195],{"nctId":245,"briefTitle":246,"status":103,"phases":7123,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":7124,"interventions":7125},[88],[253],[93,172,255],{"nctId":280,"briefTitle":281,"status":103,"phases":7127,"primaryCompletion":283,"completion":284,"start":285,"enrollment":214,"conditions":7128,"interventions":7129},[88],[33],[93,47,172,174,194,195],{"trials":7131,"activeCount":97},[],{"trials":7133,"activeCount":97},[],{"intervention":195,"totalTrials":477,"cells":7135},{"EARLY_PHASE1":7136,"PHASE1":7138,"PHASE2":7140,"PHASE3":7142,"PHASE4":7160,"NA":7162},{"trials":7137,"activeCount":97},[],{"trials":7139,"activeCount":97},[],{"trials":7141,"activeCount":97},[],{"trials":7143,"activeCount":97},[7144,7148,7152,7156],{"nctId":185,"briefTitle":186,"status":103,"phases":7145,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":7146,"interventions":7147},[88],[21],[172,47,93,174,194,195],{"nctId":209,"briefTitle":210,"status":103,"phases":7149,"primaryCompletion":212,"completion":213,"start":190,"enrollment":214,"conditions":7150,"interventions":7151},[88],[21],[217,93,218,195],{"nctId":280,"briefTitle":281,"status":103,"phases":7153,"primaryCompletion":283,"completion":284,"start":285,"enrollment":214,"conditions":7154,"interventions":7155},[88],[33],[93,47,172,174,194,195],{"nctId":289,"briefTitle":290,"status":103,"phases":7157,"primaryCompletion":212,"completion":292,"start":293,"enrollment":294,"conditions":7158,"interventions":7159},[88],[21],[217,93,218,195],{"trials":7161,"activeCount":97},[],{"trials":7163,"activeCount":97},[],{"intervention":7165,"totalTrials":477,"cells":7166},"Obinutuzumab",{"EARLY_PHASE1":7167,"PHASE1":7169,"PHASE2":7181,"PHASE3":7201,"PHASE4":7211,"NA":7213},{"trials":7168,"activeCount":97},[],{"trials":7170,"activeCount":97},[7171],{"nctId":7172,"briefTitle":7173,"status":653,"phases":7174,"primaryCompletion":7175,"completion":7175,"start":7176,"enrollment":7177,"conditions":7178,"interventions":7180},"NCT02457598","Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies",[86],"2024-09-25","2015-06-16",203,[7179],"B-cell Malignancies",[6079,1538,6683,7165],{"trials":7182,"activeCount":97},[7183,7193],{"nctId":7184,"briefTitle":7185,"status":103,"phases":7186,"primaryCompletion":7187,"completion":7188,"start":7189,"enrollment":7190,"conditions":7191,"interventions":7192},"NCT02968563","Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",[87],"2019-06-17","2021-01-14","2016-12-13",35,[36],[6079,1538,7165],{"nctId":7194,"briefTitle":7195,"status":103,"phases":7196,"primaryCompletion":7197,"completion":7198,"start":6032,"enrollment":1862,"conditions":7199,"interventions":7200},"NCT02983617","Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)",[87],"2019-02-20","2020-10-01",[36],[6079,6683,7165],{"trials":7202,"activeCount":97},[7203],{"nctId":7204,"briefTitle":7205,"status":653,"phases":7206,"primaryCompletion":6929,"completion":6929,"start":7207,"enrollment":6033,"conditions":7208,"interventions":7209},"NCT01980875","Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia",[88],"2015-04-21",[36],[1538,7210,7165],"Chlorambucil",{"trials":7212,"activeCount":97},[],{"trials":7214,"activeCount":97},[],{"intervention":7216,"totalTrials":477,"cells":7217},"Bendamustine",{"EARLY_PHASE1":7218,"PHASE1":7220,"PHASE2":7238,"PHASE3":7240,"PHASE4":7270,"NA":7272},{"trials":7219,"activeCount":97},[],{"trials":7221,"activeCount":97},[7222],{"nctId":7223,"briefTitle":7224,"status":103,"phases":7225,"primaryCompletion":7226,"completion":7226,"start":7227,"enrollment":7228,"conditions":7229,"interventions":7232},"NCT01088048","Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",[86],"2015-04-28","2010-03-25",241,[7230,36,7231],"Indolent Non-Hodgkin's Lymphoma","Mantle Cell Lymphoma",[1538,1539,7216,7233,7234,7235,7236,7210,7237],"Ofatumumab","Fludarabine","Everolimus","Bortezomib","Lenalidomide",{"trials":7239,"activeCount":97},[],{"trials":7241,"activeCount":97},[7242,7252,7262],{"nctId":7243,"briefTitle":7244,"status":653,"phases":7245,"primaryCompletion":7246,"completion":7246,"start":7247,"enrollment":7248,"conditions":7249,"interventions":7251},"NCT01732926","Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",[88],"2016-05-17","2013-01-02",475,[7250],"Indolent Non-Hodgkin's Lymphomas",[1538,1539,7216],{"nctId":7253,"briefTitle":7254,"status":653,"phases":7255,"primaryCompletion":7256,"completion":7257,"start":7258,"enrollment":7259,"conditions":7260,"interventions":7261},"NCT01980888","Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia",[88],"2016-05-30","2016-06-16","2014-02-05",311,[36],[1538,7216,1539],{"nctId":7263,"briefTitle":7264,"status":103,"phases":7265,"primaryCompletion":7266,"completion":7266,"start":7267,"enrollment":1276,"conditions":7268,"interventions":7269},"NCT01569295","Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )",[88],"2019-06-10","2012-06-15",[36],[1538,1539,7216],{"trials":7271,"activeCount":97},[],{"trials":7273,"activeCount":97},[],{"intervention":6862,"totalTrials":477,"cells":7275},{"EARLY_PHASE1":7276,"PHASE1":7278,"PHASE2":7280,"PHASE3":7290,"PHASE4":7300,"NA":7302},{"trials":7277,"activeCount":97},[],{"trials":7279,"activeCount":97},[],{"trials":7281,"activeCount":97},[7282,7286],{"nctId":6853,"briefTitle":6854,"status":653,"phases":7283,"primaryCompletion":6856,"completion":6857,"start":6858,"enrollment":792,"conditions":7284,"interventions":7285},[87],[6860],[6834,6862],{"nctId":6864,"briefTitle":6865,"status":653,"phases":7287,"primaryCompletion":6867,"completion":6867,"start":6868,"enrollment":477,"conditions":7288,"interventions":7289},[87],[6860],[6834,6862],{"trials":7291,"activeCount":97},[7292,7296],{"nctId":6874,"briefTitle":6875,"status":103,"phases":7293,"primaryCompletion":6877,"completion":3220,"start":6878,"enrollment":6879,"conditions":7294,"interventions":7295},[88],[6546],[6834,6862],{"nctId":6883,"briefTitle":6884,"status":653,"phases":7297,"primaryCompletion":6886,"completion":6886,"start":6887,"enrollment":6888,"conditions":7298,"interventions":7299},[88],[6546],[6834,6862],{"trials":7301,"activeCount":97},[],{"trials":7303,"activeCount":97},[],{"intervention":5152,"totalTrials":477,"cells":7305},{"EARLY_PHASE1":7306,"PHASE1":7308,"PHASE2":7310,"PHASE3":7332,"PHASE4":7342,"NA":7344},{"trials":7307,"activeCount":97},[],{"trials":7309,"activeCount":97},[],{"trials":7311,"activeCount":97},[7312,7320,7328],{"nctId":7313,"briefTitle":7314,"status":103,"phases":7315,"enrollment":1075,"conditions":7316,"interventions":7317},"NCT00002379","The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs",[87],[15],[7318,7319,5145,5152,2395,2394],"Indinavir sulfate","Levocarnitine",{"nctId":7321,"briefTitle":7322,"status":103,"phases":7323,"enrollment":1470,"conditions":7324,"interventions":7325},"NCT00002184","A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient",[87],[15],[7326,7319,5145,7327,5152,2395,2394],"Nelfinavir mesylate","Saquinavir",{"nctId":5147,"briefTitle":5148,"status":103,"phases":7329,"enrollment":4605,"conditions":7330,"interventions":7331},[87],[15],[5129,5145,5152,5153],{"trials":7333,"activeCount":97},[7334],{"nctId":7335,"briefTitle":7336,"status":103,"phases":7337,"primaryCompletion":5041,"completion":563,"start":7027,"enrollment":7338,"conditions":7339,"interventions":7340},"NCT00095121","Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B",[88],173,[24],[7341,5152],"Adefovir Dipivoxil",{"trials":7343,"activeCount":97},[],{"trials":7345,"activeCount":97},[],{"intervention":2394,"totalTrials":477,"cells":7347},{"EARLY_PHASE1":7348,"PHASE1":7350,"PHASE2":7359,"PHASE3":7369,"PHASE4":7375,"NA":7377},{"trials":7349,"activeCount":97},[],{"trials":7351,"activeCount":97},[7352],{"nctId":7353,"briefTitle":7354,"status":103,"phases":7355,"enrollment":34,"conditions":7356,"interventions":7357},"NCT00002326","The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients",[86],[15],[7358,2394],"Adefovir",{"trials":7360,"activeCount":97},[7361,7365],{"nctId":7313,"briefTitle":7314,"status":103,"phases":7362,"enrollment":1075,"conditions":7363,"interventions":7364},[87],[15],[7318,7319,5145,5152,2395,2394],{"nctId":7321,"briefTitle":7322,"status":103,"phases":7366,"enrollment":1470,"conditions":7367,"interventions":7368},[87],[15],[7326,7319,5145,7327,5152,2395,2394],{"trials":7370,"activeCount":97},[7371],{"nctId":2385,"briefTitle":2386,"status":103,"phases":7372,"primaryCompletion":2388,"completion":2389,"start":2390,"enrollment":2391,"conditions":7373,"interventions":7374},[88],[15],[42,2394,2395],{"trials":7376,"activeCount":97},[],{"trials":7378,"activeCount":97},[],{"intervention":1451,"totalTrials":477,"cells":7380},{"EARLY_PHASE1":7381,"PHASE1":7383,"PHASE2":7389,"PHASE3":7401,"PHASE4":7407,"NA":7409},{"trials":7382,"activeCount":97},[],{"trials":7384,"activeCount":97},[7385],{"nctId":1439,"briefTitle":1440,"status":103,"phases":7386,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":7387,"interventions":7388},[86],[1037,1010,1446,1447,1448],[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],{"trials":7390,"activeCount":97},[7391,7395],{"nctId":3387,"briefTitle":3388,"status":653,"phases":7392,"primaryCompletion":3390,"completion":3390,"start":3391,"enrollment":3392,"conditions":7393,"interventions":7394},[87],[3394],[1049,1453,1454,3396,1451],{"nctId":7396,"briefTitle":7397,"status":653,"phases":7398,"primaryCompletion":4367,"completion":533,"start":4530,"enrollment":2440,"conditions":7399,"interventions":7400},"NCT01479465","Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma",[87],[1447],[1737,1451,1454,3396],{"trials":7402,"activeCount":97},[7403],{"nctId":6253,"briefTitle":6254,"status":103,"phases":7404,"primaryCompletion":6256,"completion":6256,"start":6257,"enrollment":6258,"conditions":7405,"interventions":7406},[88],[1023],[1450,1451,6261,1452],{"trials":7408,"activeCount":97},[],{"trials":7410,"activeCount":97},[],{"intervention":6670,"totalTrials":477,"cells":7412},{"EARLY_PHASE1":7413,"PHASE1":7415,"PHASE2":7426,"PHASE3":7436,"PHASE4":7442,"NA":7444},{"trials":7414,"activeCount":97},[],{"trials":7416,"activeCount":97},[7417],{"nctId":7418,"briefTitle":7419,"status":653,"phases":7420,"primaryCompletion":7421,"completion":7421,"start":7422,"enrollment":629,"conditions":7423,"interventions":7425},"NCT03135028","Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults",[86],"2019-02-26","2017-05-19",[7424,6681],"Hematologic Malignancy",[6683,6684,6670],{"trials":7427,"activeCount":97},[7428,7432],{"nctId":6661,"briefTitle":6662,"status":653,"phases":7429,"primaryCompletion":6664,"completion":6664,"start":442,"enrollment":4841,"conditions":7430,"interventions":7431},[87],[6666],[1049,6643,6668,6669,1541,6670,6671],{"nctId":6673,"briefTitle":6674,"status":653,"phases":7433,"primaryCompletion":6676,"completion":6677,"start":6678,"enrollment":6679,"conditions":7434,"interventions":7435},[86,87],[6681],[6683,6684,6670,6685,6643],{"trials":7437,"activeCount":97},[7438],{"nctId":6698,"briefTitle":6699,"status":653,"phases":7439,"primaryCompletion":239,"completion":239,"start":6701,"enrollment":6654,"conditions":7440,"interventions":7441},[88],[6681],[1049,6668,6643,6670,6684,6704,6705],{"trials":7443,"activeCount":97},[],{"trials":7445,"activeCount":97},[],{"intervention":4600,"totalTrials":477,"cells":7447},{"EARLY_PHASE1":7448,"PHASE1":7450,"PHASE2":7460,"PHASE3":7471,"PHASE4":7477,"NA":7479},{"trials":7449,"activeCount":97},[],{"trials":7451,"activeCount":97},[7452,7456],{"nctId":4594,"briefTitle":4595,"status":103,"phases":7453,"primaryCompletion":501,"completion":501,"start":2361,"enrollment":2579,"conditions":7454,"interventions":7455},[86],[4598],[4600,4586],{"nctId":4602,"briefTitle":4603,"status":103,"phases":7457,"primaryCompletion":501,"completion":501,"start":2361,"enrollment":4605,"conditions":7458,"interventions":7459},[86],[4598],[4600,4586],{"trials":7461,"activeCount":97},[7462],{"nctId":7463,"briefTitle":7464,"status":653,"phases":7465,"primaryCompletion":6634,"completion":6634,"start":4902,"enrollment":7466,"conditions":7467,"interventions":7468},"NCT00814372","Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin",[87],242,[4598],[7469,7470,4600],"MBX-102","Actos",{"trials":7472,"activeCount":97},[7473],{"nctId":4683,"briefTitle":4684,"status":103,"phases":7474,"primaryCompletion":4176,"completion":1733,"start":4369,"enrollment":4686,"conditions":7475,"interventions":7476},[88],[4598],[4586,4600],{"trials":7478,"activeCount":97},[],{"trials":7480,"activeCount":97},[],{"intervention":554,"totalTrials":477,"cells":7482},{"EARLY_PHASE1":7483,"PHASE1":7485,"PHASE2":7487,"PHASE3":7493,"PHASE4":7507,"NA":7509},{"trials":7484,"activeCount":97},[],{"trials":7486,"activeCount":97},[],{"trials":7488,"activeCount":97},[7489],{"nctId":752,"briefTitle":753,"status":103,"phases":7490,"primaryCompletion":755,"completion":756,"start":757,"enrollment":758,"conditions":7491,"interventions":7492},[87],[537,15],[229,761,228,554],{"trials":7494,"activeCount":97},[7495,7499,7503],{"nctId":545,"briefTitle":546,"status":103,"phases":7496,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":7497,"interventions":7498},[88],[537,15],[229,230,231,232,554,555,556,413,228],{"nctId":803,"briefTitle":804,"status":103,"phases":7500,"primaryCompletion":806,"completion":807,"start":808,"enrollment":809,"conditions":7501,"interventions":7502},[88],[504,15],[228,229,554,761],{"nctId":857,"briefTitle":858,"status":103,"phases":7504,"primaryCompletion":860,"completion":861,"start":862,"enrollment":809,"conditions":7505,"interventions":7506},[88],[504,15],[228,229,554,761],{"trials":7508,"activeCount":97},[],{"trials":7510,"activeCount":97},[],{"intervention":556,"totalTrials":477,"cells":7512},{"EARLY_PHASE1":7513,"PHASE1":7515,"PHASE2":7517,"PHASE3":7523,"PHASE4":7537,"NA":7539},{"trials":7514,"activeCount":97},[],{"trials":7516,"activeCount":97},[],{"trials":7518,"activeCount":97},[7519],{"nctId":515,"briefTitle":516,"status":103,"phases":7520,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":7521,"interventions":7522},[87],[21],[308,231,230,232,524,525],{"trials":7524,"activeCount":97},[7525,7529,7533],{"nctId":545,"briefTitle":546,"status":103,"phases":7526,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":7527,"interventions":7528},[88],[537,15],[229,230,231,232,554,555,556,413,228],{"nctId":558,"briefTitle":559,"status":103,"phases":7530,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":7531,"interventions":7532},[88],[504,15],[567,230,510,232,568,555,556,413],{"nctId":594,"briefTitle":595,"status":103,"phases":7534,"primaryCompletion":597,"completion":598,"start":563,"enrollment":599,"conditions":7535,"interventions":7536},[88],[504,15],[308,231,230,232,524,525],{"trials":7538,"activeCount":97},[],{"trials":7540,"activeCount":97},[],{"intervention":4977,"totalTrials":477,"cells":7542},{"EARLY_PHASE1":7543,"PHASE1":7545,"PHASE2":7547,"PHASE3":7555,"PHASE4":7581,"NA":7583},{"trials":7544,"activeCount":97},[],{"trials":7546,"activeCount":97},[],{"trials":7548,"activeCount":97},[7549],{"nctId":7550,"briefTitle":7551,"status":103,"phases":7552,"primaryCompletion":4929,"completion":501,"start":4730,"enrollment":4339,"conditions":7553,"interventions":7554},"NCT01286740","Study to Evaluate Switching From a Regimen Consisting of the Efavirenz\u002FEmtricitabine\u002FTenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine\u002FRilpivirine\u002FTenofovir Disoproxil Fumarate STR",[87],[21],[4977],{"trials":7556,"activeCount":97},[7557,7570,7574],{"nctId":7558,"briefTitle":7559,"status":103,"phases":7560,"primaryCompletion":7561,"completion":7562,"start":7563,"enrollment":7564,"conditions":7565,"interventions":7566},"NCT02345252","Switch Study to Evaluate the Safety and Efficacy of Emtricitabine\u002FRilpivirine\u002FTenofovir Alafenamide (FTC\u002FRPV\u002FTAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine\u002FRilpivirine\u002FTenofovir Disoproxil Fumarate (FTC\u002FRPV\u002FTDF)",[88],"2016-06-22","2019-01-09","2015-01-26",632,[21],[7567,7568,4977,7569],"FTC\u002FRPV\u002FTAF","FTC\u002FRPV\u002FTDF Placebo","FTC\u002FRPV\u002FTAF Placebo",{"nctId":4971,"briefTitle":4972,"status":103,"phases":7571,"primaryCompletion":4677,"completion":4367,"start":4641,"enrollment":4974,"conditions":7572,"interventions":7573},[88],[21],[4977,4978,231,206],{"nctId":7575,"briefTitle":7576,"status":103,"phases":7577,"primaryCompletion":4385,"completion":641,"start":4633,"enrollment":7578,"conditions":7579,"interventions":7580},"NCT01309243","Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine\u002FRilpivirine\u002FTenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz\u002FEmtricitabine\u002FTenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",[88],799,[21],[4977,507],{"trials":7582,"activeCount":97},[],{"trials":7584,"activeCount":97},[],{"intervention":1452,"totalTrials":477,"cells":7586},{"EARLY_PHASE1":7587,"PHASE1":7589,"PHASE2":7599,"PHASE3":7605,"PHASE4":7611,"NA":7613},{"trials":7588,"activeCount":97},[],{"trials":7590,"activeCount":97},[7591,7595],{"nctId":1857,"briefTitle":1858,"status":653,"phases":7592,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":1862,"conditions":7593,"interventions":7594},[86],[1023],[1450,1865,1014,1452,1121],{"nctId":1439,"briefTitle":1440,"status":103,"phases":7596,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":7597,"interventions":7598},[86],[1037,1010,1446,1447,1448],[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],{"trials":7600,"activeCount":97},[7601],{"nctId":1739,"briefTitle":1740,"status":653,"phases":7602,"primaryCompletion":239,"completion":239,"start":1742,"enrollment":1743,"conditions":7603,"interventions":7604},[86,87],[1745],[1049,1539,1090,1452,1747],{"trials":7606,"activeCount":97},[7607],{"nctId":6253,"briefTitle":6254,"status":103,"phases":7608,"primaryCompletion":6256,"completion":6256,"start":6257,"enrollment":6258,"conditions":7609,"interventions":7610},[88],[1023],[1450,1451,6261,1452],{"trials":7612,"activeCount":97},[],{"trials":7614,"activeCount":97},[],{"intervention":507,"totalTrials":477,"cells":7616},{"EARLY_PHASE1":7617,"PHASE1":7619,"PHASE2":7621,"PHASE3":7627,"PHASE4":7647,"NA":7649},{"trials":7618,"activeCount":97},[],{"trials":7620,"activeCount":97},[],{"trials":7622,"activeCount":97},[7623],{"nctId":496,"briefTitle":497,"status":103,"phases":7624,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":7625,"interventions":7626},[86,87],[27,504],[506,507,508,509,230,510,232,307,511,512,513],{"trials":7628,"activeCount":97},[7629,7633,7643],{"nctId":7575,"briefTitle":7576,"status":103,"phases":7630,"primaryCompletion":4385,"completion":641,"start":4633,"enrollment":7578,"conditions":7631,"interventions":7632},[88],[21],[4977,507],{"nctId":7634,"briefTitle":7635,"status":103,"phases":7636,"primaryCompletion":7637,"completion":7638,"start":7563,"enrollment":7639,"conditions":7640,"interventions":7641},"NCT02345226","Study to Evaluate Switching From a Regimen Consisting of Efavirenz\u002FEmtricitabine\u002FTenofovir Disoproxil Fumarate (EFV\u002FFTC\u002FTDF) Fixed Dose Combination (FDC) to Emtricitabine\u002FRilpivirine\u002FTenofovir Alafenamide (FTC\u002FRPV\u002FTAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults",[88],"2016-06-29","2019-01-02",881,[21],[7567,7642,507,7569],"EFV\u002FFTC\u002FTDF Placebo",{"nctId":580,"briefTitle":581,"status":103,"phases":7644,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":7645,"interventions":7646},[88],[504,15],[228,229,507,231,230,232,308],{"trials":7648,"activeCount":97},[],{"trials":7650,"activeCount":97},[],{"intervention":6668,"totalTrials":332,"cells":7652},{"EARLY_PHASE1":7653,"PHASE1":7655,"PHASE2":7657,"PHASE3":7663,"PHASE4":7673,"NA":7675},{"trials":7654,"activeCount":97},[],{"trials":7656,"activeCount":97},[],{"trials":7658,"activeCount":97},[7659],{"nctId":6661,"briefTitle":6662,"status":653,"phases":7660,"primaryCompletion":6664,"completion":6664,"start":442,"enrollment":4841,"conditions":7661,"interventions":7662},[87],[6666],[1049,6643,6668,6669,1541,6670,6671],{"trials":7664,"activeCount":97},[7665,7669],{"nctId":6689,"briefTitle":6690,"status":653,"phases":7666,"primaryCompletion":6692,"completion":6692,"start":6693,"enrollment":6694,"conditions":7667,"interventions":7668},[88],[6681],[1049,6668,6643],{"nctId":6698,"briefTitle":6699,"status":653,"phases":7670,"primaryCompletion":239,"completion":239,"start":6701,"enrollment":6654,"conditions":7671,"interventions":7672},[88],[6681],[1049,6668,6643,6670,6684,6704,6705],{"trials":7674,"activeCount":97},[],{"trials":7676,"activeCount":97},[],{"intervention":174,"totalTrials":332,"cells":7678},{"EARLY_PHASE1":7679,"PHASE1":7681,"PHASE2":7683,"PHASE3":7689,"PHASE4":7699,"NA":7701},{"trials":7680,"activeCount":97},[],{"trials":7682,"activeCount":97},[],{"trials":7684,"activeCount":97},[7685],{"nctId":163,"briefTitle":164,"status":103,"phases":7686,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":7687,"interventions":7688},[87],[21],[161,47,172,173,174,93],{"trials":7690,"activeCount":97},[7691,7695],{"nctId":185,"briefTitle":186,"status":103,"phases":7692,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":7693,"interventions":7694},[88],[21],[172,47,93,174,194,195],{"nctId":280,"briefTitle":281,"status":103,"phases":7696,"primaryCompletion":283,"completion":284,"start":285,"enrollment":214,"conditions":7697,"interventions":7698},[88],[33],[93,47,172,174,194,195],{"trials":7700,"activeCount":97},[],{"trials":7702,"activeCount":97},[],{"intervention":206,"totalTrials":332,"cells":7704},{"EARLY_PHASE1":7705,"PHASE1":7707,"PHASE2":7709,"PHASE3":7711,"PHASE4":7725,"NA":7727},{"trials":7706,"activeCount":97},[],{"trials":7708,"activeCount":97},[],{"trials":7710,"activeCount":97},[],{"trials":7712,"activeCount":97},[7713,7717,7721],{"nctId":197,"briefTitle":198,"status":103,"phases":7714,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":7715,"interventions":7716},[88],[21],[93,206,207],{"nctId":4971,"briefTitle":4972,"status":103,"phases":7718,"primaryCompletion":4677,"completion":4367,"start":4641,"enrollment":4974,"conditions":7719,"interventions":7720},[88],[21],[4977,4978,231,206],{"nctId":692,"briefTitle":693,"status":103,"phases":7722,"primaryCompletion":695,"completion":696,"start":561,"enrollment":697,"conditions":7723,"interventions":7724},[88],[537,15],[308,307,206],{"trials":7726,"activeCount":97},[],{"trials":7728,"activeCount":97},[],{"intervention":7730,"totalTrials":332,"cells":7731},"Regadenoson",{"EARLY_PHASE1":7732,"PHASE1":7734,"PHASE2":7736,"PHASE3":7746,"PHASE4":7764,"NA":7766},{"trials":7733,"activeCount":97},[],{"trials":7735,"activeCount":97},[],{"trials":7737,"activeCount":97},[7738],{"nctId":7739,"briefTitle":7740,"status":653,"phases":7741,"primaryCompletion":563,"completion":563,"start":5339,"enrollment":31,"conditions":7742,"interventions":7744},"NCT00907764","Stress Echocardiography Study With Regadenoson",[87],[7743,4696],"Heart Disease",[7745],"regadenoson",{"trials":7747,"activeCount":97},[7748,7757],{"nctId":7749,"briefTitle":7750,"status":103,"phases":7751,"primaryCompletion":2439,"completion":2439,"start":7752,"enrollment":7753,"conditions":7754,"interventions":7755},"NCT00208312","ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)",[88],"2004-04",787,[4696],[7730,7756],"Adenosine",{"nctId":7758,"briefTitle":7759,"status":103,"phases":7760,"primaryCompletion":4862,"completion":4862,"start":5122,"enrollment":7761,"conditions":7762,"interventions":7763},"NCT00208299","ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)",[88],1231,[4696],[7730,7756],{"trials":7765,"activeCount":97},[],{"trials":7767,"activeCount":97},[],{"intervention":2395,"totalTrials":332,"cells":7769},{"EARLY_PHASE1":7770,"PHASE1":7772,"PHASE2":7774,"PHASE3":7784,"PHASE4":7790,"NA":7792},{"trials":7771,"activeCount":97},[],{"trials":7773,"activeCount":97},[],{"trials":7775,"activeCount":97},[7776,7780],{"nctId":7313,"briefTitle":7314,"status":103,"phases":7777,"enrollment":1075,"conditions":7778,"interventions":7779},[87],[15],[7318,7319,5145,5152,2395,2394],{"nctId":7321,"briefTitle":7322,"status":103,"phases":7781,"enrollment":1470,"conditions":7782,"interventions":7783},[87],[15],[7326,7319,5145,7327,5152,2395,2394],{"trials":7785,"activeCount":97},[7786],{"nctId":2385,"briefTitle":2386,"status":103,"phases":7787,"primaryCompletion":2388,"completion":2389,"start":2390,"enrollment":2391,"conditions":7788,"interventions":7789},[88],[15],[42,2394,2395],{"trials":7791,"activeCount":97},[],{"trials":7793,"activeCount":97},[],{"intervention":6684,"totalTrials":332,"cells":7795},{"EARLY_PHASE1":7796,"PHASE1":7798,"PHASE2":7804,"PHASE3":7810,"PHASE4":7816,"NA":7818},{"trials":7797,"activeCount":97},[],{"trials":7799,"activeCount":97},[7800],{"nctId":7418,"briefTitle":7419,"status":653,"phases":7801,"primaryCompletion":7421,"completion":7421,"start":7422,"enrollment":629,"conditions":7802,"interventions":7803},[86],[7424,6681],[6683,6684,6670],{"trials":7805,"activeCount":97},[7806],{"nctId":6673,"briefTitle":6674,"status":653,"phases":7807,"primaryCompletion":6676,"completion":6677,"start":6678,"enrollment":6679,"conditions":7808,"interventions":7809},[86,87],[6681],[6683,6684,6670,6685,6643],{"trials":7811,"activeCount":97},[7812],{"nctId":6698,"briefTitle":6699,"status":653,"phases":7813,"primaryCompletion":239,"completion":239,"start":6701,"enrollment":6654,"conditions":7814,"interventions":7815},[88],[6681],[1049,6668,6643,6670,6684,6704,6705],{"trials":7817,"activeCount":97},[],{"trials":7819,"activeCount":97},[],{"intervention":761,"totalTrials":332,"cells":7821},{"EARLY_PHASE1":7822,"PHASE1":7824,"PHASE2":7826,"PHASE3":7832,"PHASE4":7842,"NA":7844},{"trials":7823,"activeCount":97},[],{"trials":7825,"activeCount":97},[],{"trials":7827,"activeCount":97},[7828],{"nctId":752,"briefTitle":753,"status":103,"phases":7829,"primaryCompletion":755,"completion":756,"start":757,"enrollment":758,"conditions":7830,"interventions":7831},[87],[537,15],[229,761,228,554],{"trials":7833,"activeCount":97},[7834,7838],{"nctId":803,"briefTitle":804,"status":103,"phases":7835,"primaryCompletion":806,"completion":807,"start":808,"enrollment":809,"conditions":7836,"interventions":7837},[88],[504,15],[228,229,554,761],{"nctId":857,"briefTitle":858,"status":103,"phases":7839,"primaryCompletion":860,"completion":861,"start":862,"enrollment":809,"conditions":7840,"interventions":7841},[88],[504,15],[228,229,554,761],{"trials":7843,"activeCount":97},[],{"trials":7845,"activeCount":97},[],{"intervention":524,"totalTrials":332,"cells":7847},{"EARLY_PHASE1":7848,"PHASE1":7850,"PHASE2":7852,"PHASE3":7862,"PHASE4":7868,"NA":7870},{"trials":7849,"activeCount":97},[],{"trials":7851,"activeCount":97},[],{"trials":7853,"activeCount":97},[7854,7858],{"nctId":638,"briefTitle":639,"status":103,"phases":7855,"primaryCompletion":532,"completion":641,"start":642,"enrollment":643,"conditions":7856,"interventions":7857},[87],[537,15],[646,307,308,232,647,648,649,413],{"nctId":515,"briefTitle":516,"status":103,"phases":7859,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":7860,"interventions":7861},[87],[21],[308,231,230,232,524,525],{"trials":7863,"activeCount":97},[7864],{"nctId":594,"briefTitle":595,"status":103,"phases":7865,"primaryCompletion":597,"completion":598,"start":563,"enrollment":599,"conditions":7866,"interventions":7867},[88],[504,15],[308,231,230,232,524,525],{"trials":7869,"activeCount":97},[],{"trials":7871,"activeCount":97},[],{"intervention":7233,"totalTrials":993,"cells":7873},{"EARLY_PHASE1":7874,"PHASE1":7876,"PHASE2":7882,"PHASE3":7884,"PHASE4":7895,"NA":7897},{"trials":7875,"activeCount":97},[],{"trials":7877,"activeCount":97},[7878],{"nctId":7223,"briefTitle":7224,"status":103,"phases":7879,"primaryCompletion":7226,"completion":7226,"start":7227,"enrollment":7228,"conditions":7880,"interventions":7881},[86],[7230,36,7231],[1538,1539,7216,7233,7234,7235,7236,7210,7237],{"trials":7883,"activeCount":97},[],{"trials":7885,"activeCount":97},[7886],{"nctId":7887,"briefTitle":7888,"status":653,"phases":7889,"primaryCompletion":7890,"completion":7890,"start":7891,"enrollment":7892,"conditions":7893,"interventions":7894},"NCT01659021","Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia",[88],"2018-08-15","2012-12-04",261,[36],[1538,7233],{"trials":7896,"activeCount":97},[],{"trials":7898,"activeCount":97},[],{"intervention":207,"totalTrials":993,"cells":7900},{"EARLY_PHASE1":7901,"PHASE1":7903,"PHASE2":7905,"PHASE3":7907,"PHASE4":7917,"NA":7919},{"trials":7902,"activeCount":97},[],{"trials":7904,"activeCount":97},[],{"trials":7906,"activeCount":97},[],{"trials":7908,"activeCount":97},[7909,7913],{"nctId":197,"briefTitle":198,"status":103,"phases":7910,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":7911,"interventions":7912},[88],[21],[93,206,207],{"nctId":773,"briefTitle":774,"status":103,"phases":7914,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":7915,"interventions":7916},[88],[21],[228,782,783,232,784,785],{"trials":7918,"activeCount":97},[],{"trials":7920,"activeCount":97},[],{"intervention":7210,"totalTrials":993,"cells":7922},{"EARLY_PHASE1":7923,"PHASE1":7925,"PHASE2":7931,"PHASE3":7933,"PHASE4":7939,"NA":7941},{"trials":7924,"activeCount":97},[],{"trials":7926,"activeCount":97},[7927],{"nctId":7223,"briefTitle":7224,"status":103,"phases":7928,"primaryCompletion":7226,"completion":7226,"start":7227,"enrollment":7228,"conditions":7929,"interventions":7930},[86],[7230,36,7231],[1538,1539,7216,7233,7234,7235,7236,7210,7237],{"trials":7932,"activeCount":97},[],{"trials":7934,"activeCount":97},[7935],{"nctId":7204,"briefTitle":7205,"status":653,"phases":7936,"primaryCompletion":6929,"completion":6929,"start":7207,"enrollment":6033,"conditions":7937,"interventions":7938},[88],[36],[1538,7210,7165],{"trials":7940,"activeCount":97},[],{"trials":7942,"activeCount":97},[],{"intervention":1146,"totalTrials":993,"cells":7944},{"EARLY_PHASE1":7945,"PHASE1":7947,"PHASE2":7949,"PHASE3":7951,"PHASE4":7961,"NA":7963},{"trials":7946,"activeCount":97},[],{"trials":7948,"activeCount":97},[],{"trials":7950,"activeCount":97},[],{"trials":7952,"activeCount":97},[7953,7957],{"nctId":1755,"briefTitle":1756,"status":103,"phases":7954,"primaryCompletion":1758,"completion":1759,"start":1760,"enrollment":1761,"conditions":7955,"interventions":7956},[88],[1448],[1764,1146,1147,1090,1148],{"nctId":1137,"briefTitle":1138,"status":103,"phases":7958,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":7959,"interventions":7960},[88],[1144],[57,1146,1147,1090,1148],{"trials":7962,"activeCount":97},[],{"trials":7964,"activeCount":97},[],{"intervention":1250,"totalTrials":993,"cells":7966},{"EARLY_PHASE1":7967,"PHASE1":7969,"PHASE2":7975,"PHASE3":7977,"PHASE4":7983,"NA":7985},{"trials":7968,"activeCount":97},[],{"trials":7970,"activeCount":97},[7971],{"nctId":1241,"briefTitle":1242,"status":653,"phases":7972,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":487,"conditions":7973,"interventions":7974},[86],[1247],[1249,1089,1014,1013,1250,991],{"trials":7976,"activeCount":97},[],{"trials":7978,"activeCount":97},[7979],{"nctId":6253,"briefTitle":6254,"status":103,"phases":7980,"primaryCompletion":6256,"completion":6256,"start":6257,"enrollment":6258,"conditions":7981,"interventions":7982},[88],[1023],[1450,1451,6261,1452],{"trials":7984,"activeCount":97},[],{"trials":7986,"activeCount":97},[],{"intervention":7756,"totalTrials":993,"cells":7988},{"EARLY_PHASE1":7989,"PHASE1":7991,"PHASE2":7993,"PHASE3":7995,"PHASE4":8005,"NA":8007},{"trials":7990,"activeCount":97},[],{"trials":7992,"activeCount":97},[],{"trials":7994,"activeCount":97},[],{"trials":7996,"activeCount":97},[7997,8001],{"nctId":7749,"briefTitle":7750,"status":103,"phases":7998,"primaryCompletion":2439,"completion":2439,"start":7752,"enrollment":7753,"conditions":7999,"interventions":8000},[88],[4696],[7730,7756],{"nctId":7758,"briefTitle":7759,"status":103,"phases":8002,"primaryCompletion":4862,"completion":4862,"start":5122,"enrollment":7761,"conditions":8003,"interventions":8004},[88],[4696],[7730,7756],{"trials":8006,"activeCount":97},[],{"trials":8008,"activeCount":97},[],{"intervention":2443,"totalTrials":993,"cells":8010},{"EARLY_PHASE1":8011,"PHASE1":8013,"PHASE2":8015,"PHASE3":8017,"PHASE4":8027,"NA":8029},{"trials":8012,"activeCount":97},[],{"trials":8014,"activeCount":97},[],{"trials":8016,"activeCount":97},[],{"trials":8018,"activeCount":97},[8019,8023],{"nctId":2434,"briefTitle":2435,"status":103,"phases":8020,"primaryCompletion":2437,"completion":2438,"start":2439,"enrollment":2440,"conditions":8021,"interventions":8022},[88],[24],[782,2443,2428,2444,232],{"nctId":2469,"briefTitle":2470,"status":103,"phases":8024,"primaryCompletion":2472,"completion":2438,"start":2473,"enrollment":2474,"conditions":8025,"interventions":8026},[88],[24],[782,2443,2428,2444,232],{"trials":8028,"activeCount":97},[],{"trials":8030,"activeCount":97},[],{"intervention":2444,"totalTrials":993,"cells":8032},{"EARLY_PHASE1":8033,"PHASE1":8035,"PHASE2":8037,"PHASE3":8039,"PHASE4":8049,"NA":8051},{"trials":8034,"activeCount":97},[],{"trials":8036,"activeCount":97},[],{"trials":8038,"activeCount":97},[],{"trials":8040,"activeCount":97},[8041,8045],{"nctId":2434,"briefTitle":2435,"status":103,"phases":8042,"primaryCompletion":2437,"completion":2438,"start":2439,"enrollment":2440,"conditions":8043,"interventions":8044},[88],[24],[782,2443,2428,2444,232],{"nctId":2469,"briefTitle":2470,"status":103,"phases":8046,"primaryCompletion":2472,"completion":2438,"start":2473,"enrollment":2474,"conditions":8047,"interventions":8048},[88],[24],[782,2443,2428,2444,232],{"trials":8050,"activeCount":97},[],{"trials":8052,"activeCount":97},[],{"intervention":217,"totalTrials":993,"cells":8054},{"EARLY_PHASE1":8055,"PHASE1":8057,"PHASE2":8059,"PHASE3":8061,"PHASE4":8071,"NA":8073},{"trials":8056,"activeCount":97},[],{"trials":8058,"activeCount":97},[],{"trials":8060,"activeCount":97},[],{"trials":8062,"activeCount":97},[8063,8067],{"nctId":209,"briefTitle":210,"status":103,"phases":8064,"primaryCompletion":212,"completion":213,"start":190,"enrollment":214,"conditions":8065,"interventions":8066},[88],[21],[217,93,218,195],{"nctId":289,"briefTitle":290,"status":103,"phases":8068,"primaryCompletion":212,"completion":292,"start":293,"enrollment":294,"conditions":8069,"interventions":8070},[88],[21],[217,93,218,195],{"trials":8072,"activeCount":97},[],{"trials":8074,"activeCount":97},[],{"intervention":218,"totalTrials":993,"cells":8076},{"EARLY_PHASE1":8077,"PHASE1":8079,"PHASE2":8081,"PHASE3":8083,"PHASE4":8093,"NA":8095},{"trials":8078,"activeCount":97},[],{"trials":8080,"activeCount":97},[],{"trials":8082,"activeCount":97},[],{"trials":8084,"activeCount":97},[8085,8089],{"nctId":209,"briefTitle":210,"status":103,"phases":8086,"primaryCompletion":212,"completion":213,"start":190,"enrollment":214,"conditions":8087,"interventions":8088},[88],[21],[217,93,218,195],{"nctId":289,"briefTitle":290,"status":103,"phases":8090,"primaryCompletion":212,"completion":292,"start":293,"enrollment":294,"conditions":8091,"interventions":8092},[88],[21],[217,93,218,195],{"trials":8094,"activeCount":97},[],{"trials":8096,"activeCount":97},[],{"intervention":1787,"totalTrials":993,"cells":8098},{"EARLY_PHASE1":8099,"PHASE1":8101,"PHASE2":8103,"PHASE3":8111,"PHASE4":8117,"NA":8119},{"trials":8100,"activeCount":97},[],{"trials":8102,"activeCount":97},[],{"trials":8104,"activeCount":97},[8105],{"nctId":8106,"briefTitle":8107,"status":103,"phases":8108,"primaryCompletion":4349,"completion":1782,"start":2351,"enrollment":1056,"conditions":8109,"interventions":8110},"NCT00603863","Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer",[86,87],[1037],[1787],{"trials":8112,"activeCount":97},[8113],{"nctId":1778,"briefTitle":1779,"status":653,"phases":8114,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":1783,"conditions":8115,"interventions":8116},[88],[1785,1037],[1787,1090],{"trials":8118,"activeCount":97},[],{"trials":8120,"activeCount":97},[],{"intervention":555,"totalTrials":993,"cells":8122},{"EARLY_PHASE1":8123,"PHASE1":8125,"PHASE2":8127,"PHASE3":8129,"PHASE4":8139,"NA":8141},{"trials":8124,"activeCount":97},[],{"trials":8126,"activeCount":97},[],{"trials":8128,"activeCount":97},[],{"trials":8130,"activeCount":97},[8131,8135],{"nctId":545,"briefTitle":546,"status":103,"phases":8132,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":8133,"interventions":8134},[88],[537,15],[229,230,231,232,554,555,556,413,228],{"nctId":558,"briefTitle":559,"status":103,"phases":8136,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":8137,"interventions":8138},[88],[504,15],[567,230,510,232,568,555,556,413],{"trials":8140,"activeCount":97},[],{"trials":8142,"activeCount":97},[],{"intervention":7042,"totalTrials":993,"cells":8144},{"EARLY_PHASE1":8145,"PHASE1":8147,"PHASE2":8149,"PHASE3":8151,"PHASE4":8161,"NA":8163},{"trials":8146,"activeCount":97},[],{"trials":8148,"activeCount":97},[],{"trials":8150,"activeCount":97},[],{"trials":8152,"activeCount":97},[8153,8157],{"nctId":7035,"briefTitle":7036,"status":653,"phases":8154,"primaryCompletion":6634,"completion":7038,"start":2437,"enrollment":7039,"conditions":8155,"interventions":8156},[88],[7029],[7014,7042],{"nctId":7044,"briefTitle":7045,"status":103,"phases":8158,"primaryCompletion":5906,"completion":5906,"start":7047,"enrollment":7048,"conditions":8159,"interventions":8160},[88],[7029],[7014,7042,7051],{"trials":8162,"activeCount":97},[],{"trials":8164,"activeCount":97},[],{"intervention":8166,"totalTrials":993,"cells":8167},"Aztreonam for Inhalation Solution",{"EARLY_PHASE1":8168,"PHASE1":8170,"PHASE2":8172,"PHASE3":8181,"PHASE4":8191,"NA":8193},{"trials":8169,"activeCount":97},[],{"trials":8171,"activeCount":97},[],{"trials":8173,"activeCount":97},[8174],{"nctId":8175,"briefTitle":8176,"status":103,"phases":8177,"primaryCompletion":4113,"completion":4113,"start":4203,"enrollment":8178,"conditions":8179,"interventions":8180},"NCT01375049","Aztreonam Lysine for Pseudomonas Infection Eradication Study",[87],105,[30],[8166],{"trials":8182,"activeCount":97},[8183],{"nctId":8184,"briefTitle":8185,"status":103,"phases":8186,"primaryCompletion":7038,"completion":4641,"start":8187,"enrollment":6620,"conditions":8188,"interventions":8189},"NCT00757237","Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa",[88],"2008-08",[30],[8166,8190],"Tobramycin Inhalation Solution",{"trials":8192,"activeCount":97},[],{"trials":8194,"activeCount":97},[],{"intervention":8190,"totalTrials":993,"cells":8196},{"EARLY_PHASE1":8197,"PHASE1":8199,"PHASE2":8201,"PHASE3":8203,"PHASE4":8213,"NA":8215},{"trials":8198,"activeCount":97},[],{"trials":8200,"activeCount":97},[],{"trials":8202,"activeCount":97},[],{"trials":8204,"activeCount":97},[8205,8209],{"nctId":8184,"briefTitle":8185,"status":103,"phases":8206,"primaryCompletion":7038,"completion":4641,"start":8187,"enrollment":6620,"conditions":8207,"interventions":8208},[88],[30],[8166,8190],{"nctId":6594,"briefTitle":6595,"status":103,"phases":8210,"primaryCompletion":519,"completion":519,"start":4705,"enrollment":3722,"conditions":8211,"interventions":8212},[88],[30],[6575,6599],{"trials":8214,"activeCount":97},[],{"trials":8216,"activeCount":97},[],{"intervention":7567,"totalTrials":993,"cells":8218},{"EARLY_PHASE1":8219,"PHASE1":8221,"PHASE2":8223,"PHASE3":8225,"PHASE4":8235,"NA":8237},{"trials":8220,"activeCount":97},[],{"trials":8222,"activeCount":97},[],{"trials":8224,"activeCount":97},[],{"trials":8226,"activeCount":97},[8227,8231],{"nctId":7558,"briefTitle":7559,"status":103,"phases":8228,"primaryCompletion":7561,"completion":7562,"start":7563,"enrollment":7564,"conditions":8229,"interventions":8230},[88],[21],[7567,7568,4977,7569],{"nctId":7634,"briefTitle":7635,"status":103,"phases":8232,"primaryCompletion":7637,"completion":7638,"start":7563,"enrollment":7639,"conditions":8233,"interventions":8234},[88],[21],[7567,7642,507,7569],{"trials":8236,"activeCount":97},[],{"trials":8238,"activeCount":97},[],{"intervention":7569,"totalTrials":993,"cells":8240},{"EARLY_PHASE1":8241,"PHASE1":8243,"PHASE2":8245,"PHASE3":8247,"PHASE4":8257,"NA":8259},{"trials":8242,"activeCount":97},[],{"trials":8244,"activeCount":97},[],{"trials":8246,"activeCount":97},[],{"trials":8248,"activeCount":97},[8249,8253],{"nctId":7558,"briefTitle":7559,"status":103,"phases":8250,"primaryCompletion":7561,"completion":7562,"start":7563,"enrollment":7564,"conditions":8251,"interventions":8252},[88],[21],[7567,7568,4977,7569],{"nctId":7634,"briefTitle":7635,"status":103,"phases":8254,"primaryCompletion":7637,"completion":7638,"start":7563,"enrollment":7639,"conditions":8255,"interventions":8256},[88],[21],[7567,7642,507,7569],{"trials":8258,"activeCount":97},[],{"trials":8260,"activeCount":97},[],{"intervention":4978,"totalTrials":993,"cells":8262},{"EARLY_PHASE1":8263,"PHASE1":8265,"PHASE2":8267,"PHASE3":8269,"PHASE4":8279,"NA":8281},{"trials":8264,"activeCount":97},[],{"trials":8266,"activeCount":97},[],{"trials":8268,"activeCount":97},[],{"trials":8270,"activeCount":97},[8271,8275],{"nctId":4971,"briefTitle":4972,"status":103,"phases":8272,"primaryCompletion":4677,"completion":4367,"start":4641,"enrollment":4974,"conditions":8273,"interventions":8274},[88],[21],[4977,4978,231,206],{"nctId":4980,"briefTitle":4981,"status":103,"phases":8276,"primaryCompletion":500,"completion":4368,"start":597,"enrollment":4983,"conditions":8277,"interventions":8278},[88],[537,15],[4978,231,232,567],{"trials":8280,"activeCount":97},[],{"trials":8282,"activeCount":97},[],{"intervention":783,"totalTrials":993,"cells":8284},{"EARLY_PHASE1":8285,"PHASE1":8287,"PHASE2":8289,"PHASE3":8295,"PHASE4":8301,"NA":8303},{"trials":8286,"activeCount":97},[],{"trials":8288,"activeCount":97},[],{"trials":8290,"activeCount":97},[8291],{"nctId":2358,"briefTitle":2359,"status":103,"phases":8292,"primaryCompletion":2361,"completion":695,"start":2362,"enrollment":2363,"conditions":8293,"interventions":8294},[87],[24],[42,783],{"trials":8296,"activeCount":97},[8297],{"nctId":773,"briefTitle":774,"status":103,"phases":8298,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":8299,"interventions":8300},[88],[21],[228,782,783,232,784,785],{"trials":8302,"activeCount":97},[],{"trials":8304,"activeCount":97},[],{"intervention":568,"totalTrials":993,"cells":8306},{"EARLY_PHASE1":8307,"PHASE1":8309,"PHASE2":8311,"PHASE3":8313,"PHASE4":8323,"NA":8325},{"trials":8308,"activeCount":97},[],{"trials":8310,"activeCount":97},[],{"trials":8312,"activeCount":97},[],{"trials":8314,"activeCount":97},[8315,8319],{"nctId":5345,"briefTitle":5346,"status":103,"phases":8316,"primaryCompletion":4203,"completion":562,"start":4887,"enrollment":5348,"conditions":8317,"interventions":8318},[88],[504,15],[567,5327,568,5351],{"nctId":558,"briefTitle":559,"status":103,"phases":8320,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":8321,"interventions":8322},[88],[504,15],[567,230,510,232,568,555,556,413],{"trials":8324,"activeCount":97},[],{"trials":8326,"activeCount":97},[],{"intervention":7051,"totalTrials":993,"cells":8328},{"EARLY_PHASE1":8329,"PHASE1":8331,"PHASE2":8333,"PHASE3":8335,"PHASE4":8345,"NA":8347},{"trials":8330,"activeCount":97},[],{"trials":8332,"activeCount":97},[],{"trials":8334,"activeCount":97},[],{"trials":8336,"activeCount":97},[8337,8341],{"nctId":7044,"briefTitle":7045,"status":103,"phases":8338,"primaryCompletion":5906,"completion":5906,"start":7047,"enrollment":7048,"conditions":8339,"interventions":8340},[88],[7029],[7014,7042,7051],{"nctId":7053,"briefTitle":7054,"status":103,"phases":8342,"primaryCompletion":4720,"completion":4720,"start":2380,"enrollment":7056,"conditions":8343,"interventions":8344},[88],[7029],[7014,7051],{"trials":8346,"activeCount":97},[],{"trials":8348,"activeCount":97},[],{"intervention":8350,"totalTrials":993,"cells":8351},"Enoximone",{"EARLY_PHASE1":8352,"PHASE1":8354,"PHASE2":8356,"PHASE3":8358,"PHASE4":8377,"NA":8379},{"trials":8353,"activeCount":97},[],{"trials":8355,"activeCount":97},[],{"trials":8357,"activeCount":97},[],{"trials":8359,"activeCount":97},[8360,8368],{"nctId":8361,"briefTitle":8362,"status":653,"phases":8363,"primaryCompletion":2439,"completion":2439,"start":5160,"enrollment":3987,"conditions":8364,"interventions":8366},"NCT00077948","Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure",[88],[8365],"Heart Failure, Congestive",[8350,8367],"Metoprolol succinate",{"nctId":8369,"briefTitle":8370,"status":653,"phases":8371,"primaryCompletion":2439,"completion":2439,"start":8372,"enrollment":8373,"conditions":8374,"interventions":8375},"NCT00051285","ESSENTIAL-\"The Studies of Oral Enoximone Therapy in Advanced Heart Failure\"",[88],"2002-02",1800,[8365],[8350,8376],"Enoximone placebo",{"trials":8378,"activeCount":97},[],{"trials":8380,"activeCount":97},[],{"intervention":8382,"totalTrials":993,"cells":8383},"AZLI 75 mg two times a day",{"EARLY_PHASE1":8384,"PHASE1":8386,"PHASE2":8388,"PHASE3":8390,"PHASE4":8407,"NA":8409},{"trials":8385,"activeCount":97},[],{"trials":8387,"activeCount":97},[],{"trials":8389,"activeCount":97},[],{"trials":8391,"activeCount":97},[8392,8400],{"nctId":8393,"briefTitle":8394,"status":103,"phases":8395,"primaryCompletion":8396,"completion":4720,"start":8397,"enrollment":6620,"conditions":8398,"interventions":8399},"NCT00128492","Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)",[88],"2008-11","2005-08",[30],[8382],{"nctId":8401,"briefTitle":8402,"status":103,"phases":8403,"primaryCompletion":7047,"completion":7047,"start":2473,"enrollment":8404,"conditions":8405,"interventions":8406},"NCT00104520","Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa",[88],211,[30],[8382],{"trials":8408,"activeCount":97},[],{"trials":8410,"activeCount":97},[],{"intervention":8412,"totalTrials":993,"cells":8413},"Background regimen",{"EARLY_PHASE1":8414,"PHASE1":8416,"PHASE2":8418,"PHASE3":8420,"PHASE4":8442,"NA":8444},{"trials":8415,"activeCount":97},[],{"trials":8417,"activeCount":97},[],{"trials":8419,"activeCount":97},[],{"trials":8421,"activeCount":97},[8422,8433],{"nctId":8423,"briefTitle":8424,"status":103,"phases":8425,"primaryCompletion":4221,"completion":598,"start":4861,"enrollment":8426,"conditions":8427,"interventions":8428},"NCT00708162","Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",[88],724,[5223],[8429,8430,8431,8432,8412],"Elvitegravir","Raltegravir","EVG placebo","RAL placebo",{"nctId":8434,"briefTitle":8435,"status":653,"phases":8436,"primaryCompletion":8437,"completion":8437,"start":8438,"enrollment":8439,"conditions":8440,"interventions":8441},"NCT01923311","Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI\u002Fr Background Regimen for ARV Treatment-Experienced Pediatric Participants",[87,88],"2017-11-03","2013-08-26",31,[470,15],[4951,8412],{"trials":8443,"activeCount":97},[],{"trials":8445,"activeCount":97},[],{"intervention":6111,"totalTrials":993,"cells":8447},{"EARLY_PHASE1":8448,"PHASE1":8450,"PHASE2":8452,"PHASE3":8454,"PHASE4":8464,"NA":8466},{"trials":8449,"activeCount":97},[],{"trials":8451,"activeCount":97},[],{"trials":8453,"activeCount":97},[],{"trials":8455,"activeCount":97},[8456,8460],{"nctId":6103,"briefTitle":6104,"status":103,"phases":8457,"primaryCompletion":6106,"completion":1141,"start":6107,"enrollment":6108,"conditions":8458,"interventions":8459},[88],[3863],[5988,6111],{"nctId":6134,"briefTitle":6135,"status":103,"phases":8461,"primaryCompletion":6137,"completion":6138,"start":6139,"enrollment":6140,"conditions":8462,"interventions":8463},[88],[3863],[5988,6143,6111],{"trials":8465,"activeCount":97},[],{"trials":8467,"activeCount":97},[],{"intervention":4951,"totalTrials":993,"cells":8469},{"EARLY_PHASE1":8470,"PHASE1":8472,"PHASE2":8474,"PHASE3":8480,"PHASE4":8486,"NA":8488},{"trials":8471,"activeCount":97},[],{"trials":8473,"activeCount":97},[],{"trials":8475,"activeCount":97},[8476],{"nctId":4946,"briefTitle":4947,"status":103,"phases":8477,"primaryCompletion":4212,"completion":4212,"start":4668,"enrollment":1111,"conditions":8478,"interventions":8479},[87],[15],[4951,231,661],{"trials":8481,"activeCount":97},[8482],{"nctId":8434,"briefTitle":8435,"status":653,"phases":8483,"primaryCompletion":8437,"completion":8437,"start":8438,"enrollment":8439,"conditions":8484,"interventions":8485},[87,88],[470,15],[4951,8412],{"trials":8487,"activeCount":97},[],{"trials":8489,"activeCount":97},[],{"intervention":6143,"totalTrials":993,"cells":8491},{"EARLY_PHASE1":8492,"PHASE1":8494,"PHASE2":8496,"PHASE3":8498,"PHASE4":8508,"NA":8510},{"trials":8493,"activeCount":97},[],{"trials":8495,"activeCount":97},[],{"trials":8497,"activeCount":97},[],{"trials":8499,"activeCount":97},[8500,8504],{"nctId":6134,"briefTitle":6135,"status":103,"phases":8501,"primaryCompletion":6137,"completion":6138,"start":6139,"enrollment":6140,"conditions":8502,"interventions":8503},[88],[3863],[5988,6143,6111],{"nctId":6163,"briefTitle":6164,"status":653,"phases":8505,"primaryCompletion":6166,"completion":6167,"start":6168,"enrollment":3300,"conditions":8506,"interventions":8507},[88],[6131],[5988,6143],{"trials":8509,"activeCount":97},[],{"trials":8511,"activeCount":97},[],{"intervention":7469,"totalTrials":993,"cells":8513},{"EARLY_PHASE1":8514,"PHASE1":8516,"PHASE2":8518,"PHASE3":8524,"PHASE4":8534,"NA":8536},{"trials":8515,"activeCount":97},[],{"trials":8517,"activeCount":97},[],{"trials":8519,"activeCount":97},[8520],{"nctId":7463,"briefTitle":7464,"status":653,"phases":8521,"primaryCompletion":6634,"completion":6634,"start":4902,"enrollment":7466,"conditions":8522,"interventions":8523},[87],[4598],[7469,7470,4600],{"trials":8525,"activeCount":97},[8526],{"nctId":8527,"briefTitle":8528,"status":103,"phases":8529,"primaryCompletion":4731,"completion":4731,"start":5041,"enrollment":8530,"conditions":8531,"interventions":8533},"NCT00353587","Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin",[87,88],396,[8532],"Type 2 Diabetes",[7469,7469,7469,7470],{"trials":8535,"activeCount":97},[],{"trials":8537,"activeCount":97},[],{"intervention":7470,"totalTrials":993,"cells":8539},{"EARLY_PHASE1":8540,"PHASE1":8542,"PHASE2":8544,"PHASE3":8550,"PHASE4":8556,"NA":8558},{"trials":8541,"activeCount":97},[],{"trials":8543,"activeCount":97},[],{"trials":8545,"activeCount":97},[8546],{"nctId":7463,"briefTitle":7464,"status":653,"phases":8547,"primaryCompletion":6634,"completion":6634,"start":4902,"enrollment":7466,"conditions":8548,"interventions":8549},[87],[4598],[7469,7470,4600],{"trials":8551,"activeCount":97},[8552],{"nctId":8527,"briefTitle":8528,"status":103,"phases":8553,"primaryCompletion":4731,"completion":4731,"start":5041,"enrollment":8530,"conditions":8554,"interventions":8555},[87,88],[8532],[7469,7469,7469,7470],{"trials":8557,"activeCount":97},[],{"trials":8559,"activeCount":97},[],{"intervention":539,"totalTrials":147,"cells":8561},{"EARLY_PHASE1":8562,"PHASE1":8564,"PHASE2":8566,"PHASE3":8568,"PHASE4":8574,"NA":8576},{"trials":8563,"activeCount":97},[],{"trials":8565,"activeCount":97},[],{"trials":8567,"activeCount":97},[],{"trials":8569,"activeCount":97},[8570],{"nctId":529,"briefTitle":530,"status":103,"phases":8571,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":8572,"interventions":8573},[88],[537,15],[229,308,230,307,539],{"trials":8575,"activeCount":97},[],{"trials":8577,"activeCount":97},[],{"intervention":412,"totalTrials":147,"cells":8579},{"EARLY_PHASE1":8580,"PHASE1":8582,"PHASE2":8584,"PHASE3":8586,"PHASE4":8592,"NA":8594},{"trials":8581,"activeCount":97},[],{"trials":8583,"activeCount":97},[],{"trials":8585,"activeCount":97},[],{"trials":8587,"activeCount":97},[8588],{"nctId":403,"briefTitle":404,"status":103,"phases":8589,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":8590,"interventions":8591},[88],[21],[232,47,412,413,194],{"trials":8593,"activeCount":97},[],{"trials":8595,"activeCount":97},[],{"intervention":6704,"totalTrials":147,"cells":8597},{"EARLY_PHASE1":8598,"PHASE1":8600,"PHASE2":8602,"PHASE3":8604,"PHASE4":8610,"NA":8612},{"trials":8599,"activeCount":97},[],{"trials":8601,"activeCount":97},[],{"trials":8603,"activeCount":97},[],{"trials":8605,"activeCount":97},[8606],{"nctId":6698,"briefTitle":6699,"status":653,"phases":8607,"primaryCompletion":239,"completion":239,"start":6701,"enrollment":6654,"conditions":8608,"interventions":8609},[88],[6681],[1049,6668,6643,6670,6684,6704,6705],{"trials":8611,"activeCount":97},[],{"trials":8613,"activeCount":97},[],{"intervention":6705,"totalTrials":147,"cells":8615},{"EARLY_PHASE1":8616,"PHASE1":8618,"PHASE2":8620,"PHASE3":8622,"PHASE4":8628,"NA":8630},{"trials":8617,"activeCount":97},[],{"trials":8619,"activeCount":97},[],{"trials":8621,"activeCount":97},[],{"trials":8623,"activeCount":97},[8624],{"nctId":6698,"briefTitle":6699,"status":653,"phases":8625,"primaryCompletion":239,"completion":239,"start":6701,"enrollment":6654,"conditions":8626,"interventions":8627},[88],[6681],[1049,6668,6643,6670,6684,6704,6705],{"trials":8629,"activeCount":97},[],{"trials":8631,"activeCount":97},[],{"intervention":7568,"totalTrials":147,"cells":8633},{"EARLY_PHASE1":8634,"PHASE1":8636,"PHASE2":8638,"PHASE3":8640,"PHASE4":8646,"NA":8648},{"trials":8635,"activeCount":97},[],{"trials":8637,"activeCount":97},[],{"trials":8639,"activeCount":97},[],{"trials":8641,"activeCount":97},[8642],{"nctId":7558,"briefTitle":7559,"status":103,"phases":8643,"primaryCompletion":7561,"completion":7562,"start":7563,"enrollment":7564,"conditions":8644,"interventions":8645},[88],[21],[7567,7568,4977,7569],{"trials":8647,"activeCount":97},[],{"trials":8649,"activeCount":97},[],{"intervention":784,"totalTrials":147,"cells":8651},{"EARLY_PHASE1":8652,"PHASE1":8654,"PHASE2":8656,"PHASE3":8658,"PHASE4":8664,"NA":8666},{"trials":8653,"activeCount":97},[],{"trials":8655,"activeCount":97},[],{"trials":8657,"activeCount":97},[],{"trials":8659,"activeCount":97},[8660],{"nctId":773,"briefTitle":774,"status":103,"phases":8661,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":8662,"interventions":8663},[88],[21],[228,782,783,232,784,785],{"trials":8665,"activeCount":97},[],{"trials":8667,"activeCount":97},[],{"intervention":796,"totalTrials":147,"cells":8669},{"EARLY_PHASE1":8670,"PHASE1":8672,"PHASE2":8674,"PHASE3":8676,"PHASE4":8682,"NA":8684},{"trials":8671,"activeCount":97},[],{"trials":8673,"activeCount":97},[],{"trials":8675,"activeCount":97},[],{"trials":8677,"activeCount":97},[8678],{"nctId":787,"briefTitle":788,"status":103,"phases":8679,"primaryCompletion":790,"completion":316,"start":791,"enrollment":792,"conditions":8680,"interventions":8681},[88],[21,794],[228,796,797],{"trials":8683,"activeCount":97},[],{"trials":8685,"activeCount":97},[],{"intervention":438,"totalTrials":147,"cells":8687},{"EARLY_PHASE1":8688,"PHASE1":8690,"PHASE2":8692,"PHASE3":8694,"PHASE4":8700,"NA":8702},{"trials":8689,"activeCount":97},[],{"trials":8691,"activeCount":97},[],{"trials":8693,"activeCount":97},[],{"trials":8695,"activeCount":97},[8696],{"nctId":427,"briefTitle":428,"status":103,"phases":8697,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":8698,"interventions":8699},[87,88],[435],[47,437,438],{"trials":8701,"activeCount":97},[],{"trials":8703,"activeCount":97},[],{"intervention":5351,"totalTrials":147,"cells":8705},{"EARLY_PHASE1":8706,"PHASE1":8708,"PHASE2":8710,"PHASE3":8712,"PHASE4":8718,"NA":8720},{"trials":8707,"activeCount":97},[],{"trials":8709,"activeCount":97},[],{"trials":8711,"activeCount":97},[],{"trials":8713,"activeCount":97},[8714],{"nctId":5345,"briefTitle":5346,"status":103,"phases":8715,"primaryCompletion":4203,"completion":562,"start":4887,"enrollment":5348,"conditions":8716,"interventions":8717},[88],[504,15],[567,5327,568,5351],{"trials":8719,"activeCount":97},[],{"trials":8721,"activeCount":97},[],{"intervention":8723,"totalTrials":147,"cells":8724},"zidovudine and lamivudine",{"EARLY_PHASE1":8725,"PHASE1":8727,"PHASE2":8729,"PHASE3":8731,"PHASE4":8741,"NA":8743},{"trials":8726,"activeCount":97},[],{"trials":8728,"activeCount":97},[],{"trials":8730,"activeCount":97},[],{"trials":8732,"activeCount":97},[8733],{"nctId":8734,"briefTitle":8735,"status":103,"phases":8736,"primaryCompletion":8737,"completion":5174,"start":2340,"enrollment":6746,"conditions":8738,"interventions":8739},"NCT00323544","SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection",[88],"2007-06",[15],[8723,8740],"emtricitabine and tenofovir DF",{"trials":8742,"activeCount":97},[],{"trials":8744,"activeCount":97},[],{"intervention":8740,"totalTrials":147,"cells":8746},{"EARLY_PHASE1":8747,"PHASE1":8749,"PHASE2":8751,"PHASE3":8753,"PHASE4":8759,"NA":8761},{"trials":8748,"activeCount":97},[],{"trials":8750,"activeCount":97},[],{"trials":8752,"activeCount":97},[],{"trials":8754,"activeCount":97},[8755],{"nctId":8734,"briefTitle":8735,"status":103,"phases":8756,"primaryCompletion":8737,"completion":5174,"start":2340,"enrollment":6746,"conditions":8757,"interventions":8758},[88],[15],[8723,8740],{"trials":8760,"activeCount":97},[],{"trials":8762,"activeCount":97},[],{"intervention":8764,"totalTrials":147,"cells":8765},"Adefovir Dipivoxil for oral suspension, 2 mg\u002FmL",{"EARLY_PHASE1":8766,"PHASE1":8768,"PHASE2":8770,"PHASE3":8772,"PHASE4":8781,"NA":8783},{"trials":8767,"activeCount":97},[],{"trials":8769,"activeCount":97},[],{"trials":8771,"activeCount":97},[],{"trials":8773,"activeCount":97},[8774],{"nctId":8775,"briefTitle":8776,"status":103,"phases":8777,"primaryCompletion":2353,"completion":2353,"start":8778,"enrollment":7002,"conditions":8779,"interventions":8780},"NCT00071201","Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B",[88],"2003-06",[24],[8764],{"trials":8782,"activeCount":97},[],{"trials":8784,"activeCount":97},[],{"intervention":578,"totalTrials":147,"cells":8786},{"EARLY_PHASE1":8787,"PHASE1":8789,"PHASE2":8791,"PHASE3":8793,"PHASE4":8799,"NA":8801},{"trials":8788,"activeCount":97},[],{"trials":8790,"activeCount":97},[],{"trials":8792,"activeCount":97},[],{"trials":8794,"activeCount":97},[8795],{"nctId":570,"briefTitle":571,"status":103,"phases":8796,"primaryCompletion":573,"completion":574,"start":575,"enrollment":319,"conditions":8797,"interventions":8798},[88],[504,15,537],[126,228,578,230],{"trials":8800,"activeCount":97},[],{"trials":8802,"activeCount":97},[],{"intervention":7642,"totalTrials":147,"cells":8804},{"EARLY_PHASE1":8805,"PHASE1":8807,"PHASE2":8809,"PHASE3":8811,"PHASE4":8817,"NA":8819},{"trials":8806,"activeCount":97},[],{"trials":8808,"activeCount":97},[],{"trials":8810,"activeCount":97},[],{"trials":8812,"activeCount":97},[8813],{"nctId":7634,"briefTitle":7635,"status":103,"phases":8814,"primaryCompletion":7637,"completion":7638,"start":7563,"enrollment":7639,"conditions":8815,"interventions":8816},[88],[21],[7567,7642,507,7569],{"trials":8818,"activeCount":97},[],{"trials":8820,"activeCount":97},[],{"intervention":6957,"totalTrials":147,"cells":8822},{"EARLY_PHASE1":8823,"PHASE1":8825,"PHASE2":8827,"PHASE3":8829,"PHASE4":8835,"NA":8837},{"trials":8824,"activeCount":97},[],{"trials":8826,"activeCount":97},[],{"trials":8828,"activeCount":97},[],{"trials":8830,"activeCount":97},[8831],{"nctId":6948,"briefTitle":6949,"status":653,"phases":8832,"primaryCompletion":6951,"completion":6952,"start":6953,"enrollment":433,"conditions":8833,"interventions":8834},[88],[6955],[6904,6957],{"trials":8836,"activeCount":97},[],{"trials":8838,"activeCount":97},[],{"intervention":8367,"totalTrials":147,"cells":8840},{"EARLY_PHASE1":8841,"PHASE1":8843,"PHASE2":8845,"PHASE3":8847,"PHASE4":8853,"NA":8855},{"trials":8842,"activeCount":97},[],{"trials":8844,"activeCount":97},[],{"trials":8846,"activeCount":97},[],{"trials":8848,"activeCount":97},[8849],{"nctId":8361,"briefTitle":8362,"status":653,"phases":8850,"primaryCompletion":2439,"completion":2439,"start":5160,"enrollment":3987,"conditions":8851,"interventions":8852},[88],[8365],[8350,8367],{"trials":8854,"activeCount":97},[],{"trials":8856,"activeCount":97},[],{"intervention":6101,"totalTrials":147,"cells":8858},{"EARLY_PHASE1":8859,"PHASE1":8861,"PHASE2":8863,"PHASE3":8865,"PHASE4":8871,"NA":8873},{"trials":8860,"activeCount":97},[],{"trials":8862,"activeCount":97},[],{"trials":8864,"activeCount":97},[],{"trials":8866,"activeCount":97},[8867],{"nctId":6093,"briefTitle":6094,"status":103,"phases":8868,"primaryCompletion":6096,"completion":6096,"start":6097,"enrollment":6098,"conditions":8869,"interventions":8870},[88],[3568],[5988,6101],{"trials":8872,"activeCount":97},[],{"trials":8874,"activeCount":97},[],{"intervention":456,"totalTrials":147,"cells":8876},{"EARLY_PHASE1":8877,"PHASE1":8879,"PHASE2":8881,"PHASE3":8883,"PHASE4":8889,"NA":8891},{"trials":8878,"activeCount":97},[],{"trials":8880,"activeCount":97},[],{"trials":8882,"activeCount":97},[],{"trials":8884,"activeCount":97},[8885],{"nctId":448,"briefTitle":449,"status":103,"phases":8886,"primaryCompletion":451,"completion":452,"start":453,"enrollment":214,"conditions":8887,"interventions":8888},[88],[21],[47,311,456,194,437],{"trials":8890,"activeCount":97},[],{"trials":8892,"activeCount":97},[],{"intervention":8894,"totalTrials":147,"cells":8895},"RDV",{"EARLY_PHASE1":8896,"PHASE1":8898,"PHASE2":8900,"PHASE3":8902,"PHASE4":8913,"NA":8915},{"trials":8897,"activeCount":97},[],{"trials":8899,"activeCount":97},[],{"trials":8901,"activeCount":97},[],{"trials":8903,"activeCount":97},[8904],{"nctId":8905,"briefTitle":8906,"status":653,"phases":8907,"primaryCompletion":8908,"completion":8908,"start":8909,"enrollment":8910,"conditions":8911,"interventions":8912},"NCT04501952","Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting",[88],"2021-05-06","2020-09-18",584,[6546],[8894],{"trials":8914,"activeCount":97},[],{"trials":8916,"activeCount":97},[],{"intervention":8376,"totalTrials":147,"cells":8918},{"EARLY_PHASE1":8919,"PHASE1":8921,"PHASE2":8923,"PHASE3":8925,"PHASE4":8931,"NA":8933},{"trials":8920,"activeCount":97},[],{"trials":8922,"activeCount":97},[],{"trials":8924,"activeCount":97},[],{"trials":8926,"activeCount":97},[8927],{"nctId":8369,"briefTitle":8370,"status":653,"phases":8928,"primaryCompletion":2439,"completion":2439,"start":8372,"enrollment":8373,"conditions":8929,"interventions":8930},[88],[8365],[8350,8376],{"trials":8932,"activeCount":97},[],{"trials":8934,"activeCount":97},[],{"intervention":8936,"totalTrials":147,"cells":8937},"EVG\u002FCOBI\u002FFTC\u002FTDF",{"EARLY_PHASE1":8938,"PHASE1":8940,"PHASE2":8942,"PHASE3":8944,"PHASE4":8954,"NA":8956},{"trials":8939,"activeCount":97},[],{"trials":8941,"activeCount":97},[],{"trials":8943,"activeCount":97},[],{"trials":8945,"activeCount":97},[8946],{"nctId":8947,"briefTitle":8948,"status":103,"phases":8949,"primaryCompletion":8950,"completion":8951,"start":2371,"enrollment":4339,"conditions":8952,"interventions":8953},"NCT01721109","Pharmacokinetics, Safety, and Efficacy of Elvitegravir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents",[87,88],"2015-10-22","2018-01-29",[537,15],[8936],{"trials":8955,"activeCount":97},[],{"trials":8957,"activeCount":97},[],{"intervention":2104,"totalTrials":147,"cells":8959},{"EARLY_PHASE1":8960,"PHASE1":8962,"PHASE2":8964,"PHASE3":8966,"PHASE4":8972,"NA":8974},{"trials":8961,"activeCount":97},[],{"trials":8963,"activeCount":97},[],{"trials":8965,"activeCount":97},[],{"trials":8967,"activeCount":97},[8968],{"nctId":2096,"briefTitle":2097,"status":103,"phases":8969,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":2101,"conditions":8970,"interventions":8971},[88],[2093],[2104,2105],{"trials":8973,"activeCount":97},[],{"trials":8975,"activeCount":97},[],{"intervention":8429,"totalTrials":147,"cells":8977},{"EARLY_PHASE1":8978,"PHASE1":8980,"PHASE2":8982,"PHASE3":8984,"PHASE4":8990,"NA":8992},{"trials":8979,"activeCount":97},[],{"trials":8981,"activeCount":97},[],{"trials":8983,"activeCount":97},[],{"trials":8985,"activeCount":97},[8986],{"nctId":8423,"briefTitle":8424,"status":103,"phases":8987,"primaryCompletion":4221,"completion":598,"start":4861,"enrollment":8426,"conditions":8988,"interventions":8989},[88],[5223],[8429,8430,8431,8432,8412],{"trials":8991,"activeCount":97},[],{"trials":8993,"activeCount":97},[],{"intervention":8430,"totalTrials":147,"cells":8995},{"EARLY_PHASE1":8996,"PHASE1":8998,"PHASE2":9000,"PHASE3":9002,"PHASE4":9008,"NA":9010},{"trials":8997,"activeCount":97},[],{"trials":8999,"activeCount":97},[],{"trials":9001,"activeCount":97},[],{"trials":9003,"activeCount":97},[9004],{"nctId":8423,"briefTitle":8424,"status":103,"phases":9005,"primaryCompletion":4221,"completion":598,"start":4861,"enrollment":8426,"conditions":9006,"interventions":9007},[88],[5223],[8429,8430,8431,8432,8412],{"trials":9009,"activeCount":97},[],{"trials":9011,"activeCount":97},[],{"intervention":8431,"totalTrials":147,"cells":9013},{"EARLY_PHASE1":9014,"PHASE1":9016,"PHASE2":9018,"PHASE3":9020,"PHASE4":9026,"NA":9028},{"trials":9015,"activeCount":97},[],{"trials":9017,"activeCount":97},[],{"trials":9019,"activeCount":97},[],{"trials":9021,"activeCount":97},[9022],{"nctId":8423,"briefTitle":8424,"status":103,"phases":9023,"primaryCompletion":4221,"completion":598,"start":4861,"enrollment":8426,"conditions":9024,"interventions":9025},[88],[5223],[8429,8430,8431,8432,8412],{"trials":9027,"activeCount":97},[],{"trials":9029,"activeCount":97},[],{"intervention":8432,"totalTrials":147,"cells":9031},{"EARLY_PHASE1":9032,"PHASE1":9034,"PHASE2":9036,"PHASE3":9038,"PHASE4":9044,"NA":9046},{"trials":9033,"activeCount":97},[],{"trials":9035,"activeCount":97},[],{"trials":9037,"activeCount":97},[],{"trials":9039,"activeCount":97},[9040],{"nctId":8423,"briefTitle":8424,"status":103,"phases":9041,"primaryCompletion":4221,"completion":598,"start":4861,"enrollment":8426,"conditions":9042,"interventions":9043},[88],[5223],[8429,8430,8431,8432,8412],{"trials":9045,"activeCount":97},[],{"trials":9047,"activeCount":97},[],{"intervention":4681,"totalTrials":147,"cells":9049},{"EARLY_PHASE1":9050,"PHASE1":9052,"PHASE2":9054,"PHASE3":9056,"PHASE4":9062,"NA":9064},{"trials":9051,"activeCount":97},[],{"trials":9053,"activeCount":97},[],{"trials":9055,"activeCount":97},[],{"trials":9057,"activeCount":97},[9058],{"nctId":4674,"briefTitle":4675,"status":103,"phases":9059,"primaryCompletion":499,"completion":499,"start":4677,"enrollment":4678,"conditions":9060,"interventions":9061},[88],[4598],[4586,4681],{"trials":9063,"activeCount":97},[],{"trials":9065,"activeCount":97},[],{"intervention":5166,"totalTrials":147,"cells":9067},{"EARLY_PHASE1":9068,"PHASE1":9070,"PHASE2":9072,"PHASE3":9074,"PHASE4":9080,"NA":9082},{"trials":9069,"activeCount":97},[],{"trials":9071,"activeCount":97},[],{"trials":9073,"activeCount":97},[],{"trials":9075,"activeCount":97},[9076],{"nctId":5157,"briefTitle":5158,"status":103,"phases":9077,"primaryCompletion":2473,"completion":4719,"start":5160,"enrollment":5161,"conditions":9078,"interventions":9079},[88],[15],[5164,5165,5129,232,5166,5167],{"trials":9081,"activeCount":97},[],{"trials":9083,"activeCount":97},[],{"intervention":5167,"totalTrials":147,"cells":9085},{"EARLY_PHASE1":9086,"PHASE1":9088,"PHASE2":9090,"PHASE3":9092,"PHASE4":9098,"NA":9100},{"trials":9087,"activeCount":97},[],{"trials":9089,"activeCount":97},[],{"trials":9091,"activeCount":97},[],{"trials":9093,"activeCount":97},[9094],{"nctId":5157,"briefTitle":5158,"status":103,"phases":9095,"primaryCompletion":2473,"completion":4719,"start":5160,"enrollment":5161,"conditions":9096,"interventions":9097},[88],[15],[5164,5165,5129,232,5166,5167],{"trials":9099,"activeCount":97},[],{"trials":9101,"activeCount":97},[],{"intervention":309,"totalTrials":147,"cells":9103},{"EARLY_PHASE1":9104,"PHASE1":9106,"PHASE2":9108,"PHASE3":9110,"PHASE4":9116,"NA":9118},{"trials":9105,"activeCount":97},[],{"trials":9107,"activeCount":97},[],{"trials":9109,"activeCount":97},[],{"trials":9111,"activeCount":97},[9112],{"nctId":298,"briefTitle":299,"status":103,"phases":9113,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":9114,"interventions":9115},[88],[21],[231,230,307,308,309,310,232,311,93],{"trials":9117,"activeCount":97},[],{"trials":9119,"activeCount":97},[],{"intervention":310,"totalTrials":147,"cells":9121},{"EARLY_PHASE1":9122,"PHASE1":9124,"PHASE2":9126,"PHASE3":9128,"PHASE4":9134,"NA":9136},{"trials":9123,"activeCount":97},[],{"trials":9125,"activeCount":97},[],{"trials":9127,"activeCount":97},[],{"trials":9129,"activeCount":97},[9130],{"nctId":298,"briefTitle":299,"status":103,"phases":9131,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":9132,"interventions":9133},[88],[21],[231,230,307,308,309,310,232,311,93],{"trials":9135,"activeCount":97},[],{"trials":9137,"activeCount":97},[],{"intervention":9139,"totalTrials":147,"cells":9140},"AZLI 75 mg three times a day",{"EARLY_PHASE1":9141,"PHASE1":9143,"PHASE2":9145,"PHASE3":9147,"PHASE4":9156,"NA":9158},{"trials":9142,"activeCount":97},[],{"trials":9144,"activeCount":97},[],{"trials":9146,"activeCount":97},[],{"trials":9148,"activeCount":97},[9149],{"nctId":9150,"briefTitle":9151,"status":103,"phases":9152,"primaryCompletion":2472,"completion":2472,"start":4852,"enrollment":9153,"conditions":9154,"interventions":9155},"NCT00112359","International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa",[88],166,[30],[9139],{"trials":9157,"activeCount":97},[],{"trials":9159,"activeCount":97},[],{"intervention":690,"totalTrials":147,"cells":9161},{"EARLY_PHASE1":9162,"PHASE1":9164,"PHASE2":9166,"PHASE3":9168,"PHASE4":9174,"NA":9176},{"trials":9163,"activeCount":97},[],{"trials":9165,"activeCount":97},[],{"trials":9167,"activeCount":97},[],{"trials":9169,"activeCount":97},[9170],{"nctId":681,"briefTitle":682,"status":103,"phases":9171,"primaryCompletion":684,"completion":685,"start":686,"enrollment":687,"conditions":9172,"interventions":9173},[88],[435,15,537],[228,307,690],{"trials":9175,"activeCount":97},[],{"trials":9177,"activeCount":97},[],{"intervention":1197,"totalTrials":147,"cells":9179},{"EARLY_PHASE1":9180,"PHASE1":9182,"PHASE2":9184,"PHASE3":9186,"PHASE4":9192,"NA":9194},{"trials":9181,"activeCount":97},[],{"trials":9183,"activeCount":97},[],{"trials":9185,"activeCount":97},[],{"trials":9187,"activeCount":97},[9188],{"nctId":1188,"briefTitle":1189,"status":103,"phases":9189,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":9190,"interventions":9191},[88],[1195],[57,1051,991,1197],{"trials":9193,"activeCount":97},[],{"trials":9195,"activeCount":97},[],{"intervention":5308,"totalTrials":147,"cells":9197},{"EARLY_PHASE1":9198,"PHASE1":9200,"PHASE2":9202,"PHASE3":9204,"PHASE4":9210,"NA":9212},{"trials":9199,"activeCount":97},[],{"trials":9201,"activeCount":97},[],{"trials":9203,"activeCount":97},[],{"trials":9205,"activeCount":97},[9206],{"nctId":5300,"briefTitle":5301,"status":103,"phases":9207,"primaryCompletion":5303,"completion":4082,"start":5304,"enrollment":5305,"conditions":9208,"interventions":9209},[88],[15],[5027,5308,5309,5310],{"trials":9211,"activeCount":97},[],{"trials":9213,"activeCount":97},[],{"intervention":5309,"totalTrials":147,"cells":9215},{"EARLY_PHASE1":9216,"PHASE1":9218,"PHASE2":9220,"PHASE3":9222,"PHASE4":9228,"NA":9230},{"trials":9217,"activeCount":97},[],{"trials":9219,"activeCount":97},[],{"trials":9221,"activeCount":97},[],{"trials":9223,"activeCount":97},[9224],{"nctId":5300,"briefTitle":5301,"status":103,"phases":9225,"primaryCompletion":5303,"completion":4082,"start":5304,"enrollment":5305,"conditions":9226,"interventions":9227},[88],[15],[5027,5308,5309,5310],{"trials":9229,"activeCount":97},[],{"trials":9231,"activeCount":97},[],{"intervention":5310,"totalTrials":147,"cells":9233},{"EARLY_PHASE1":9234,"PHASE1":9236,"PHASE2":9238,"PHASE3":9240,"PHASE4":9246,"NA":9248},{"trials":9235,"activeCount":97},[],{"trials":9237,"activeCount":97},[],{"trials":9239,"activeCount":97},[],{"trials":9241,"activeCount":97},[9242],{"nctId":5300,"briefTitle":5301,"status":103,"phases":9243,"primaryCompletion":5303,"completion":4082,"start":5304,"enrollment":5305,"conditions":9244,"interventions":9245},[88],[15],[5027,5308,5309,5310],{"trials":9247,"activeCount":97},[],{"trials":9249,"activeCount":97},[],{"intervention":5982,"totalTrials":147,"cells":9251},{"EARLY_PHASE1":9252,"PHASE1":9254,"PHASE2":9256,"PHASE3":9258,"PHASE4":9264,"NA":9266},{"trials":9253,"activeCount":97},[],{"trials":9255,"activeCount":97},[],{"trials":9257,"activeCount":97},[],{"trials":9259,"activeCount":97},[9260],{"nctId":5976,"briefTitle":5977,"status":103,"phases":9261,"primaryCompletion":500,"completion":4368,"start":4530,"enrollment":5979,"conditions":9262,"interventions":9263},[88],[537,15],[5982,232,567],{"trials":9265,"activeCount":97},[],{"trials":9267,"activeCount":97},[],{"intervention":9269,"totalTrials":147,"cells":9270},"AZLI 75 mg three times daily",{"EARLY_PHASE1":9271,"PHASE1":9273,"PHASE2":9275,"PHASE3":9277,"PHASE4":9287,"NA":9289},{"trials":9272,"activeCount":97},[],{"trials":9274,"activeCount":97},[],{"trials":9276,"activeCount":97},[],{"trials":9278,"activeCount":97},[9279],{"nctId":9280,"briefTitle":9281,"status":103,"phases":9282,"primaryCompletion":4719,"completion":5906,"start":5425,"enrollment":9283,"conditions":9284,"interventions":9286},"NCT00712166","Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa",[88],160,[30,9285,6628],"Lung Infection",[9269],{"trials":9288,"activeCount":97},[],{"trials":9290,"activeCount":97},[],{"intervention":6122,"totalTrials":147,"cells":9292},{"EARLY_PHASE1":9293,"PHASE1":9295,"PHASE2":9297,"PHASE3":9299,"PHASE4":9305,"NA":9307},{"trials":9294,"activeCount":97},[],{"trials":9296,"activeCount":97},[],{"trials":9298,"activeCount":97},[],{"trials":9300,"activeCount":97},[9301],{"nctId":6113,"briefTitle":6114,"status":103,"phases":9302,"primaryCompletion":6116,"completion":6117,"start":6118,"enrollment":6119,"conditions":9303,"interventions":9304},[88],[3863],[5988,6122],{"trials":9306,"activeCount":97},[],{"trials":9308,"activeCount":97},[],{"intervention":6569,"totalTrials":147,"cells":9310},{"EARLY_PHASE1":9311,"PHASE1":9313,"PHASE2":9315,"PHASE3":9317,"PHASE4":9323,"NA":9325},{"trials":9312,"activeCount":97},[],{"trials":9314,"activeCount":97},[],{"trials":9316,"activeCount":97},[],{"trials":9318,"activeCount":97},[9319],{"nctId":6560,"briefTitle":6561,"status":653,"phases":9320,"primaryCompletion":6563,"completion":6564,"start":6565,"enrollment":6566,"conditions":9321,"interventions":9322},[88],[6546],[6548,6569,112],{"trials":9324,"activeCount":97},[],{"trials":9326,"activeCount":97},[],{"intervention":893,"totalTrials":147,"cells":9328},{"EARLY_PHASE1":9329,"PHASE1":9331,"PHASE2":9333,"PHASE3":9335,"PHASE4":9341,"NA":9343},{"trials":9330,"activeCount":97},[],{"trials":9332,"activeCount":97},[],{"trials":9334,"activeCount":97},[],{"trials":9336,"activeCount":97},[9337],{"nctId":884,"briefTitle":885,"status":103,"phases":9338,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":9339,"interventions":9340},[88],[21],[228,311,893],{"trials":9342,"activeCount":97},[],{"trials":9344,"activeCount":97},[],{"intervention":6079,"totalTrials":1122,"cells":9346},{"EARLY_PHASE1":9347,"PHASE1":9349,"PHASE2":9384,"PHASE3":9408,"PHASE4":9410,"NA":9412},{"trials":9348,"activeCount":97},[],{"trials":9350,"activeCount":97},[9351,9359,9370,9380],{"nctId":9352,"briefTitle":9353,"status":103,"phases":9354,"primaryCompletion":3211,"completion":3211,"start":9355,"enrollment":9356,"conditions":9357,"interventions":9358},"NCT02626026","Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)",[86],"2016-01-26",42,[3863],[6079],{"nctId":9360,"briefTitle":9361,"status":103,"phases":9362,"primaryCompletion":9363,"completion":9364,"start":9365,"enrollment":2091,"conditions":9366,"interventions":9369},"NCT01659255","Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO\u002FGS-4059) Given as Monotherapy in Participants With Relapsed\u002FRefractory NHL and CLL",[86],"2015-02-23","2016-01-11","2012-08-17",[9367,9368],"Non Hodgkins Lymphoma","Chronic Lymphocytic Leukaemia",[6079],{"nctId":9371,"briefTitle":9372,"status":103,"phases":9373,"primaryCompletion":9374,"completion":9374,"start":9375,"enrollment":9376,"conditions":9377,"interventions":9379},"NCT02457559","Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed\u002FRefractory B-cell Malignancies",[86],"2020-12-30","2015-09-10",29,[9378],"Relapsed\u002FRefractory B-cell Malignancies",[6079],{"nctId":7172,"briefTitle":7173,"status":653,"phases":9381,"primaryCompletion":7175,"completion":7175,"start":7176,"enrollment":7177,"conditions":9382,"interventions":9383},[86],[7179],[6079,1538,6683,7165],{"trials":9385,"activeCount":97},[9386,9390,9394,9404],{"nctId":7184,"briefTitle":7185,"status":103,"phases":9387,"primaryCompletion":7187,"completion":7188,"start":7189,"enrollment":7190,"conditions":9388,"interventions":9389},[87],[36],[6079,1538,7165],{"nctId":7194,"briefTitle":7195,"status":103,"phases":9391,"primaryCompletion":7197,"completion":7198,"start":6032,"enrollment":1862,"conditions":9392,"interventions":9393},[87],[36],[6079,6683,7165],{"nctId":9395,"briefTitle":9396,"status":1529,"phases":9397,"primaryCompletion":9398,"completion":9399,"start":9400,"enrollment":97,"conditions":9401,"interventions":9403},"NCT04827589","Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria",[87],"2022-04","2022-09","2021-07",[9402],"Chronic Spontaneous Urticaria",[6079],{"nctId":6069,"briefTitle":6070,"status":103,"phases":9405,"primaryCompletion":6072,"completion":6073,"start":6074,"enrollment":6075,"conditions":9406,"interventions":9407},[87],[6077],[6066,5988,6079,6067,6024,6080],{"trials":9409,"activeCount":97},[],{"trials":9411,"activeCount":97},[],{"trials":9413,"activeCount":97},[],{"intervention":1737,"totalTrials":1122,"cells":9415},{"EARLY_PHASE1":9416,"PHASE1":9418,"PHASE2":9420,"PHASE3":9483,"PHASE4":9485,"NA":9487},{"trials":9417,"activeCount":97},[],{"trials":9419,"activeCount":97},[],{"trials":9421,"activeCount":97},[9422,9433,9443,9452,9456,9462,9472,9476],{"nctId":9423,"briefTitle":9424,"status":103,"phases":9425,"primaryCompletion":9426,"completion":9427,"start":9428,"enrollment":4841,"conditions":9429,"interventions":9431},"NCT01369498","Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis",[87],"2014-06-05","2014-09-24","2011-06-30",[9430],"Myelofibrosis",[1737,9432],"Ruxolitinib",{"nctId":9434,"briefTitle":9435,"status":103,"phases":9436,"primaryCompletion":9437,"completion":9437,"start":9438,"enrollment":720,"conditions":9439,"interventions":9442},"NCT01707472","Study of Simtuzumab in HIV and\u002For Hepatitis C- Infected Adults With Liver Fibrosis",[87],"2014-10-17","2012-10-04",[9440,27,504,9441],"Liver Fibrosis","HIV\u002FHCV Co-infection",[1737],{"nctId":9444,"briefTitle":9445,"status":103,"phases":9446,"primaryCompletion":6107,"completion":9447,"start":9448,"enrollment":9449,"conditions":9450,"interventions":9451},"NCT01672853","Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)",[87],"2016-08-24","2013-03-04",235,[6350],[1737],{"nctId":7396,"briefTitle":7397,"status":653,"phases":9453,"primaryCompletion":4367,"completion":533,"start":4530,"enrollment":2440,"conditions":9454,"interventions":9455},[87],[1447],[1737,1451,1454,3396],{"nctId":9457,"briefTitle":9458,"status":103,"phases":9459,"primaryCompletion":532,"completion":499,"start":597,"enrollment":34,"conditions":9460,"interventions":9461},"NCT01452308","Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis",[87],[9440],[1737],{"nctId":9463,"briefTitle":9464,"status":653,"phases":9465,"primaryCompletion":9466,"completion":9466,"start":9467,"enrollment":9468,"conditions":9469,"interventions":9470},"NCT01769196","Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)",[87],"2016-02-23","2013-01-31",544,[4871],[1737,9471],"Simtuzumab placebo",{"nctId":1730,"briefTitle":1731,"status":103,"phases":9473,"primaryCompletion":1733,"completion":533,"start":597,"enrollment":1734,"conditions":9474,"interventions":9475},[87],[1037],[1737,1090],{"nctId":9477,"briefTitle":9478,"status":653,"phases":9479,"primaryCompletion":224,"completion":224,"start":9480,"enrollment":3419,"conditions":9481,"interventions":9482},"NCT01759511","Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)",[87],"2012-10-18",[4871],[1737],{"trials":9484,"activeCount":97},[],{"trials":9486,"activeCount":97},[],{"trials":9488,"activeCount":97},[],{"intervention":6683,"totalTrials":1122,"cells":9490},{"EARLY_PHASE1":9491,"PHASE1":9493,"PHASE2":9512,"PHASE3":9553,"PHASE4":9555,"NA":9557},{"trials":9492,"activeCount":97},[],{"trials":9494,"activeCount":97},[9495,9504,9508],{"nctId":9496,"briefTitle":9497,"status":103,"phases":9498,"primaryCompletion":9499,"completion":9499,"start":2481,"enrollment":9500,"conditions":9501,"interventions":9503},"NCT02521376","Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function",[86],"2017-10-25",56,[9502],"Oncology",[6683],{"nctId":7418,"briefTitle":7419,"status":653,"phases":9505,"primaryCompletion":7421,"completion":7421,"start":7422,"enrollment":629,"conditions":9506,"interventions":9507},[86],[7424,6681],[6683,6684,6670],{"nctId":7172,"briefTitle":7173,"status":653,"phases":9509,"primaryCompletion":7175,"completion":7175,"start":7176,"enrollment":7177,"conditions":9510,"interventions":9511},[86],[7179],[6079,1538,6683,7165],{"trials":9513,"activeCount":97},[9514,9522,9526,9537,9541],{"nctId":9515,"briefTitle":9516,"status":653,"phases":9517,"primaryCompletion":519,"completion":6214,"start":9518,"enrollment":819,"conditions":9519,"interventions":9521},"NCT01796470","Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies",[87],"2013-06-20",[36,7231,9520,7230],"Diffuse Large B-cell Lymphoma",[6683,1538],{"nctId":7194,"briefTitle":7195,"status":103,"phases":9523,"primaryCompletion":7197,"completion":7198,"start":6032,"enrollment":1862,"conditions":9524,"interventions":9525},[87],[36],[6079,6683,7165],{"nctId":9527,"briefTitle":9528,"status":653,"phases":9529,"primaryCompletion":9530,"completion":9531,"start":9532,"enrollment":1335,"conditions":9533,"interventions":9535},"NCT02568683","Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)",[86,87],"2016-10-03","2017-06-22","2016-02-11",[9534],"Non-Hodgkin Lymphoma",[6683,9536],"Vincristine",{"nctId":6673,"briefTitle":6674,"status":653,"phases":9538,"primaryCompletion":6676,"completion":6677,"start":6678,"enrollment":6679,"conditions":9539,"interventions":9540},[86,87],[6681],[6683,6684,6670,6685,6643],{"nctId":9542,"briefTitle":9543,"status":653,"phases":9544,"primaryCompletion":9545,"completion":9546,"start":9547,"enrollment":25,"conditions":9548,"interventions":9550},"NCT02404220","Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)",[86,87],"2018-11-16","2018-12-17","2015-05-06",[9549],"Acute Lymphoblastic Leukemia",[6683,9536,9551,9552],"Dexamethasone","CNS Prophylaxis",{"trials":9554,"activeCount":97},[],{"trials":9556,"activeCount":97},[],{"trials":9558,"activeCount":97},[],{"intervention":4294,"totalTrials":1219,"cells":9560},{"EARLY_PHASE1":9561,"PHASE1":9563,"PHASE2":9571,"PHASE3":9617,"PHASE4":9619,"NA":9621},{"trials":9562,"activeCount":97},[],{"trials":9564,"activeCount":97},[9565],{"nctId":9566,"briefTitle":9567,"status":103,"phases":9568,"primaryCompletion":4730,"completion":4530,"start":2332,"enrollment":16,"conditions":9569,"interventions":9570},"NCT01193478","A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C",[86],[794],[4294,4294,4294,4294,4294,4294],{"trials":9572,"activeCount":97},[9573,9581,9591,9599,9603,9611],{"nctId":9574,"briefTitle":9575,"status":103,"phases":9576,"primaryCompletion":532,"completion":4349,"start":561,"enrollment":3200,"conditions":9577,"interventions":9578},"NCT01435226","GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection",[87],[4116],[4294,4295,9579,9580],"tegobuvir","Ribavirin",{"nctId":9582,"briefTitle":9583,"status":103,"phases":9584,"primaryCompletion":4082,"completion":4082,"start":4929,"enrollment":9585,"conditions":9586,"interventions":9587},"NCT01356160","GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus",[87],351,[4116],[4294,4295,9588,9589,9590],"peginterferon alfa-2a","ribavirin","GS-9451 Placebo",{"nctId":9592,"briefTitle":9593,"status":103,"phases":9594,"primaryCompletion":532,"completion":532,"start":561,"enrollment":9595,"conditions":9596,"interventions":9598},"NCT01434498","GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection",[87],163,[9597],"Chronic Genotype 1a or 1b HCV Infection",[4294,4295,9579,9589],{"nctId":4288,"briefTitle":4289,"status":653,"phases":9600,"primaryCompletion":4082,"completion":4082,"start":4203,"enrollment":4291,"conditions":9601,"interventions":9602},[87],[4190],[4294,4295,513,512],{"nctId":9604,"briefTitle":9605,"status":103,"phases":9606,"primaryCompletion":4277,"completion":4462,"start":534,"enrollment":9607,"conditions":9608,"interventions":9609},"NCT01353248","GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection",[87],141,[4116],[4294,9610,4295,9589,4294],"Tegobuvir",{"nctId":9612,"briefTitle":9613,"status":103,"phases":9614,"primaryCompletion":4462,"completion":4462,"start":4929,"enrollment":9595,"conditions":9615,"interventions":9616},"NCT01371578","Oral Antivirals (GS-5885, Tegobuvir, and\u002For GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection",[87],[4116],[4294,4295,9588,9589],{"trials":9618,"activeCount":97},[],{"trials":9620,"activeCount":97},[],{"trials":9622,"activeCount":97},[],{"intervention":4295,"totalTrials":1219,"cells":9624},{"EARLY_PHASE1":9625,"PHASE1":9627,"PHASE2":9629,"PHASE3":9666,"PHASE4":9668,"NA":9670},{"trials":9626,"activeCount":97},[],{"trials":9628,"activeCount":97},[],{"trials":9630,"activeCount":97},[9631,9635,9639,9643,9654,9658,9662],{"nctId":9574,"briefTitle":9575,"status":103,"phases":9632,"primaryCompletion":532,"completion":4349,"start":561,"enrollment":3200,"conditions":9633,"interventions":9634},[87],[4116],[4294,4295,9579,9580],{"nctId":9582,"briefTitle":9583,"status":103,"phases":9636,"primaryCompletion":4082,"completion":4082,"start":4929,"enrollment":9585,"conditions":9637,"interventions":9638},[87],[4116],[4294,4295,9588,9589,9590],{"nctId":9592,"briefTitle":9593,"status":103,"phases":9640,"primaryCompletion":532,"completion":532,"start":561,"enrollment":9595,"conditions":9641,"interventions":9642},[87],[9597],[4294,4295,9579,9589],{"nctId":9644,"briefTitle":9645,"status":103,"phases":9646,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":9647,"conditions":9648,"interventions":9649},"NCT01271790","A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C",[87],245,[4116],[9610,4295,9650,9651,4295,9652,9650,9651,9652,9653,9650,9651],"Pegasys®","Copegus®","Tegobuvir placebo","GS-9451 placebo",{"nctId":4288,"briefTitle":4289,"status":653,"phases":9655,"primaryCompletion":4082,"completion":4082,"start":4203,"enrollment":4291,"conditions":9656,"interventions":9657},[87],[4190],[4294,4295,513,512],{"nctId":9604,"briefTitle":9605,"status":103,"phases":9659,"primaryCompletion":4277,"completion":4462,"start":534,"enrollment":9607,"conditions":9660,"interventions":9661},[87],[4116],[4294,9610,4295,9589,4294],{"nctId":9612,"briefTitle":9613,"status":103,"phases":9663,"primaryCompletion":4462,"completion":4462,"start":4929,"enrollment":9595,"conditions":9664,"interventions":9665},[87],[4116],[4294,4295,9588,9589],{"trials":9667,"activeCount":97},[],{"trials":9669,"activeCount":97},[],{"trials":9671,"activeCount":97},[],{"intervention":724,"totalTrials":1645,"cells":9673},{"EARLY_PHASE1":9674,"PHASE1":9676,"PHASE2":9697,"PHASE3":9722,"PHASE4":9724,"NA":9726},{"trials":9675,"activeCount":97},[],{"trials":9677,"activeCount":97},[9678,9682,9690],{"nctId":715,"briefTitle":716,"status":653,"phases":9679,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":9680,"interventions":9681},[86],[722],[724,355,725,726],{"nctId":9683,"briefTitle":9684,"status":103,"phases":9685,"primaryCompletion":9686,"completion":9686,"start":212,"enrollment":4605,"conditions":9687,"interventions":9688},"NCT03060447","Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers",[86],"2020-02-13",[21],[724,9689],"ART",{"nctId":9691,"briefTitle":9692,"status":103,"phases":9693,"primaryCompletion":9694,"completion":9694,"start":2045,"enrollment":7002,"conditions":9695,"interventions":9696},"NCT02858401","Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults",[86],"2019-02-14",[21],[724,661],{"trials":9698,"activeCount":97},[9699,9708,9712],{"nctId":9700,"briefTitle":9701,"status":103,"phases":9702,"primaryCompletion":9703,"completion":9703,"start":1904,"enrollment":34,"conditions":9704,"interventions":9705},"NCT05281510","Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women",[87],"2025-01-16",[33],[724,9706,9707],"VRC07523LS","CAP256V2LS",{"nctId":4760,"briefTitle":4761,"status":103,"phases":9709,"primaryCompletion":4763,"completion":4764,"start":4765,"enrollment":1111,"conditions":9710,"interventions":9711},[87],[24],[782,724],{"nctId":9713,"briefTitle":9714,"status":103,"phases":9715,"primaryCompletion":9716,"completion":9717,"start":9718,"enrollment":9719,"conditions":9720,"interventions":9721},"NCT02166047","Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants",[87],"2016-05-11","2016-10-20","2014-06-30",162,[24],[724],{"trials":9723,"activeCount":97},[],{"trials":9725,"activeCount":97},[],{"trials":9727,"activeCount":97},[],{"intervention":9729,"totalTrials":477,"cells":9730},"Presatovir",{"EARLY_PHASE1":9731,"PHASE1":9733,"PHASE2":9735,"PHASE3":9775,"PHASE4":9777,"NA":9779},{"trials":9732,"activeCount":97},[],{"trials":9734,"activeCount":97},[],{"trials":9736,"activeCount":97},[9737,9747,9759,9767],{"nctId":9738,"briefTitle":9739,"status":103,"phases":9740,"primaryCompletion":9741,"completion":9742,"start":9743,"enrollment":4058,"conditions":9744,"interventions":9746},"NCT02534350","Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection",[87],"2017-02-20","2017-09-27","2015-12-31",[9745],"Respiratory Syncytial Virus (RSV)",[9729],{"nctId":9748,"briefTitle":9749,"status":103,"phases":9750,"primaryCompletion":9751,"completion":9752,"start":9753,"enrollment":9754,"conditions":9755,"interventions":9757},"NCT02135614","Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection",[87],"2017-03-27","2017-04-12","2014-06-09",189,[9756],"Respiratory Syncytial Virus Infection",[9729,9758],"Presatovir placebo",{"nctId":9760,"briefTitle":9761,"status":103,"phases":9762,"primaryCompletion":9763,"completion":9763,"start":826,"enrollment":9754,"conditions":9764,"interventions":9766},"NCT02254408","Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract",[87],"2017-07-14",[9765],"Respiratory Syncytial Virus",[9729],{"nctId":9768,"briefTitle":9769,"status":103,"phases":9770,"primaryCompletion":9771,"completion":9771,"start":9772,"enrollment":880,"conditions":9773,"interventions":9774},"NCT02254421","Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract",[87],"2017-04-17","2015-01-31",[9756],[9729],{"trials":9776,"activeCount":97},[],{"trials":9778,"activeCount":97},[],{"trials":9780,"activeCount":97},[],{"intervention":9782,"totalTrials":477,"cells":9783},"milatuzumab",{"EARLY_PHASE1":9784,"PHASE1":9786,"PHASE2":9812,"PHASE3":9830,"PHASE4":9832,"NA":9834},{"trials":9785,"activeCount":97},[],{"trials":9787,"activeCount":97},[9788,9801],{"nctId":9789,"briefTitle":9790,"status":653,"phases":9791,"primaryCompletion":4212,"completion":4212,"start":1782,"enrollment":371,"conditions":9792,"interventions":9800},"NCT01663766","Phase I Study of Milatuzumab for Graft Versus Host Disease",[86],[9793,9794,9795,9796,9797,9798,9799],"GVHD (Acute or Chronic)","Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)","Myelodysplastic Syndrome","Chronic Myelogenous Leukemia (CML)","Multiple Myeloma (MM)","Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)","Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)",[9782],{"nctId":9802,"briefTitle":9803,"status":103,"phases":9804,"primaryCompletion":4719,"completion":4719,"start":5023,"enrollment":31,"conditions":9805,"interventions":9811},"NCT01845740","Phase Ib Study of SC Milatuzumab in SLE",[86],[9806,9807,9808,9809,9810],"Lupus Erythematosus, Cutaneous","Lupus Erythematosus, Discoid","Lupus Erythematosus, Systemic","Lupus Vasculitis, Central Nervous System","Lupus Nephritis",[9782],{"trials":9813,"activeCount":97},[9814,9821],{"nctId":9815,"briefTitle":9816,"status":103,"phases":9817,"primaryCompletion":532,"completion":4177,"start":8187,"enrollment":12,"conditions":9818,"interventions":9820},"NCT00603668","Phase I\u002FII Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL",[86,87],[9819],"Chronic Lymphocytic Lymphoma",[9782],{"nctId":9822,"briefTitle":9823,"status":103,"phases":9824,"primaryCompletion":4719,"completion":4719,"start":5023,"enrollment":4605,"conditions":9825,"interventions":9829},"NCT00421525","Phase I\u002FII Study of hLL1 in Multiple Myeloma",[86,87],[9826,9827,9828],"Multiple Myeloma","Myeloma, Plasma-Cell","PLASMACYTOMA",[9782],{"trials":9831,"activeCount":97},[],{"trials":9833,"activeCount":97},[],{"trials":9835,"activeCount":97},[],{"intervention":9837,"totalTrials":477,"cells":9838},"Arhalofenate",{"EARLY_PHASE1":9839,"PHASE1":9841,"PHASE2":9843,"PHASE3":9873,"PHASE4":9875,"NA":9877},{"trials":9840,"activeCount":97},[],{"trials":9842,"activeCount":97},[],{"trials":9844,"activeCount":97},[9845,9855,9861,9867],{"nctId":9846,"briefTitle":9847,"status":103,"phases":9848,"primaryCompletion":4368,"completion":4368,"start":4081,"enrollment":22,"conditions":9849,"interventions":9852},"NCT02252835","Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout",[87],[9850,9851],"Gout","Hyperuricemia",[9837,9853,9837,9853,9854],"Febuxostat","Colchicine",{"nctId":9856,"briefTitle":9857,"status":103,"phases":9858,"primaryCompletion":2361,"completion":2361,"start":1556,"enrollment":1075,"conditions":9859,"interventions":9860},"NCT01399008","Safety\u002FEfficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients",[87],[9850],[9837,1747,9854],{"nctId":9862,"briefTitle":9863,"status":103,"phases":9864,"primaryCompletion":597,"completion":597,"start":534,"enrollment":3300,"conditions":9865,"interventions":9866},"NCT01336686","Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout",[87],[9851,9850],[9837,9837,9854],{"nctId":9868,"briefTitle":9869,"status":103,"phases":9870,"primaryCompletion":4693,"completion":4693,"start":4203,"enrollment":5999,"conditions":9871,"interventions":9872},"NCT01416402","Open Label Safety\u002FEfficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients",[87],[9851,9850],[9837,9853,9854],{"trials":9874,"activeCount":97},[],{"trials":9876,"activeCount":97},[],{"trials":9878,"activeCount":97},[],{"intervention":9854,"totalTrials":477,"cells":9880},{"EARLY_PHASE1":9881,"PHASE1":9883,"PHASE2":9885,"PHASE3":9903,"PHASE4":9905,"NA":9907},{"trials":9882,"activeCount":97},[],{"trials":9884,"activeCount":97},[],{"trials":9886,"activeCount":97},[9887,9891,9895,9899],{"nctId":9846,"briefTitle":9847,"status":103,"phases":9888,"primaryCompletion":4368,"completion":4368,"start":4081,"enrollment":22,"conditions":9889,"interventions":9890},[87],[9850,9851],[9837,9853,9837,9853,9854],{"nctId":9856,"briefTitle":9857,"status":103,"phases":9892,"primaryCompletion":2361,"completion":2361,"start":1556,"enrollment":1075,"conditions":9893,"interventions":9894},[87],[9850],[9837,1747,9854],{"nctId":9862,"briefTitle":9863,"status":103,"phases":9896,"primaryCompletion":597,"completion":597,"start":534,"enrollment":3300,"conditions":9897,"interventions":9898},[87],[9851,9850],[9837,9837,9854],{"nctId":9868,"briefTitle":9869,"status":103,"phases":9900,"primaryCompletion":4693,"completion":4693,"start":4203,"enrollment":5999,"conditions":9901,"interventions":9902},[87],[9851,9850],[9837,9853,9854],{"trials":9904,"activeCount":97},[],{"trials":9906,"activeCount":97},[],{"trials":9908,"activeCount":97},[],{"intervention":9579,"totalTrials":477,"cells":9910},{"EARLY_PHASE1":9911,"PHASE1":9913,"PHASE2":9915,"PHASE3":9933,"PHASE4":9935,"NA":9937},{"trials":9912,"activeCount":97},[],{"trials":9914,"activeCount":97},[],{"trials":9916,"activeCount":97},[9917,9921,9925,9929],{"nctId":9574,"briefTitle":9575,"status":103,"phases":9918,"primaryCompletion":532,"completion":4349,"start":561,"enrollment":3200,"conditions":9919,"interventions":9920},[87],[4116],[4294,4295,9579,9580],{"nctId":9592,"briefTitle":9593,"status":103,"phases":9922,"primaryCompletion":532,"completion":532,"start":561,"enrollment":9595,"conditions":9923,"interventions":9924},[87],[9597],[4294,4295,9579,9589],{"nctId":9644,"briefTitle":9645,"status":103,"phases":9926,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":9647,"conditions":9927,"interventions":9928},[87],[4116],[9610,4295,9650,9651,4295,9652,9650,9651,9652,9653,9650,9651],{"nctId":9604,"briefTitle":9605,"status":103,"phases":9930,"primaryCompletion":4277,"completion":4462,"start":534,"enrollment":9607,"conditions":9931,"interventions":9932},[87],[4116],[4294,9610,4295,9589,4294],{"trials":9934,"activeCount":97},[],{"trials":9936,"activeCount":97},[],{"trials":9938,"activeCount":97},[],{"intervention":6024,"totalTrials":477,"cells":9940},{"EARLY_PHASE1":9941,"PHASE1":9943,"PHASE2":9945,"PHASE3":9963,"PHASE4":9965,"NA":9967},{"trials":9942,"activeCount":97},[],{"trials":9944,"activeCount":97},[],{"trials":9946,"activeCount":97},[9947,9951,9955,9959],{"nctId":6015,"briefTitle":6016,"status":103,"phases":9948,"primaryCompletion":6018,"completion":6019,"start":328,"enrollment":1361,"conditions":9949,"interventions":9950},[87],[3863],[6022,5988,6023,6024,6025],{"nctId":6059,"briefTitle":6060,"status":103,"phases":9952,"primaryCompletion":4764,"completion":6062,"start":4267,"enrollment":629,"conditions":9953,"interventions":9954},[87],[6064],[5988,6066,6024,6067],{"nctId":6069,"briefTitle":6070,"status":103,"phases":9956,"primaryCompletion":6072,"completion":6073,"start":6074,"enrollment":6075,"conditions":9957,"interventions":9958},[87],[6077],[6066,5988,6079,6067,6024,6080],{"nctId":6082,"briefTitle":6083,"status":103,"phases":9960,"primaryCompletion":452,"completion":6085,"start":6086,"enrollment":4178,"conditions":9961,"interventions":9962},[87],[6088],[6066,5988,6067,6024],{"trials":9964,"activeCount":97},[],{"trials":9966,"activeCount":97},[],{"trials":9968,"activeCount":97},[],{"intervention":9970,"totalTrials":477,"cells":9971},"hMN14",{"EARLY_PHASE1":9972,"PHASE1":9974,"PHASE2":9983,"PHASE3":10011,"PHASE4":10013,"NA":10015},{"trials":9973,"activeCount":97},[],{"trials":9975,"activeCount":97},[9976],{"nctId":9977,"briefTitle":9978,"status":653,"phases":9979,"enrollment":25,"conditions":9980,"interventions":9982},"NCT00041691","Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery",[86],[9981],"Colorectal Neoplasms",[9970],{"trials":9984,"activeCount":97},[9985,9996,10003],{"nctId":9986,"briefTitle":9987,"status":103,"phases":9988,"completion":4919,"start":9989,"enrollment":615,"conditions":9990,"interventions":9995},"NCT00040599","Safety Study of 90Y-hMN14 to Treat Colorectal Cancer",[86,87],"2000-01",[1447,9991,9992,9981,9993,9994],"Colon Cancer","Rectal Cancer","Colorectal Carcinoma","Colorectal Tumor",[9970],{"nctId":9997,"briefTitle":9998,"status":103,"phases":9999,"completion":4878,"start":9989,"enrollment":1414,"conditions":10000,"interventions":10002},"NCT00041639","Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer",[86,87],[10001],"Pancreatic Neoplasms",[9970],{"nctId":10004,"briefTitle":10005,"status":103,"phases":10006,"completion":8778,"start":10007,"enrollment":25,"conditions":10008,"interventions":10010},"NCT00041652","Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer",[86,87],"2000-02",[1447,9991,9992,9981,9993,1448,10009],"Breast Neoplasms",[9970],{"trials":10012,"activeCount":97},[],{"trials":10014,"activeCount":97},[],{"trials":10016,"activeCount":97},[],{"intervention":4106,"totalTrials":477,"cells":10018},{"EARLY_PHASE1":10019,"PHASE1":10021,"PHASE2":10032,"PHASE3":10051,"PHASE4":10053,"NA":10055},{"trials":10020,"activeCount":97},[],{"trials":10022,"activeCount":97},[10023],{"nctId":10024,"briefTitle":10025,"status":103,"phases":10026,"primaryCompletion":10027,"completion":10027,"start":10028,"enrollment":3270,"conditions":10029,"interventions":10030},"NCT02533427","Study to Evaluate Effect of Sofosbuvir\u002FVelpatasvir\u002FGS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate\u002FEthinyl Estradiol",[86],"2016-03-18","2015-10-29",[794],[4129,4106,10031],"Norgestimate\u002Fethinyl estradiol",{"trials":10033,"activeCount":97},[10034,10038,10047],{"nctId":4097,"briefTitle":4098,"status":103,"phases":10035,"primaryCompletion":4100,"completion":4101,"start":4102,"enrollment":4103,"conditions":10036,"interventions":10037},[87],[18],[4106,4107,513],{"nctId":10039,"briefTitle":10040,"status":103,"phases":10041,"primaryCompletion":10042,"completion":9355,"start":10043,"enrollment":10044,"conditions":10045,"interventions":10046},"NCT02378961","Safety and Efficacy of Voxilaprevir Plus Sofosbuvir\u002FVelpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection",[87],"2015-09-21","2015-02-16",128,[18],[4106,4107],{"nctId":4182,"briefTitle":4183,"status":103,"phases":10048,"primaryCompletion":4185,"completion":4186,"start":4187,"enrollment":4188,"conditions":10049,"interventions":10050},[87],[4190],[797,513,4107,4106],{"trials":10052,"activeCount":97},[],{"trials":10054,"activeCount":97},[],{"trials":10056,"activeCount":97},[],{"intervention":9588,"totalTrials":477,"cells":10058},{"EARLY_PHASE1":10059,"PHASE1":10061,"PHASE2":10063,"PHASE3":10086,"PHASE4":10088,"NA":10090},{"trials":10060,"activeCount":97},[],{"trials":10062,"activeCount":97},[],{"trials":10064,"activeCount":97},[10065,10069,10073,10082],{"nctId":3981,"briefTitle":3982,"status":103,"phases":10066,"primaryCompletion":3984,"completion":3985,"start":3986,"enrollment":3987,"conditions":10067,"interventions":10068},[87],[3724],[3952,3990],{"nctId":9582,"briefTitle":9583,"status":103,"phases":10070,"primaryCompletion":4082,"completion":4082,"start":4929,"enrollment":9585,"conditions":10071,"interventions":10072},[87],[4116],[4294,4295,9588,9589,9590],{"nctId":10074,"briefTitle":10075,"status":103,"phases":10076,"primaryCompletion":2352,"completion":4677,"start":6634,"enrollment":19,"conditions":10077,"interventions":10078},"NCT01072695","Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection",[87],[794],[10079,10080,9580,10081],"GS-9256","GS-9190","Peginterferon alfa-2a",{"nctId":9612,"briefTitle":9613,"status":103,"phases":10083,"primaryCompletion":4462,"completion":4462,"start":4929,"enrollment":9595,"conditions":10084,"interventions":10085},[87],[4116],[4294,4295,9588,9589],{"trials":10087,"activeCount":97},[],{"trials":10089,"activeCount":97},[],{"trials":10091,"activeCount":97},[],{"intervention":10093,"totalTrials":477,"cells":10094},"GS-6615",{"EARLY_PHASE1":10095,"PHASE1":10097,"PHASE2":10119,"PHASE3":10128,"PHASE4":10130,"NA":10132},{"trials":10096,"activeCount":97},[],{"trials":10098,"activeCount":97},[10099,10106,10113],{"nctId":10100,"briefTitle":10101,"status":103,"phases":10102,"primaryCompletion":500,"completion":500,"start":4113,"enrollment":1862,"conditions":10103,"interventions":10105},"NCT01847391","A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects",[86],[10104],"Ischemic Heart Disease",[10093],{"nctId":10107,"briefTitle":10108,"status":103,"phases":10109,"primaryCompletion":4144,"completion":4144,"start":533,"enrollment":880,"conditions":10110,"interventions":10111},"NCT02365532","Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults",[86],[6917],[10093,10112],"Dofetilide",{"nctId":10114,"briefTitle":10115,"status":103,"phases":10116,"primaryCompletion":4196,"completion":4196,"start":4113,"enrollment":2579,"conditions":10117,"interventions":10118},"NCT01849003","Study of the Effect of GS-6615 in Subjects With LQT-3",[86],[6917],[10093],{"trials":10120,"activeCount":97},[10121],{"nctId":10122,"briefTitle":10123,"status":1529,"phases":10124,"primaryCompletion":10125,"completion":10125,"start":4144,"enrollment":97,"conditions":10126,"interventions":10127},"NCT02377336","GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease",[87],"2016-08",[10104],[10093],{"trials":10129,"activeCount":97},[],{"trials":10131,"activeCount":97},[],{"trials":10133,"activeCount":97},[],{"intervention":4095,"totalTrials":477,"cells":10135},{"EARLY_PHASE1":10136,"PHASE1":10138,"PHASE2":10147,"PHASE3":10161,"PHASE4":10163,"NA":10165},{"trials":10137,"activeCount":97},[],{"trials":10139,"activeCount":97},[10140],{"nctId":10141,"briefTitle":10142,"status":103,"phases":10143,"primaryCompletion":4530,"completion":4231,"start":561,"enrollment":10144,"conditions":10145,"interventions":10146},"NCT01431898","Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection",[86],82,[27],[4095],{"trials":10148,"activeCount":97},[10149,10153,10157],{"nctId":4088,"briefTitle":4089,"status":103,"phases":10150,"primaryCompletion":4071,"completion":4091,"start":1733,"enrollment":4092,"conditions":10151,"interventions":10152},[87],[4074],[797,513,4095],{"nctId":4209,"briefTitle":4210,"status":103,"phases":10154,"primaryCompletion":4212,"completion":4144,"start":4112,"enrollment":4213,"conditions":10155,"interventions":10156},[87],[4190],[797,506,513,4216,4095,4086],{"nctId":4218,"briefTitle":4219,"status":103,"phases":10158,"primaryCompletion":1733,"completion":1782,"start":4221,"enrollment":4222,"conditions":10159,"interventions":10160},[87],[4224],[506,513,512,4226,4095,797],{"trials":10162,"activeCount":97},[],{"trials":10164,"activeCount":97},[],{"trials":10166,"activeCount":97},[],{"intervention":10168,"totalTrials":477,"cells":10169},"veltuzumab",{"EARLY_PHASE1":10170,"PHASE1":10172,"PHASE2":10174,"PHASE3":10230,"PHASE4":10232,"NA":10234},{"trials":10171,"activeCount":97},[],{"trials":10173,"activeCount":97},[],{"trials":10175,"activeCount":97},[10176,10185,10209,10218],{"nctId":10177,"briefTitle":10178,"status":653,"phases":10179,"primaryCompletion":597,"completion":597,"start":4731,"enrollment":7002,"conditions":10180,"interventions":10184},"NCT00547066","Study of Veltuzumab (hA20) at Different Doses in Patients With ITP",[86,87],[10181,10182,10183],"Purpura, Thrombocytopenic, Idiopathic","Autoimmune Thrombocytopenic Purpura","Purpura, Thrombocytopenic, Autoimmune",[10168],{"nctId":10186,"briefTitle":10187,"status":103,"phases":10188,"primaryCompletion":4462,"completion":4462,"start":2351,"enrollment":22,"conditions":10189,"interventions":10208},"NCT00546793","Ph I\u002FII Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL",[86,87],[10190,10191,10192,10193,10194,10195,10196,10197,10198,10199,10200,10201,10202,10203,10204,10205,10206,10207],"NHL","Lymphoma, Non-Hodgkin","Lymphoma, B-Cell","Lymphoma, Follicular","Lymphoma, Intermediate-Grade","Lymphoma, Large-Cell","Lymphoma, Low-Grade","Lymphoma, Mixed-Cell","Lymphoma, Small-Cell","Leukemia, Lymphocytic, Chronic","Leukemia, B-Cell, Chronic","Leukemia, Prolymphocytic","Leukemia, Small Lymphocytic","Lymphoma, Small Lymphocytic","Lymphoma, Lymphoplasmacytoid, CLL","Lymphoplasmacytoid Lymphoma, CLL","CLL","SLL",[10168],{"nctId":10210,"briefTitle":10211,"status":103,"phases":10212,"primaryCompletion":4731,"completion":4731,"start":5104,"enrollment":5113,"conditions":10213,"interventions":10217},"NCT00596804","Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma",[86,87],[10214,10215,10216],"Non-Hodgkin's Lymphoma","Lymphoma, Diffuse","Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic",[10168],{"nctId":10219,"briefTitle":10220,"status":1529,"phases":10221,"primaryCompletion":10222,"completion":10223,"start":7038,"enrollment":97,"conditions":10224,"interventions":10227},"NCT01101581","Study of Veltuzumab and 90Y-Epratuzumab in Relapsed\u002FRefractory, Aggressive NHL",[86,87],"2016-12","2017-03",[10225,10190,10226,9520],"Non Hodgkin's Lymphoma","Aggressive NHL",[10228,10229,10168],"Veltuzumab and 90Y-Epratuzumab Tetraxetan","90Y-epratuzumab tetraxetan",{"trials":10231,"activeCount":97},[],{"trials":10233,"activeCount":97},[],{"trials":10235,"activeCount":97},[],{"intervention":10237,"totalTrials":477,"cells":10238},"Selonsertib",{"EARLY_PHASE1":10239,"PHASE1":10241,"PHASE2":10251,"PHASE3":10279,"PHASE4":10281,"NA":10283},{"trials":10240,"activeCount":97},[],{"trials":10242,"activeCount":97},[10243],{"nctId":10244,"briefTitle":10245,"status":103,"phases":10246,"primaryCompletion":10247,"completion":10247,"start":10248,"enrollment":502,"conditions":10249,"interventions":10250},"NCT02509624","Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function",[86],"2015-12-15","2015-08-18",[6770],[10237],{"trials":10252,"activeCount":97},[10253,10261,10272],{"nctId":10254,"briefTitle":10255,"status":103,"phases":10256,"primaryCompletion":10257,"completion":10222,"start":4196,"enrollment":10258,"conditions":10259,"interventions":10260},"NCT02234141","Selonsertib in Adults With Pulmonary Arterial Hypertension",[87],"2016-04",151,[4881],[10237],{"nctId":10262,"briefTitle":10263,"status":103,"phases":10264,"primaryCompletion":10265,"completion":10266,"start":3211,"enrollment":10267,"conditions":10268,"interventions":10270},"NCT02854631","Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)",[87],"2018-02-16","2018-05-31",104,[10269],"Alcoholic Hepatitis (AH)",[10237,10271],"Prednisolone",{"nctId":10273,"briefTitle":10274,"status":103,"phases":10275,"primaryCompletion":10276,"completion":10125,"start":4406,"enrollment":1783,"conditions":10277,"interventions":10278},"NCT02177786","Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease",[87],"2016-07",[6770],[10237],{"trials":10280,"activeCount":97},[],{"trials":10282,"activeCount":97},[],{"trials":10284,"activeCount":97},[],{"intervention":161,"totalTrials":332,"cells":10286},{"EARLY_PHASE1":10287,"PHASE1":10289,"PHASE2":10291,"PHASE3":10305,"PHASE4":10307,"NA":10309},{"trials":10288,"activeCount":97},[],{"trials":10290,"activeCount":97},[],{"trials":10292,"activeCount":97},[10293,10297,10301],{"nctId":151,"briefTitle":152,"status":103,"phases":10294,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":10295,"interventions":10296},[87],[33],[52,47,160,126,161,93],{"nctId":163,"briefTitle":164,"status":103,"phases":10298,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":10299,"interventions":10300},[87],[21],[161,47,172,173,174,93],{"nctId":651,"briefTitle":652,"status":653,"phases":10302,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":10303,"interventions":10304},[87],[33],[660,161,126,661,307,231],{"trials":10306,"activeCount":97},[],{"trials":10308,"activeCount":97},[],{"trials":10310,"activeCount":97},[],{"intervention":6385,"totalTrials":332,"cells":10312},{"EARLY_PHASE1":10313,"PHASE1":10315,"PHASE2":10327,"PHASE3":10339,"PHASE4":10341,"NA":10343},{"trials":10314,"activeCount":97},[],{"trials":10316,"activeCount":97},[10317],{"nctId":10318,"briefTitle":10319,"status":103,"phases":10320,"primaryCompletion":10321,"completion":10322,"start":10323,"enrollment":3974,"conditions":10324,"interventions":10325},"NCT02891408","Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function",[86],"2019-05-05","2019-05-13","2016-09-23",[6333],[6385,10326],"Fenofibrate",{"trials":10328,"activeCount":97},[10329,10335],{"nctId":10330,"briefTitle":10331,"status":103,"phases":10332,"primaryCompletion":4328,"completion":4328,"start":6107,"enrollment":4523,"conditions":10333,"interventions":10334},"NCT02856555","Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis",[87],[6333],[6385],{"nctId":6377,"briefTitle":6378,"status":103,"phases":10336,"primaryCompletion":6380,"completion":6380,"start":6381,"enrollment":6382,"conditions":10337,"interventions":10338},[87],[6371],[6373,6385,6321],{"trials":10340,"activeCount":97},[],{"trials":10342,"activeCount":97},[],{"trials":10344,"activeCount":97},[],{"intervention":3228,"totalTrials":332,"cells":10346},{"EARLY_PHASE1":10347,"PHASE1":10349,"PHASE2":10351,"PHASE3":10370,"PHASE4":10372,"NA":10374},{"trials":10348,"activeCount":97},[],{"trials":10350,"activeCount":97},[],{"trials":10352,"activeCount":97},[10353,10362,10366],{"nctId":10354,"briefTitle":10355,"status":103,"phases":10356,"primaryCompletion":10357,"completion":2598,"start":10358,"enrollment":7002,"conditions":10359,"interventions":10360},"NCT03491553","Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B",[87],"2019-03-22","2018-04-06",[24],[3228,10361],"Hepatitis B virus (HBV) OAV Therapy",{"nctId":3295,"briefTitle":3296,"status":103,"phases":10363,"primaryCompletion":3298,"completion":3299,"start":202,"enrollment":3300,"conditions":10364,"interventions":10365},[87],[24],[3228,126],{"nctId":3217,"briefTitle":3218,"status":103,"phases":10367,"primaryCompletion":3220,"completion":3221,"start":3222,"enrollment":3223,"conditions":10368,"interventions":10369},[87],[24],[3226,3227,1121,3228],{"trials":10371,"activeCount":97},[],{"trials":10373,"activeCount":97},[],{"trials":10375,"activeCount":97},[],{"intervention":10080,"totalTrials":332,"cells":10377},{"EARLY_PHASE1":10378,"PHASE1":10380,"PHASE2":10382,"PHASE3":10404,"PHASE4":10406,"NA":10408},{"trials":10379,"activeCount":97},[],{"trials":10381,"activeCount":97},[],{"trials":10383,"activeCount":97},[10384,10393,10400],{"nctId":10385,"briefTitle":10386,"status":103,"phases":10387,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":10388,"conditions":10389,"interventions":10390},"NCT01225380","A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C",[87],324,[4224],[10080,10079,9650,9651,10391,10079,9650,9651,10391,10392,9650,9651],"GS-9190 placebo","GS-9256 placebo",{"nctId":10394,"briefTitle":10395,"status":103,"phases":10396,"primaryCompletion":4869,"completion":4176,"start":5575,"enrollment":853,"conditions":10397,"interventions":10398},"NCT00743795","Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection",[87],[794],[10080,10399,9580],"Peginterferon Alfa 2a",{"nctId":10074,"briefTitle":10075,"status":103,"phases":10401,"primaryCompletion":2352,"completion":4677,"start":6634,"enrollment":19,"conditions":10402,"interventions":10403},[87],[794],[10079,10080,9580,10081],{"trials":10405,"activeCount":97},[],{"trials":10407,"activeCount":97},[],{"trials":10409,"activeCount":97},[],{"intervention":4086,"totalTrials":332,"cells":10411},{"EARLY_PHASE1":10412,"PHASE1":10414,"PHASE2":10416,"PHASE3":10430,"PHASE4":10432,"NA":10434},{"trials":10413,"activeCount":97},[],{"trials":10415,"activeCount":97},[],{"trials":10417,"activeCount":97},[10418,10422,10426],{"nctId":4077,"briefTitle":4078,"status":103,"phases":10419,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":4083,"conditions":10420,"interventions":10421},[87],[27],[506,4086,513],{"nctId":4166,"briefTitle":4167,"status":103,"phases":10423,"primaryCompletion":4080,"completion":4081,"start":4112,"enrollment":4169,"conditions":10424,"interventions":10425},[87],[27],[506,4086,513],{"nctId":4209,"briefTitle":4210,"status":103,"phases":10427,"primaryCompletion":4212,"completion":4144,"start":4112,"enrollment":4213,"conditions":10428,"interventions":10429},[87],[4190],[797,506,513,4216,4095,4086],{"trials":10431,"activeCount":97},[],{"trials":10433,"activeCount":97},[],{"trials":10435,"activeCount":97},[],{"intervention":10437,"totalTrials":332,"cells":10438},"GS-9450",{"EARLY_PHASE1":10439,"PHASE1":10441,"PHASE2":10443,"PHASE3":10466,"PHASE4":10468,"NA":10470},{"trials":10440,"activeCount":97},[],{"trials":10442,"activeCount":97},[],{"trials":10444,"activeCount":97},[10445,10452,10458],{"nctId":10446,"briefTitle":10447,"status":103,"phases":10448,"primaryCompletion":5575,"completion":4851,"start":4930,"enrollment":342,"conditions":10449,"interventions":10450},"NCT00725803","Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV",[87],[794],[10437,10451],"GS-9450 Placebo",{"nctId":10453,"briefTitle":10454,"status":103,"phases":10455,"primaryCompletion":5906,"completion":5574,"start":8187,"enrollment":3320,"conditions":10456,"interventions":10457},"NCT00740610","Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)",[87],[6371],[10437,10451],{"nctId":10459,"briefTitle":10460,"status":653,"phases":10461,"primaryCompletion":563,"completion":10462,"start":520,"enrollment":10463,"conditions":10464,"interventions":10465},"NCT00874796","Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection",[87],"2010-07",307,[794],[10437],{"trials":10467,"activeCount":97},[],{"trials":10469,"activeCount":97},[],{"trials":10471,"activeCount":97},[],{"intervention":1454,"totalTrials":332,"cells":10473},{"EARLY_PHASE1":10474,"PHASE1":10476,"PHASE2":10482,"PHASE3":10492,"PHASE4":10494,"NA":10496},{"trials":10475,"activeCount":97},[],{"trials":10477,"activeCount":97},[10478],{"nctId":1439,"briefTitle":1440,"status":103,"phases":10479,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":10480,"interventions":10481},[86],[1037,1010,1446,1447,1448],[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],{"trials":10483,"activeCount":97},[10484,10488],{"nctId":3387,"briefTitle":3388,"status":653,"phases":10485,"primaryCompletion":3390,"completion":3390,"start":3391,"enrollment":3392,"conditions":10486,"interventions":10487},[87],[3394],[1049,1453,1454,3396,1451],{"nctId":7396,"briefTitle":7397,"status":653,"phases":10489,"primaryCompletion":4367,"completion":533,"start":4530,"enrollment":2440,"conditions":10490,"interventions":10491},[87],[1447],[1737,1451,1454,3396],{"trials":10493,"activeCount":97},[],{"trials":10495,"activeCount":97},[],{"trials":10497,"activeCount":97},[],{"intervention":6761,"totalTrials":332,"cells":10499},{"EARLY_PHASE1":10500,"PHASE1":10502,"PHASE2":10504,"PHASE3":10530,"PHASE4":10532,"NA":10534},{"trials":10501,"activeCount":97},[],{"trials":10503,"activeCount":97},[],{"trials":10505,"activeCount":97},[10506,10517,10521],{"nctId":10507,"briefTitle":10508,"status":653,"phases":10509,"primaryCompletion":10510,"completion":10511,"start":10512,"enrollment":10513,"conditions":10514,"interventions":10516},"NCT01672879","Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH",[87],"2016-09-26","2017-01-03","2012-10-29",259,[10515],"Liver Fibrosis Due to NASH",[6761],{"nctId":6753,"briefTitle":6754,"status":103,"phases":10518,"primaryCompletion":6756,"completion":6756,"start":6757,"enrollment":615,"conditions":10519,"interventions":10520},[87],[6759],[6721,6761],{"nctId":10522,"briefTitle":10523,"status":653,"phases":10524,"primaryCompletion":10525,"completion":2505,"start":10526,"enrollment":10527,"conditions":10528,"interventions":10529},"NCT01672866","Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)",[87],"2016-08-02","2012-12-05",222,[10515],[6761],{"trials":10531,"activeCount":97},[],{"trials":10533,"activeCount":97},[],{"trials":10535,"activeCount":97},[],{"intervention":6066,"totalTrials":332,"cells":10537},{"EARLY_PHASE1":10538,"PHASE1":10540,"PHASE2":10542,"PHASE3":10556,"PHASE4":10558,"NA":10560},{"trials":10539,"activeCount":97},[],{"trials":10541,"activeCount":97},[],{"trials":10543,"activeCount":97},[10544,10548,10552],{"nctId":6059,"briefTitle":6060,"status":103,"phases":10545,"primaryCompletion":4764,"completion":6062,"start":4267,"enrollment":629,"conditions":10546,"interventions":10547},[87],[6064],[5988,6066,6024,6067],{"nctId":6069,"briefTitle":6070,"status":103,"phases":10549,"primaryCompletion":6072,"completion":6073,"start":6074,"enrollment":6075,"conditions":10550,"interventions":10551},[87],[6077],[6066,5988,6079,6067,6024,6080],{"nctId":6082,"briefTitle":6083,"status":103,"phases":10553,"primaryCompletion":452,"completion":6085,"start":6086,"enrollment":4178,"conditions":10554,"interventions":10555},[87],[6088],[6066,5988,6067,6024],{"trials":10557,"activeCount":97},[],{"trials":10559,"activeCount":97},[],{"trials":10561,"activeCount":97},[],{"intervention":6067,"totalTrials":332,"cells":10563},{"EARLY_PHASE1":10564,"PHASE1":10566,"PHASE2":10568,"PHASE3":10582,"PHASE4":10584,"NA":10586},{"trials":10565,"activeCount":97},[],{"trials":10567,"activeCount":97},[],{"trials":10569,"activeCount":97},[10570,10574,10578],{"nctId":6059,"briefTitle":6060,"status":103,"phases":10571,"primaryCompletion":4764,"completion":6062,"start":4267,"enrollment":629,"conditions":10572,"interventions":10573},[87],[6064],[5988,6066,6024,6067],{"nctId":6069,"briefTitle":6070,"status":103,"phases":10575,"primaryCompletion":6072,"completion":6073,"start":6074,"enrollment":6075,"conditions":10576,"interventions":10577},[87],[6077],[6066,5988,6079,6067,6024,6080],{"nctId":6082,"briefTitle":6083,"status":103,"phases":10579,"primaryCompletion":452,"completion":6085,"start":6086,"enrollment":4178,"conditions":10580,"interventions":10581},[87],[6088],[6066,5988,6067,6024],{"trials":10583,"activeCount":97},[],{"trials":10585,"activeCount":97},[],{"trials":10587,"activeCount":97},[],{"intervention":10589,"totalTrials":332,"cells":10590},"GS-5806",{"EARLY_PHASE1":10591,"PHASE1":10593,"PHASE2":10608,"PHASE3":10616,"PHASE4":10618,"NA":10620},{"trials":10592,"activeCount":97},[],{"trials":10594,"activeCount":97},[10595,10601],{"nctId":10596,"briefTitle":10597,"status":103,"phases":10598,"primaryCompletion":4112,"completion":4112,"start":4462,"enrollment":1122,"conditions":10599,"interventions":10600},"NCT01801293","A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806",[86],[6860],[10589],{"nctId":10602,"briefTitle":10603,"status":1529,"phases":10604,"primaryCompletion":499,"completion":499,"start":4113,"enrollment":97,"conditions":10605,"interventions":10607},"NCT01797419","Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)",[86],[10606],"Respiratory Syncytial Virus Infections",[10589],{"trials":10609,"activeCount":97},[10610],{"nctId":10611,"briefTitle":10612,"status":103,"phases":10613,"primaryCompletion":4082,"completion":4082,"start":4134,"enrollment":4912,"conditions":10614,"interventions":10615},"NCT01756482","Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)",[87],[10606],[10589],{"trials":10617,"activeCount":97},[],{"trials":10619,"activeCount":97},[],{"trials":10621,"activeCount":97},[],{"intervention":661,"totalTrials":332,"cells":10623},{"EARLY_PHASE1":10624,"PHASE1":10626,"PHASE2":10632,"PHASE3":10642,"PHASE4":10644,"NA":10646},{"trials":10625,"activeCount":97},[],{"trials":10627,"activeCount":97},[10628],{"nctId":9691,"briefTitle":9692,"status":103,"phases":10629,"primaryCompletion":9694,"completion":9694,"start":2045,"enrollment":7002,"conditions":10630,"interventions":10631},[86],[21],[724,661],{"trials":10633,"activeCount":97},[10634,10638],{"nctId":4946,"briefTitle":4947,"status":103,"phases":10635,"primaryCompletion":4212,"completion":4212,"start":4668,"enrollment":1111,"conditions":10636,"interventions":10637},[87],[15],[4951,231,661],{"nctId":651,"briefTitle":652,"status":653,"phases":10639,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":10640,"interventions":10641},[87],[33],[660,161,126,661,307,231],{"trials":10643,"activeCount":97},[],{"trials":10645,"activeCount":97},[],{"trials":10647,"activeCount":97},[],{"intervention":2327,"totalTrials":993,"cells":10649},{"EARLY_PHASE1":10650,"PHASE1":10652,"PHASE2":10654,"PHASE3":10664,"PHASE4":10666,"NA":10668},{"trials":10651,"activeCount":97},[],{"trials":10653,"activeCount":97},[],{"trials":10655,"activeCount":97},[10656,10660],{"nctId":2320,"briefTitle":2321,"status":103,"phases":10657,"primaryCompletion":2323,"completion":2323,"start":2324,"enrollment":25,"conditions":10658,"interventions":10659},[86,87],[15],[42,2327],{"nctId":3217,"briefTitle":3218,"status":103,"phases":10661,"primaryCompletion":3220,"completion":3221,"start":3222,"enrollment":3223,"conditions":10662,"interventions":10663},[87],[24],[3226,3227,1121,3228],{"trials":10665,"activeCount":97},[],{"trials":10667,"activeCount":97},[],{"trials":10669,"activeCount":97},[],{"intervention":9853,"totalTrials":993,"cells":10671},{"EARLY_PHASE1":10672,"PHASE1":10674,"PHASE2":10676,"PHASE3":10686,"PHASE4":10688,"NA":10690},{"trials":10673,"activeCount":97},[],{"trials":10675,"activeCount":97},[],{"trials":10677,"activeCount":97},[10678,10682],{"nctId":9846,"briefTitle":9847,"status":103,"phases":10679,"primaryCompletion":4368,"completion":4368,"start":4081,"enrollment":22,"conditions":10680,"interventions":10681},[87],[9850,9851],[9837,9853,9837,9853,9854],{"nctId":9868,"briefTitle":9869,"status":103,"phases":10683,"primaryCompletion":4693,"completion":4693,"start":4203,"enrollment":5999,"conditions":10684,"interventions":10685},[87],[9851,9850],[9837,9853,9854],{"trials":10687,"activeCount":97},[],{"trials":10689,"activeCount":97},[],{"trials":10691,"activeCount":97},[],{"intervention":10693,"totalTrials":993,"cells":10694},"Alobresib",{"EARLY_PHASE1":10695,"PHASE1":10697,"PHASE2":10709,"PHASE3":10721,"PHASE4":10723,"NA":10725},{"trials":10696,"activeCount":97},[],{"trials":10698,"activeCount":97},[10699],{"nctId":10700,"briefTitle":10701,"status":103,"phases":10702,"primaryCompletion":10703,"completion":10703,"start":583,"enrollment":342,"conditions":10704,"interventions":10706},"NCT02392611","Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer",[86],"2017-10-11",[10705],"Solid Tumors and Lymphomas",[10693,10707,10708],"Exemestane","Fulvestrant",{"trials":10710,"activeCount":97},[10711],{"nctId":10712,"briefTitle":10713,"status":653,"phases":10714,"primaryCompletion":9499,"completion":10715,"start":10716,"enrollment":8439,"conditions":10717,"interventions":10719},"NCT02607228","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",[86,87],"2019-09-03","2015-12-08",[10718],"Metastatic Castrate-Resistant Prostate Cancer",[10693,10720],"Enzalutamide",{"trials":10722,"activeCount":97},[],{"trials":10724,"activeCount":97},[],{"trials":10726,"activeCount":97},[],{"intervention":1291,"totalTrials":993,"cells":10728},{"EARLY_PHASE1":10729,"PHASE1":10731,"PHASE2":10737,"PHASE3":10743,"PHASE4":10745,"NA":10747},{"trials":10730,"activeCount":97},[],{"trials":10732,"activeCount":97},[10733],{"nctId":1439,"briefTitle":1440,"status":103,"phases":10734,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":1444,"conditions":10735,"interventions":10736},[86],[1037,1010,1446,1447,1448],[1450,1090,1120,1013,1119,1451,1452,1291,1453,1454,1051],{"trials":10738,"activeCount":97},[10739],{"nctId":1283,"briefTitle":1284,"status":653,"phases":10740,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1008,"conditions":10741,"interventions":10742},[87],[1289],[1049,1012,991,1291,1014,1013,1089],{"trials":10744,"activeCount":97},[],{"trials":10746,"activeCount":97},[],{"trials":10748,"activeCount":97},[],{"intervention":6002,"totalTrials":993,"cells":10750},{"EARLY_PHASE1":10751,"PHASE1":10753,"PHASE2":10759,"PHASE3":10770,"PHASE4":10772,"NA":10774},{"trials":10752,"activeCount":97},[],{"trials":10754,"activeCount":97},[10755],{"nctId":5995,"briefTitle":5996,"status":103,"phases":10756,"primaryCompletion":1192,"completion":1192,"start":5998,"enrollment":5999,"conditions":10757,"interventions":10758},[86],[3863],[6002,6003,6004,5988],{"trials":10760,"activeCount":97},[10761],{"nctId":10762,"briefTitle":10763,"status":103,"phases":10764,"primaryCompletion":8187,"completion":8187,"start":10765,"enrollment":157,"conditions":10766,"interventions":10768},"NCT00701883","Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol",[87],"2007-08",[10767],"Hyperlipidemia",[10769,10769,6002,10769,10769],"MBX-8025",{"trials":10771,"activeCount":97},[],{"trials":10773,"activeCount":97},[],{"trials":10775,"activeCount":97},[],{"intervention":6025,"totalTrials":993,"cells":10777},{"EARLY_PHASE1":10778,"PHASE1":10780,"PHASE2":10782,"PHASE3":10792,"PHASE4":10794,"NA":10796},{"trials":10779,"activeCount":97},[],{"trials":10781,"activeCount":97},[],{"trials":10783,"activeCount":97},[10784,10788],{"nctId":6015,"briefTitle":6016,"status":103,"phases":10785,"primaryCompletion":6018,"completion":6019,"start":328,"enrollment":1361,"conditions":10786,"interventions":10787},[87],[3863],[6022,5988,6023,6024,6025],{"nctId":6221,"briefTitle":6222,"status":653,"phases":10789,"primaryCompletion":6224,"completion":41,"start":6225,"enrollment":3270,"conditions":10790,"interventions":10791},[87],[3863],[1450,6025,6228],{"trials":10793,"activeCount":97},[],{"trials":10795,"activeCount":97},[],{"trials":10797,"activeCount":97},[],{"intervention":10079,"totalTrials":993,"cells":10799},{"EARLY_PHASE1":10800,"PHASE1":10802,"PHASE2":10804,"PHASE3":10814,"PHASE4":10816,"NA":10818},{"trials":10801,"activeCount":97},[],{"trials":10803,"activeCount":97},[],{"trials":10805,"activeCount":97},[10806,10810],{"nctId":10385,"briefTitle":10386,"status":103,"phases":10807,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":10388,"conditions":10808,"interventions":10809},[87],[4224],[10080,10079,9650,9651,10391,10079,9650,9651,10391,10392,9650,9651],{"nctId":10074,"briefTitle":10075,"status":103,"phases":10811,"primaryCompletion":2352,"completion":4677,"start":6634,"enrollment":19,"conditions":10812,"interventions":10813},[87],[794],[10079,10080,9580,10081],{"trials":10815,"activeCount":97},[],{"trials":10817,"activeCount":97},[],{"trials":10819,"activeCount":97},[],{"intervention":9650,"totalTrials":993,"cells":10821},{"EARLY_PHASE1":10822,"PHASE1":10824,"PHASE2":10826,"PHASE3":10836,"PHASE4":10838,"NA":10840},{"trials":10823,"activeCount":97},[],{"trials":10825,"activeCount":97},[],{"trials":10827,"activeCount":97},[10828,10832],{"nctId":10385,"briefTitle":10386,"status":103,"phases":10829,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":10388,"conditions":10830,"interventions":10831},[87],[4224],[10080,10079,9650,9651,10391,10079,9650,9651,10391,10392,9650,9651],{"nctId":9644,"briefTitle":9645,"status":103,"phases":10833,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":9647,"conditions":10834,"interventions":10835},[87],[4116],[9610,4295,9650,9651,4295,9652,9650,9651,9652,9653,9650,9651],{"trials":10837,"activeCount":97},[],{"trials":10839,"activeCount":97},[],{"trials":10841,"activeCount":97},[],{"intervention":9651,"totalTrials":993,"cells":10843},{"EARLY_PHASE1":10844,"PHASE1":10846,"PHASE2":10848,"PHASE3":10858,"PHASE4":10860,"NA":10862},{"trials":10845,"activeCount":97},[],{"trials":10847,"activeCount":97},[],{"trials":10849,"activeCount":97},[10850,10854],{"nctId":10385,"briefTitle":10386,"status":103,"phases":10851,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":10388,"conditions":10852,"interventions":10853},[87],[4224],[10080,10079,9650,9651,10391,10079,9650,9651,10391,10392,9650,9651],{"nctId":9644,"briefTitle":9645,"status":103,"phases":10855,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":9647,"conditions":10856,"interventions":10857},[87],[4116],[9610,4295,9650,9651,4295,9652,9650,9651,9652,9653,9650,9651],{"trials":10859,"activeCount":97},[],{"trials":10861,"activeCount":97},[],{"trials":10863,"activeCount":97},[],{"intervention":6738,"totalTrials":993,"cells":10865},{"EARLY_PHASE1":10866,"PHASE1":10868,"PHASE2":10870,"PHASE3":10880,"PHASE4":10882,"NA":10884},{"trials":10867,"activeCount":97},[],{"trials":10869,"activeCount":97},[],{"trials":10871,"activeCount":97},[10872,10876],{"nctId":6730,"briefTitle":6731,"status":103,"phases":10873,"primaryCompletion":6733,"completion":6734,"start":777,"enrollment":6735,"conditions":10874,"interventions":10875},[87],[6371],[6721,6738,6739],{"nctId":6741,"briefTitle":6742,"status":103,"phases":10877,"primaryCompletion":6744,"completion":6744,"start":6745,"enrollment":6746,"conditions":10878,"interventions":10879},[87],[6333,6748],[6721,6738,6739,6750,6751],{"trials":10881,"activeCount":97},[],{"trials":10883,"activeCount":97},[],{"trials":10885,"activeCount":97},[],{"intervention":6739,"totalTrials":993,"cells":10887},{"EARLY_PHASE1":10888,"PHASE1":10890,"PHASE2":10892,"PHASE3":10902,"PHASE4":10904,"NA":10906},{"trials":10889,"activeCount":97},[],{"trials":10891,"activeCount":97},[],{"trials":10893,"activeCount":97},[10894,10898],{"nctId":6730,"briefTitle":6731,"status":103,"phases":10895,"primaryCompletion":6733,"completion":6734,"start":777,"enrollment":6735,"conditions":10896,"interventions":10897},[87],[6371],[6721,6738,6739],{"nctId":6741,"briefTitle":6742,"status":103,"phases":10899,"primaryCompletion":6744,"completion":6744,"start":6745,"enrollment":6746,"conditions":10900,"interventions":10901},[87],[6333,6748],[6721,6738,6739,6750,6751],{"trials":10903,"activeCount":97},[],{"trials":10905,"activeCount":97},[],{"trials":10907,"activeCount":97},[],{"intervention":9432,"totalTrials":993,"cells":10909},{"EARLY_PHASE1":10910,"PHASE1":10912,"PHASE2":10922,"PHASE3":10928,"PHASE4":10930,"NA":10932},{"trials":10911,"activeCount":97},[],{"trials":10913,"activeCount":97},[10914],{"nctId":10915,"briefTitle":10916,"status":653,"phases":10917,"primaryCompletion":10918,"completion":10918,"start":10919,"enrollment":1335,"conditions":10920,"interventions":10921},"NCT02436135","Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease",[86],"2017-11-20","2015-06-05",[9430],[1538,9432],{"trials":10923,"activeCount":97},[10924],{"nctId":9423,"briefTitle":9424,"status":103,"phases":10925,"primaryCompletion":9426,"completion":9427,"start":9428,"enrollment":4841,"conditions":10926,"interventions":10927},[87],[9430],[1737,9432],{"trials":10929,"activeCount":97},[],{"trials":10931,"activeCount":97},[],{"trials":10933,"activeCount":97},[],{"intervention":6522,"totalTrials":993,"cells":10935},{"EARLY_PHASE1":10936,"PHASE1":10938,"PHASE2":10944,"PHASE3":10956,"PHASE4":10958,"NA":10960},{"trials":10937,"activeCount":97},[],{"trials":10939,"activeCount":97},[10940],{"nctId":6515,"briefTitle":6516,"status":653,"phases":10941,"primaryCompletion":6518,"completion":6518,"start":6519,"enrollment":332,"conditions":10942,"interventions":10943},[86],[6088],[6522,112],{"trials":10945,"activeCount":97},[10946],{"nctId":10947,"briefTitle":6516,"status":653,"phases":10948,"primaryCompletion":10949,"completion":10950,"start":10951,"enrollment":34,"conditions":10952,"interventions":10954},"NCT05629208",[87],"2025-12-17","2026-01-14","2023-04-17",[10953],"Cutaneous Lupus Erythematosus (CLE)",[6522,10955],"Edecesertib Placebo",{"trials":10957,"activeCount":97},[],{"trials":10959,"activeCount":97},[],{"trials":10961,"activeCount":97},[],{"intervention":10451,"totalTrials":993,"cells":10963},{"EARLY_PHASE1":10964,"PHASE1":10966,"PHASE2":10968,"PHASE3":10978,"PHASE4":10980,"NA":10982},{"trials":10965,"activeCount":97},[],{"trials":10967,"activeCount":97},[],{"trials":10969,"activeCount":97},[10970,10974],{"nctId":10446,"briefTitle":10447,"status":103,"phases":10971,"primaryCompletion":5575,"completion":4851,"start":4930,"enrollment":342,"conditions":10972,"interventions":10973},[87],[794],[10437,10451],{"nctId":10453,"briefTitle":10454,"status":103,"phases":10975,"primaryCompletion":5906,"completion":5574,"start":8187,"enrollment":3320,"conditions":10976,"interventions":10977},[87],[6371],[10437,10451],{"trials":10979,"activeCount":97},[],{"trials":10981,"activeCount":97},[],{"trials":10983,"activeCount":97},[],{"intervention":3396,"totalTrials":993,"cells":10985},{"EARLY_PHASE1":10986,"PHASE1":10988,"PHASE2":10990,"PHASE3":11000,"PHASE4":11002,"NA":11004},{"trials":10987,"activeCount":97},[],{"trials":10989,"activeCount":97},[],{"trials":10991,"activeCount":97},[10992,10996],{"nctId":3387,"briefTitle":3388,"status":653,"phases":10993,"primaryCompletion":3390,"completion":3390,"start":3391,"enrollment":3392,"conditions":10994,"interventions":10995},[87],[3394],[1049,1453,1454,3396,1451],{"nctId":7396,"briefTitle":7397,"status":653,"phases":10997,"primaryCompletion":4367,"completion":533,"start":4530,"enrollment":2440,"conditions":10998,"interventions":10999},[87],[1447],[1737,1451,1454,3396],{"trials":11001,"activeCount":97},[],{"trials":11003,"activeCount":97},[],{"trials":11005,"activeCount":97},[],{"intervention":10707,"totalTrials":993,"cells":11007},{"EARLY_PHASE1":11008,"PHASE1":11010,"PHASE2":11016,"PHASE3":11029,"PHASE4":11031,"NA":11033},{"trials":11009,"activeCount":97},[],{"trials":11011,"activeCount":97},[11012],{"nctId":10700,"briefTitle":10701,"status":103,"phases":11013,"primaryCompletion":10703,"completion":10703,"start":583,"enrollment":342,"conditions":11014,"interventions":11015},[86],[10705],[10693,10707,10708],{"trials":11017,"activeCount":97},[11018],{"nctId":11019,"briefTitle":11020,"status":653,"phases":11021,"primaryCompletion":11022,"completion":11022,"start":11023,"enrollment":11024,"conditions":11025,"interventions":11027},"NCT02983604","GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer",[86,87],"2018-07-19","2017-01-10",14,[11026],"Advanced Estrogen Receptor Positive HER2- Breast Cancer",[11028,10707,10708],"GS-5829",{"trials":11030,"activeCount":97},[],{"trials":11032,"activeCount":97},[],{"trials":11034,"activeCount":97},[],{"intervention":10708,"totalTrials":993,"cells":11036},{"EARLY_PHASE1":11037,"PHASE1":11039,"PHASE2":11045,"PHASE3":11051,"PHASE4":11053,"NA":11055},{"trials":11038,"activeCount":97},[],{"trials":11040,"activeCount":97},[11041],{"nctId":10700,"briefTitle":10701,"status":103,"phases":11042,"primaryCompletion":10703,"completion":10703,"start":583,"enrollment":342,"conditions":11043,"interventions":11044},[86],[10705],[10693,10707,10708],{"trials":11046,"activeCount":97},[11047],{"nctId":11019,"briefTitle":11020,"status":653,"phases":11048,"primaryCompletion":11022,"completion":11022,"start":11023,"enrollment":11024,"conditions":11049,"interventions":11050},[86,87],[11026],[11028,10707,10708],{"trials":11052,"activeCount":97},[],{"trials":11054,"activeCount":97},[],{"trials":11056,"activeCount":97},[],{"intervention":9590,"totalTrials":993,"cells":11058},{"EARLY_PHASE1":11059,"PHASE1":11061,"PHASE2":11063,"PHASE3":11073,"PHASE4":11075,"NA":11077},{"trials":11060,"activeCount":97},[],{"trials":11062,"activeCount":97},[],{"trials":11064,"activeCount":97},[11065,11069],{"nctId":9582,"briefTitle":9583,"status":103,"phases":11066,"primaryCompletion":4082,"completion":4082,"start":4929,"enrollment":9585,"conditions":11067,"interventions":11068},[87],[4116],[4294,4295,9588,9589,9590],{"nctId":9644,"briefTitle":9645,"status":103,"phases":11070,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":9647,"conditions":11071,"interventions":11072},[87],[4116],[9610,4295,9650,9651,4295,9652,9650,9651,9652,9653,9650,9651],{"trials":11074,"activeCount":97},[],{"trials":11076,"activeCount":97},[],{"trials":11078,"activeCount":97},[],{"intervention":11080,"totalTrials":993,"cells":11081},"90Y-hPAM4",{"EARLY_PHASE1":11082,"PHASE1":11084,"PHASE2":11094,"PHASE3":11102,"PHASE4":11104,"NA":11106},{"trials":11083,"activeCount":97},[],{"trials":11085,"activeCount":97},[11086],{"nctId":11087,"briefTitle":11088,"status":1529,"phases":11089,"primaryCompletion":4580,"completion":4430,"start":501,"enrollment":97,"conditions":11090,"interventions":11092},"NCT01510561","A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.",[86],[11091,1037,1785],"Metastatic Pancreatic Adenocarcinoma",[11080,11080,11093],"90Y-hPAM4 + gemcitabine",{"trials":11095,"activeCount":97},[11096],{"nctId":11097,"briefTitle":11098,"status":103,"phases":11099,"primaryCompletion":5174,"completion":5174,"start":4659,"enrollment":657,"conditions":11100,"interventions":11101},"NCT00597129","Safety and Efficacy Study of 90Y-hPAM4 at Different Doses",[86,87],[1037],[11080],{"trials":11103,"activeCount":97},[],{"trials":11105,"activeCount":97},[],{"trials":11107,"activeCount":97},[],{"intervention":1541,"totalTrials":993,"cells":11109},{"EARLY_PHASE1":11110,"PHASE1":11112,"PHASE2":11118,"PHASE3":11124,"PHASE4":11126,"NA":11128},{"trials":11111,"activeCount":97},[],{"trials":11113,"activeCount":97},[11114],{"nctId":1527,"briefTitle":1528,"status":1529,"phases":11115,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":97,"conditions":11116,"interventions":11117},[86],[1535,1536],[1538,1539,1540,1013,1541],{"trials":11119,"activeCount":97},[11120],{"nctId":6661,"briefTitle":6662,"status":653,"phases":11121,"primaryCompletion":6664,"completion":6664,"start":442,"enrollment":4841,"conditions":11122,"interventions":11123},[87],[6666],[1049,6643,6668,6669,1541,6670,6671],{"trials":11125,"activeCount":97},[],{"trials":11127,"activeCount":97},[],{"trials":11129,"activeCount":97},[],{"intervention":7236,"totalTrials":993,"cells":11131},{"EARLY_PHASE1":11132,"PHASE1":11134,"PHASE2":11140,"PHASE3":11153,"PHASE4":11155,"NA":11157},{"trials":11133,"activeCount":97},[],{"trials":11135,"activeCount":97},[11136],{"nctId":7223,"briefTitle":7224,"status":103,"phases":11137,"primaryCompletion":7226,"completion":7226,"start":7227,"enrollment":7228,"conditions":11138,"interventions":11139},[86],[7230,36,7231],[1538,1539,7216,7233,7234,7235,7236,7210,7237],{"trials":11141,"activeCount":97},[11142],{"nctId":11143,"briefTitle":11144,"status":653,"phases":11145,"primaryCompletion":11146,"completion":11146,"start":11147,"enrollment":1862,"conditions":11148,"interventions":11149},"NCT04892446","Study of Magrolimab Combinations in Patients With Relapsed\u002FRefractory Multiple Myeloma",[87],"2024-04-25","2021-11-09",[9826],[1049,11150,11151,9551,7236,11152],"Daratumumab","Pomalidomide","Carfilzomib",{"trials":11154,"activeCount":97},[],{"trials":11156,"activeCount":97},[],{"trials":11158,"activeCount":97},[],{"intervention":1560,"totalTrials":993,"cells":11160},{"EARLY_PHASE1":11161,"PHASE1":11163,"PHASE2":11165,"PHASE3":11178,"PHASE4":11180,"NA":11182},{"trials":11162,"activeCount":97},[],{"trials":11164,"activeCount":97},[],{"trials":11166,"activeCount":97},[11167,11171],{"nctId":1553,"briefTitle":1554,"status":653,"phases":11168,"primaryCompletion":1556,"completion":1556,"start":1557,"enrollment":34,"conditions":11169,"interventions":11170},[86,87],[1035],[1560,1013],{"nctId":11172,"briefTitle":11173,"status":653,"phases":11174,"primaryCompletion":4633,"completion":4633,"start":2351,"enrollment":1507,"conditions":11175,"interventions":11177},"NCT00664378","Efficacy Study of CYT997 in Multiple Myeloma",[87],[11176],"Relapsed and Refractory Multiple Myeloma",[1560],{"trials":11179,"activeCount":97},[],{"trials":11181,"activeCount":97},[],{"trials":11183,"activeCount":97},[],{"intervention":6373,"totalTrials":993,"cells":11185},{"EARLY_PHASE1":11186,"PHASE1":11188,"PHASE2":11190,"PHASE3":11200,"PHASE4":11202,"NA":11204},{"trials":11187,"activeCount":97},[],{"trials":11189,"activeCount":97},[],{"trials":11191,"activeCount":97},[11192,11196],{"nctId":6363,"briefTitle":6364,"status":103,"phases":11193,"primaryCompletion":6366,"completion":6367,"start":6368,"enrollment":6369,"conditions":11194,"interventions":11195},[87],[6371],[6373,6321,6374,6375],{"nctId":6377,"briefTitle":6378,"status":103,"phases":11197,"primaryCompletion":6380,"completion":6380,"start":6381,"enrollment":6382,"conditions":11198,"interventions":11199},[87],[6371],[6373,6385,6321],{"trials":11201,"activeCount":97},[],{"trials":11203,"activeCount":97},[],{"trials":11205,"activeCount":97},[],{"intervention":9536,"totalTrials":993,"cells":11207},{"EARLY_PHASE1":11208,"PHASE1":11210,"PHASE2":11212,"PHASE3":11222,"PHASE4":11224,"NA":11226},{"trials":11209,"activeCount":97},[],{"trials":11211,"activeCount":97},[],{"trials":11213,"activeCount":97},[11214,11218],{"nctId":9527,"briefTitle":9528,"status":653,"phases":11215,"primaryCompletion":9530,"completion":9531,"start":9532,"enrollment":1335,"conditions":11216,"interventions":11217},[86,87],[9534],[6683,9536],{"nctId":9542,"briefTitle":9543,"status":653,"phases":11219,"primaryCompletion":9545,"completion":9546,"start":9547,"enrollment":25,"conditions":11220,"interventions":11221},[86,87],[9549],[6683,9536,9551,9552],{"trials":11223,"activeCount":97},[],{"trials":11225,"activeCount":97},[],{"trials":11227,"activeCount":97},[],{"intervention":9551,"totalTrials":993,"cells":11229},{"EARLY_PHASE1":11230,"PHASE1":11232,"PHASE2":11234,"PHASE3":11244,"PHASE4":11246,"NA":11248},{"trials":11231,"activeCount":97},[],{"trials":11233,"activeCount":97},[],{"trials":11235,"activeCount":97},[11236,11240],{"nctId":11143,"briefTitle":11144,"status":653,"phases":11237,"primaryCompletion":11146,"completion":11146,"start":11147,"enrollment":1862,"conditions":11238,"interventions":11239},[87],[9826],[1049,11150,11151,9551,7236,11152],{"nctId":9542,"briefTitle":9543,"status":653,"phases":11241,"primaryCompletion":9545,"completion":9546,"start":9547,"enrollment":25,"conditions":11242,"interventions":11243},[86,87],[9549],[6683,9536,9551,9552],{"trials":11245,"activeCount":97},[],{"trials":11247,"activeCount":97},[],{"trials":11249,"activeCount":97},[],{"intervention":1747,"totalTrials":993,"cells":11251},{"EARLY_PHASE1":11252,"PHASE1":11254,"PHASE2":11256,"PHASE3":11266,"PHASE4":11268,"NA":11270},{"trials":11253,"activeCount":97},[],{"trials":11255,"activeCount":97},[],{"trials":11257,"activeCount":97},[11258,11262],{"nctId":9856,"briefTitle":9857,"status":103,"phases":11259,"primaryCompletion":2361,"completion":2361,"start":1556,"enrollment":1075,"conditions":11260,"interventions":11261},[87],[9850],[9837,1747,9854],{"nctId":1739,"briefTitle":1740,"status":653,"phases":11263,"primaryCompletion":239,"completion":239,"start":1742,"enrollment":1743,"conditions":11264,"interventions":11265},[86,87],[1745],[1049,1539,1090,1452,1747],{"trials":11267,"activeCount":97},[],{"trials":11269,"activeCount":97},[],{"trials":11271,"activeCount":97},[],{"intervention":7326,"totalTrials":993,"cells":11273},{"EARLY_PHASE1":11274,"PHASE1":11276,"PHASE2":11278,"PHASE3":11291,"PHASE4":11293,"NA":11295},{"trials":11275,"activeCount":97},[],{"trials":11277,"activeCount":97},[],{"trials":11279,"activeCount":97},[11280,11284],{"nctId":7321,"briefTitle":7322,"status":103,"phases":11281,"enrollment":1470,"conditions":11282,"interventions":11283},[87],[15],[7326,7319,5145,7327,5152,2395,2394],{"nctId":11285,"briefTitle":11286,"status":11287,"phases":11288,"enrollment":1862,"conditions":11289,"interventions":11290},"NCT00002219","Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children","UNKNOWN",[87],[15],[7326,7319,5145],{"trials":11292,"activeCount":97},[],{"trials":11294,"activeCount":97},[],{"trials":11296,"activeCount":97},[],{"intervention":11298,"totalTrials":993,"cells":11299},"hLL1-DOX",{"EARLY_PHASE1":11300,"PHASE1":11302,"PHASE2":11304,"PHASE3":11319,"PHASE4":11321,"NA":11323},{"trials":11301,"activeCount":97},[],{"trials":11303,"activeCount":97},[],{"trials":11305,"activeCount":97},[11306,11313],{"nctId":11307,"briefTitle":11308,"status":653,"phases":11309,"primaryCompletion":1781,"completion":11310,"start":695,"enrollment":487,"conditions":11311,"interventions":11312},"NCT01585688","Phase I\u002FII Study of hLL1-DOX in Relapsed NHL and CLL",[86,87],"2017-10",[10214,36],[11298],{"nctId":11314,"briefTitle":11315,"status":653,"phases":11316,"primaryCompletion":4349,"completion":4349,"start":10462,"enrollment":4587,"conditions":11317,"interventions":11318},"NCT01101594","A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma",[86,87],[9826],[11298],{"trials":11320,"activeCount":97},[],{"trials":11322,"activeCount":97},[],{"trials":11324,"activeCount":97},[],{"intervention":10720,"totalTrials":147,"cells":11326},{"EARLY_PHASE1":11327,"PHASE1":11329,"PHASE2":11331,"PHASE3":11337,"PHASE4":11339,"NA":11341},{"trials":11328,"activeCount":97},[],{"trials":11330,"activeCount":97},[],{"trials":11332,"activeCount":97},[11333],{"nctId":10712,"briefTitle":10713,"status":653,"phases":11334,"primaryCompletion":9499,"completion":10715,"start":10716,"enrollment":8439,"conditions":11335,"interventions":11336},[86,87],[10718],[10693,10720],{"trials":11338,"activeCount":97},[],{"trials":11340,"activeCount":97},[],{"trials":11342,"activeCount":97},[],{"intervention":10361,"totalTrials":147,"cells":11344},{"EARLY_PHASE1":11345,"PHASE1":11347,"PHASE2":11349,"PHASE3":11355,"PHASE4":11357,"NA":11359},{"trials":11346,"activeCount":97},[],{"trials":11348,"activeCount":97},[],{"trials":11350,"activeCount":97},[11351],{"nctId":10354,"briefTitle":10355,"status":103,"phases":11352,"primaryCompletion":10357,"completion":2598,"start":10358,"enrollment":7002,"conditions":11353,"interventions":11354},[87],[24],[3228,10361],{"trials":11356,"activeCount":97},[],{"trials":11358,"activeCount":97},[],{"trials":11360,"activeCount":97},[],{"intervention":11362,"totalTrials":147,"cells":11363},"BSF 208075",{"EARLY_PHASE1":11364,"PHASE1":11366,"PHASE2":11368,"PHASE3":11377,"PHASE4":11379,"NA":11381},{"trials":11365,"activeCount":97},[],{"trials":11367,"activeCount":97},[],{"trials":11369,"activeCount":97},[11370],{"nctId":11371,"briefTitle":11372,"status":103,"phases":11373,"completion":8778,"start":11374,"enrollment":880,"conditions":11375,"interventions":11376},"NCT00046319","Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension",[87],"2002-09",[4843],[11362],{"trials":11378,"activeCount":97},[],{"trials":11380,"activeCount":97},[],{"trials":11382,"activeCount":97},[],{"intervention":6022,"totalTrials":147,"cells":11384},{"EARLY_PHASE1":11385,"PHASE1":11387,"PHASE2":11389,"PHASE3":11395,"PHASE4":11397,"NA":11399},{"trials":11386,"activeCount":97},[],{"trials":11388,"activeCount":97},[],{"trials":11390,"activeCount":97},[11391],{"nctId":6015,"briefTitle":6016,"status":103,"phases":11392,"primaryCompletion":6018,"completion":6019,"start":328,"enrollment":1361,"conditions":11393,"interventions":11394},[87],[3863],[6022,5988,6023,6024,6025],{"trials":11396,"activeCount":97},[],{"trials":11398,"activeCount":97},[],{"trials":11400,"activeCount":97},[],{"intervention":6023,"totalTrials":147,"cells":11402},{"EARLY_PHASE1":11403,"PHASE1":11405,"PHASE2":11407,"PHASE3":11413,"PHASE4":11415,"NA":11417},{"trials":11404,"activeCount":97},[],{"trials":11406,"activeCount":97},[],{"trials":11408,"activeCount":97},[11409],{"nctId":6015,"briefTitle":6016,"status":103,"phases":11410,"primaryCompletion":6018,"completion":6019,"start":328,"enrollment":1361,"conditions":11411,"interventions":11412},[87],[3863],[6022,5988,6023,6024,6025],{"trials":11414,"activeCount":97},[],{"trials":11416,"activeCount":97},[],{"trials":11418,"activeCount":97},[],{"intervention":10391,"totalTrials":147,"cells":11420},{"EARLY_PHASE1":11421,"PHASE1":11423,"PHASE2":11425,"PHASE3":11431,"PHASE4":11433,"NA":11435},{"trials":11422,"activeCount":97},[],{"trials":11424,"activeCount":97},[],{"trials":11426,"activeCount":97},[11427],{"nctId":10385,"briefTitle":10386,"status":103,"phases":11428,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":10388,"conditions":11429,"interventions":11430},[87],[4224],[10080,10079,9650,9651,10391,10079,9650,9651,10391,10392,9650,9651],{"trials":11432,"activeCount":97},[],{"trials":11434,"activeCount":97},[],{"trials":11436,"activeCount":97},[],{"intervention":10392,"totalTrials":147,"cells":11438},{"EARLY_PHASE1":11439,"PHASE1":11441,"PHASE2":11443,"PHASE3":11449,"PHASE4":11451,"NA":11453},{"trials":11440,"activeCount":97},[],{"trials":11442,"activeCount":97},[],{"trials":11444,"activeCount":97},[11445],{"nctId":10385,"briefTitle":10386,"status":103,"phases":11446,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":10388,"conditions":11447,"interventions":11448},[87],[4224],[10080,10079,9650,9651,10391,10079,9650,9651,10391,10392,9650,9651],{"trials":11450,"activeCount":97},[],{"trials":11452,"activeCount":97},[],{"trials":11454,"activeCount":97},[],{"intervention":10955,"totalTrials":147,"cells":11456},{"EARLY_PHASE1":11457,"PHASE1":11459,"PHASE2":11461,"PHASE3":11467,"PHASE4":11469,"NA":11471},{"trials":11458,"activeCount":97},[],{"trials":11460,"activeCount":97},[],{"trials":11462,"activeCount":97},[11463],{"nctId":10947,"briefTitle":6516,"status":653,"phases":11464,"primaryCompletion":10949,"completion":10950,"start":10951,"enrollment":34,"conditions":11465,"interventions":11466},[87],[10953],[6522,10955],{"trials":11468,"activeCount":97},[],{"trials":11470,"activeCount":97},[],{"trials":11472,"activeCount":97},[],{"intervention":11474,"totalTrials":147,"cells":11475},"90Y-hLL2",{"EARLY_PHASE1":11476,"PHASE1":11478,"PHASE2":11480,"PHASE3":11492,"PHASE4":11494,"NA":11496},{"trials":11477,"activeCount":97},[],{"trials":11479,"activeCount":97},[],{"trials":11481,"activeCount":97},[11482],{"nctId":11483,"briefTitle":11484,"status":103,"phases":11485,"primaryCompletion":5174,"completion":5174,"start":11486,"enrollment":11487,"conditions":11488,"interventions":11491},"NCT00421395","Safety Study of NHL With 90Y-hLL2 IgG",[86,87],"2002-08",59,[10190,11489,11490],"B-cell NHL","Non-Hodgkins Lymphoma",[11474],{"trials":11493,"activeCount":97},[],{"trials":11495,"activeCount":97},[],{"trials":11497,"activeCount":97},[],{"intervention":2427,"totalTrials":147,"cells":11499},{"EARLY_PHASE1":11500,"PHASE1":11502,"PHASE2":11504,"PHASE3":11510,"PHASE4":11512,"NA":11514},{"trials":11501,"activeCount":97},[],{"trials":11503,"activeCount":97},[],{"trials":11505,"activeCount":97},[11506],{"nctId":2418,"briefTitle":2419,"status":103,"phases":11507,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2423,"conditions":11508,"interventions":11509},[87],[24],[2426,1356,2427,2428,2429,2430],{"trials":11511,"activeCount":97},[],{"trials":11513,"activeCount":97},[],{"trials":11515,"activeCount":97},[],{"intervention":2430,"totalTrials":147,"cells":11517},{"EARLY_PHASE1":11518,"PHASE1":11520,"PHASE2":11522,"PHASE3":11528,"PHASE4":11530,"NA":11532},{"trials":11519,"activeCount":97},[],{"trials":11521,"activeCount":97},[],{"trials":11523,"activeCount":97},[11524],{"nctId":2418,"briefTitle":2419,"status":103,"phases":11525,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2423,"conditions":11526,"interventions":11527},[87],[24],[2426,1356,2427,2428,2429,2430],{"trials":11529,"activeCount":97},[],{"trials":11531,"activeCount":97},[],{"trials":11533,"activeCount":97},[],{"intervention":11535,"totalTrials":147,"cells":11536},"OAV Regimen",{"EARLY_PHASE1":11537,"PHASE1":11539,"PHASE2":11541,"PHASE3":11553,"PHASE4":11555,"NA":11557},{"trials":11538,"activeCount":97},[],{"trials":11540,"activeCount":97},[],{"trials":11542,"activeCount":97},[11543],{"nctId":11544,"briefTitle":11545,"status":103,"phases":11546,"primaryCompletion":11547,"completion":11548,"start":11549,"enrollment":1743,"conditions":11550,"interventions":11551},"NCT01943799","Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B",[87],"2014-09-09","2015-03-03","2013-09-13",[2497],[11552,11535],"GS-4774",{"trials":11554,"activeCount":97},[],{"trials":11556,"activeCount":97},[],{"trials":11558,"activeCount":97},[],{"intervention":11560,"totalTrials":147,"cells":11561},"GS-9674",{"EARLY_PHASE1":11562,"PHASE1":11564,"PHASE2":11566,"PHASE3":11575,"PHASE4":11577,"NA":11579},{"trials":11563,"activeCount":97},[],{"trials":11565,"activeCount":97},[],{"trials":11567,"activeCount":97},[11568],{"nctId":11569,"briefTitle":11570,"status":103,"phases":11571,"primaryCompletion":11572,"completion":11572,"start":827,"enrollment":4912,"conditions":11573,"interventions":11574},"NCT02854605","Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)",[87],"2018-01-09",[6333],[11560],{"trials":11576,"activeCount":97},[],{"trials":11578,"activeCount":97},[],{"trials":11580,"activeCount":97},[],{"intervention":4626,"totalTrials":147,"cells":11582},{"EARLY_PHASE1":11583,"PHASE1":11585,"PHASE2":11587,"PHASE3":11593,"PHASE4":11595,"NA":11597},{"trials":11584,"activeCount":97},[],{"trials":11586,"activeCount":97},[],{"trials":11588,"activeCount":97},[11589],{"nctId":4618,"briefTitle":4619,"status":103,"phases":11590,"primaryCompletion":4621,"completion":4621,"start":4622,"enrollment":3902,"conditions":11591,"interventions":11592},[87],[4624],[4586,4626,4627,4628],{"trials":11594,"activeCount":97},[],{"trials":11596,"activeCount":97},[],{"trials":11598,"activeCount":97},[],{"intervention":4628,"totalTrials":147,"cells":11600},{"EARLY_PHASE1":11601,"PHASE1":11603,"PHASE2":11605,"PHASE3":11611,"PHASE4":11613,"NA":11615},{"trials":11602,"activeCount":97},[],{"trials":11604,"activeCount":97},[],{"trials":11606,"activeCount":97},[11607],{"nctId":4618,"briefTitle":4619,"status":103,"phases":11608,"primaryCompletion":4621,"completion":4621,"start":4622,"enrollment":3902,"conditions":11609,"interventions":11610},[87],[4624],[4586,4626,4627,4628],{"trials":11612,"activeCount":97},[],{"trials":11614,"activeCount":97},[],{"trials":11616,"activeCount":97},[],{"intervention":9758,"totalTrials":147,"cells":11618},{"EARLY_PHASE1":11619,"PHASE1":11621,"PHASE2":11623,"PHASE3":11629,"PHASE4":11631,"NA":11633},{"trials":11620,"activeCount":97},[],{"trials":11622,"activeCount":97},[],{"trials":11624,"activeCount":97},[11625],{"nctId":9748,"briefTitle":9749,"status":103,"phases":11626,"primaryCompletion":9751,"completion":9752,"start":9753,"enrollment":9754,"conditions":11627,"interventions":11628},[87],[9756],[9729,9758],{"trials":11630,"activeCount":97},[],{"trials":11632,"activeCount":97},[],{"trials":11634,"activeCount":97},[],{"intervention":4119,"totalTrials":147,"cells":11636},{"EARLY_PHASE1":11637,"PHASE1":11639,"PHASE2":11641,"PHASE3":11647,"PHASE4":11649,"NA":11651},{"trials":11638,"activeCount":97},[],{"trials":11640,"activeCount":97},[],{"trials":11642,"activeCount":97},[11643],{"nctId":4109,"briefTitle":4110,"status":103,"phases":11644,"primaryCompletion":4112,"completion":4113,"start":561,"enrollment":4114,"conditions":11645,"interventions":11646},[87],[4116],[4118,4119,513],{"trials":11648,"activeCount":97},[],{"trials":11650,"activeCount":97},[],{"trials":11652,"activeCount":97},[],{"intervention":7318,"totalTrials":147,"cells":11654},{"EARLY_PHASE1":11655,"PHASE1":11657,"PHASE2":11659,"PHASE3":11665,"PHASE4":11667,"NA":11669},{"trials":11656,"activeCount":97},[],{"trials":11658,"activeCount":97},[],{"trials":11660,"activeCount":97},[11661],{"nctId":7313,"briefTitle":7314,"status":103,"phases":11662,"enrollment":1075,"conditions":11663,"interventions":11664},[87],[15],[7318,7319,5145,5152,2395,2394],{"trials":11666,"activeCount":97},[],{"trials":11668,"activeCount":97},[],{"trials":11670,"activeCount":97},[],{"intervention":3312,"totalTrials":147,"cells":11672},{"EARLY_PHASE1":11673,"PHASE1":11675,"PHASE2":11677,"PHASE3":11683,"PHASE4":11685,"NA":11687},{"trials":11674,"activeCount":97},[],{"trials":11676,"activeCount":97},[],{"trials":11678,"activeCount":97},[11679],{"nctId":3304,"briefTitle":3305,"status":653,"phases":11680,"primaryCompletion":3307,"completion":3308,"start":2402,"enrollment":3309,"conditions":11681,"interventions":11682},[87],[24],[3312,126],{"trials":11684,"activeCount":97},[],{"trials":11686,"activeCount":97},[],{"trials":11688,"activeCount":97},[],{"intervention":11690,"totalTrials":147,"cells":11691},"MBX-8025 2 mg",{"EARLY_PHASE1":11692,"PHASE1":11694,"PHASE2":11696,"PHASE3":11710,"PHASE4":11712,"NA":11714},{"trials":11693,"activeCount":97},[],{"trials":11695,"activeCount":97},[],{"trials":11697,"activeCount":97},[11698],{"nctId":11699,"briefTitle":11700,"status":103,"phases":11701,"primaryCompletion":11702,"completion":11703,"start":11704,"enrollment":11705,"conditions":11706,"interventions":11707},"NCT02955602","Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)",[87],"2018-09-07","2019-07-08","2016-11-28",119,[2113],[11690,11708,11709],"MBX-8025 5 mg","MBX-8025 10 mg",{"trials":11711,"activeCount":97},[],{"trials":11713,"activeCount":97},[],{"trials":11715,"activeCount":97},[],{"intervention":11708,"totalTrials":147,"cells":11717},{"EARLY_PHASE1":11718,"PHASE1":11720,"PHASE2":11722,"PHASE3":11728,"PHASE4":11730,"NA":11732},{"trials":11719,"activeCount":97},[],{"trials":11721,"activeCount":97},[],{"trials":11723,"activeCount":97},[11724],{"nctId":11699,"briefTitle":11700,"status":103,"phases":11725,"primaryCompletion":11702,"completion":11703,"start":11704,"enrollment":11705,"conditions":11726,"interventions":11727},[87],[2113],[11690,11708,11709],{"trials":11729,"activeCount":97},[],{"trials":11731,"activeCount":97},[],{"trials":11733,"activeCount":97},[],{"intervention":11709,"totalTrials":147,"cells":11735},{"EARLY_PHASE1":11736,"PHASE1":11738,"PHASE2":11740,"PHASE3":11746,"PHASE4":11748,"NA":11750},{"trials":11737,"activeCount":97},[],{"trials":11739,"activeCount":97},[],{"trials":11741,"activeCount":97},[11742],{"nctId":11699,"briefTitle":11700,"status":103,"phases":11743,"primaryCompletion":11702,"completion":11703,"start":11704,"enrollment":11705,"conditions":11744,"interventions":11745},[87],[2113],[11690,11708,11709],{"trials":11747,"activeCount":97},[],{"trials":11749,"activeCount":97},[],{"trials":11751,"activeCount":97},[],{"intervention":11753,"totalTrials":147,"cells":11754},"Cetuximab",{"EARLY_PHASE1":11755,"PHASE1":11757,"PHASE2":11759,"PHASE3":11769,"PHASE4":11771,"NA":11773},{"trials":11756,"activeCount":97},[],{"trials":11758,"activeCount":97},[],{"trials":11760,"activeCount":97},[11761],{"nctId":11762,"briefTitle":11763,"status":103,"phases":11764,"primaryCompletion":11765,"completion":11765,"start":11766,"enrollment":6043,"conditions":11767,"interventions":11768},"NCT02953782","Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer",[86,87],"2020-02-10","2016-11-02",[1067,1447],[1049,11753],{"trials":11770,"activeCount":97},[],{"trials":11772,"activeCount":97},[],{"trials":11774,"activeCount":97},[],{"intervention":6057,"totalTrials":147,"cells":11776},{"EARLY_PHASE1":11777,"PHASE1":11779,"PHASE2":11781,"PHASE3":11787,"PHASE4":11789,"NA":11791},{"trials":11778,"activeCount":97},[],{"trials":11780,"activeCount":97},[],{"trials":11782,"activeCount":97},[11783],{"nctId":6048,"briefTitle":6049,"status":653,"phases":11784,"primaryCompletion":6051,"completion":6052,"start":6053,"enrollment":3974,"conditions":11785,"interventions":11786},[87],[6055],[5988,6057],{"trials":11788,"activeCount":97},[],{"trials":11790,"activeCount":97},[],{"trials":11792,"activeCount":97},[],{"intervention":5901,"totalTrials":147,"cells":11794},{"EARLY_PHASE1":11795,"PHASE1":11797,"PHASE2":11799,"PHASE3":11805,"PHASE4":11807,"NA":11809},{"trials":11796,"activeCount":97},[],{"trials":11798,"activeCount":97},[],{"trials":11800,"activeCount":97},[11801],{"nctId":5896,"briefTitle":5897,"status":103,"phases":11802,"primaryCompletion":534,"completion":534,"start":2362,"enrollment":4135,"conditions":11803,"interventions":11804},[87],[24],[232,5901],{"trials":11806,"activeCount":97},[],{"trials":11808,"activeCount":97},[],{"trials":11810,"activeCount":97},[],{"intervention":11812,"totalTrials":147,"cells":11813},"IMMU 130",{"EARLY_PHASE1":11814,"PHASE1":11816,"PHASE2":11818,"PHASE3":11826,"PHASE4":11828,"NA":11830},{"trials":11815,"activeCount":97},[],{"trials":11817,"activeCount":97},[],{"trials":11819,"activeCount":97},[11820],{"nctId":11821,"briefTitle":11822,"status":1529,"phases":11823,"primaryCompletion":4070,"completion":4070,"start":4176,"enrollment":97,"conditions":11824,"interventions":11825},"NCT01915472","A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer",[87],[3394],[11812],{"trials":11827,"activeCount":97},[],{"trials":11829,"activeCount":97},[],{"trials":11831,"activeCount":97},[],{"intervention":11028,"totalTrials":147,"cells":11833},{"EARLY_PHASE1":11834,"PHASE1":11836,"PHASE2":11838,"PHASE3":11844,"PHASE4":11846,"NA":11848},{"trials":11835,"activeCount":97},[],{"trials":11837,"activeCount":97},[],{"trials":11839,"activeCount":97},[11840],{"nctId":11019,"briefTitle":11020,"status":653,"phases":11841,"primaryCompletion":11022,"completion":11022,"start":11023,"enrollment":11024,"conditions":11842,"interventions":11843},[86,87],[11026],[11028,10707,10708],{"trials":11845,"activeCount":97},[],{"trials":11847,"activeCount":97},[],{"trials":11849,"activeCount":97},[],{"intervention":11851,"totalTrials":147,"cells":11852},"Labetuzumab Govitecan",{"EARLY_PHASE1":11853,"PHASE1":11855,"PHASE2":11857,"PHASE3":11866,"PHASE4":11868,"NA":11870},{"trials":11854,"activeCount":97},[],{"trials":11856,"activeCount":97},[],{"trials":11858,"activeCount":97},[11859],{"nctId":11860,"briefTitle":11861,"status":653,"phases":11862,"primaryCompletion":10511,"completion":10511,"start":11863,"enrollment":1045,"conditions":11864,"interventions":11865},"NCT01605318","Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer",[86,87],"2013-02-12",[3394,9991,9992],[11851],{"trials":11867,"activeCount":97},[],{"trials":11869,"activeCount":97},[],{"trials":11871,"activeCount":97},[],{"intervention":6750,"totalTrials":147,"cells":11873},{"EARLY_PHASE1":11874,"PHASE1":11876,"PHASE2":11878,"PHASE3":11884,"PHASE4":11886,"NA":11888},{"trials":11875,"activeCount":97},[],{"trials":11877,"activeCount":97},[],{"trials":11879,"activeCount":97},[11880],{"nctId":6741,"briefTitle":6742,"status":103,"phases":11881,"primaryCompletion":6744,"completion":6744,"start":6745,"enrollment":6746,"conditions":11882,"interventions":11883},[87],[6333,6748],[6721,6738,6739,6750,6751],{"trials":11885,"activeCount":97},[],{"trials":11887,"activeCount":97},[],{"trials":11889,"activeCount":97},[],{"intervention":6751,"totalTrials":147,"cells":11891},{"EARLY_PHASE1":11892,"PHASE1":11894,"PHASE2":11896,"PHASE3":11902,"PHASE4":11904,"NA":11906},{"trials":11893,"activeCount":97},[],{"trials":11895,"activeCount":97},[],{"trials":11897,"activeCount":97},[11898],{"nctId":6741,"briefTitle":6742,"status":103,"phases":11899,"primaryCompletion":6744,"completion":6744,"start":6745,"enrollment":6746,"conditions":11900,"interventions":11901},[87],[6333,6748],[6721,6738,6739,6750,6751],{"trials":11903,"activeCount":97},[],{"trials":11905,"activeCount":97},[],{"trials":11907,"activeCount":97},[],{"intervention":11909,"totalTrials":147,"cells":11910},"FTI, AZLI",{"EARLY_PHASE1":11911,"PHASE1":11913,"PHASE2":11915,"PHASE3":11923,"PHASE4":11925,"NA":11927},{"trials":11912,"activeCount":97},[],{"trials":11914,"activeCount":97},[],{"trials":11916,"activeCount":97},[11917],{"nctId":11918,"briefTitle":11919,"status":103,"phases":11920,"primaryCompletion":6634,"completion":4887,"start":8396,"enrollment":1470,"conditions":11921,"interventions":11922},"NCT00794586","Study Evaluating Fosfomycin\u002FTobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection",[87],[30],[11909],{"trials":11924,"activeCount":97},[],{"trials":11926,"activeCount":97},[],{"trials":11928,"activeCount":97},[],{"intervention":11930,"totalTrials":147,"cells":11931},"Aztreonam for Inhalation",{"EARLY_PHASE1":11932,"PHASE1":11934,"PHASE2":11936,"PHASE3":11945,"PHASE4":11947,"NA":11949},{"trials":11933,"activeCount":97},[],{"trials":11935,"activeCount":97},[],{"trials":11937,"activeCount":97},[11938],{"nctId":11939,"briefTitle":11940,"status":103,"phases":11941,"primaryCompletion":4659,"completion":5050,"start":8778,"enrollment":8178,"conditions":11942,"interventions":11944},"NCT01055847","Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection",[87],[30,11943,9285,6628],"CF",[11930],{"trials":11946,"activeCount":97},[],{"trials":11948,"activeCount":97},[],{"trials":11950,"activeCount":97},[],{"intervention":11952,"totalTrials":147,"cells":11953},"GS-1101",{"EARLY_PHASE1":11954,"PHASE1":11956,"PHASE2":11958,"PHASE3":11966,"PHASE4":11968,"NA":11970},{"trials":11955,"activeCount":97},[],{"trials":11957,"activeCount":97},[],{"trials":11959,"activeCount":97},[11960],{"nctId":11961,"briefTitle":11962,"status":1529,"phases":11963,"primaryCompletion":4368,"completion":4161,"start":695,"enrollment":97,"conditions":11964,"interventions":11965},"NCT01659047","A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia",[87],[36],[11952],{"trials":11967,"activeCount":97},[],{"trials":11969,"activeCount":97},[],{"trials":11971,"activeCount":97},[],{"intervention":6669,"totalTrials":147,"cells":11973},{"EARLY_PHASE1":11974,"PHASE1":11976,"PHASE2":11978,"PHASE3":11984,"PHASE4":11986,"NA":11988},{"trials":11975,"activeCount":97},[],{"trials":11977,"activeCount":97},[],{"trials":11979,"activeCount":97},[11980],{"nctId":6661,"briefTitle":6662,"status":653,"phases":11981,"primaryCompletion":6664,"completion":6664,"start":442,"enrollment":4841,"conditions":11982,"interventions":11983},[87],[6666],[1049,6643,6668,6669,1541,6670,6671],{"trials":11985,"activeCount":97},[],{"trials":11987,"activeCount":97},[],{"trials":11989,"activeCount":97},[],{"intervention":6671,"totalTrials":147,"cells":11991},{"EARLY_PHASE1":11992,"PHASE1":11994,"PHASE2":11996,"PHASE3":12002,"PHASE4":12004,"NA":12006},{"trials":11993,"activeCount":97},[],{"trials":11995,"activeCount":97},[],{"trials":11997,"activeCount":97},[11998],{"nctId":6661,"briefTitle":6662,"status":653,"phases":11999,"primaryCompletion":6664,"completion":6664,"start":442,"enrollment":4841,"conditions":12000,"interventions":12001},[87],[6666],[1049,6643,6668,6669,1541,6670,6671],{"trials":12003,"activeCount":97},[],{"trials":12005,"activeCount":97},[],{"trials":12007,"activeCount":97},[],{"intervention":12009,"totalTrials":147,"cells":12010},"MBX-8025 50 mg",{"EARLY_PHASE1":12011,"PHASE1":12013,"PHASE2":12015,"PHASE3":12027,"PHASE4":12029,"NA":12031},{"trials":12012,"activeCount":97},[],{"trials":12014,"activeCount":97},[],{"trials":12016,"activeCount":97},[12017],{"nctId":12018,"briefTitle":12019,"status":103,"phases":12020,"primaryCompletion":12021,"completion":12021,"start":598,"enrollment":487,"conditions":12022,"interventions":12024},"NCT02472535","Study to Evaluate the Effects of MBX-8025 in Patients With HoFH",[87],"2016-02",[12023],"Homozygous Familial Hypercholesterolemia",[12009,12025,12026],"MBX-8025 50 mg or 100 mg","MBX-8025 50 mg, 100 mg or 200 mg",{"trials":12028,"activeCount":97},[],{"trials":12030,"activeCount":97},[],{"trials":12032,"activeCount":97},[],{"intervention":12025,"totalTrials":147,"cells":12034},{"EARLY_PHASE1":12035,"PHASE1":12037,"PHASE2":12039,"PHASE3":12045,"PHASE4":12047,"NA":12049},{"trials":12036,"activeCount":97},[],{"trials":12038,"activeCount":97},[],{"trials":12040,"activeCount":97},[12041],{"nctId":12018,"briefTitle":12019,"status":103,"phases":12042,"primaryCompletion":12021,"completion":12021,"start":598,"enrollment":487,"conditions":12043,"interventions":12044},[87],[12023],[12009,12025,12026],{"trials":12046,"activeCount":97},[],{"trials":12048,"activeCount":97},[],{"trials":12050,"activeCount":97},[],{"intervention":12026,"totalTrials":147,"cells":12052},{"EARLY_PHASE1":12053,"PHASE1":12055,"PHASE2":12057,"PHASE3":12063,"PHASE4":12065,"NA":12067},{"trials":12054,"activeCount":97},[],{"trials":12056,"activeCount":97},[],{"trials":12058,"activeCount":97},[12059],{"nctId":12018,"briefTitle":12019,"status":103,"phases":12060,"primaryCompletion":12021,"completion":12021,"start":598,"enrollment":487,"conditions":12061,"interventions":12062},[87],[12023],[12009,12025,12026],{"trials":12064,"activeCount":97},[],{"trials":12066,"activeCount":97},[],{"trials":12068,"activeCount":97},[],{"intervention":12070,"totalTrials":147,"cells":12071},"Experimental: Seladelpar 50 mg",{"EARLY_PHASE1":12072,"PHASE1":12074,"PHASE2":12076,"PHASE3":12088,"PHASE4":12090,"NA":12092},{"trials":12073,"activeCount":97},[],{"trials":12075,"activeCount":97},[],{"trials":12077,"activeCount":97},[12078],{"nctId":12079,"briefTitle":12080,"status":653,"phases":12081,"primaryCompletion":12082,"completion":12082,"start":12083,"enrollment":433,"conditions":12084,"interventions":12086},"NCT02609048","Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)",[87],"2016-07-01","2015-11-04",[12085],"Primary Biliary Cirrhosis (PBC)",[12070,12087],"Experimental: Seladelpar \u002F MBX-8025 200 mg",{"trials":12089,"activeCount":97},[],{"trials":12091,"activeCount":97},[],{"trials":12093,"activeCount":97},[],{"intervention":12087,"totalTrials":147,"cells":12095},{"EARLY_PHASE1":12096,"PHASE1":12098,"PHASE2":12100,"PHASE3":12106,"PHASE4":12108,"NA":12110},{"trials":12097,"activeCount":97},[],{"trials":12099,"activeCount":97},[],{"trials":12101,"activeCount":97},[12102],{"nctId":12079,"briefTitle":12080,"status":653,"phases":12103,"primaryCompletion":12082,"completion":12082,"start":12083,"enrollment":433,"conditions":12104,"interventions":12105},[87],[12085],[12070,12087],{"trials":12107,"activeCount":97},[],{"trials":12109,"activeCount":97},[],{"trials":12111,"activeCount":97},[],{"intervention":6374,"totalTrials":147,"cells":12113},{"EARLY_PHASE1":12114,"PHASE1":12116,"PHASE2":12118,"PHASE3":12124,"PHASE4":12126,"NA":12128},{"trials":12115,"activeCount":97},[],{"trials":12117,"activeCount":97},[],{"trials":12119,"activeCount":97},[12120],{"nctId":6363,"briefTitle":6364,"status":103,"phases":12121,"primaryCompletion":6366,"completion":6367,"start":6368,"enrollment":6369,"conditions":12122,"interventions":12123},[87],[6371],[6373,6321,6374,6375],{"trials":12125,"activeCount":97},[],{"trials":12127,"activeCount":97},[],{"trials":12129,"activeCount":97},[],{"intervention":6375,"totalTrials":147,"cells":12131},{"EARLY_PHASE1":12132,"PHASE1":12134,"PHASE2":12136,"PHASE3":12142,"PHASE4":12144,"NA":12146},{"trials":12133,"activeCount":97},[],{"trials":12135,"activeCount":97},[],{"trials":12137,"activeCount":97},[12138],{"nctId":6363,"briefTitle":6364,"status":103,"phases":12139,"primaryCompletion":6366,"completion":6367,"start":6368,"enrollment":6369,"conditions":12140,"interventions":12141},[87],[6371],[6373,6321,6374,6375],{"trials":12143,"activeCount":97},[],{"trials":12145,"activeCount":97},[],{"trials":12147,"activeCount":97},[],{"intervention":2346,"totalTrials":147,"cells":12149},{"EARLY_PHASE1":12150,"PHASE1":12152,"PHASE2":12154,"PHASE3":12160,"PHASE4":12162,"NA":12164},{"trials":12151,"activeCount":97},[],{"trials":12153,"activeCount":97},[],{"trials":12155,"activeCount":97},[12156],{"nctId":2337,"briefTitle":2338,"status":103,"phases":12157,"primaryCompletion":2340,"completion":2341,"start":2323,"enrollment":1075,"conditions":12158,"interventions":12159},[87],[2343],[2345,2346],{"trials":12161,"activeCount":97},[],{"trials":12163,"activeCount":97},[],{"trials":12165,"activeCount":97},[],{"intervention":12167,"totalTrials":147,"cells":12168},"MBX-2982",{"EARLY_PHASE1":12169,"PHASE1":12171,"PHASE2":12173,"PHASE3":12183,"PHASE4":12185,"NA":12187},{"trials":12170,"activeCount":97},[],{"trials":12172,"activeCount":97},[],{"trials":12174,"activeCount":97},[12175],{"nctId":12176,"briefTitle":12177,"status":103,"phases":12178,"primaryCompletion":2332,"completion":2332,"start":518,"enrollment":1075,"conditions":12179,"interventions":12181},"NCT01035879","Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes",[87],[12180],"Diabetes",[12167,12167,12167,12182],"Sitagliptin",{"trials":12184,"activeCount":97},[],{"trials":12186,"activeCount":97},[],{"trials":12188,"activeCount":97},[],{"intervention":12182,"totalTrials":147,"cells":12190},{"EARLY_PHASE1":12191,"PHASE1":12193,"PHASE2":12195,"PHASE3":12201,"PHASE4":12203,"NA":12205},{"trials":12192,"activeCount":97},[],{"trials":12194,"activeCount":97},[],{"trials":12196,"activeCount":97},[12197],{"nctId":12176,"briefTitle":12177,"status":103,"phases":12198,"primaryCompletion":2332,"completion":2332,"start":518,"enrollment":1075,"conditions":12199,"interventions":12200},[87],[12180],[12167,12167,12167,12182],{"trials":12202,"activeCount":97},[],{"trials":12204,"activeCount":97},[],{"trials":12206,"activeCount":97},[],{"intervention":2603,"totalTrials":147,"cells":12208},{"EARLY_PHASE1":12209,"PHASE1":12211,"PHASE2":12213,"PHASE3":12219,"PHASE4":12221,"NA":12223},{"trials":12210,"activeCount":97},[],{"trials":12212,"activeCount":97},[],{"trials":12214,"activeCount":97},[12215],{"nctId":2595,"briefTitle":2596,"status":653,"phases":12216,"primaryCompletion":1141,"completion":2598,"start":2599,"enrollment":1379,"conditions":12217,"interventions":12218},[87],[2601],[2556,2603],{"trials":12220,"activeCount":97},[],{"trials":12222,"activeCount":97},[],{"trials":12224,"activeCount":97},[],{"intervention":12226,"totalTrials":147,"cells":12227},"GS-9219",{"EARLY_PHASE1":12228,"PHASE1":12230,"PHASE2":12232,"PHASE3":12240,"PHASE4":12242,"NA":12244},{"trials":12229,"activeCount":97},[],{"trials":12231,"activeCount":97},[],{"trials":12233,"activeCount":97},[12234],{"nctId":12235,"briefTitle":12236,"status":653,"phases":12237,"primaryCompletion":10462,"completion":2352,"start":5057,"enrollment":22,"conditions":12238,"interventions":12239},"NCT00499239","A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)",[86,87],[10214,36,9826],[12226],{"trials":12241,"activeCount":97},[],{"trials":12243,"activeCount":97},[],{"trials":12245,"activeCount":97},[],{"intervention":12247,"totalTrials":147,"cells":12248},"Arhalofenate 600 mg",{"EARLY_PHASE1":12249,"PHASE1":12251,"PHASE2":12253,"PHASE3":12264,"PHASE4":12266,"NA":12268},{"trials":12250,"activeCount":97},[],{"trials":12252,"activeCount":97},[],{"trials":12254,"activeCount":97},[12255],{"nctId":12256,"briefTitle":12257,"status":103,"phases":12258,"primaryCompletion":519,"completion":519,"start":4405,"enrollment":4291,"conditions":12259,"interventions":12260},"NCT02063997","Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients",[87],[9850],[12247,12261,12262,12263],"Allopurinol 300 mg","Colchicine 0.6 mg","Arhalofenate 800 mg",{"trials":12265,"activeCount":97},[],{"trials":12267,"activeCount":97},[],{"trials":12269,"activeCount":97},[],{"intervention":12261,"totalTrials":147,"cells":12271},{"EARLY_PHASE1":12272,"PHASE1":12274,"PHASE2":12276,"PHASE3":12282,"PHASE4":12284,"NA":12286},{"trials":12273,"activeCount":97},[],{"trials":12275,"activeCount":97},[],{"trials":12277,"activeCount":97},[12278],{"nctId":12256,"briefTitle":12257,"status":103,"phases":12279,"primaryCompletion":519,"completion":519,"start":4405,"enrollment":4291,"conditions":12280,"interventions":12281},[87],[9850],[12247,12261,12262,12263],{"trials":12283,"activeCount":97},[],{"trials":12285,"activeCount":97},[],{"trials":12287,"activeCount":97},[],{"intervention":12262,"totalTrials":147,"cells":12289},{"EARLY_PHASE1":12290,"PHASE1":12292,"PHASE2":12294,"PHASE3":12300,"PHASE4":12302,"NA":12304},{"trials":12291,"activeCount":97},[],{"trials":12293,"activeCount":97},[],{"trials":12295,"activeCount":97},[12296],{"nctId":12256,"briefTitle":12257,"status":103,"phases":12297,"primaryCompletion":519,"completion":519,"start":4405,"enrollment":4291,"conditions":12298,"interventions":12299},[87],[9850],[12247,12261,12262,12263],{"trials":12301,"activeCount":97},[],{"trials":12303,"activeCount":97},[],{"trials":12305,"activeCount":97},[],{"intervention":12263,"totalTrials":147,"cells":12307},{"EARLY_PHASE1":12308,"PHASE1":12310,"PHASE2":12312,"PHASE3":12318,"PHASE4":12320,"NA":12322},{"trials":12309,"activeCount":97},[],{"trials":12311,"activeCount":97},[],{"trials":12313,"activeCount":97},[12314],{"nctId":12256,"briefTitle":12257,"status":103,"phases":12315,"primaryCompletion":519,"completion":519,"start":4405,"enrollment":4291,"conditions":12316,"interventions":12317},[87],[9850],[12247,12261,12262,12263],{"trials":12319,"activeCount":97},[],{"trials":12321,"activeCount":97},[],{"trials":12323,"activeCount":97},[],{"intervention":6080,"totalTrials":147,"cells":12325},{"EARLY_PHASE1":12326,"PHASE1":12328,"PHASE2":12330,"PHASE3":12336,"PHASE4":12338,"NA":12340},{"trials":12327,"activeCount":97},[],{"trials":12329,"activeCount":97},[],{"trials":12331,"activeCount":97},[12332],{"nctId":6069,"briefTitle":6070,"status":103,"phases":12333,"primaryCompletion":6072,"completion":6073,"start":6074,"enrollment":6075,"conditions":12334,"interventions":12335},[87],[6077],[6066,5988,6079,6067,6024,6080],{"trials":12337,"activeCount":97},[],{"trials":12339,"activeCount":97},[],{"trials":12341,"activeCount":97},[],{"intervention":10399,"totalTrials":147,"cells":12343},{"EARLY_PHASE1":12344,"PHASE1":12346,"PHASE2":12348,"PHASE3":12354,"PHASE4":12356,"NA":12358},{"trials":12345,"activeCount":97},[],{"trials":12347,"activeCount":97},[],{"trials":12349,"activeCount":97},[12350],{"nctId":10394,"briefTitle":10395,"status":103,"phases":12351,"primaryCompletion":4869,"completion":4176,"start":5575,"enrollment":853,"conditions":12352,"interventions":12353},[87],[794],[10080,10399,9580],{"trials":12355,"activeCount":97},[],{"trials":12357,"activeCount":97},[],{"trials":12359,"activeCount":97},[],{"intervention":4226,"totalTrials":147,"cells":12361},{"EARLY_PHASE1":12362,"PHASE1":12364,"PHASE2":12366,"PHASE3":12372,"PHASE4":12374,"NA":12376},{"trials":12363,"activeCount":97},[],{"trials":12365,"activeCount":97},[],{"trials":12367,"activeCount":97},[12368],{"nctId":4218,"briefTitle":4219,"status":103,"phases":12369,"primaryCompletion":1733,"completion":1782,"start":4221,"enrollment":4222,"conditions":12370,"interventions":12371},[87],[4224],[506,513,512,4226,4095,797],{"trials":12373,"activeCount":97},[],{"trials":12375,"activeCount":97},[],{"trials":12377,"activeCount":97},[],{"intervention":9652,"totalTrials":147,"cells":12379},{"EARLY_PHASE1":12380,"PHASE1":12382,"PHASE2":12384,"PHASE3":12390,"PHASE4":12392,"NA":12394},{"trials":12381,"activeCount":97},[],{"trials":12383,"activeCount":97},[],{"trials":12385,"activeCount":97},[12386],{"nctId":9644,"briefTitle":9645,"status":103,"phases":12387,"primaryCompletion":532,"completion":4176,"start":2352,"enrollment":9647,"conditions":12388,"interventions":12389},[87],[4116],[9610,4295,9650,9651,4295,9652,9650,9651,9652,9653,9650,9651],{"trials":12391,"activeCount":97},[],{"trials":12393,"activeCount":97},[],{"trials":12395,"activeCount":97},[],{"intervention":6228,"totalTrials":147,"cells":12397},{"EARLY_PHASE1":12398,"PHASE1":12400,"PHASE2":12402,"PHASE3":12408,"PHASE4":12410,"NA":12412},{"trials":12399,"activeCount":97},[],{"trials":12401,"activeCount":97},[],{"trials":12403,"activeCount":97},[12404],{"nctId":6221,"briefTitle":6222,"status":653,"phases":12405,"primaryCompletion":6224,"completion":41,"start":6225,"enrollment":3270,"conditions":12406,"interventions":12407},[87],[3863],[1450,6025,6228],{"trials":12409,"activeCount":97},[],{"trials":12411,"activeCount":97},[],{"trials":12413,"activeCount":97},[],{"intervention":11150,"totalTrials":147,"cells":12415},{"EARLY_PHASE1":12416,"PHASE1":12418,"PHASE2":12420,"PHASE3":12426,"PHASE4":12428,"NA":12430},{"trials":12417,"activeCount":97},[],{"trials":12419,"activeCount":97},[],{"trials":12421,"activeCount":97},[12422],{"nctId":11143,"briefTitle":11144,"status":653,"phases":12423,"primaryCompletion":11146,"completion":11146,"start":11147,"enrollment":1862,"conditions":12424,"interventions":12425},[87],[9826],[1049,11150,11151,9551,7236,11152],{"trials":12427,"activeCount":97},[],{"trials":12429,"activeCount":97},[],{"trials":12431,"activeCount":97},[],{"intervention":11151,"totalTrials":147,"cells":12433},{"EARLY_PHASE1":12434,"PHASE1":12436,"PHASE2":12438,"PHASE3":12444,"PHASE4":12446,"NA":12448},{"trials":12435,"activeCount":97},[],{"trials":12437,"activeCount":97},[],{"trials":12439,"activeCount":97},[12440],{"nctId":11143,"briefTitle":11144,"status":653,"phases":12441,"primaryCompletion":11146,"completion":11146,"start":11147,"enrollment":1862,"conditions":12442,"interventions":12443},[87],[9826],[1049,11150,11151,9551,7236,11152],{"trials":12445,"activeCount":97},[],{"trials":12447,"activeCount":97},[],{"trials":12449,"activeCount":97},[],{"intervention":11152,"totalTrials":147,"cells":12451},{"EARLY_PHASE1":12452,"PHASE1":12454,"PHASE2":12456,"PHASE3":12462,"PHASE4":12464,"NA":12466},{"trials":12453,"activeCount":97},[],{"trials":12455,"activeCount":97},[],{"trials":12457,"activeCount":97},[12458],{"nctId":11143,"briefTitle":11144,"status":653,"phases":12459,"primaryCompletion":11146,"completion":11146,"start":11147,"enrollment":1862,"conditions":12460,"interventions":12461},[87],[9826],[1049,11150,11151,9551,7236,11152],{"trials":12463,"activeCount":97},[],{"trials":12465,"activeCount":97},[],{"trials":12467,"activeCount":97},[],{"intervention":6685,"totalTrials":147,"cells":12469},{"EARLY_PHASE1":12470,"PHASE1":12472,"PHASE2":12474,"PHASE3":12480,"PHASE4":12482,"NA":12484},{"trials":12471,"activeCount":97},[],{"trials":12473,"activeCount":97},[],{"trials":12475,"activeCount":97},[12476],{"nctId":6673,"briefTitle":6674,"status":653,"phases":12477,"primaryCompletion":6676,"completion":6677,"start":6678,"enrollment":6679,"conditions":12478,"interventions":12479},[86,87],[6681],[6683,6684,6670,6685,6643],{"trials":12481,"activeCount":97},[],{"trials":12483,"activeCount":97},[],{"trials":12485,"activeCount":97},[],{"intervention":5143,"totalTrials":147,"cells":12487},{"EARLY_PHASE1":12488,"PHASE1":12490,"PHASE2":12492,"PHASE3":12498,"PHASE4":12500,"NA":12502},{"trials":12489,"activeCount":97},[],{"trials":12491,"activeCount":97},[],{"trials":12493,"activeCount":97},[12494],{"nctId":5138,"briefTitle":5139,"status":103,"phases":12495,"enrollment":4605,"conditions":12496,"interventions":12497},[87],[15],[5143,5144,5129,5145],{"trials":12499,"activeCount":97},[],{"trials":12501,"activeCount":97},[],{"trials":12503,"activeCount":97},[],{"intervention":5144,"totalTrials":147,"cells":12505},{"EARLY_PHASE1":12506,"PHASE1":12508,"PHASE2":12510,"PHASE3":12516,"PHASE4":12518,"NA":12520},{"trials":12507,"activeCount":97},[],{"trials":12509,"activeCount":97},[],{"trials":12511,"activeCount":97},[12512],{"nctId":5138,"briefTitle":5139,"status":103,"phases":12513,"enrollment":4605,"conditions":12514,"interventions":12515},[87],[15],[5143,5144,5129,5145],{"trials":12517,"activeCount":97},[],{"trials":12519,"activeCount":97},[],{"trials":12521,"activeCount":97},[],{"intervention":2356,"totalTrials":147,"cells":12523},{"EARLY_PHASE1":12524,"PHASE1":12526,"PHASE2":12528,"PHASE3":12534,"PHASE4":12536,"NA":12538},{"trials":12525,"activeCount":97},[],{"trials":12527,"activeCount":97},[],{"trials":12529,"activeCount":97},[12530],{"nctId":2348,"briefTitle":2349,"status":103,"phases":12531,"primaryCompletion":2351,"completion":2352,"start":2353,"enrollment":535,"conditions":12532,"interventions":12533},[87],[24],[2345,2356],{"trials":12535,"activeCount":97},[],{"trials":12537,"activeCount":97},[],{"trials":12539,"activeCount":97},[],{"intervention":9471,"totalTrials":147,"cells":12541},{"EARLY_PHASE1":12542,"PHASE1":12544,"PHASE2":12546,"PHASE3":12552,"PHASE4":12554,"NA":12556},{"trials":12543,"activeCount":97},[],{"trials":12545,"activeCount":97},[],{"trials":12547,"activeCount":97},[12548],{"nctId":9463,"briefTitle":9464,"status":653,"phases":12549,"primaryCompletion":9466,"completion":9466,"start":9467,"enrollment":9468,"conditions":12550,"interventions":12551},[87],[4871],[1737,9471],{"trials":12553,"activeCount":97},[],{"trials":12555,"activeCount":97},[],{"trials":12557,"activeCount":97},[],{"intervention":12559,"totalTrials":147,"cells":12560},"IMMU-132 infusion is administered to participants in one arm for the study",{"EARLY_PHASE1":12561,"PHASE1":12563,"PHASE2":12565,"PHASE3":12575,"PHASE4":12577,"NA":12579},{"trials":12562,"activeCount":97},[],{"trials":12564,"activeCount":97},[],{"trials":12566,"activeCount":97},[12567],{"nctId":12568,"briefTitle":12569,"status":1529,"phases":12570,"primaryCompletion":10125,"completion":10125,"start":10125,"enrollment":97,"conditions":12571,"interventions":12573},"NCT02161679","Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer",[87],[12572],"Triple-negative Breast Cancer",[12559,12574],"IMMU-132 plus Carboplatin",{"trials":12576,"activeCount":97},[],{"trials":12578,"activeCount":97},[],{"trials":12580,"activeCount":97},[],{"intervention":12574,"totalTrials":147,"cells":12582},{"EARLY_PHASE1":12583,"PHASE1":12585,"PHASE2":12587,"PHASE3":12593,"PHASE4":12595,"NA":12597},{"trials":12584,"activeCount":97},[],{"trials":12586,"activeCount":97},[],{"trials":12588,"activeCount":97},[12589],{"nctId":12568,"briefTitle":12569,"status":1529,"phases":12590,"primaryCompletion":10125,"completion":10125,"start":10125,"enrollment":97,"conditions":12591,"interventions":12592},[87],[12572],[12559,12574],{"trials":12594,"activeCount":97},[],{"trials":12596,"activeCount":97},[],{"trials":12598,"activeCount":97},[],{"intervention":9706,"totalTrials":147,"cells":12600},{"EARLY_PHASE1":12601,"PHASE1":12603,"PHASE2":12605,"PHASE3":12611,"PHASE4":12613,"NA":12615},{"trials":12602,"activeCount":97},[],{"trials":12604,"activeCount":97},[],{"trials":12606,"activeCount":97},[12607],{"nctId":9700,"briefTitle":9701,"status":103,"phases":12608,"primaryCompletion":9703,"completion":9703,"start":1904,"enrollment":34,"conditions":12609,"interventions":12610},[87],[33],[724,9706,9707],{"trials":12612,"activeCount":97},[],{"trials":12614,"activeCount":97},[],{"trials":12616,"activeCount":97},[],{"intervention":9707,"totalTrials":147,"cells":12618},{"EARLY_PHASE1":12619,"PHASE1":12621,"PHASE2":12623,"PHASE3":12629,"PHASE4":12631,"NA":12633},{"trials":12620,"activeCount":97},[],{"trials":12622,"activeCount":97},[],{"trials":12624,"activeCount":97},[12625],{"nctId":9700,"briefTitle":9701,"status":103,"phases":12626,"primaryCompletion":9703,"completion":9703,"start":1904,"enrollment":34,"conditions":12627,"interventions":12628},[87],[33],[724,9706,9707],{"trials":12630,"activeCount":97},[],{"trials":12632,"activeCount":97},[],{"trials":12634,"activeCount":97},[],{"intervention":10271,"totalTrials":147,"cells":12636},{"EARLY_PHASE1":12637,"PHASE1":12639,"PHASE2":12641,"PHASE3":12647,"PHASE4":12649,"NA":12651},{"trials":12638,"activeCount":97},[],{"trials":12640,"activeCount":97},[],{"trials":12642,"activeCount":97},[12643],{"nctId":10262,"briefTitle":10263,"status":103,"phases":12644,"primaryCompletion":10265,"completion":10266,"start":3211,"enrollment":10267,"conditions":12645,"interventions":12646},[87],[10269],[10237,10271],{"trials":12648,"activeCount":97},[],{"trials":12650,"activeCount":97},[],{"trials":12652,"activeCount":97},[],{"intervention":12654,"totalTrials":147,"cells":12655},"Epratuzumab",{"EARLY_PHASE1":12656,"PHASE1":12658,"PHASE2":12660,"PHASE3":12670,"PHASE4":12672,"NA":12674},{"trials":12657,"activeCount":97},[],{"trials":12659,"activeCount":97},[],{"trials":12661,"activeCount":97},[12662],{"nctId":12663,"briefTitle":12664,"status":653,"phases":12665,"primaryCompletion":12666,"completion":12666,"start":4659,"enrollment":8439,"conditions":12667,"interventions":12669},"NCT00113802","Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia",[87],"2006-12",[12668],"Waldenstrom Macroglobulinemia",[12654],{"trials":12671,"activeCount":97},[],{"trials":12673,"activeCount":97},[],{"trials":12675,"activeCount":97},[],{"intervention":12677,"totalTrials":147,"cells":12678},"radiolabeled epratuzumab",{"EARLY_PHASE1":12679,"PHASE1":12681,"PHASE2":12683,"PHASE3":12692,"PHASE4":12694,"NA":12696},{"trials":12680,"activeCount":97},[],{"trials":12682,"activeCount":97},[],{"trials":12684,"activeCount":97},[12685],{"nctId":12686,"briefTitle":12687,"status":103,"phases":12688,"primaryCompletion":4731,"start":12689,"conditions":12690,"interventions":12691},"NCT00061425","Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG",[86,87],"2000-08",[10214,10192],[12677],{"trials":12693,"activeCount":97},[],{"trials":12695,"activeCount":97},[],{"trials":12697,"activeCount":97},[],{"intervention":3339,"totalTrials":147,"cells":12699},{"EARLY_PHASE1":12700,"PHASE1":12702,"PHASE2":12704,"PHASE3":12710,"PHASE4":12712,"NA":12714},{"trials":12701,"activeCount":97},[],{"trials":12703,"activeCount":97},[],{"trials":12705,"activeCount":97},[12706],{"nctId":3330,"briefTitle":3331,"status":103,"phases":12707,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":3336,"conditions":12708,"interventions":12709},[87],[24],[126,782,3339],{"trials":12711,"activeCount":97},[],{"trials":12713,"activeCount":97},[],{"trials":12715,"activeCount":97},[],{"intervention":7327,"totalTrials":147,"cells":12717},{"EARLY_PHASE1":12718,"PHASE1":12720,"PHASE2":12722,"PHASE3":12728,"PHASE4":12730,"NA":12732},{"trials":12719,"activeCount":97},[],{"trials":12721,"activeCount":97},[],{"trials":12723,"activeCount":97},[12724],{"nctId":7321,"briefTitle":7322,"status":103,"phases":12725,"enrollment":1470,"conditions":12726,"interventions":12727},[87],[15],[7326,7319,5145,7327,5152,2395,2394],{"trials":12729,"activeCount":97},[],{"trials":12731,"activeCount":97},[],{"trials":12733,"activeCount":97},[],{"intervention":646,"totalTrials":147,"cells":12735},{"EARLY_PHASE1":12736,"PHASE1":12738,"PHASE2":12740,"PHASE3":12746,"PHASE4":12748,"NA":12750},{"trials":12737,"activeCount":97},[],{"trials":12739,"activeCount":97},[],{"trials":12741,"activeCount":97},[12742],{"nctId":638,"briefTitle":639,"status":103,"phases":12743,"primaryCompletion":532,"completion":641,"start":642,"enrollment":643,"conditions":12744,"interventions":12745},[87],[537,15],[646,307,308,232,647,648,649,413],{"trials":12747,"activeCount":97},[],{"trials":12749,"activeCount":97},[],{"trials":12751,"activeCount":97},[],{"intervention":647,"totalTrials":147,"cells":12753},{"EARLY_PHASE1":12754,"PHASE1":12756,"PHASE2":12758,"PHASE3":12764,"PHASE4":12766,"NA":12768},{"trials":12755,"activeCount":97},[],{"trials":12757,"activeCount":97},[],{"trials":12759,"activeCount":97},[12760],{"nctId":638,"briefTitle":639,"status":103,"phases":12761,"primaryCompletion":532,"completion":641,"start":642,"enrollment":643,"conditions":12762,"interventions":12763},[87],[537,15],[646,307,308,232,647,648,649,413],{"trials":12765,"activeCount":97},[],{"trials":12767,"activeCount":97},[],{"trials":12769,"activeCount":97},[],{"intervention":648,"totalTrials":147,"cells":12771},{"EARLY_PHASE1":12772,"PHASE1":12774,"PHASE2":12776,"PHASE3":12782,"PHASE4":12784,"NA":12786},{"trials":12773,"activeCount":97},[],{"trials":12775,"activeCount":97},[],{"trials":12777,"activeCount":97},[12778],{"nctId":638,"briefTitle":639,"status":103,"phases":12779,"primaryCompletion":532,"completion":641,"start":642,"enrollment":643,"conditions":12780,"interventions":12781},[87],[537,15],[646,307,308,232,647,648,649,413],{"trials":12783,"activeCount":97},[],{"trials":12785,"activeCount":97},[],{"trials":12787,"activeCount":97},[],{"intervention":173,"totalTrials":147,"cells":12789},{"EARLY_PHASE1":12790,"PHASE1":12792,"PHASE2":12794,"PHASE3":12800,"PHASE4":12802,"NA":12804},{"trials":12791,"activeCount":97},[],{"trials":12793,"activeCount":97},[],{"trials":12795,"activeCount":97},[12796],{"nctId":163,"briefTitle":164,"status":103,"phases":12797,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":12798,"interventions":12799},[87],[21],[161,47,172,173,174,93],{"trials":12801,"activeCount":97},[],{"trials":12803,"activeCount":97},[],{"trials":12805,"activeCount":97},[],{"intervention":12807,"totalTrials":147,"cells":12808},"Entospletinib MM",{"EARLY_PHASE1":12809,"PHASE1":12811,"PHASE2":12813,"PHASE3":12826,"PHASE4":12828,"NA":12830},{"trials":12810,"activeCount":97},[],{"trials":12812,"activeCount":97},[],{"trials":12814,"activeCount":97},[12815],{"nctId":12816,"briefTitle":12817,"status":653,"phases":12818,"primaryCompletion":790,"completion":2504,"start":12819,"enrollment":12820,"conditions":12821,"interventions":12824},"NCT01799889","Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies",[87],"2013-03-14",326,[36,7231,9520,12822,12823],"Non-FL Indolent Non-Hodgkin's Lymphoma","Follicular Lymphoma",[12807,12825],"Entospletinib SDD",{"trials":12827,"activeCount":97},[],{"trials":12829,"activeCount":97},[],{"trials":12831,"activeCount":97},[],{"intervention":12825,"totalTrials":147,"cells":12833},{"EARLY_PHASE1":12834,"PHASE1":12836,"PHASE2":12838,"PHASE3":12844,"PHASE4":12846,"NA":12848},{"trials":12835,"activeCount":97},[],{"trials":12837,"activeCount":97},[],{"trials":12839,"activeCount":97},[12840],{"nctId":12816,"briefTitle":12817,"status":653,"phases":12841,"primaryCompletion":790,"completion":2504,"start":12819,"enrollment":12820,"conditions":12842,"interventions":12843},[87],[36,7231,9520,12822,12823],[12807,12825],{"trials":12845,"activeCount":97},[],{"trials":12847,"activeCount":97},[],{"trials":12849,"activeCount":97},[],{"intervention":9552,"totalTrials":147,"cells":12851},{"EARLY_PHASE1":12852,"PHASE1":12854,"PHASE2":12856,"PHASE3":12862,"PHASE4":12864,"NA":12866},{"trials":12853,"activeCount":97},[],{"trials":12855,"activeCount":97},[],{"trials":12857,"activeCount":97},[12858],{"nctId":9542,"briefTitle":9543,"status":653,"phases":12859,"primaryCompletion":9545,"completion":9546,"start":9547,"enrollment":25,"conditions":12860,"interventions":12861},[86,87],[9549],[6683,9536,9551,9552],{"trials":12863,"activeCount":97},[],{"trials":12865,"activeCount":97},[],{"trials":12867,"activeCount":97},[],{"intervention":12869,"totalTrials":147,"cells":12870},"Tecadenoson",{"EARLY_PHASE1":12871,"PHASE1":12873,"PHASE2":12875,"PHASE3":12885,"PHASE4":12887,"NA":12889},{"trials":12872,"activeCount":97},[],{"trials":12874,"activeCount":97},[],{"trials":12876,"activeCount":97},[12877],{"nctId":12878,"briefTitle":12879,"status":103,"phases":12880,"primaryCompletion":4930,"completion":4861,"start":12881,"enrollment":657,"conditions":12882,"interventions":12883},"NCT00713401","Safety Study of Tecadenoson to Treat Atrial Fibrillation",[87],"2008-02",[4624],[12869,12884],"Esmolol",{"trials":12886,"activeCount":97},[],{"trials":12888,"activeCount":97},[],{"trials":12890,"activeCount":97},[],{"intervention":12884,"totalTrials":147,"cells":12892},{"EARLY_PHASE1":12893,"PHASE1":12895,"PHASE2":12897,"PHASE3":12903,"PHASE4":12905,"NA":12907},{"trials":12894,"activeCount":97},[],{"trials":12896,"activeCount":97},[],{"trials":12898,"activeCount":97},[12899],{"nctId":12878,"briefTitle":12879,"status":103,"phases":12900,"primaryCompletion":4930,"completion":4861,"start":12881,"enrollment":657,"conditions":12901,"interventions":12902},[87],[4624],[12869,12884],{"trials":12904,"activeCount":97},[],{"trials":12906,"activeCount":97},[],{"trials":12908,"activeCount":97},[],{"intervention":4286,"totalTrials":147,"cells":12910},{"EARLY_PHASE1":12911,"PHASE1":12913,"PHASE2":12915,"PHASE3":12921,"PHASE4":12923,"NA":12925},{"trials":12912,"activeCount":97},[],{"trials":12914,"activeCount":97},[],{"trials":12916,"activeCount":97},[12917],{"nctId":4281,"briefTitle":4282,"status":103,"phases":12918,"primaryCompletion":533,"completion":533,"start":4091,"enrollment":4178,"conditions":12919,"interventions":12920},[87],[18],[797,4286,513],{"trials":12922,"activeCount":97},[],{"trials":12924,"activeCount":97},[],{"trials":12926,"activeCount":97},[],{"intervention":12928,"totalTrials":147,"cells":12929},"GS-9137 - A Novel HIV-1 Integrase Inhibitor",{"EARLY_PHASE1":12930,"PHASE1":12932,"PHASE2":12934,"PHASE3":12942,"PHASE4":12944,"NA":12946},{"trials":12931,"activeCount":97},[],{"trials":12933,"activeCount":97},[],{"trials":12935,"activeCount":97},[12936],{"nctId":12937,"briefTitle":12938,"status":103,"phases":12939,"primaryCompletion":8737,"completion":5057,"start":2341,"enrollment":2140,"conditions":12940,"interventions":12941},"NCT00298350","Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.",[87],[504,435,4361],[12928],{"trials":12943,"activeCount":97},[],{"trials":12945,"activeCount":97},[],{"trials":12947,"activeCount":97},[],{"intervention":12949,"totalTrials":147,"cells":12950},"hA20-humanized anti-CD20 antibody",{"EARLY_PHASE1":12951,"PHASE1":12953,"PHASE2":12955,"PHASE3":12963,"PHASE4":12965,"NA":12967},{"trials":12952,"activeCount":97},[],{"trials":12954,"activeCount":97},[],{"trials":12956,"activeCount":97},[12957],{"nctId":12958,"briefTitle":12959,"status":103,"phases":12960,"primaryCompletion":5174,"completion":5174,"start":5050,"enrollment":10144,"conditions":12961,"interventions":12962},"NCT00285428","Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma",[86,87],[10214],[12949],{"trials":12964,"activeCount":97},[],{"trials":12966,"activeCount":97},[],{"trials":12968,"activeCount":97},[],{"intervention":12970,"totalTrials":147,"cells":12971},"ENTO",{"EARLY_PHASE1":12972,"PHASE1":12974,"PHASE2":12976,"PHASE3":12988,"PHASE4":12990,"NA":12992},{"trials":12973,"activeCount":97},[],{"trials":12975,"activeCount":97},[],{"trials":12977,"activeCount":97},[12978],{"nctId":12979,"briefTitle":12980,"status":653,"phases":12981,"primaryCompletion":12982,"completion":12983,"start":12984,"enrollment":819,"conditions":12985,"interventions":12987},"NCT02701634","Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)",[87],"2017-12-19","2018-03-06","2016-05-27",[12986],"Chronic Graft Versus Host Disease",[12970],{"trials":12989,"activeCount":97},[],{"trials":12991,"activeCount":97},[],{"trials":12993,"activeCount":97},[],{"intervention":3227,"totalTrials":147,"cells":12995},{"EARLY_PHASE1":12996,"PHASE1":12998,"PHASE2":13000,"PHASE3":13006,"PHASE4":13008,"NA":13010},{"trials":12997,"activeCount":97},[],{"trials":12999,"activeCount":97},[],{"trials":13001,"activeCount":97},[13002],{"nctId":3217,"briefTitle":3218,"status":103,"phases":13003,"primaryCompletion":3220,"completion":3221,"start":3222,"enrollment":3223,"conditions":13004,"interventions":13005},[87],[24],[3226,3227,1121,3228],{"trials":13007,"activeCount":97},[],{"trials":13009,"activeCount":97},[],{"trials":13011,"activeCount":97},[],{"intervention":13013,"totalTrials":147,"cells":13014},"MBX-2044",{"EARLY_PHASE1":13015,"PHASE1":13017,"PHASE2":13019,"PHASE3":13027,"PHASE4":13029,"NA":13031},{"trials":13016,"activeCount":97},[],{"trials":13018,"activeCount":97},[],{"trials":13020,"activeCount":97},[13021],{"nctId":13022,"briefTitle":13023,"status":103,"phases":13024,"primaryCompletion":10765,"completion":2362,"start":5049,"enrollment":880,"conditions":13025,"interventions":13026},"NCT00422487","Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes",[87],[4598],[13013,13013,13013,13013,13013,13013],{"trials":13028,"activeCount":97},[],{"trials":13030,"activeCount":97},[],{"trials":13032,"activeCount":97},[],{"intervention":13034,"totalTrials":147,"cells":13035},"GS-5718",{"EARLY_PHASE1":13036,"PHASE1":13038,"PHASE2":13040,"PHASE3":13052,"PHASE4":13054,"NA":13056},{"trials":13037,"activeCount":97},[],{"trials":13039,"activeCount":97},[],{"trials":13041,"activeCount":97},[13042],{"nctId":13043,"briefTitle":13044,"status":1529,"phases":13045,"primaryCompletion":13046,"completion":13047,"start":13048,"enrollment":97,"conditions":13049,"interventions":13050},"NCT05165771","Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment",[87],"2023-02","2023-03","2022-07",[3863],[13034,13034,13051],"Tofacitinib 5 mg",{"trials":13053,"activeCount":97},[],{"trials":13055,"activeCount":97},[],{"trials":13057,"activeCount":97},[],{"intervention":13051,"totalTrials":147,"cells":13059},{"EARLY_PHASE1":13060,"PHASE1":13062,"PHASE2":13064,"PHASE3":13070,"PHASE4":13072,"NA":13074},{"trials":13061,"activeCount":97},[],{"trials":13063,"activeCount":97},[],{"trials":13065,"activeCount":97},[13066],{"nctId":13043,"briefTitle":13044,"status":1529,"phases":13067,"primaryCompletion":13046,"completion":13047,"start":13048,"enrollment":97,"conditions":13068,"interventions":13069},[87],[3863],[13034,13034,13051],{"trials":13071,"activeCount":97},[],{"trials":13073,"activeCount":97},[],{"trials":13075,"activeCount":97},[],{"intervention":660,"totalTrials":147,"cells":13077},{"EARLY_PHASE1":13078,"PHASE1":13080,"PHASE2":13082,"PHASE3":13088,"PHASE4":13090,"NA":13092},{"trials":13079,"activeCount":97},[],{"trials":13081,"activeCount":97},[],{"trials":13083,"activeCount":97},[13084],{"nctId":651,"briefTitle":652,"status":653,"phases":13085,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":13086,"interventions":13087},[87],[33],[660,161,126,661,307,231],{"trials":13089,"activeCount":97},[],{"trials":13091,"activeCount":97},[],{"trials":13093,"activeCount":97},[],{"intervention":10769,"totalTrials":147,"cells":13095},{"EARLY_PHASE1":13096,"PHASE1":13098,"PHASE2":13100,"PHASE3":13106,"PHASE4":13108,"NA":13110},{"trials":13097,"activeCount":97},[],{"trials":13099,"activeCount":97},[],{"trials":13101,"activeCount":97},[13102],{"nctId":10762,"briefTitle":10763,"status":103,"phases":13103,"primaryCompletion":8187,"completion":8187,"start":10765,"enrollment":157,"conditions":13104,"interventions":13105},[87],[10767],[10769,10769,6002,10769,10769],{"trials":13107,"activeCount":97},[],{"trials":13109,"activeCount":97},[],{"trials":13111,"activeCount":97},[],{"intervention":5153,"totalTrials":147,"cells":13113},{"EARLY_PHASE1":13114,"PHASE1":13116,"PHASE2":13118,"PHASE3":13124,"PHASE4":13126,"NA":13128},{"trials":13115,"activeCount":97},[],{"trials":13117,"activeCount":97},[],{"trials":13119,"activeCount":97},[13120],{"nctId":5147,"briefTitle":5148,"status":103,"phases":13121,"enrollment":4605,"conditions":13122,"interventions":13123},[87],[15],[5129,5145,5152,5153],{"trials":13125,"activeCount":97},[],{"trials":13127,"activeCount":97},[],{"trials":13129,"activeCount":97},[],{"intervention":13131,"totalTrials":147,"cells":13132},"Tilpisertib",{"EARLY_PHASE1":13133,"PHASE1":13135,"PHASE2":13137,"PHASE3":13147,"PHASE4":13149,"NA":13151},{"trials":13134,"activeCount":97},[],{"trials":13136,"activeCount":97},[],{"trials":13138,"activeCount":97},[13139],{"nctId":13140,"briefTitle":13141,"status":653,"phases":13142,"primaryCompletion":13143,"completion":1044,"start":13144,"enrollment":12,"conditions":13145,"interventions":13146},"NCT04130919","Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis",[87],"2021-02-25","2019-12-20",[3568],[13131],{"trials":13148,"activeCount":97},[],{"trials":13150,"activeCount":97},[],{"trials":13152,"activeCount":97},[],{"intervention":13154,"totalTrials":147,"cells":13155},"Cicletanine",{"EARLY_PHASE1":13156,"PHASE1":13158,"PHASE2":13160,"PHASE3":13169,"PHASE4":13171,"NA":13173},{"trials":13157,"activeCount":97},[],{"trials":13159,"activeCount":97},[],{"trials":13161,"activeCount":97},[13162],{"nctId":13163,"briefTitle":13164,"status":653,"phases":13165,"primaryCompletion":4693,"completion":501,"start":4720,"enrollment":9719,"conditions":13166,"interventions":13167},"NCT00832507","Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)",[87],[4881],[13154,13168],"Cicletanine Placebo",{"trials":13170,"activeCount":97},[],{"trials":13172,"activeCount":97},[],{"trials":13174,"activeCount":97},[],{"intervention":13168,"totalTrials":147,"cells":13176},{"EARLY_PHASE1":13177,"PHASE1":13179,"PHASE2":13181,"PHASE3":13187,"PHASE4":13189,"NA":13191},{"trials":13178,"activeCount":97},[],{"trials":13180,"activeCount":97},[],{"trials":13182,"activeCount":97},[13183],{"nctId":13163,"briefTitle":13164,"status":653,"phases":13184,"primaryCompletion":4693,"completion":501,"start":4720,"enrollment":9719,"conditions":13185,"interventions":13186},[87],[4881],[13154,13168],{"trials":13188,"activeCount":97},[],{"trials":13190,"activeCount":97},[],{"trials":13192,"activeCount":97},[],{"intervention":508,"totalTrials":147,"cells":13194},{"EARLY_PHASE1":13195,"PHASE1":13197,"PHASE2":13199,"PHASE3":13205,"PHASE4":13207,"NA":13209},{"trials":13196,"activeCount":97},[],{"trials":13198,"activeCount":97},[],{"trials":13200,"activeCount":97},[13201],{"nctId":496,"briefTitle":497,"status":103,"phases":13202,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":13203,"interventions":13204},[86,87],[27,504],[506,507,508,509,230,510,232,307,511,512,513],{"trials":13206,"activeCount":97},[],{"trials":13208,"activeCount":97},[],{"trials":13210,"activeCount":97},[],{"intervention":509,"totalTrials":147,"cells":13212},{"EARLY_PHASE1":13213,"PHASE1":13215,"PHASE2":13217,"PHASE3":13223,"PHASE4":13225,"NA":13227},{"trials":13214,"activeCount":97},[],{"trials":13216,"activeCount":97},[],{"trials":13218,"activeCount":97},[13219],{"nctId":496,"briefTitle":497,"status":103,"phases":13220,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":13221,"interventions":13222},[86,87],[27,504],[506,507,508,509,230,510,232,307,511,512,513],{"trials":13224,"activeCount":97},[],{"trials":13226,"activeCount":97},[],{"trials":13228,"activeCount":97},[],{"intervention":511,"totalTrials":147,"cells":13230},{"EARLY_PHASE1":13231,"PHASE1":13233,"PHASE2":13235,"PHASE3":13241,"PHASE4":13243,"NA":13245},{"trials":13232,"activeCount":97},[],{"trials":13234,"activeCount":97},[],{"trials":13236,"activeCount":97},[13237],{"nctId":496,"briefTitle":497,"status":103,"phases":13238,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":13239,"interventions":13240},[86,87],[27,504],[506,507,508,509,230,510,232,307,511,512,513],{"trials":13242,"activeCount":97},[],{"trials":13244,"activeCount":97},[],{"trials":13246,"activeCount":97},[],{"intervention":10228,"totalTrials":147,"cells":13248},{"EARLY_PHASE1":13249,"PHASE1":13251,"PHASE2":13253,"PHASE3":13259,"PHASE4":13261,"NA":13263},{"trials":13250,"activeCount":97},[],{"trials":13252,"activeCount":97},[],{"trials":13254,"activeCount":97},[13255],{"nctId":10219,"briefTitle":10220,"status":1529,"phases":13256,"primaryCompletion":10222,"completion":10223,"start":7038,"enrollment":97,"conditions":13257,"interventions":13258},[86,87],[10225,10190,10226,9520],[10228,10229,10168],{"trials":13260,"activeCount":97},[],{"trials":13262,"activeCount":97},[],{"trials":13264,"activeCount":97},[],{"intervention":10229,"totalTrials":147,"cells":13266},{"EARLY_PHASE1":13267,"PHASE1":13269,"PHASE2":13271,"PHASE3":13277,"PHASE4":13279,"NA":13281},{"trials":13268,"activeCount":97},[],{"trials":13270,"activeCount":97},[],{"trials":13272,"activeCount":97},[13273],{"nctId":10219,"briefTitle":10220,"status":1529,"phases":13274,"primaryCompletion":10222,"completion":10223,"start":7038,"enrollment":97,"conditions":13275,"interventions":13276},[86,87],[10225,10190,10226,9520],[10228,10229,10168],{"trials":13278,"activeCount":97},[],{"trials":13280,"activeCount":97},[],{"trials":13282,"activeCount":97},[],{"intervention":13284,"totalTrials":477,"cells":13285},"GS-9411",{"EARLY_PHASE1":13286,"PHASE1":13288,"PHASE2":13317,"PHASE3":13319,"PHASE4":13321,"NA":13323},{"trials":13287,"activeCount":97},[],{"trials":13289,"activeCount":97},[13290,13298,13304,13310],{"nctId":13291,"briefTitle":13292,"status":103,"phases":13293,"primaryCompletion":5574,"completion":5574,"start":5574,"enrollment":3270,"conditions":13294,"interventions":13297},"NCT00951522","A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers",[86],[30,13295,13296],"Mucociliary Clearance","Airway Hydration",[13284],{"nctId":13299,"briefTitle":13300,"status":1529,"phases":13301,"primaryCompletion":4887,"completion":563,"start":518,"enrollment":97,"conditions":13302,"interventions":13303},"NCT01025713","A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)",[86],[30,13295],[13284],{"nctId":13305,"briefTitle":13306,"status":103,"phases":13307,"primaryCompletion":6634,"completion":4887,"start":5358,"enrollment":2579,"conditions":13308,"interventions":13309},"NCT00999531","A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers",[86],[30,13295,13296],[13284],{"nctId":13311,"briefTitle":13312,"status":103,"phases":13313,"primaryCompletion":13314,"completion":13314,"start":8396,"enrollment":371,"conditions":13315,"interventions":13316},"NCT00800579","Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers",[86],"2009-02",[30],[13284],{"trials":13318,"activeCount":97},[],{"trials":13320,"activeCount":97},[],{"trials":13322,"activeCount":97},[],{"trials":13324,"activeCount":97},[],{"intervention":13326,"totalTrials":332,"cells":13327},"Voxilaprevir",{"EARLY_PHASE1":13328,"PHASE1":13330,"PHASE2":13355,"PHASE3":13357,"PHASE4":13359,"NA":13361},{"trials":13329,"activeCount":97},[],{"trials":13331,"activeCount":97},[13332,13340,13348],{"nctId":13333,"briefTitle":13334,"status":103,"phases":13335,"primaryCompletion":13336,"completion":13336,"start":13337,"enrollment":342,"conditions":13338,"interventions":13339},"NCT02397707","Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment",[86],"2016-03-04","2015-03-24",[794],[13326],{"nctId":13341,"briefTitle":13342,"status":103,"phases":13343,"primaryCompletion":13344,"completion":13344,"start":13345,"enrollment":34,"conditions":13346,"interventions":13347},"NCT02402452","Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment",[86],"2015-09-28","2015-05-05",[794],[13326],{"nctId":13349,"briefTitle":13350,"status":103,"phases":13351,"primaryCompletion":3280,"completion":13344,"start":13352,"enrollment":4092,"conditions":13353,"interventions":13354},"NCT02185794","Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection",[86],"2014-06-13",[18],[13326,4107],{"trials":13356,"activeCount":97},[],{"trials":13358,"activeCount":97},[],{"trials":13360,"activeCount":97},[],{"trials":13362,"activeCount":97},[],{"intervention":13364,"totalTrials":993,"cells":13365},"Single Ascending Dose (SAD) Cohorts GS-9620",{"EARLY_PHASE1":13366,"PHASE1":13368,"PHASE2":13384,"PHASE3":13386,"PHASE4":13388,"NA":13390},{"trials":13367,"activeCount":97},[],{"trials":13369,"activeCount":97},[13370,13377],{"nctId":13371,"briefTitle":13372,"status":103,"phases":13373,"primaryCompletion":500,"completion":1782,"start":642,"enrollment":3336,"conditions":13374,"interventions":13375},"NCT01590654","A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection",[86],[2334],[13364,13376],"Multiple Ascending Dose (MAD) Cohorts GS-9620",{"nctId":13378,"briefTitle":13379,"status":103,"phases":13380,"primaryCompletion":4176,"completion":1733,"start":642,"enrollment":108,"conditions":13381,"interventions":13382},"NCT01590641","A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B",[86],[2334,831],[13364,13383],"Multiple Ascending Dose (MAD) Cohorts",{"trials":13385,"activeCount":97},[],{"trials":13387,"activeCount":97},[],{"trials":13389,"activeCount":97},[],{"trials":13391,"activeCount":97},[],{"intervention":7358,"totalTrials":993,"cells":13393},{"EARLY_PHASE1":13394,"PHASE1":13396,"PHASE2":13408,"PHASE3":13410,"PHASE4":13412,"NA":13414},{"trials":13395,"activeCount":97},[],{"trials":13397,"activeCount":97},[13398,13404],{"nctId":13399,"briefTitle":13400,"status":103,"phases":13401,"enrollment":34,"conditions":13402,"interventions":13403},"NCT00002115","A Phase I\u002FII Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.",[86],[15],[7358],{"nctId":7353,"briefTitle":7354,"status":103,"phases":13405,"enrollment":34,"conditions":13406,"interventions":13407},[86],[15],[7358,2394],{"trials":13409,"activeCount":97},[],{"trials":13411,"activeCount":97},[],{"trials":13413,"activeCount":97},[],{"trials":13415,"activeCount":97},[],{"intervention":13417,"totalTrials":993,"cells":13418},"GS-5737",{"EARLY_PHASE1":13419,"PHASE1":13421,"PHASE2":13435,"PHASE3":13437,"PHASE4":13439,"NA":13441},{"trials":13420,"activeCount":97},[],{"trials":13422,"activeCount":97},[13423,13429],{"nctId":13424,"briefTitle":13425,"status":653,"phases":13426,"primaryCompletion":4082,"completion":4082,"start":4277,"enrollment":1219,"conditions":13427,"interventions":13428},"NCT01793649","A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects",[86],[30,6201],[13417],{"nctId":13430,"briefTitle":13431,"status":103,"phases":13432,"primaryCompletion":4349,"completion":499,"start":4113,"enrollment":1122,"conditions":13433,"interventions":13434},"NCT01840735","Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF",[86],[30],[13417],{"trials":13436,"activeCount":97},[],{"trials":13438,"activeCount":97},[],{"trials":13440,"activeCount":97},[],{"trials":13442,"activeCount":97},[],{"intervention":13444,"totalTrials":993,"cells":13445},"Hu5F9-G4",{"EARLY_PHASE1":13446,"PHASE1":13448,"PHASE2":13467,"PHASE3":13469,"PHASE4":13471,"NA":13473},{"trials":13447,"activeCount":97},[],{"trials":13449,"activeCount":97},[13450,13459],{"nctId":13451,"briefTitle":13452,"status":103,"phases":13453,"primaryCompletion":13454,"completion":13455,"start":4081,"enrollment":13456,"conditions":13457,"interventions":13458},"NCT02216409","Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody",[86],"2018-10","2018-12",88,[1067],[13444],{"nctId":13460,"briefTitle":13461,"status":103,"phases":13462,"primaryCompletion":13463,"completion":13464,"start":4307,"enrollment":34,"conditions":13465,"interventions":13466},"NCT02678338","CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies",[86],"2018-11","2019-02",[6681,9795],[13444],{"trials":13468,"activeCount":97},[],{"trials":13470,"activeCount":97},[],{"trials":13472,"activeCount":97},[],{"trials":13474,"activeCount":97},[],{"intervention":7234,"totalTrials":993,"cells":13476},{"EARLY_PHASE1":13477,"PHASE1":13479,"PHASE2":13497,"PHASE3":13499,"PHASE4":13501,"NA":13503},{"trials":13478,"activeCount":97},[],{"trials":13480,"activeCount":97},[13481,13485],{"nctId":7223,"briefTitle":7224,"status":103,"phases":13482,"primaryCompletion":7226,"completion":7226,"start":7227,"enrollment":7228,"conditions":13483,"interventions":13484},[86],[7230,36,7231],[1538,1539,7216,7233,7234,7235,7236,7210,7237],{"nctId":13486,"briefTitle":13487,"status":653,"phases":13488,"primaryCompletion":13489,"completion":13489,"start":13490,"enrollment":1122,"conditions":13491,"interventions":13493},"NCT03912831","Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed\u002FRefractory HPV16+ Cancers",[86],"2022-02-18","2019-04-30",[13492],"Human Papillomavirus (HPV) 16+ Relapsed\u002FRefractory Cancer",[13494,13495,7234,13496],"KITE-439","Cyclophosphamide","Interleukin-2",{"trials":13498,"activeCount":97},[],{"trials":13500,"activeCount":97},[],{"trials":13502,"activeCount":97},[],{"trials":13504,"activeCount":97},[],{"intervention":6513,"totalTrials":993,"cells":13506},{"EARLY_PHASE1":13507,"PHASE1":13509,"PHASE2":13519,"PHASE3":13521,"PHASE4":13523,"NA":13525},{"trials":13508,"activeCount":97},[],{"trials":13510,"activeCount":97},[13511,13515],{"nctId":6504,"briefTitle":6505,"status":103,"phases":13512,"primaryCompletion":6507,"completion":6508,"start":6509,"enrollment":5999,"conditions":13513,"interventions":13514},[86],[33],[6512,6513,112],{"nctId":6524,"briefTitle":6525,"status":653,"phases":13516,"primaryCompletion":6527,"completion":6528,"start":6529,"enrollment":477,"conditions":13517,"interventions":13518},[86],[33],[6532,6513,112],{"trials":13520,"activeCount":97},[],{"trials":13522,"activeCount":97},[],{"trials":13524,"activeCount":97},[],{"trials":13526,"activeCount":97},[],{"intervention":13528,"totalTrials":993,"cells":13529},"Velpatasvir",{"EARLY_PHASE1":13530,"PHASE1":13532,"PHASE2":13550,"PHASE3":13552,"PHASE4":13554,"NA":13556},{"trials":13531,"activeCount":97},[],{"trials":13533,"activeCount":97},[13534,13543],{"nctId":13535,"briefTitle":13536,"status":103,"phases":13537,"primaryCompletion":13538,"completion":13539,"start":13540,"enrollment":3223,"conditions":13541,"interventions":13542},"NCT01740791","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection",[86],"2013-03-15","2014-01-24","2012-11-06",[4351],[13528],{"nctId":13544,"briefTitle":13545,"status":103,"phases":13546,"primaryCompletion":9753,"completion":9753,"start":13547,"enrollment":12,"conditions":13548,"interventions":13549},"NCT02002767","Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment",[86],"2013-12-16",[4234],[13528],{"trials":13551,"activeCount":97},[],{"trials":13553,"activeCount":97},[],{"trials":13555,"activeCount":97},[],{"trials":13557,"activeCount":97},[],{"intervention":13559,"totalTrials":993,"cells":13560},"CAL-101",{"EARLY_PHASE1":13561,"PHASE1":13563,"PHASE2":13582,"PHASE3":13584,"PHASE4":13586,"NA":13588},{"trials":13562,"activeCount":97},[],{"trials":13564,"activeCount":97},[13565,13572],{"nctId":13566,"briefTitle":13567,"status":103,"phases":13568,"primaryCompletion":4851,"completion":4851,"start":13314,"enrollment":433,"conditions":13569,"interventions":13571},"NCT00836914","Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber",[86],[13570],"Allergic Rhinitis",[13559],{"nctId":13573,"briefTitle":13574,"status":103,"phases":13575,"primaryCompletion":4530,"completion":695,"start":13576,"enrollment":1111,"conditions":13577,"interventions":13581},"NCT00710528","Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies",[86],"2008-06",[13578,13579,13580,9797],"Chronic Lymphocytic Leukemia (CLL)","Lymphoma, Non-Hodgkin (NHL)","Acute Myeloid Leukemia (AML)",[13559],{"trials":13583,"activeCount":97},[],{"trials":13585,"activeCount":97},[],{"trials":13587,"activeCount":97},[],{"trials":13589,"activeCount":97},[],{"intervention":6003,"totalTrials":147,"cells":13591},{"EARLY_PHASE1":13592,"PHASE1":13594,"PHASE2":13600,"PHASE3":13602,"PHASE4":13604,"NA":13606},{"trials":13593,"activeCount":97},[],{"trials":13595,"activeCount":97},[13596],{"nctId":5995,"briefTitle":5996,"status":103,"phases":13597,"primaryCompletion":1192,"completion":1192,"start":5998,"enrollment":5999,"conditions":13598,"interventions":13599},[86],[3863],[6002,6003,6004,5988],{"trials":13601,"activeCount":97},[],{"trials":13603,"activeCount":97},[],{"trials":13605,"activeCount":97},[],{"trials":13607,"activeCount":97},[],{"intervention":6004,"totalTrials":147,"cells":13609},{"EARLY_PHASE1":13610,"PHASE1":13612,"PHASE2":13618,"PHASE3":13620,"PHASE4":13622,"NA":13624},{"trials":13611,"activeCount":97},[],{"trials":13613,"activeCount":97},[13614],{"nctId":5995,"briefTitle":5996,"status":103,"phases":13615,"primaryCompletion":1192,"completion":1192,"start":5998,"enrollment":5999,"conditions":13616,"interventions":13617},[86],[3863],[6002,6003,6004,5988],{"trials":13619,"activeCount":97},[],{"trials":13621,"activeCount":97},[],{"trials":13623,"activeCount":97},[],{"trials":13625,"activeCount":97},[],{"intervention":10031,"totalTrials":147,"cells":13627},{"EARLY_PHASE1":13628,"PHASE1":13630,"PHASE2":13636,"PHASE3":13638,"PHASE4":13640,"NA":13642},{"trials":13629,"activeCount":97},[],{"trials":13631,"activeCount":97},[13632],{"nctId":10024,"briefTitle":10025,"status":103,"phases":13633,"primaryCompletion":10027,"completion":10027,"start":10028,"enrollment":3270,"conditions":13634,"interventions":13635},[86],[794],[4129,4106,10031],{"trials":13637,"activeCount":97},[],{"trials":13639,"activeCount":97},[],{"trials":13641,"activeCount":97},[],{"trials":13643,"activeCount":97},[],{"intervention":13645,"totalTrials":147,"cells":13646},"IMMU-130",{"EARLY_PHASE1":13647,"PHASE1":13649,"PHASE2":13658,"PHASE3":13660,"PHASE4":13662,"NA":13664},{"trials":13648,"activeCount":97},[],{"trials":13650,"activeCount":97},[13651],{"nctId":13652,"briefTitle":13653,"status":103,"phases":13654,"primaryCompletion":4368,"completion":4368,"start":534,"enrollment":13655,"conditions":13656,"interventions":13657},"NCT01270698","Study of IMMU-130 in Patients With Relapsed\u002FRefractory Colorectal Cancer",[86],26,[3394],[13645],{"trials":13659,"activeCount":97},[],{"trials":13661,"activeCount":97},[],{"trials":13663,"activeCount":97},[],{"trials":13665,"activeCount":97},[],{"intervention":13376,"totalTrials":147,"cells":13667},{"EARLY_PHASE1":13668,"PHASE1":13670,"PHASE2":13676,"PHASE3":13678,"PHASE4":13680,"NA":13682},{"trials":13669,"activeCount":97},[],{"trials":13671,"activeCount":97},[13672],{"nctId":13371,"briefTitle":13372,"status":103,"phases":13673,"primaryCompletion":500,"completion":1782,"start":642,"enrollment":3336,"conditions":13674,"interventions":13675},[86],[2334],[13364,13376],{"trials":13677,"activeCount":97},[],{"trials":13679,"activeCount":97},[],{"trials":13681,"activeCount":97},[],{"trials":13683,"activeCount":97},[],{"intervention":13685,"totalTrials":147,"cells":13686},"RANEXA",{"EARLY_PHASE1":13687,"PHASE1":13689,"PHASE2":13698,"PHASE3":13700,"PHASE4":13702,"NA":13704},{"trials":13688,"activeCount":97},[],{"trials":13690,"activeCount":97},[13691],{"nctId":13692,"briefTitle":13693,"status":653,"phases":13694,"primaryCompletion":695,"completion":695,"start":4338,"enrollment":477,"conditions":13695,"interventions":13697},"NCT01675973","A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety\u002FTolerability, of Ranolazine",[86],[13696],"Severe Renal Impairment",[13685],{"trials":13699,"activeCount":97},[],{"trials":13701,"activeCount":97},[],{"trials":13703,"activeCount":97},[],{"trials":13705,"activeCount":97},[],{"intervention":1249,"totalTrials":147,"cells":13707},{"EARLY_PHASE1":13708,"PHASE1":13710,"PHASE2":13716,"PHASE3":13718,"PHASE4":13720,"NA":13722},{"trials":13709,"activeCount":97},[],{"trials":13711,"activeCount":97},[13712],{"nctId":1241,"briefTitle":1242,"status":653,"phases":13713,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":487,"conditions":13714,"interventions":13715},[86],[1247],[1249,1089,1014,1013,1250,991],{"trials":13717,"activeCount":97},[],{"trials":13719,"activeCount":97},[],{"trials":13721,"activeCount":97},[],{"trials":13723,"activeCount":97},[],{"intervention":13725,"totalTrials":147,"cells":13726},"GS-7340",{"EARLY_PHASE1":13727,"PHASE1":13729,"PHASE2":13737,"PHASE3":13739,"PHASE4":13741,"NA":13743},{"trials":13728,"activeCount":97},[],{"trials":13730,"activeCount":97},[13731],{"nctId":13732,"briefTitle":13733,"status":103,"phases":13734,"primaryCompletion":4112,"completion":4112,"start":501,"enrollment":3336,"conditions":13735,"interventions":13736},"NCT01671787","A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B",[86],[24],[13725,2426],{"trials":13738,"activeCount":97},[],{"trials":13740,"activeCount":97},[],{"trials":13742,"activeCount":97},[],{"trials":13744,"activeCount":97},[],{"intervention":13746,"totalTrials":147,"cells":13747},"PSI-352938",{"EARLY_PHASE1":13748,"PHASE1":13750,"PHASE2":13759,"PHASE3":13761,"PHASE4":13763,"NA":13765},{"trials":13749,"activeCount":97},[],{"trials":13751,"activeCount":97},[13752],{"nctId":13753,"briefTitle":13754,"status":103,"phases":13755,"primaryCompletion":4677,"completion":4677,"start":4929,"enrollment":2579,"conditions":13756,"interventions":13757},"NCT01497327","Open-Label Hepatic Impairment Study",[86],[27],[13746,13758],"PSI-7977",{"trials":13760,"activeCount":97},[],{"trials":13762,"activeCount":97},[],{"trials":13764,"activeCount":97},[],{"trials":13766,"activeCount":97},[],{"intervention":13758,"totalTrials":147,"cells":13768},{"EARLY_PHASE1":13769,"PHASE1":13771,"PHASE2":13777,"PHASE3":13779,"PHASE4":13781,"NA":13783},{"trials":13770,"activeCount":97},[],{"trials":13772,"activeCount":97},[13773],{"nctId":13753,"briefTitle":13754,"status":103,"phases":13774,"primaryCompletion":4677,"completion":4677,"start":4929,"enrollment":2579,"conditions":13775,"interventions":13776},[86],[27],[13746,13758],{"trials":13778,"activeCount":97},[],{"trials":13780,"activeCount":97},[],{"trials":13782,"activeCount":97},[],{"trials":13784,"activeCount":97},[],{"intervention":13786,"totalTrials":147,"cells":13787},"IMMU-114",{"EARLY_PHASE1":13788,"PHASE1":13790,"PHASE2":13801,"PHASE3":13803,"PHASE4":13805,"NA":13807},{"trials":13789,"activeCount":97},[],{"trials":13791,"activeCount":97},[13792],{"nctId":13793,"briefTitle":13794,"status":653,"phases":13795,"primaryCompletion":10223,"completion":10223,"start":4462,"enrollment":25,"conditions":13796,"interventions":13800},"NCT01728207","Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL",[86],[13797,12823,7231,13798,36,13799],"Non-hodgkin's Lymphoma","Marginal Zone Lymphoma","Small Lymphocytic Lymphoma",[13786],{"trials":13802,"activeCount":97},[],{"trials":13804,"activeCount":97},[],{"trials":13806,"activeCount":97},[],{"trials":13808,"activeCount":97},[],{"intervention":13810,"totalTrials":147,"cells":13811},"GS-0976",{"EARLY_PHASE1":13812,"PHASE1":13814,"PHASE2":13823,"PHASE3":13825,"PHASE4":13827,"NA":13829},{"trials":13813,"activeCount":97},[],{"trials":13815,"activeCount":97},[13816],{"nctId":13817,"briefTitle":13818,"status":103,"phases":13819,"primaryCompletion":4430,"completion":696,"start":4070,"enrollment":25,"conditions":13820,"interventions":13822},"NCT02876796","Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects",[86],[13821],"PD Effects of GS-0976 (NDI-010976) on Fractional DNL",[13810],{"trials":13824,"activeCount":97},[],{"trials":13826,"activeCount":97},[],{"trials":13828,"activeCount":97},[],{"trials":13830,"activeCount":97},[],{"intervention":13832,"totalTrials":147,"cells":13833},"TF2\u002FIMP288",{"EARLY_PHASE1":13834,"PHASE1":13836,"PHASE2":13845,"PHASE3":13847,"PHASE4":13849,"NA":13851},{"trials":13835,"activeCount":97},[],{"trials":13837,"activeCount":97},[13838],{"nctId":13839,"briefTitle":13840,"status":1529,"phases":13841,"primaryCompletion":4177,"completion":13842,"start":4633,"enrollment":97,"conditions":13843,"interventions":13844},"NCT01273402","Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer",[86],"2018-08",[3394],[13832],{"trials":13846,"activeCount":97},[],{"trials":13848,"activeCount":97},[],{"trials":13850,"activeCount":97},[],{"trials":13852,"activeCount":97},[],{"intervention":1865,"totalTrials":147,"cells":13854},{"EARLY_PHASE1":13855,"PHASE1":13857,"PHASE2":13863,"PHASE3":13865,"PHASE4":13867,"NA":13869},{"trials":13856,"activeCount":97},[],{"trials":13858,"activeCount":97},[13859],{"nctId":1857,"briefTitle":1858,"status":653,"phases":13860,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":1862,"conditions":13861,"interventions":13862},[86],[1023],[1450,1865,1014,1452,1121],{"trials":13864,"activeCount":97},[],{"trials":13866,"activeCount":97},[],{"trials":13868,"activeCount":97},[],{"trials":13870,"activeCount":97},[],{"intervention":111,"totalTrials":147,"cells":13872},{"EARLY_PHASE1":13873,"PHASE1":13875,"PHASE2":13881,"PHASE3":13883,"PHASE4":13885,"NA":13887},{"trials":13874,"activeCount":97},[],{"trials":13876,"activeCount":97},[13877],{"nctId":101,"briefTitle":102,"status":103,"phases":13878,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":13879,"interventions":13880},[86],[33],[111,93,112,113,112,114,112],{"trials":13882,"activeCount":97},[],{"trials":13884,"activeCount":97},[],{"trials":13886,"activeCount":97},[],{"trials":13888,"activeCount":97},[],{"intervention":113,"totalTrials":147,"cells":13890},{"EARLY_PHASE1":13891,"PHASE1":13893,"PHASE2":13899,"PHASE3":13901,"PHASE4":13903,"NA":13905},{"trials":13892,"activeCount":97},[],{"trials":13894,"activeCount":97},[13895],{"nctId":101,"briefTitle":102,"status":103,"phases":13896,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":13897,"interventions":13898},[86],[33],[111,93,112,113,112,114,112],{"trials":13900,"activeCount":97},[],{"trials":13902,"activeCount":97},[],{"trials":13904,"activeCount":97},[],{"trials":13906,"activeCount":97},[],{"intervention":114,"totalTrials":147,"cells":13908},{"EARLY_PHASE1":13909,"PHASE1":13911,"PHASE2":13917,"PHASE3":13919,"PHASE4":13921,"NA":13923},{"trials":13910,"activeCount":97},[],{"trials":13912,"activeCount":97},[13913],{"nctId":101,"briefTitle":102,"status":103,"phases":13914,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":13915,"interventions":13916},[86],[33],[111,93,112,113,112,114,112],{"trials":13918,"activeCount":97},[],{"trials":13920,"activeCount":97},[],{"trials":13922,"activeCount":97},[],{"trials":13924,"activeCount":97},[],{"intervention":11093,"totalTrials":147,"cells":13926},{"EARLY_PHASE1":13927,"PHASE1":13929,"PHASE2":13935,"PHASE3":13937,"PHASE4":13939,"NA":13941},{"trials":13928,"activeCount":97},[],{"trials":13930,"activeCount":97},[13931],{"nctId":11087,"briefTitle":11088,"status":1529,"phases":13932,"primaryCompletion":4580,"completion":4430,"start":501,"enrollment":97,"conditions":13933,"interventions":13934},[86],[11091,1037,1785],[11080,11080,11093],{"trials":13936,"activeCount":97},[],{"trials":13938,"activeCount":97},[],{"trials":13940,"activeCount":97},[],{"trials":13942,"activeCount":97},[],{"intervention":13944,"totalTrials":147,"cells":13945},"CAL-263",{"EARLY_PHASE1":13946,"PHASE1":13948,"PHASE2":13956,"PHASE3":13958,"PHASE4":13960,"NA":13962},{"trials":13947,"activeCount":97},[],{"trials":13949,"activeCount":97},[13950],{"nctId":13951,"briefTitle":13952,"status":103,"phases":13953,"primaryCompletion":563,"completion":563,"start":4204,"enrollment":7002,"conditions":13954,"interventions":13955},"NCT01066611","Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber",[86],[13570],[13944],{"trials":13957,"activeCount":97},[],{"trials":13959,"activeCount":97},[],{"trials":13961,"activeCount":97},[],{"trials":13963,"activeCount":97},[],{"intervention":7235,"totalTrials":147,"cells":13965},{"EARLY_PHASE1":13966,"PHASE1":13968,"PHASE2":13974,"PHASE3":13976,"PHASE4":13978,"NA":13980},{"trials":13967,"activeCount":97},[],{"trials":13969,"activeCount":97},[13970],{"nctId":7223,"briefTitle":7224,"status":103,"phases":13971,"primaryCompletion":7226,"completion":7226,"start":7227,"enrollment":7228,"conditions":13972,"interventions":13973},[86],[7230,36,7231],[1538,1539,7216,7233,7234,7235,7236,7210,7237],{"trials":13975,"activeCount":97},[],{"trials":13977,"activeCount":97},[],{"trials":13979,"activeCount":97},[],{"trials":13981,"activeCount":97},[],{"intervention":7237,"totalTrials":147,"cells":13983},{"EARLY_PHASE1":13984,"PHASE1":13986,"PHASE2":13992,"PHASE3":13994,"PHASE4":13996,"NA":13998},{"trials":13985,"activeCount":97},[],{"trials":13987,"activeCount":97},[13988],{"nctId":7223,"briefTitle":7224,"status":103,"phases":13989,"primaryCompletion":7226,"completion":7226,"start":7227,"enrollment":7228,"conditions":13990,"interventions":13991},[86],[7230,36,7231],[1538,1539,7216,7233,7234,7235,7236,7210,7237],{"trials":13993,"activeCount":97},[],{"trials":13995,"activeCount":97},[],{"trials":13997,"activeCount":97},[],{"trials":13999,"activeCount":97},[],{"intervention":10112,"totalTrials":147,"cells":14001},{"EARLY_PHASE1":14002,"PHASE1":14004,"PHASE2":14010,"PHASE3":14012,"PHASE4":14014,"NA":14016},{"trials":14003,"activeCount":97},[],{"trials":14005,"activeCount":97},[14006],{"nctId":10107,"briefTitle":10108,"status":103,"phases":14007,"primaryCompletion":4144,"completion":4144,"start":533,"enrollment":880,"conditions":14008,"interventions":14009},[86],[6917],[10093,10112],{"trials":14011,"activeCount":97},[],{"trials":14013,"activeCount":97},[],{"trials":14015,"activeCount":97},[],{"trials":14017,"activeCount":97},[],{"intervention":14019,"totalTrials":147,"cells":14020},"Dalutrafusp alfa",{"EARLY_PHASE1":14021,"PHASE1":14023,"PHASE2":14035,"PHASE3":14037,"PHASE4":14039,"NA":14041},{"trials":14022,"activeCount":97},[],{"trials":14024,"activeCount":97},[14025],{"nctId":14026,"briefTitle":14027,"status":653,"phases":14028,"primaryCompletion":14029,"completion":14030,"start":14031,"enrollment":31,"conditions":14032,"interventions":14033},"NCT03954704","Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors",[86],"2020-10-27","2021-04-15","2019-06-03",[1247],[14019,14034,14019],"mFOLFOX6 Regimen",{"trials":14036,"activeCount":97},[],{"trials":14038,"activeCount":97},[],{"trials":14040,"activeCount":97},[],{"trials":14042,"activeCount":97},[],{"intervention":14034,"totalTrials":147,"cells":14044},{"EARLY_PHASE1":14045,"PHASE1":14047,"PHASE2":14053,"PHASE3":14055,"PHASE4":14057,"NA":14059},{"trials":14046,"activeCount":97},[],{"trials":14048,"activeCount":97},[14049],{"nctId":14026,"briefTitle":14027,"status":653,"phases":14050,"primaryCompletion":14029,"completion":14030,"start":14031,"enrollment":31,"conditions":14051,"interventions":14052},[86],[1247],[14019,14034,14019],{"trials":14054,"activeCount":97},[],{"trials":14056,"activeCount":97},[],{"trials":14058,"activeCount":97},[],{"trials":14060,"activeCount":97},[],{"intervention":14062,"totalTrials":147,"cells":14063},"Evixapodlin",{"EARLY_PHASE1":14064,"PHASE1":14066,"PHASE2":14076,"PHASE3":14078,"PHASE4":14080,"NA":14082},{"trials":14065,"activeCount":97},[],{"trials":14067,"activeCount":97},[14068],{"nctId":14069,"briefTitle":14070,"status":653,"phases":14071,"primaryCompletion":14072,"completion":14072,"start":14073,"enrollment":720,"conditions":14074,"interventions":14075},"NCT04049617","Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors",[86],"2021-03-30","2019-08-26",[1247],[14062],{"trials":14077,"activeCount":97},[],{"trials":14079,"activeCount":97},[],{"trials":14081,"activeCount":97},[],{"trials":14083,"activeCount":97},[],{"intervention":14085,"totalTrials":147,"cells":14086},"Lanraplenib.",{"EARLY_PHASE1":14087,"PHASE1":14089,"PHASE2":14098,"PHASE3":14100,"PHASE4":14102,"NA":14104},{"trials":14088,"activeCount":97},[],{"trials":14090,"activeCount":97},[14091],{"nctId":14092,"briefTitle":14093,"status":103,"phases":14094,"primaryCompletion":6106,"completion":6106,"start":1742,"enrollment":1862,"conditions":14095,"interventions":14097},"NCT02959138","Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function",[86],[14096],"Inflammatory Disease",[14085],{"trials":14099,"activeCount":97},[],{"trials":14101,"activeCount":97},[],{"trials":14103,"activeCount":97},[],{"trials":14105,"activeCount":97},[],{"intervention":13383,"totalTrials":147,"cells":14107},{"EARLY_PHASE1":14108,"PHASE1":14110,"PHASE2":14116,"PHASE3":14118,"PHASE4":14120,"NA":14122},{"trials":14109,"activeCount":97},[],{"trials":14111,"activeCount":97},[14112],{"nctId":13378,"briefTitle":13379,"status":103,"phases":14113,"primaryCompletion":4176,"completion":1733,"start":642,"enrollment":108,"conditions":14114,"interventions":14115},[86],[2334,831],[13364,13383],{"trials":14117,"activeCount":97},[],{"trials":14119,"activeCount":97},[],{"trials":14121,"activeCount":97},[],{"trials":14123,"activeCount":97},[],{"intervention":14125,"totalTrials":147,"cells":14126},"Treatment A",{"EARLY_PHASE1":14127,"PHASE1":14129,"PHASE2":14146,"PHASE3":14148,"PHASE4":14150,"NA":14152},{"trials":14128,"activeCount":97},[],{"trials":14130,"activeCount":97},[14131],{"nctId":14132,"briefTitle":14133,"status":103,"phases":14134,"primaryCompletion":499,"completion":1733,"start":4113,"enrollment":9500,"conditions":14135,"interventions":14136},"NCT01841489","A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics",[86],[36],[14125,14137,14138,14139,14140,14141,14142,14143,14144,14145],"Treatment B","Treatment C","Treatment D","Treatment E","Treatment F","Treatment G","Treatment H","Treatment I","Treatment J",{"trials":14147,"activeCount":97},[],{"trials":14149,"activeCount":97},[],{"trials":14151,"activeCount":97},[],{"trials":14153,"activeCount":97},[],{"intervention":14137,"totalTrials":147,"cells":14155},{"EARLY_PHASE1":14156,"PHASE1":14158,"PHASE2":14164,"PHASE3":14166,"PHASE4":14168,"NA":14170},{"trials":14157,"activeCount":97},[],{"trials":14159,"activeCount":97},[14160],{"nctId":14132,"briefTitle":14133,"status":103,"phases":14161,"primaryCompletion":499,"completion":1733,"start":4113,"enrollment":9500,"conditions":14162,"interventions":14163},[86],[36],[14125,14137,14138,14139,14140,14141,14142,14143,14144,14145],{"trials":14165,"activeCount":97},[],{"trials":14167,"activeCount":97},[],{"trials":14169,"activeCount":97},[],{"trials":14171,"activeCount":97},[],{"intervention":14138,"totalTrials":147,"cells":14173},{"EARLY_PHASE1":14174,"PHASE1":14176,"PHASE2":14182,"PHASE3":14184,"PHASE4":14186,"NA":14188},{"trials":14175,"activeCount":97},[],{"trials":14177,"activeCount":97},[14178],{"nctId":14132,"briefTitle":14133,"status":103,"phases":14179,"primaryCompletion":499,"completion":1733,"start":4113,"enrollment":9500,"conditions":14180,"interventions":14181},[86],[36],[14125,14137,14138,14139,14140,14141,14142,14143,14144,14145],{"trials":14183,"activeCount":97},[],{"trials":14185,"activeCount":97},[],{"trials":14187,"activeCount":97},[],{"trials":14189,"activeCount":97},[],{"intervention":14139,"totalTrials":147,"cells":14191},{"EARLY_PHASE1":14192,"PHASE1":14194,"PHASE2":14200,"PHASE3":14202,"PHASE4":14204,"NA":14206},{"trials":14193,"activeCount":97},[],{"trials":14195,"activeCount":97},[14196],{"nctId":14132,"briefTitle":14133,"status":103,"phases":14197,"primaryCompletion":499,"completion":1733,"start":4113,"enrollment":9500,"conditions":14198,"interventions":14199},[86],[36],[14125,14137,14138,14139,14140,14141,14142,14143,14144,14145],{"trials":14201,"activeCount":97},[],{"trials":14203,"activeCount":97},[],{"trials":14205,"activeCount":97},[],{"trials":14207,"activeCount":97},[],{"intervention":14140,"totalTrials":147,"cells":14209},{"EARLY_PHASE1":14210,"PHASE1":14212,"PHASE2":14218,"PHASE3":14220,"PHASE4":14222,"NA":14224},{"trials":14211,"activeCount":97},[],{"trials":14213,"activeCount":97},[14214],{"nctId":14132,"briefTitle":14133,"status":103,"phases":14215,"primaryCompletion":499,"completion":1733,"start":4113,"enrollment":9500,"conditions":14216,"interventions":14217},[86],[36],[14125,14137,14138,14139,14140,14141,14142,14143,14144,14145],{"trials":14219,"activeCount":97},[],{"trials":14221,"activeCount":97},[],{"trials":14223,"activeCount":97},[],{"trials":14225,"activeCount":97},[],{"intervention":14141,"totalTrials":147,"cells":14227},{"EARLY_PHASE1":14228,"PHASE1":14230,"PHASE2":14236,"PHASE3":14238,"PHASE4":14240,"NA":14242},{"trials":14229,"activeCount":97},[],{"trials":14231,"activeCount":97},[14232],{"nctId":14132,"briefTitle":14133,"status":103,"phases":14233,"primaryCompletion":499,"completion":1733,"start":4113,"enrollment":9500,"conditions":14234,"interventions":14235},[86],[36],[14125,14137,14138,14139,14140,14141,14142,14143,14144,14145],{"trials":14237,"activeCount":97},[],{"trials":14239,"activeCount":97},[],{"trials":14241,"activeCount":97},[],{"trials":14243,"activeCount":97},[],{"intervention":14142,"totalTrials":147,"cells":14245},{"EARLY_PHASE1":14246,"PHASE1":14248,"PHASE2":14254,"PHASE3":14256,"PHASE4":14258,"NA":14260},{"trials":14247,"activeCount":97},[],{"trials":14249,"activeCount":97},[14250],{"nctId":14132,"briefTitle":14133,"status":103,"phases":14251,"primaryCompletion":499,"completion":1733,"start":4113,"enrollment":9500,"conditions":14252,"interventions":14253},[86],[36],[14125,14137,14138,14139,14140,14141,14142,14143,14144,14145],{"trials":14255,"activeCount":97},[],{"trials":14257,"activeCount":97},[],{"trials":14259,"activeCount":97},[],{"trials":14261,"activeCount":97},[],{"intervention":14143,"totalTrials":147,"cells":14263},{"EARLY_PHASE1":14264,"PHASE1":14266,"PHASE2":14272,"PHASE3":14274,"PHASE4":14276,"NA":14278},{"trials":14265,"activeCount":97},[],{"trials":14267,"activeCount":97},[14268],{"nctId":14132,"briefTitle":14133,"status":103,"phases":14269,"primaryCompletion":499,"completion":1733,"start":4113,"enrollment":9500,"conditions":14270,"interventions":14271},[86],[36],[14125,14137,14138,14139,14140,14141,14142,14143,14144,14145],{"trials":14273,"activeCount":97},[],{"trials":14275,"activeCount":97},[],{"trials":14277,"activeCount":97},[],{"trials":14279,"activeCount":97},[],{"intervention":14144,"totalTrials":147,"cells":14281},{"EARLY_PHASE1":14282,"PHASE1":14284,"PHASE2":14290,"PHASE3":14292,"PHASE4":14294,"NA":14296},{"trials":14283,"activeCount":97},[],{"trials":14285,"activeCount":97},[14286],{"nctId":14132,"briefTitle":14133,"status":103,"phases":14287,"primaryCompletion":499,"completion":1733,"start":4113,"enrollment":9500,"conditions":14288,"interventions":14289},[86],[36],[14125,14137,14138,14139,14140,14141,14142,14143,14144,14145],{"trials":14291,"activeCount":97},[],{"trials":14293,"activeCount":97},[],{"trials":14295,"activeCount":97},[],{"trials":14297,"activeCount":97},[],{"intervention":14145,"totalTrials":147,"cells":14299},{"EARLY_PHASE1":14300,"PHASE1":14302,"PHASE2":14308,"PHASE3":14310,"PHASE4":14312,"NA":14314},{"trials":14301,"activeCount":97},[],{"trials":14303,"activeCount":97},[14304],{"nctId":14132,"briefTitle":14133,"status":103,"phases":14305,"primaryCompletion":499,"completion":1733,"start":4113,"enrollment":9500,"conditions":14306,"interventions":14307},[86],[36],[14125,14137,14138,14139,14140,14141,14142,14143,14144,14145],{"trials":14309,"activeCount":97},[],{"trials":14311,"activeCount":97},[],{"trials":14313,"activeCount":97},[],{"trials":14315,"activeCount":97},[],{"intervention":14317,"totalTrials":147,"cells":14318},"hLL2",{"EARLY_PHASE1":14319,"PHASE1":14321,"PHASE2":14329,"PHASE3":14331,"PHASE4":14333,"NA":14335},{"trials":14320,"activeCount":97},[],{"trials":14322,"activeCount":97},[14323],{"nctId":14324,"briefTitle":14325,"status":653,"phases":14326,"start":5321,"enrollment":5999,"conditions":14327,"interventions":14328},"NCT00054834","Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma",[86],[11490],[14317],{"trials":14330,"activeCount":97},[],{"trials":14332,"activeCount":97},[],{"trials":14334,"activeCount":97},[],{"trials":14336,"activeCount":97},[],{"intervention":14338,"totalTrials":147,"cells":14339},"Single Ascending Dose Cohorts GS-9620",{"EARLY_PHASE1":14340,"PHASE1":14342,"PHASE2":14351,"PHASE3":14353,"PHASE4":14355,"NA":14357},{"trials":14341,"activeCount":97},[],{"trials":14343,"activeCount":97},[14344],{"nctId":14345,"briefTitle":14346,"status":103,"phases":14347,"primaryCompletion":4705,"completion":4705,"start":501,"enrollment":3336,"conditions":14348,"interventions":14349},"NCT01591668","A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C",[86],[27],[14338,14350],"Multiple Ascending Dose Cohorts GS-9620",{"trials":14352,"activeCount":97},[],{"trials":14354,"activeCount":97},[],{"trials":14356,"activeCount":97},[],{"trials":14358,"activeCount":97},[],{"intervention":14350,"totalTrials":147,"cells":14360},{"EARLY_PHASE1":14361,"PHASE1":14363,"PHASE2":14369,"PHASE3":14371,"PHASE4":14373,"NA":14375},{"trials":14362,"activeCount":97},[],{"trials":14364,"activeCount":97},[14365],{"nctId":14345,"briefTitle":14346,"status":103,"phases":14366,"primaryCompletion":4705,"completion":4705,"start":501,"enrollment":3336,"conditions":14367,"interventions":14368},[86],[27],[14338,14350],{"trials":14370,"activeCount":97},[],{"trials":14372,"activeCount":97},[],{"trials":14374,"activeCount":97},[],{"trials":14376,"activeCount":97},[],{"intervention":13494,"totalTrials":147,"cells":14378},{"EARLY_PHASE1":14379,"PHASE1":14381,"PHASE2":14387,"PHASE3":14389,"PHASE4":14391,"NA":14393},{"trials":14380,"activeCount":97},[],{"trials":14382,"activeCount":97},[14383],{"nctId":13486,"briefTitle":13487,"status":653,"phases":14384,"primaryCompletion":13489,"completion":13489,"start":13490,"enrollment":1122,"conditions":14385,"interventions":14386},[86],[13492],[13494,13495,7234,13496],{"trials":14388,"activeCount":97},[],{"trials":14390,"activeCount":97},[],{"trials":14392,"activeCount":97},[],{"trials":14394,"activeCount":97},[],{"intervention":13495,"totalTrials":147,"cells":14396},{"EARLY_PHASE1":14397,"PHASE1":14399,"PHASE2":14405,"PHASE3":14407,"PHASE4":14409,"NA":14411},{"trials":14398,"activeCount":97},[],{"trials":14400,"activeCount":97},[14401],{"nctId":13486,"briefTitle":13487,"status":653,"phases":14402,"primaryCompletion":13489,"completion":13489,"start":13490,"enrollment":1122,"conditions":14403,"interventions":14404},[86],[13492],[13494,13495,7234,13496],{"trials":14406,"activeCount":97},[],{"trials":14408,"activeCount":97},[],{"trials":14410,"activeCount":97},[],{"trials":14412,"activeCount":97},[],{"intervention":13496,"totalTrials":147,"cells":14414},{"EARLY_PHASE1":14415,"PHASE1":14417,"PHASE2":14423,"PHASE3":14425,"PHASE4":14427,"NA":14429},{"trials":14416,"activeCount":97},[],{"trials":14418,"activeCount":97},[14419],{"nctId":13486,"briefTitle":13487,"status":653,"phases":14420,"primaryCompletion":13489,"completion":13489,"start":13490,"enrollment":1122,"conditions":14421,"interventions":14422},[86],[13492],[13494,13495,7234,13496],{"trials":14424,"activeCount":97},[],{"trials":14426,"activeCount":97},[],{"trials":14428,"activeCount":97},[],{"trials":14430,"activeCount":97},[],{"intervention":14432,"totalTrials":147,"cells":14433},"GS-5745 SC",{"EARLY_PHASE1":14434,"PHASE1":14436,"PHASE2":14446,"PHASE3":14448,"PHASE4":14450,"NA":14452},{"trials":14435,"activeCount":97},[],{"trials":14437,"activeCount":97},[14438],{"nctId":14439,"briefTitle":14440,"status":103,"phases":14441,"primaryCompletion":4367,"completion":4367,"start":4081,"enrollment":14442,"conditions":14443,"interventions":14444},"NCT02209987","Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults",[86],28,[3568],[14432,14445],"GS-5745 IV",{"trials":14447,"activeCount":97},[],{"trials":14449,"activeCount":97},[],{"trials":14451,"activeCount":97},[],{"trials":14453,"activeCount":97},[],{"intervention":14445,"totalTrials":147,"cells":14455},{"EARLY_PHASE1":14456,"PHASE1":14458,"PHASE2":14464,"PHASE3":14466,"PHASE4":14468,"NA":14470},{"trials":14457,"activeCount":97},[],{"trials":14459,"activeCount":97},[14460],{"nctId":14439,"briefTitle":14440,"status":103,"phases":14461,"primaryCompletion":4367,"completion":4367,"start":4081,"enrollment":14442,"conditions":14462,"interventions":14463},[86],[3568],[14432,14445],{"trials":14465,"activeCount":97},[],{"trials":14467,"activeCount":97},[],{"trials":14469,"activeCount":97},[],{"trials":14471,"activeCount":97},[],{"intervention":6512,"totalTrials":147,"cells":14473},{"EARLY_PHASE1":14474,"PHASE1":14476,"PHASE2":14482,"PHASE3":14484,"PHASE4":14486,"NA":14488},{"trials":14475,"activeCount":97},[],{"trials":14477,"activeCount":97},[14478],{"nctId":6504,"briefTitle":6505,"status":103,"phases":14479,"primaryCompletion":6507,"completion":6508,"start":6509,"enrollment":5999,"conditions":14480,"interventions":14481},[86],[33],[6512,6513,112],{"trials":14483,"activeCount":97},[],{"trials":14485,"activeCount":97},[],{"trials":14487,"activeCount":97},[],{"trials":14489,"activeCount":97},[],{"intervention":10326,"totalTrials":147,"cells":14491},{"EARLY_PHASE1":14492,"PHASE1":14494,"PHASE2":14500,"PHASE3":14502,"PHASE4":14504,"NA":14506},{"trials":14493,"activeCount":97},[],{"trials":14495,"activeCount":97},[14496],{"nctId":10318,"briefTitle":10319,"status":103,"phases":14497,"primaryCompletion":10321,"completion":10322,"start":10323,"enrollment":3974,"conditions":14498,"interventions":14499},[86],[6333],[6385,10326],{"trials":14501,"activeCount":97},[],{"trials":14503,"activeCount":97},[],{"trials":14505,"activeCount":97},[],{"trials":14507,"activeCount":97},[],{"intervention":14509,"totalTrials":147,"cells":14510},"GS-5816",{"EARLY_PHASE1":14511,"PHASE1":14513,"PHASE2":14521,"PHASE3":14523,"PHASE4":14525,"NA":14527},{"trials":14512,"activeCount":97},[],{"trials":14514,"activeCount":97},[14515],{"nctId":14516,"briefTitle":14517,"status":103,"phases":14518,"primaryCompletion":499,"completion":499,"start":4462,"enrollment":342,"conditions":14519,"interventions":14520},"NCT01817985","A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment",[86],[4190],[14509],{"trials":14522,"activeCount":97},[],{"trials":14524,"activeCount":97},[],{"trials":14526,"activeCount":97},[],{"trials":14528,"activeCount":97},[],{"intervention":14530,"totalTrials":147,"cells":14531},"GS-2829",{"EARLY_PHASE1":14532,"PHASE1":14534,"PHASE2":14544,"PHASE3":14546,"PHASE4":14548,"NA":14550},{"trials":14533,"activeCount":97},[],{"trials":14535,"activeCount":97},[14536],{"nctId":14537,"briefTitle":14538,"status":103,"phases":14539,"primaryCompletion":83,"completion":83,"start":14540,"enrollment":1361,"conditions":14541,"interventions":14542},"NCT05770895","Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B",[86],"2023-04-03",[24],[14530,14543],"GS-6779",{"trials":14545,"activeCount":97},[],{"trials":14547,"activeCount":97},[],{"trials":14549,"activeCount":97},[],{"trials":14551,"activeCount":97},[],{"intervention":14543,"totalTrials":147,"cells":14553},{"EARLY_PHASE1":14554,"PHASE1":14556,"PHASE2":14562,"PHASE3":14564,"PHASE4":14566,"NA":14568},{"trials":14555,"activeCount":97},[],{"trials":14557,"activeCount":97},[14558],{"nctId":14537,"briefTitle":14538,"status":103,"phases":14559,"primaryCompletion":83,"completion":83,"start":14540,"enrollment":1361,"conditions":14560,"interventions":14561},[86],[24],[14530,14543],{"trials":14563,"activeCount":97},[],{"trials":14565,"activeCount":97},[],{"trials":14567,"activeCount":97},[],{"trials":14569,"activeCount":97},[],{"intervention":725,"totalTrials":147,"cells":14571},{"EARLY_PHASE1":14572,"PHASE1":14574,"PHASE2":14580,"PHASE3":14582,"PHASE4":14584,"NA":14586},{"trials":14573,"activeCount":97},[],{"trials":14575,"activeCount":97},[14576],{"nctId":715,"briefTitle":716,"status":653,"phases":14577,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":14578,"interventions":14579},[86],[722],[724,355,725,726],{"trials":14581,"activeCount":97},[],{"trials":14583,"activeCount":97},[],{"trials":14585,"activeCount":97},[],{"trials":14587,"activeCount":97},[],{"intervention":726,"totalTrials":147,"cells":14589},{"EARLY_PHASE1":14590,"PHASE1":14592,"PHASE2":14598,"PHASE3":14600,"PHASE4":14602,"NA":14604},{"trials":14591,"activeCount":97},[],{"trials":14593,"activeCount":97},[14594],{"nctId":715,"briefTitle":716,"status":653,"phases":14595,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":14596,"interventions":14597},[86],[722],[724,355,725,726],{"trials":14599,"activeCount":97},[],{"trials":14601,"activeCount":97},[],{"trials":14603,"activeCount":97},[],{"trials":14605,"activeCount":97},[],{"intervention":14607,"totalTrials":147,"cells":14608},"GS-5745",{"EARLY_PHASE1":14609,"PHASE1":14611,"PHASE2":14619,"PHASE3":14621,"PHASE4":14623,"NA":14625},{"trials":14610,"activeCount":97},[],{"trials":14612,"activeCount":97},[14613],{"nctId":14614,"briefTitle":14615,"status":103,"phases":14616,"primaryCompletion":598,"completion":4580,"start":4081,"enrollment":720,"conditions":14617,"interventions":14618},"NCT02176876","Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis",[86],[3863],[14607],{"trials":14620,"activeCount":97},[],{"trials":14622,"activeCount":97},[],{"trials":14624,"activeCount":97},[],{"trials":14626,"activeCount":97},[],{"intervention":1540,"totalTrials":147,"cells":14628},{"EARLY_PHASE1":14629,"PHASE1":14631,"PHASE2":14637,"PHASE3":14639,"PHASE4":14641,"NA":14643},{"trials":14630,"activeCount":97},[],{"trials":14632,"activeCount":97},[14633],{"nctId":1527,"briefTitle":1528,"status":1529,"phases":14634,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":97,"conditions":14635,"interventions":14636},[86],[1535,1536],[1538,1539,1540,1013,1541],{"trials":14638,"activeCount":97},[],{"trials":14640,"activeCount":97},[],{"trials":14642,"activeCount":97},[],{"trials":14644,"activeCount":97},[],{"intervention":1611,"totalTrials":147,"cells":14646},{"EARLY_PHASE1":14647,"PHASE1":14649,"PHASE2":14655,"PHASE3":14657,"PHASE4":14659,"NA":14661},{"trials":14648,"activeCount":97},[],{"trials":14650,"activeCount":97},[14651],{"nctId":1602,"briefTitle":1603,"status":653,"phases":14652,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":134,"conditions":14653,"interventions":14654},[86],[1608,1609],[1538,1120,1611],{"trials":14656,"activeCount":97},[],{"trials":14658,"activeCount":97},[],{"trials":14660,"activeCount":97},[],{"trials":14662,"activeCount":97},[],{"intervention":14664,"totalTrials":147,"cells":14665},"GS-9901",{"EARLY_PHASE1":14666,"PHASE1":14668,"PHASE2":14676,"PHASE3":14678,"PHASE4":14680,"NA":14682},{"trials":14667,"activeCount":97},[],{"trials":14669,"activeCount":97},[14670],{"nctId":14671,"briefTitle":14672,"status":653,"phases":14673,"primaryCompletion":4070,"completion":4070,"start":519,"enrollment":1219,"conditions":14674,"interventions":14675},"NCT02258555","Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma",[86],[12823,36,13799,13798],[14664],{"trials":14677,"activeCount":97},[],{"trials":14679,"activeCount":97},[],{"trials":14681,"activeCount":97},[],{"trials":14683,"activeCount":97},[],{"intervention":14685,"totalTrials":147,"cells":14686},"GS-6620",{"EARLY_PHASE1":14687,"PHASE1":14689,"PHASE2":14698,"PHASE3":14700,"PHASE4":14702,"NA":14704},{"trials":14688,"activeCount":97},[],{"trials":14690,"activeCount":97},[14691],{"nctId":14692,"briefTitle":14693,"status":103,"phases":14694,"primaryCompletion":4693,"completion":4677,"start":4730,"enrollment":2091,"conditions":14695,"interventions":14696},"NCT01316237","A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection",[86],[4116],[14685,14685,14685,14685,14685,14685,14697,14685,14685],"GS-6620 tablet, 450 mg BID",{"trials":14699,"activeCount":97},[],{"trials":14701,"activeCount":97},[],{"trials":14703,"activeCount":97},[],{"trials":14705,"activeCount":97},[],{"intervention":14697,"totalTrials":147,"cells":14707},{"EARLY_PHASE1":14708,"PHASE1":14710,"PHASE2":14716,"PHASE3":14718,"PHASE4":14720,"NA":14722},{"trials":14709,"activeCount":97},[],{"trials":14711,"activeCount":97},[14712],{"nctId":14692,"briefTitle":14693,"status":103,"phases":14713,"primaryCompletion":4693,"completion":4677,"start":4730,"enrollment":2091,"conditions":14714,"interventions":14715},[86],[4116],[14685,14685,14685,14685,14685,14685,14697,14685,14685],{"trials":14717,"activeCount":97},[],{"trials":14719,"activeCount":97},[],{"trials":14721,"activeCount":97},[],{"trials":14723,"activeCount":97},[],{"intervention":9689,"totalTrials":147,"cells":14725},{"EARLY_PHASE1":14726,"PHASE1":14728,"PHASE2":14734,"PHASE3":14736,"PHASE4":14738,"NA":14740},{"trials":14727,"activeCount":97},[],{"trials":14729,"activeCount":97},[14730],{"nctId":9683,"briefTitle":9684,"status":103,"phases":14731,"primaryCompletion":9686,"completion":9686,"start":212,"enrollment":4605,"conditions":14732,"interventions":14733},[86],[21],[724,9689],{"trials":14735,"activeCount":97},[],{"trials":14737,"activeCount":97},[],{"trials":14739,"activeCount":97},[],{"trials":14741,"activeCount":97},[],{"intervention":14743,"totalTrials":147,"cells":14744},"AB0024",{"EARLY_PHASE1":14745,"PHASE1":14747,"PHASE2":14756,"PHASE3":14758,"PHASE4":14760,"NA":14762},{"trials":14746,"activeCount":97},[],{"trials":14748,"activeCount":97},[14749],{"nctId":14750,"briefTitle":14751,"status":103,"phases":14752,"primaryCompletion":501,"completion":501,"start":4642,"enrollment":22,"conditions":14753,"interventions":14755},"NCT01323933","First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors",[86],[14754],"Neoplasms",[14743],{"trials":14757,"activeCount":97},[],{"trials":14759,"activeCount":97},[],{"trials":14761,"activeCount":97},[],{"trials":14763,"activeCount":97},[],{"intervention":14765,"totalTrials":147,"cells":14766},"Tenofovir",{"EARLY_PHASE1":14767,"PHASE1":14769,"PHASE2":14777,"PHASE3":14779,"PHASE4":14781,"NA":14783},{"trials":14768,"activeCount":97},[],{"trials":14770,"activeCount":97},[14771],{"nctId":14772,"briefTitle":14773,"status":103,"phases":14774,"conditions":14775,"interventions":14776},"NCT00002180","A Study of PMPA in HIV-Infected Patients",[86],[15],[14765],{"trials":14778,"activeCount":97},[],{"trials":14780,"activeCount":97},[],{"trials":14782,"activeCount":97},[],{"trials":14784,"activeCount":97},[],{"intervention":14786,"totalTrials":147,"cells":14787},"GS-0189",{"EARLY_PHASE1":14788,"PHASE1":14790,"PHASE2":14801,"PHASE3":14803,"PHASE4":14805,"NA":14807},{"trials":14789,"activeCount":97},[],{"trials":14791,"activeCount":97},[14792],{"nctId":14793,"briefTitle":14794,"status":653,"phases":14795,"primaryCompletion":14796,"completion":14796,"start":14797,"enrollment":629,"conditions":14798,"interventions":14800},"NCT04502706","Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed\u002FRefractory Non-Hodgkin Lymphoma",[86],"2022-03-31","2020-11-17",[14799],"Non-hodgkin Lymphoma",[14786,1539],{"trials":14802,"activeCount":97},[],{"trials":14804,"activeCount":97},[],{"trials":14806,"activeCount":97},[],{"trials":14808,"activeCount":97},[],{"intervention":14810,"totalTrials":147,"cells":14811},"BI 836826",{"EARLY_PHASE1":14812,"PHASE1":14814,"PHASE2":14824,"PHASE3":14826,"PHASE4":14828,"NA":14830},{"trials":14813,"activeCount":97},[],{"trials":14815,"activeCount":97},[14816],{"nctId":14817,"briefTitle":14818,"status":653,"phases":14819,"primaryCompletion":14820,"completion":14820,"start":14821,"enrollment":993,"conditions":14822,"interventions":14823},"NCT02538614","Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia",[86],"2017-07-05","2015-12-29",[13578],[1538,14810],{"trials":14825,"activeCount":97},[],{"trials":14827,"activeCount":97},[],{"trials":14829,"activeCount":97},[],{"trials":14831,"activeCount":97},[],{"intervention":14833,"totalTrials":147,"cells":14834},"GS-9191 ointment",{"EARLY_PHASE1":14835,"PHASE1":14837,"PHASE2":14847,"PHASE3":14849,"PHASE4":14851,"NA":14853},{"trials":14836,"activeCount":97},[],{"trials":14838,"activeCount":97},[14839],{"nctId":14840,"briefTitle":14841,"status":103,"phases":14842,"primaryCompletion":13314,"completion":4851,"start":10765,"enrollment":4455,"conditions":14843,"interventions":14845},"NCT00499967","Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts",[86],[14844],"Genital Warts",[14833,14846],"GS-9191",{"trials":14848,"activeCount":97},[],{"trials":14850,"activeCount":97},[],{"trials":14852,"activeCount":97},[],{"trials":14854,"activeCount":97},[],{"intervention":14846,"totalTrials":147,"cells":14856},{"EARLY_PHASE1":14857,"PHASE1":14859,"PHASE2":14865,"PHASE3":14867,"PHASE4":14869,"NA":14871},{"trials":14858,"activeCount":97},[],{"trials":14860,"activeCount":97},[14861],{"nctId":14840,"briefTitle":14841,"status":103,"phases":14862,"primaryCompletion":13314,"completion":4851,"start":10765,"enrollment":4455,"conditions":14863,"interventions":14864},[86],[14844],[14833,14846],{"trials":14866,"activeCount":97},[],{"trials":14868,"activeCount":97},[],{"trials":14870,"activeCount":97},[],{"trials":14872,"activeCount":97},[],{"intervention":14874,"totalTrials":147,"cells":14875},"GS-6624",{"EARLY_PHASE1":14876,"PHASE1":14878,"PHASE2":14886,"PHASE3":14888,"PHASE4":14890,"NA":14892},{"trials":14877,"activeCount":97},[],{"trials":14879,"activeCount":97},[14880],{"nctId":14881,"briefTitle":14882,"status":103,"phases":14883,"primaryCompletion":4705,"completion":4705,"start":4221,"enrollment":7002,"conditions":14884,"interventions":14885},"NCT01362231","A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis",[86],[4871],[14874],{"trials":14887,"activeCount":97},[],{"trials":14889,"activeCount":97},[],{"trials":14891,"activeCount":97},[],{"trials":14893,"activeCount":97},[],{"intervention":6532,"totalTrials":147,"cells":14895},{"EARLY_PHASE1":14896,"PHASE1":14898,"PHASE2":14904,"PHASE3":14906,"PHASE4":14908,"NA":14910},{"trials":14897,"activeCount":97},[],{"trials":14899,"activeCount":97},[14900],{"nctId":6524,"briefTitle":6525,"status":653,"phases":14901,"primaryCompletion":6527,"completion":6528,"start":6529,"enrollment":477,"conditions":14902,"interventions":14903},[86],[33],[6532,6513,112],{"trials":14905,"activeCount":97},[],{"trials":14907,"activeCount":97},[],{"trials":14909,"activeCount":97},[],{"trials":14911,"activeCount":97},[],{"intervention":14913,"totalTrials":147,"cells":14914},"CB-0406 100 mg",{"EARLY_PHASE1":14915,"PHASE1":14917,"PHASE2":14934,"PHASE3":14936,"PHASE4":14938,"NA":14940},{"trials":14916,"activeCount":97},[],{"trials":14918,"activeCount":97},[14919],{"nctId":14920,"briefTitle":14921,"status":103,"phases":14922,"primaryCompletion":14923,"completion":14924,"start":14925,"enrollment":2091,"conditions":14926,"interventions":14928},"NCT04467684","Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406",[86],"2021-05-30","2021-06-06","2020-07-07",[14927],"Healthy Volunteers",[14913,14929,14930,14931,14932,14933],"CB-0406 200 mg","CB-0406 400 mg","CB-0406 800 mg","CB-0406 1,000 mg","Matched placebo",{"trials":14935,"activeCount":97},[],{"trials":14937,"activeCount":97},[],{"trials":14939,"activeCount":97},[],{"trials":14941,"activeCount":97},[],{"intervention":14929,"totalTrials":147,"cells":14943},{"EARLY_PHASE1":14944,"PHASE1":14946,"PHASE2":14952,"PHASE3":14954,"PHASE4":14956,"NA":14958},{"trials":14945,"activeCount":97},[],{"trials":14947,"activeCount":97},[14948],{"nctId":14920,"briefTitle":14921,"status":103,"phases":14949,"primaryCompletion":14923,"completion":14924,"start":14925,"enrollment":2091,"conditions":14950,"interventions":14951},[86],[14927],[14913,14929,14930,14931,14932,14933],{"trials":14953,"activeCount":97},[],{"trials":14955,"activeCount":97},[],{"trials":14957,"activeCount":97},[],{"trials":14959,"activeCount":97},[],{"intervention":14930,"totalTrials":147,"cells":14961},{"EARLY_PHASE1":14962,"PHASE1":14964,"PHASE2":14970,"PHASE3":14972,"PHASE4":14974,"NA":14976},{"trials":14963,"activeCount":97},[],{"trials":14965,"activeCount":97},[14966],{"nctId":14920,"briefTitle":14921,"status":103,"phases":14967,"primaryCompletion":14923,"completion":14924,"start":14925,"enrollment":2091,"conditions":14968,"interventions":14969},[86],[14927],[14913,14929,14930,14931,14932,14933],{"trials":14971,"activeCount":97},[],{"trials":14973,"activeCount":97},[],{"trials":14975,"activeCount":97},[],{"trials":14977,"activeCount":97},[],{"intervention":14931,"totalTrials":147,"cells":14979},{"EARLY_PHASE1":14980,"PHASE1":14982,"PHASE2":14988,"PHASE3":14990,"PHASE4":14992,"NA":14994},{"trials":14981,"activeCount":97},[],{"trials":14983,"activeCount":97},[14984],{"nctId":14920,"briefTitle":14921,"status":103,"phases":14985,"primaryCompletion":14923,"completion":14924,"start":14925,"enrollment":2091,"conditions":14986,"interventions":14987},[86],[14927],[14913,14929,14930,14931,14932,14933],{"trials":14989,"activeCount":97},[],{"trials":14991,"activeCount":97},[],{"trials":14993,"activeCount":97},[],{"trials":14995,"activeCount":97},[],{"intervention":14932,"totalTrials":147,"cells":14997},{"EARLY_PHASE1":14998,"PHASE1":15000,"PHASE2":15006,"PHASE3":15008,"PHASE4":15010,"NA":15012},{"trials":14999,"activeCount":97},[],{"trials":15001,"activeCount":97},[15002],{"nctId":14920,"briefTitle":14921,"status":103,"phases":15003,"primaryCompletion":14923,"completion":14924,"start":14925,"enrollment":2091,"conditions":15004,"interventions":15005},[86],[14927],[14913,14929,14930,14931,14932,14933],{"trials":15007,"activeCount":97},[],{"trials":15009,"activeCount":97},[],{"trials":15011,"activeCount":97},[],{"trials":15013,"activeCount":97},[],{"intervention":14933,"totalTrials":147,"cells":15015},{"EARLY_PHASE1":15016,"PHASE1":15018,"PHASE2":15024,"PHASE3":15026,"PHASE4":15028,"NA":15030},{"trials":15017,"activeCount":97},[],{"trials":15019,"activeCount":97},[15020],{"nctId":14920,"briefTitle":14921,"status":103,"phases":15021,"primaryCompletion":14923,"completion":14924,"start":14925,"enrollment":2091,"conditions":15022,"interventions":15023},[86],[14927],[14913,14929,14930,14931,14932,14933],{"trials":15025,"activeCount":97},[],{"trials":15027,"activeCount":97},[],{"trials":15029,"activeCount":97},[],{"trials":15031,"activeCount":97},[],{"intervention":15033,"totalTrials":147,"cells":15034},"GS-9820",{"EARLY_PHASE1":15035,"PHASE1":15037,"PHASE2":15047,"PHASE3":15049,"PHASE4":15051,"NA":15053},{"trials":15036,"activeCount":97},[],{"trials":15038,"activeCount":97},[15039],{"nctId":15040,"briefTitle":15041,"status":103,"phases":15042,"primaryCompletion":15043,"completion":15043,"start":4134,"enrollment":5113,"conditions":15044,"interventions":15046},"NCT01705847","A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies",[86],"2016-05",[15045],"Lymphoid Malignancies",[15033],{"trials":15048,"activeCount":97},[],{"trials":15050,"activeCount":97},[],{"trials":15052,"activeCount":97},[],{"trials":15054,"activeCount":97},[],{"intervention":4614,"totalTrials":147,"cells":15056},{"EARLY_PHASE1":15057,"PHASE1":15059,"PHASE2":15065,"PHASE3":15067,"PHASE4":15069,"NA":15071},{"trials":15058,"activeCount":97},[],{"trials":15060,"activeCount":97},[15061],{"nctId":4609,"briefTitle":4610,"status":103,"phases":15062,"primaryCompletion":4176,"completion":4176,"start":4112,"enrollment":2579,"conditions":15063,"interventions":15064},[86],[4598],[4586,4614],{"trials":15066,"activeCount":97},[],{"trials":15068,"activeCount":97},[],{"trials":15070,"activeCount":97},[],{"trials":15072,"activeCount":97},[],{"intervention":15074,"totalTrials":147,"cells":15075},"GS-0272",{"EARLY_PHASE1":15076,"PHASE1":15078,"PHASE2":15088,"PHASE3":15090,"PHASE4":15092,"NA":15094},{"trials":15077,"activeCount":97},[],{"trials":15079,"activeCount":97},[15080],{"nctId":15081,"briefTitle":15082,"status":653,"phases":15083,"primaryCompletion":15084,"completion":15084,"start":15085,"enrollment":319,"conditions":15086,"interventions":15087},"NCT06031415","Study of GS-0272 in Participants With Rheumatoid Arthritis",[86],"2026-05-11","2023-09-28",[3863],[15074],{"trials":15089,"activeCount":97},[],{"trials":15091,"activeCount":97},[],{"trials":15093,"activeCount":97},[],{"trials":15095,"activeCount":97},[],{"intervention":797,"totalTrials":15097,"cells":15098},37,{"EARLY_PHASE1":15099,"PHASE1":15101,"PHASE2":15103,"PHASE3":15230,"PHASE4":15287,"NA":15289},{"trials":15100,"activeCount":97},[],{"trials":15102,"activeCount":97},[],{"trials":15104,"activeCount":97},[15105,15111,15120,15124,15128,15132,15138,15142,15149,15153,15157,15161,15165,15173,15177,15186,15193,15197,15205,15209,15213,15222,15226],{"nctId":15106,"briefTitle":15107,"status":103,"phases":15108,"primaryCompletion":4080,"completion":4081,"start":4349,"enrollment":1507,"conditions":15109,"interventions":15110},"NCT01924949","Ledipasvir\u002FSofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection",[87],[27],[797],{"nctId":15112,"briefTitle":15113,"status":103,"phases":15114,"primaryCompletion":15115,"completion":15116,"start":15117,"enrollment":12,"conditions":15118,"interventions":15119},"NCT02868242","Efficacy and Safety of Ledipasvir\u002FSofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy",[87],"2018-11-12","2019-02-03","2016-08-28",[18],[797],{"nctId":4067,"briefTitle":4068,"status":103,"phases":15121,"primaryCompletion":4070,"completion":4070,"start":4071,"enrollment":4072,"conditions":15122,"interventions":15123},[87],[4074],[797,506,513],{"nctId":4088,"briefTitle":4089,"status":103,"phases":15125,"primaryCompletion":4071,"completion":4091,"start":1733,"enrollment":4092,"conditions":15126,"interventions":15127},[87],[4074],[797,513,4095],{"nctId":4141,"briefTitle":4142,"status":103,"phases":15129,"primaryCompletion":4144,"completion":4070,"start":4145,"enrollment":1783,"conditions":15130,"interventions":15131},[87],[4074],[797,513],{"nctId":15133,"briefTitle":15134,"status":103,"phases":15135,"primaryCompletion":4070,"completion":10257,"start":4081,"enrollment":4135,"conditions":15136,"interventions":15137},"NCT02219685","Ledipasvir\u002FSofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection",[87],[18],[797],{"nctId":4158,"briefTitle":4159,"status":103,"phases":15139,"primaryCompletion":4161,"completion":2438,"start":598,"enrollment":4162,"conditions":15140,"interventions":15141},[87],[18],[797,513],{"nctId":15143,"briefTitle":15144,"status":103,"phases":15145,"primaryCompletion":4124,"completion":6914,"start":15146,"enrollment":4587,"conditions":15147,"interventions":15148},"NCT02350569","Safety and Efficacy of Ledipasvir\u002FSofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting",[87],"2015-05-22",[18],[797],{"nctId":4182,"briefTitle":4183,"status":103,"phases":15150,"primaryCompletion":4185,"completion":4186,"start":4187,"enrollment":4188,"conditions":15151,"interventions":15152},[87],[4190],[797,513,4107,4106],{"nctId":4193,"briefTitle":4194,"status":103,"phases":15154,"primaryCompletion":4081,"completion":4196,"start":1733,"enrollment":2495,"conditions":15155,"interventions":15156},[87],[794],[797,513],{"nctId":4209,"briefTitle":4210,"status":103,"phases":15158,"primaryCompletion":4212,"completion":4144,"start":4112,"enrollment":4213,"conditions":15159,"interventions":15160},[87],[4190],[797,506,513,4216,4095,4086],{"nctId":4218,"briefTitle":4219,"status":103,"phases":15162,"primaryCompletion":1733,"completion":1782,"start":4221,"enrollment":4222,"conditions":15163,"interventions":15164},[87],[4224],[506,513,512,4226,4095,797],{"nctId":15166,"briefTitle":15167,"status":103,"phases":15168,"primaryCompletion":4196,"completion":533,"start":4405,"enrollment":521,"conditions":15169,"interventions":15172},"NCT02081079","Efficacy and Safety of Ledipasvir\u002FSofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection",[87],[15170,15171],"Chronic Genotype 4 HCV","Chronic Genotype 5 HCV",[797],{"nctId":4245,"briefTitle":4246,"status":103,"phases":15174,"primaryCompletion":4248,"completion":4249,"start":4250,"enrollment":4251,"conditions":15175,"interventions":15176},[87],[18],[797,513],{"nctId":15178,"briefTitle":15179,"status":103,"phases":15180,"primaryCompletion":15181,"completion":7257,"start":15182,"enrollment":15183,"conditions":15184,"interventions":15185},"NCT02251717","Safety and Efficacy of Ledipasvir\u002FSofosbuvir (LDV\u002FSOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection",[87],"2016-03-24","2014-10-14",114,[18],[797],{"nctId":15187,"briefTitle":15188,"status":103,"phases":15189,"primaryCompletion":2438,"completion":2438,"start":4580,"enrollment":13655,"conditions":15190,"interventions":15192},"NCT02457611","Safety and Efficacy of Ledipasvir\u002FSofosbuvir (LDV\u002FSOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection",[87],[15191],"Hepatitis C Infection With HIV Co-Infection",[797],{"nctId":4281,"briefTitle":4282,"status":103,"phases":15194,"primaryCompletion":533,"completion":533,"start":4091,"enrollment":4178,"conditions":15195,"interventions":15196},[87],[18],[797,4286,513],{"nctId":15198,"briefTitle":15199,"status":103,"phases":15200,"primaryCompletion":15201,"completion":15201,"start":15202,"enrollment":1335,"conditions":15203,"interventions":15204},"NCT02301936","Ledipasvir\u002FSofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease",[87],"2016-04-18","2015-03-02",[18],[797],{"nctId":4297,"briefTitle":4298,"status":103,"phases":15206,"primaryCompletion":519,"completion":4212,"start":4176,"enrollment":4300,"conditions":15207,"interventions":15208},[87],[4074],[797,513],{"nctId":4304,"briefTitle":4305,"status":103,"phases":15210,"primaryCompletion":4307,"completion":4307,"start":4091,"enrollment":1075,"conditions":15211,"interventions":15212},[87],[794],[797,513],{"nctId":15214,"briefTitle":15215,"status":103,"phases":15216,"primaryCompletion":15217,"completion":9694,"start":15218,"enrollment":15219,"conditions":15220,"interventions":15221},"NCT03036839","Ledipasvir\u002FSofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease",[87],"2018-11-22","2017-06-27",95,[18],[797],{"nctId":4325,"briefTitle":4326,"status":103,"phases":15223,"primaryCompletion":4328,"completion":4329,"start":4330,"enrollment":4331,"conditions":15224,"interventions":15225},[87],[794],[506,513,797],{"nctId":4346,"briefTitle":4347,"status":103,"phases":15227,"primaryCompletion":4349,"completion":4145,"start":4277,"enrollment":1075,"conditions":15228,"interventions":15229},[87],[4351],[797,513],{"trials":15231,"activeCount":97},[15232,15239,15243,15247,15251,15255,15259,15263,15267,15275,15279,15283],{"nctId":15233,"briefTitle":15234,"status":103,"phases":15235,"primaryCompletion":15236,"completion":316,"start":4540,"enrollment":6768,"conditions":15237,"interventions":15238},"NCT02021656","Efficacy and Safety of Ledipasvir\u002FSofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection",[88],"2017-07-08",[4074],[797],{"nctId":4374,"briefTitle":4375,"status":103,"phases":15240,"primaryCompletion":4377,"completion":4378,"start":4101,"enrollment":4114,"conditions":15241,"interventions":15242},[88],[18],[797,506,513],{"nctId":787,"briefTitle":788,"status":103,"phases":15244,"primaryCompletion":790,"completion":316,"start":791,"enrollment":792,"conditions":15245,"interventions":15246},[88],[21,794],[228,796,797],{"nctId":4410,"briefTitle":4411,"status":103,"phases":15248,"primaryCompletion":4406,"completion":4081,"start":1733,"enrollment":4413,"conditions":15249,"interventions":15250},[88],[4074],[797,513],{"nctId":4417,"briefTitle":4418,"status":103,"phases":15252,"primaryCompletion":4420,"completion":4421,"start":4422,"enrollment":643,"conditions":15253,"interventions":15254},[88],[18],[797,513],{"nctId":4442,"briefTitle":4443,"status":103,"phases":15256,"primaryCompletion":4445,"completion":4446,"start":4447,"enrollment":4448,"conditions":15257,"interventions":15258},[88],[18],[797,513],{"nctId":4479,"briefTitle":4480,"status":653,"phases":15260,"primaryCompletion":2513,"completion":4482,"start":190,"enrollment":2381,"conditions":15261,"interventions":15262},[88],[18],[797,513],{"nctId":4486,"briefTitle":4487,"status":103,"phases":15264,"primaryCompletion":1782,"completion":4405,"start":4113,"enrollment":4489,"conditions":15265,"interventions":15266},[88],[4351],[797,513],{"nctId":15268,"briefTitle":15269,"status":103,"phases":15270,"primaryCompletion":15271,"completion":15272,"start":778,"enrollment":4162,"conditions":15273,"interventions":15274},"NCT02613871","Safety and Efficacy of Ledipasvir\u002FSofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection",[88],"2017-01-04","2018-11-07",[18],[797],{"nctId":4545,"briefTitle":4546,"status":103,"phases":15276,"primaryCompletion":500,"completion":641,"start":532,"enrollment":4548,"conditions":15277,"interventions":15278},[88],[4351],[797,513],{"nctId":4552,"briefTitle":4553,"status":103,"phases":15280,"primaryCompletion":4405,"completion":4071,"start":4385,"enrollment":4555,"conditions":15281,"interventions":15282},[88],[4351],[797,513],{"nctId":4559,"briefTitle":4560,"status":103,"phases":15284,"primaryCompletion":4196,"completion":4161,"start":641,"enrollment":4562,"conditions":15285,"interventions":15286},[88],[4234,504],[797,513],{"trials":15288,"activeCount":97},[],{"trials":15290,"activeCount":97},[15291,15301],{"nctId":15292,"briefTitle":15293,"status":653,"phases":15294,"primaryCompletion":15295,"completion":15295,"start":15296,"enrollment":15297,"conditions":15298,"interventions":15299},"NCT02292706","A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection",[],"2021-12-31","2014-12-29",1609,[18],[4118,9580,797,4107,4129,15300],"Other SOF-Based Regimen",{"nctId":15302,"briefTitle":15303,"status":103,"phases":15304,"primaryCompletion":15305,"completion":15305,"start":15306,"enrollment":15307,"conditions":15308,"interventions":15309},"NCT02951364","Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea",[],"2021-06-11","2016-12-05",1081,[4234],[797],{"intervention":1538,"totalTrials":9376,"cells":15311},{"EARLY_PHASE1":15312,"PHASE1":15314,"PHASE2":15351,"PHASE3":15417,"PHASE4":15473,"NA":15483},{"trials":15313,"activeCount":97},[],{"trials":15315,"activeCount":97},[15316,15320,15324,15328,15332,15336,15347],{"nctId":7223,"briefTitle":7224,"status":103,"phases":15317,"primaryCompletion":7226,"completion":7226,"start":7227,"enrollment":7228,"conditions":15318,"interventions":15319},[86],[7230,36,7231],[1538,1539,7216,7233,7234,7235,7236,7210,7237],{"nctId":10915,"briefTitle":10916,"status":653,"phases":15321,"primaryCompletion":10918,"completion":10918,"start":10919,"enrollment":1335,"conditions":15322,"interventions":15323},[86],[9430],[1538,9432],{"nctId":1527,"briefTitle":1528,"status":1529,"phases":15325,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":97,"conditions":15326,"interventions":15327},[86],[1535,1536],[1538,1539,1540,1013,1541],{"nctId":1602,"briefTitle":1603,"status":653,"phases":15329,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":134,"conditions":15330,"interventions":15331},[86],[1608,1609],[1538,1120,1611],{"nctId":14817,"briefTitle":14818,"status":653,"phases":15333,"primaryCompletion":14820,"completion":14820,"start":14821,"enrollment":993,"conditions":15334,"interventions":15335},[86],[13578],[1538,14810],{"nctId":15337,"briefTitle":15338,"status":103,"phases":15339,"primaryCompletion":15340,"completion":15341,"start":15342,"enrollment":1645,"conditions":15343,"interventions":15346},"NCT02242045","Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)",[86],"2014-12-25","2017-10-17","2014-10-01",[36,15344,12823,13799,15345,13798],"Indolent Non-Hodgkin Lymphoma","Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)",[1538],{"nctId":7172,"briefTitle":7173,"status":653,"phases":15348,"primaryCompletion":7175,"completion":7175,"start":7176,"enrollment":7177,"conditions":15349,"interventions":15350},[86],[7179],[6079,1538,6683,7165],{"trials":15352,"activeCount":97},[15353,15357,15361,15369,15377,15388,15394,15402,15409],{"nctId":7184,"briefTitle":7185,"status":103,"phases":15354,"primaryCompletion":7187,"completion":7188,"start":7189,"enrollment":7190,"conditions":15355,"interventions":15356},[87],[36],[6079,1538,7165],{"nctId":9515,"briefTitle":9516,"status":653,"phases":15358,"primaryCompletion":519,"completion":6214,"start":9518,"enrollment":819,"conditions":15359,"interventions":15360},[87],[36,7231,9520,7230],[6683,1538],{"nctId":15362,"briefTitle":15363,"status":653,"phases":15364,"primaryCompletion":1605,"completion":7246,"start":15365,"enrollment":4516,"conditions":15366,"interventions":15368},"NCT02044822","Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion",[87],"2014-08-06",[15367],"B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion",[1538,1539],{"nctId":15370,"briefTitle":15371,"status":653,"phases":15372,"primaryCompletion":4070,"completion":15373,"start":2352,"enrollment":8178,"conditions":15374,"interventions":15376},"NCT01203930","A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL",[87],"2016-06",[13578,15375],"Small Lymphocytic Lymphoma (SLL)",[1538,1539],{"nctId":15378,"briefTitle":15379,"status":103,"phases":15380,"primaryCompletion":15381,"completion":15382,"start":15383,"enrollment":15384,"conditions":15385,"interventions":15387},"NCT01282424","Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas",[87],"2018-05-02","2018-05-16","2011-03-18",125,[12823,13799,15386,13798],"Lymphoplasmacytic Lymphoma",[1538],{"nctId":15389,"briefTitle":15390,"status":103,"phases":15391,"primaryCompletion":4070,"completion":4070,"start":4633,"enrollment":720,"conditions":15392,"interventions":15393},"NCT01306643","Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma",[86,87],[7230,12823,13799,13798],[1538],{"nctId":15395,"briefTitle":15396,"status":653,"phases":15397,"primaryCompletion":4101,"completion":15398,"start":15399,"enrollment":1335,"conditions":15400,"interventions":15401},"NCT02258529","Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma",[87],"2016-05-03","2015-09-14",[12823,13799],[1538,1539],{"nctId":15403,"briefTitle":15404,"status":103,"phases":15405,"primaryCompletion":4081,"completion":4081,"start":561,"enrollment":4605,"conditions":15406,"interventions":15408},"NCT01393106","Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma",[87],[15407],"Hodgkin Lymphoma",[1538],{"nctId":15410,"briefTitle":15411,"status":653,"phases":15412,"primaryCompletion":15413,"completion":15413,"start":15414,"enrollment":4455,"conditions":15415,"interventions":15416},"NCT01090414","An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study",[86,87],"2018-06-18","2010-03-22",[36,10191],[1538],{"trials":15418,"activeCount":97},[15419,15423,15427,15436,15440,15446,15450,15460,15464],{"nctId":7887,"briefTitle":7888,"status":653,"phases":15420,"primaryCompletion":7890,"completion":7890,"start":7891,"enrollment":7892,"conditions":15421,"interventions":15422},[88],[36],[1538,7233],{"nctId":7204,"briefTitle":7205,"status":653,"phases":15424,"primaryCompletion":6929,"completion":6929,"start":7207,"enrollment":6033,"conditions":15425,"interventions":15426},[88],[36],[1538,7210,7165],{"nctId":15428,"briefTitle":15429,"status":653,"phases":15430,"primaryCompletion":15431,"completion":15431,"start":15432,"enrollment":15433,"conditions":15434,"interventions":15435},"NCT02536300","Dose Optimization Study of Idelalisib in Follicular Lymphoma",[88],"2022-09-27","2016-01-14",96,[12823],[1538],{"nctId":7243,"briefTitle":7244,"status":653,"phases":15437,"primaryCompletion":7246,"completion":7246,"start":7247,"enrollment":7248,"conditions":15438,"interventions":15439},[88],[7250],[1538,1539,7216],{"nctId":15441,"briefTitle":15442,"status":103,"phases":15443,"primaryCompletion":1733,"completion":4071,"start":642,"enrollment":6746,"conditions":15444,"interventions":15445},"NCT01539512","A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",[88],[36],[1538,1539],{"nctId":7253,"briefTitle":7254,"status":653,"phases":15447,"primaryCompletion":7256,"completion":7257,"start":7258,"enrollment":7259,"conditions":15448,"interventions":15449},[88],[36],[1538,7216,1539],{"nctId":15451,"briefTitle":15452,"status":653,"phases":15453,"primaryCompletion":15454,"completion":15455,"start":15456,"enrollment":15457,"conditions":15458,"interventions":15459},"NCT01539291","Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)",[88],"2018-05-21","2018-06-29","2012-10-03",161,[36],[1538],{"nctId":7263,"briefTitle":7264,"status":103,"phases":15461,"primaryCompletion":7266,"completion":7266,"start":7267,"enrollment":1276,"conditions":15462,"interventions":15463},[88],[36],[1538,1539,7216],{"nctId":15465,"briefTitle":15466,"status":653,"phases":15467,"primaryCompletion":15468,"completion":15468,"start":15469,"enrollment":15470,"conditions":15471,"interventions":15472},"NCT01732913","Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",[88],"2016-05-18","2013-01-16",295,[7250],[1539,1538],{"trials":15474,"activeCount":97},[15475],{"nctId":15476,"briefTitle":15477,"status":653,"phases":15478,"primaryCompletion":15479,"completion":15479,"start":15480,"enrollment":332,"conditions":15481,"interventions":15482},"NCT02739360","Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820",[89],"2017-12-28","2016-05-04",[15045],[1538],{"trials":15484,"activeCount":97},[15485,15495,15502],{"nctId":15486,"briefTitle":15487,"status":103,"phases":15488,"primaryCompletion":15489,"completion":15489,"start":15490,"enrollment":15491,"conditions":15492,"interventions":15494},"NCT03568929","Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma",[],"2021-10-29","2018-05-25",257,[15493],"Follicular Non-Hodgkin's Lymphoma Refractory",[1538],{"nctId":15496,"briefTitle":15497,"status":15498,"phases":15499,"conditions":15500,"interventions":15501},"NCT02136511","Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia","APPROVED_FOR_MARKETING",[],[13578],[1538,1539],{"nctId":15503,"briefTitle":15504,"status":103,"phases":15505,"primaryCompletion":15506,"completion":15506,"start":15507,"enrollment":2423,"conditions":15508,"interventions":15509},"NCT03582098","Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland",[],"2019-03-26","2018-09-12",[9368],[1538,1539],{"intervention":4107,"totalTrials":14442,"cells":15511},{"EARLY_PHASE1":15512,"PHASE1":15514,"PHASE2":15520,"PHASE3":15577,"PHASE4":15692,"NA":15694},{"trials":15513,"activeCount":97},[],{"trials":15515,"activeCount":97},[15516],{"nctId":13349,"briefTitle":13350,"status":103,"phases":15517,"primaryCompletion":3280,"completion":13344,"start":13352,"enrollment":4092,"conditions":15518,"interventions":15519},[86],[18],[13326,4107],{"trials":15521,"activeCount":97},[15522,15526,15530,15539,15543,15547,15555,15559,15566,15573],{"nctId":4097,"briefTitle":4098,"status":103,"phases":15523,"primaryCompletion":4100,"completion":4101,"start":4102,"enrollment":4103,"conditions":15524,"interventions":15525},[87],[18],[4106,4107,513],{"nctId":4149,"briefTitle":4150,"status":103,"phases":15527,"primaryCompletion":4152,"completion":4153,"start":4154,"enrollment":22,"conditions":15528,"interventions":15529},[87],[18],[4107,513],{"nctId":15531,"briefTitle":15532,"status":103,"phases":15533,"primaryCompletion":6734,"completion":15534,"start":15535,"enrollment":15536,"conditions":15537,"interventions":15538},"NCT03022981","Study to Investigate the Safety and Efficacy of Sofosbuvir\u002FVelpatasvir in Adolescents and Children With Chronic HCV Infection",[87],"2020-02-26","2017-01-26",216,[18],[4107,4107],{"nctId":10039,"briefTitle":10040,"status":103,"phases":15540,"primaryCompletion":10042,"completion":9355,"start":10043,"enrollment":10044,"conditions":15541,"interventions":15542},[87],[18],[4106,4107],{"nctId":4182,"briefTitle":4183,"status":103,"phases":15544,"primaryCompletion":4185,"completion":4186,"start":4187,"enrollment":4188,"conditions":15545,"interventions":15546},[87],[4190],[797,513,4107,4106],{"nctId":15548,"briefTitle":15549,"status":103,"phases":15550,"primaryCompletion":15551,"completion":15551,"start":15552,"enrollment":629,"conditions":15553,"interventions":15554},"NCT02728206","Sofosbuvir\u002FVelpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation",[87],"2018-01-16","2016-06-12",[18],[4107],{"nctId":4264,"briefTitle":4265,"status":103,"phases":15556,"primaryCompletion":4267,"completion":4268,"start":4269,"enrollment":4270,"conditions":15557,"interventions":15558},[87],[18],[4107,513],{"nctId":15560,"briefTitle":15561,"status":103,"phases":15562,"primaryCompletion":15563,"completion":15563,"start":6118,"enrollment":829,"conditions":15564,"interventions":15565},"NCT02781571","Sofosbuvir\u002FVelpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant",[87],"2017-07-28",[18],[4107],{"nctId":15567,"briefTitle":15568,"status":103,"phases":15569,"primaryCompletion":1083,"completion":15272,"start":15570,"enrollment":11487,"conditions":15571,"interventions":15572},"NCT03036852","Sofosbuvir\u002FVelpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease",[87],"2017-03-22",[4190],[4107],{"nctId":4311,"briefTitle":4312,"status":103,"phases":15574,"primaryCompletion":4314,"completion":4315,"start":4316,"enrollment":4317,"conditions":15575,"interventions":15576},[87],[18],[4107,513],{"trials":15578,"activeCount":97},[15579,15589,15596,15600,15609,15617,15621,15631,15640,15647,15651,15655,15663,15672,15676,15684],{"nctId":15580,"briefTitle":15581,"status":103,"phases":15582,"primaryCompletion":15583,"completion":15584,"start":15585,"enrollment":15586,"conditions":15587,"interventions":15588},"NCT02671500","Efficacy and Safety of Sofosbuvir\u002FVelpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV",[88],"2018-01-05","2018-03-27","2016-04-19",375,[18],[4107],{"nctId":15590,"briefTitle":15591,"status":103,"phases":15592,"primaryCompletion":15593,"completion":7561,"start":6678,"enrollment":3722,"conditions":15594,"interventions":15595},"NCT02480712","Efficacy and Safety of Sofosbuvir\u002FVelpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection",[88],"2016-04-29",[18],[4107],{"nctId":4390,"briefTitle":4391,"status":103,"phases":15597,"primaryCompletion":4070,"completion":4307,"start":4091,"enrollment":1353,"conditions":15598,"interventions":15599},[88],[18],[4107,513],{"nctId":15601,"briefTitle":15602,"status":103,"phases":15603,"primaryCompletion":15604,"completion":15605,"start":2481,"enrollment":15606,"conditions":15607,"interventions":15608},"NCT02607800","Safety and Efficacy of Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir and Sofosbuvir\u002FVelpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy",[88],"2016-10-10","2017-01-11",943,[27],[4129,4107],{"nctId":15610,"briefTitle":15611,"status":103,"phases":15612,"primaryCompletion":15613,"completion":15614,"start":9363,"enrollment":4162,"conditions":15615,"interventions":15616},"NCT02346721","Sofosbuvir\u002FVelpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection",[88],"2016-03-23","2016-06-15",[18],[4107],{"nctId":4426,"briefTitle":4427,"status":103,"phases":15618,"primaryCompletion":4429,"completion":4430,"start":562,"enrollment":4431,"conditions":15619,"interventions":15620},[88],[18],[4107,506,513],{"nctId":15622,"briefTitle":15623,"status":103,"phases":15624,"primaryCompletion":15625,"completion":15626,"start":15627,"enrollment":15628,"conditions":15629,"interventions":15630},"NCT02639247","Safety and Efficacy of SOF\u002FVEL\u002FVOX FDC for 12 Weeks and SOF\u002FVEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor",[88],"2016-10-05","2017-01-18","2015-12-23",333,[18],[4129,4107],{"nctId":15632,"briefTitle":15633,"status":103,"phases":15634,"primaryCompletion":15635,"completion":15636,"start":15637,"enrollment":15097,"conditions":15638,"interventions":15639},"NCT04112303","Study to Investigate the Efficacy and Safety of Sofosbuvir\u002FVelpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis",[88],"2021-03-26","2021-06-25","2019-10-16",[18],[4107],{"nctId":15641,"briefTitle":15642,"status":103,"phases":15643,"primaryCompletion":4580,"completion":4430,"start":4091,"enrollment":15644,"conditions":15645,"interventions":15646},"NCT02201940","Sofosbuvir\u002FVelpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection",[88],741,[18],[4107],{"nctId":4503,"briefTitle":4504,"status":103,"phases":15648,"primaryCompletion":4430,"completion":4161,"start":4091,"enrollment":4506,"conditions":15649,"interventions":15650},[88],[18],[4107,506,513],{"nctId":4510,"briefTitle":4511,"status":103,"phases":15652,"primaryCompletion":4513,"completion":4514,"start":4515,"enrollment":4516,"conditions":15653,"interventions":15654},[88],[18],[4107,513],{"nctId":15656,"briefTitle":15657,"status":103,"phases":15658,"primaryCompletion":15659,"completion":15659,"start":15660,"enrollment":2381,"conditions":15661,"interventions":15662},"NCT04211909","Study to Investigate the Efficacy and Safety of Sofosbuvir\u002FVelpatasvir (SOF\u002FVEL) Fixed-Dose Combination (FDC) and Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir (SOF\u002FVEL\u002FVOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection",[88],"2020-11-12","2020-01-03",[18],[4107,4129],{"nctId":15664,"briefTitle":15665,"status":103,"phases":15666,"primaryCompletion":15667,"completion":15667,"start":15668,"enrollment":15669,"conditions":15670,"interventions":15671},"NCT03074331","Sofosbuvir\u002FVelpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection",[88],"2018-02-07","2017-03-23",130,[18],[4107],{"nctId":4566,"briefTitle":4567,"status":103,"phases":15673,"primaryCompletion":4569,"completion":4570,"start":4571,"enrollment":4438,"conditions":15674,"interventions":15675},[88],[18],[4107,513],{"nctId":15677,"briefTitle":15678,"status":103,"phases":15679,"primaryCompletion":15680,"completion":15681,"start":15627,"enrollment":6746,"conditions":15682,"interventions":15683},"NCT02639338","Safety and Efficacy of SOF\u002FVEL\u002FVOX FDC for 8 Weeks and SOF\u002FVEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis",[88],"2016-10-12","2017-01-02",[18],[4129,4107],{"nctId":15685,"briefTitle":15686,"status":103,"phases":15687,"primaryCompletion":6224,"completion":15688,"start":15689,"enrollment":11705,"conditions":15690,"interventions":15691},"NCT02722837","Efficacy and Safety of Sofosbuvir\u002FVelpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection",[88],"2017-09-13","2016-04-04",[18],[4107],{"trials":15693,"activeCount":97},[],{"trials":15695,"activeCount":97},[15696],{"nctId":15292,"briefTitle":15293,"status":653,"phases":15697,"primaryCompletion":15295,"completion":15295,"start":15296,"enrollment":15297,"conditions":15698,"interventions":15699},[],[18],[4118,9580,797,4107,4129,15300],{"intervention":506,"totalTrials":4605,"cells":15701},{"EARLY_PHASE1":15702,"PHASE1":15704,"PHASE2":15706,"PHASE3":15752,"PHASE4":15798,"NA":15800},{"trials":15703,"activeCount":97},[],{"trials":15705,"activeCount":97},[],{"trials":15707,"activeCount":97},[15708,15712,15716,15720,15724,15728,15732,15736,15740,15744,15748],{"nctId":4067,"briefTitle":4068,"status":103,"phases":15709,"primaryCompletion":4070,"completion":4070,"start":4071,"enrollment":4072,"conditions":15710,"interventions":15711},[87],[4074],[797,506,513],{"nctId":4077,"briefTitle":4078,"status":103,"phases":15713,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":4083,"conditions":15714,"interventions":15715},[87],[27],[506,4086,513],{"nctId":4166,"briefTitle":4167,"status":103,"phases":15717,"primaryCompletion":4080,"completion":4081,"start":4112,"enrollment":4169,"conditions":15718,"interventions":15719},[87],[27],[506,4086,513],{"nctId":4173,"briefTitle":4174,"status":103,"phases":15721,"primaryCompletion":4176,"completion":1782,"start":4177,"enrollment":4178,"conditions":15722,"interventions":15723},[87],[27],[506,512,513],{"nctId":4209,"briefTitle":4210,"status":103,"phases":15725,"primaryCompletion":4212,"completion":4144,"start":4112,"enrollment":4213,"conditions":15726,"interventions":15727},[87],[4190],[797,506,513,4216,4095,4086],{"nctId":4218,"briefTitle":4219,"status":103,"phases":15729,"primaryCompletion":1733,"completion":1782,"start":4221,"enrollment":4222,"conditions":15730,"interventions":15731},[87],[4224],[506,513,512,4226,4095,797],{"nctId":4255,"briefTitle":4256,"status":103,"phases":15733,"primaryCompletion":4258,"completion":4259,"start":4260,"enrollment":535,"conditions":15734,"interventions":15735},[87],[18],[506,513],{"nctId":4274,"briefTitle":4275,"status":103,"phases":15737,"primaryCompletion":500,"completion":641,"start":4277,"enrollment":880,"conditions":15738,"interventions":15739},[87],[4234],[506,513],{"nctId":496,"briefTitle":497,"status":103,"phases":15741,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":15742,"interventions":15743},[86,87],[27,504],[506,507,508,509,230,510,232,307,511,512,513],{"nctId":4325,"briefTitle":4326,"status":103,"phases":15745,"primaryCompletion":4328,"completion":4329,"start":4330,"enrollment":4331,"conditions":15746,"interventions":15747},[87],[794],[506,513,797],{"nctId":4335,"briefTitle":4336,"status":103,"phases":15749,"primaryCompletion":519,"completion":696,"start":4338,"enrollment":4339,"conditions":15750,"interventions":15751},[87],[27,4341,4342,4343],[506,513],{"trials":15753,"activeCount":97},[15754,15758,15762,15766,15770,15774,15778,15782,15786,15790,15794],{"nctId":4356,"briefTitle":4357,"status":103,"phases":15755,"primaryCompletion":500,"completion":641,"start":4338,"enrollment":4359,"conditions":15756,"interventions":15757},[88],[27,4361],[506,513],{"nctId":4364,"briefTitle":4365,"status":103,"phases":15759,"primaryCompletion":4367,"completion":4368,"start":4369,"enrollment":4370,"conditions":15760,"interventions":15761},[88],[4190],[506,513,4216],{"nctId":4374,"briefTitle":4375,"status":103,"phases":15763,"primaryCompletion":4377,"completion":4378,"start":4101,"enrollment":4114,"conditions":15764,"interventions":15765},[88],[18],[797,506,513],{"nctId":4382,"briefTitle":4383,"status":103,"phases":15767,"primaryCompletion":1733,"completion":4145,"start":4385,"enrollment":4386,"conditions":15768,"interventions":15769},[88],[27],[506,513],{"nctId":4426,"briefTitle":4427,"status":103,"phases":15771,"primaryCompletion":4429,"completion":4430,"start":562,"enrollment":4431,"conditions":15772,"interventions":15773},[88],[18],[4107,506,513],{"nctId":4452,"briefTitle":4453,"status":103,"phases":15775,"primaryCompletion":4177,"completion":4113,"start":4369,"enrollment":4455,"conditions":15776,"interventions":15777},[88],[4190],[506,513],{"nctId":4459,"briefTitle":4460,"status":103,"phases":15779,"primaryCompletion":4080,"completion":4081,"start":4462,"enrollment":3223,"conditions":15780,"interventions":15781},[88],[4234],[506,513],{"nctId":4466,"briefTitle":4467,"status":103,"phases":15783,"primaryCompletion":4134,"completion":4177,"start":501,"enrollment":2140,"conditions":15784,"interventions":15785},[88],[4190],[506,513],{"nctId":4493,"briefTitle":4494,"status":103,"phases":15787,"primaryCompletion":4496,"completion":4497,"start":4498,"enrollment":4499,"conditions":15788,"interventions":15789},[88],[27],[506,513,4216],{"nctId":4503,"briefTitle":4504,"status":103,"phases":15791,"primaryCompletion":4430,"completion":4161,"start":4091,"enrollment":4506,"conditions":15792,"interventions":15793},[88],[18],[4107,506,513],{"nctId":4520,"briefTitle":4521,"status":103,"phases":15795,"primaryCompletion":4071,"completion":4406,"start":4082,"enrollment":4523,"conditions":15796,"interventions":15797},[88],[27],[506,513],{"trials":15799,"activeCount":97},[],{"trials":15801,"activeCount":97},[15802,15811,15821],{"nctId":15803,"briefTitle":15804,"status":103,"phases":15805,"primaryCompletion":15806,"completion":15807,"start":166,"enrollment":15808,"conditions":15809,"interventions":15810},"NCT02592057","Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India",[],"2017-11-30","2018-04-23",532,[4234],[506],{"nctId":15812,"briefTitle":15813,"status":103,"phases":15814,"primaryCompletion":15815,"completion":15815,"start":15816,"enrollment":15817,"conditions":15818,"interventions":15819},"NCT02537379","Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection",[],"2017-06-05","2015-09-15",552,[18],[506,15820],"COPE",{"nctId":15822,"briefTitle":15823,"status":103,"phases":15824,"primaryCompletion":285,"completion":285,"start":15825,"enrollment":15826,"conditions":15827,"interventions":15828},"NCT02562742","Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection",[],"2015-11-12",554,[27],[506,15829],"REB",{"intervention":4118,"totalTrials":4587,"cells":15831},{"EARLY_PHASE1":15832,"PHASE1":15834,"PHASE2":15836,"PHASE3":15864,"PHASE4":15890,"NA":15896},{"trials":15833,"activeCount":97},[],{"trials":15835,"activeCount":97},[],{"trials":15837,"activeCount":97},[15838,15842,15846,15852,15856,15860],{"nctId":4109,"briefTitle":4110,"status":103,"phases":15839,"primaryCompletion":4112,"completion":4113,"start":561,"enrollment":4114,"conditions":15840,"interventions":15841},[87],[4116],[4118,4119,513],{"nctId":4131,"briefTitle":4132,"status":103,"phases":15843,"primaryCompletion":1782,"completion":4081,"start":4134,"enrollment":4135,"conditions":15844,"interventions":15845},[87],[4137,4138],[4118,513],{"nctId":15847,"briefTitle":15848,"status":103,"phases":15849,"primaryCompletion":4080,"completion":4367,"start":501,"enrollment":4058,"conditions":15850,"interventions":15851},"NCT01559844","Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant",[87],[27,1025],[4118,9580],{"nctId":4200,"briefTitle":4201,"status":103,"phases":15853,"primaryCompletion":563,"completion":4203,"start":4204,"enrollment":4205,"conditions":15854,"interventions":15855},[87],[27],[4118,512,513],{"nctId":4228,"briefTitle":4229,"status":103,"phases":15857,"primaryCompletion":2421,"completion":4231,"start":2332,"enrollment":4232,"conditions":15858,"interventions":15859},[87],[4234],[4118,512,513],{"nctId":4237,"briefTitle":4238,"status":103,"phases":15861,"primaryCompletion":695,"completion":695,"start":4240,"enrollment":4241,"conditions":15862,"interventions":15863},[87],[4116],[4118,513,512],{"trials":15865,"activeCount":97},[15866,15870,15874,15878,15882,15886],{"nctId":4396,"briefTitle":4397,"status":103,"phases":15867,"primaryCompletion":4071,"completion":4091,"start":532,"enrollment":890,"conditions":15868,"interventions":15869},[88],[4190,4361],[4118,513],{"nctId":4402,"briefTitle":4403,"status":103,"phases":15871,"primaryCompletion":4405,"completion":4406,"start":4177,"enrollment":643,"conditions":15872,"interventions":15873},[88],[27],[4118,513],{"nctId":4435,"briefTitle":4436,"status":103,"phases":15875,"primaryCompletion":4430,"completion":4307,"start":4405,"enrollment":4438,"conditions":15876,"interventions":15877},[88],[4074],[4118,513],{"nctId":4472,"briefTitle":4473,"status":103,"phases":15879,"primaryCompletion":532,"completion":4112,"start":4369,"enrollment":4475,"conditions":15880,"interventions":15881},[88],[4190],[4118,513,512],{"nctId":4527,"briefTitle":4528,"status":103,"phases":15883,"primaryCompletion":532,"completion":4112,"start":4530,"enrollment":4531,"conditions":15884,"interventions":15885},[88],[27],[4118,512,513],{"nctId":4535,"briefTitle":4536,"status":103,"phases":15887,"primaryCompletion":4538,"completion":4539,"start":4540,"enrollment":4541,"conditions":15888,"interventions":15889},[88],[4074],[4118,513,512],{"trials":15891,"activeCount":97},[15892],{"nctId":4577,"briefTitle":4578,"status":103,"phases":15893,"primaryCompletion":4580,"completion":4580,"start":4406,"enrollment":819,"conditions":15894,"interventions":15895},[89],[18],[4118,513],{"trials":15897,"activeCount":97},[15898,15906,15910,15922],{"nctId":15899,"briefTitle":15900,"status":15498,"phases":15901,"conditions":15902,"interventions":15904},"NCT01779518","Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C",[],[15903],"Post-transplant Hepatitis C",[4118,9580,15905],"Pegylated Interferon",{"nctId":15292,"briefTitle":15293,"status":653,"phases":15907,"primaryCompletion":15295,"completion":15295,"start":15296,"enrollment":15297,"conditions":15908,"interventions":15909},[],[18],[4118,9580,797,4107,4129,15300],{"nctId":15911,"briefTitle":15912,"status":653,"phases":15913,"primaryCompletion":15914,"completion":15914,"start":15915,"enrollment":15916,"conditions":15917,"interventions":15918},"NCT02510300","A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials",[],"2023-01-06","2015-10-21",461,[18],[4118,15919,15920,15921],"Ledipasvir\u002FSofosbuvir","Sofosbuvir\u002FVelpatasvir","Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir",{"nctId":15923,"briefTitle":15924,"status":103,"phases":15925,"primaryCompletion":15926,"completion":15926,"start":15927,"enrollment":15928,"conditions":15929,"interventions":15930},"NCT02907996","Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea",[],"2021-12-09","2016-09-09",2033,[4234],[4118],{"intervention":2426,"totalTrials":134,"cells":15932},{"EARLY_PHASE1":15933,"PHASE1":15935,"PHASE2":15947,"PHASE3":15971,"PHASE4":15996,"NA":16008},{"trials":15934,"activeCount":97},[],{"trials":15936,"activeCount":97},[15937,15941],{"nctId":13732,"briefTitle":13733,"status":103,"phases":15938,"primaryCompletion":4112,"completion":4112,"start":501,"enrollment":3336,"conditions":15939,"interventions":15940},[86],[24],[13725,2426],{"nctId":15942,"briefTitle":15943,"status":11287,"phases":15944,"enrollment":880,"conditions":15945,"interventions":15946},"NCT00002396","The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients",[86],[15],[2426],{"trials":15948,"activeCount":97},[15949,15953,15957,15965],{"nctId":2418,"briefTitle":2419,"status":103,"phases":15950,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2423,"conditions":15951,"interventions":15952},[87],[24],[2426,1356,2427,2428,2429,2430],{"nctId":5441,"briefTitle":5442,"status":103,"phases":15954,"completion":2340,"start":5444,"enrollment":1075,"conditions":15955,"interventions":15956},[87],[504],[5447,5448],{"nctId":15958,"briefTitle":15959,"status":103,"phases":15960,"primaryCompletion":613,"completion":250,"start":15961,"enrollment":15962,"conditions":15963,"interventions":15964},"NCT02174276","Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment",[87],"2014-07-24",195,[24],[2426,11552],{"nctId":15966,"briefTitle":15967,"status":103,"phases":15968,"enrollment":3987,"conditions":15969,"interventions":15970},"NCT00002415","Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients",[87],[15],[2426],{"trials":15972,"activeCount":97},[15973,15980,15986,15992],{"nctId":15974,"briefTitle":15975,"status":103,"phases":15976,"primaryCompletion":4240,"completion":4161,"start":4902,"enrollment":535,"conditions":15977,"interventions":15979},"NCT00734162","Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection",[88],[15978],"Hepatitis B Virus (HBV)",[2426],{"nctId":15981,"briefTitle":15982,"status":103,"phases":15983,"enrollment":2232,"conditions":15984,"interventions":15985},"NCT00002450","Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients",[88],[15],[2426],{"nctId":15987,"briefTitle":15988,"status":11287,"phases":15989,"conditions":15990,"interventions":15991},"NCT00007436","The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients",[88],[15],[2426],{"nctId":5157,"briefTitle":5158,"status":103,"phases":15993,"primaryCompletion":2473,"completion":4719,"start":5160,"enrollment":5161,"conditions":15994,"interventions":15995},[88],[15],[5164,5165,5129,232,5166,5167],{"trials":15997,"activeCount":97},[15998,16004],{"nctId":15999,"briefTitle":16000,"status":103,"phases":16001,"primaryCompletion":10462,"completion":10462,"start":8187,"enrollment":2091,"conditions":16002,"interventions":16003},"NCT00736190","A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection",[89],[24],[2426],{"nctId":5837,"briefTitle":5838,"status":103,"phases":16005,"primaryCompletion":4731,"completion":5840,"start":5175,"enrollment":1122,"conditions":16006,"interventions":16007},[89],[15],[5165,5824],{"trials":16009,"activeCount":97},[16010,16017,16024,16031],{"nctId":16011,"briefTitle":16012,"status":103,"phases":16013,"start":16014,"enrollment":5176,"conditions":16015,"interventions":16016},"NCT00002453","A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection",[90],"1999-12",[15],[2426],{"nctId":16018,"briefTitle":16019,"status":103,"phases":16020,"start":16021,"conditions":16022,"interventions":16023},"NCT00016588","Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs",[90],"2001-05",[15],[2426],{"nctId":16025,"briefTitle":16026,"status":11287,"phases":16027,"start":16028,"conditions":16029,"interventions":16030},"NCT00011089","Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations",[90],"2001-02",[15],[2426],{"nctId":16032,"briefTitle":16033,"status":653,"phases":16034,"primaryCompletion":16035,"completion":16035,"start":16036,"enrollment":7228,"conditions":16037,"interventions":16038},"NCT02258581","Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection",[],"2017-08-14","2014-12-09",[24],[11552,16039,2426],"GS-9620",{"intervention":5145,"totalTrials":3270,"cells":16041},{"EARLY_PHASE1":16042,"PHASE1":16044,"PHASE2":16064,"PHASE3":16099,"PHASE4":16105,"NA":16107},{"trials":16043,"activeCount":97},[],{"trials":16045,"activeCount":97},[16046,16052,16058],{"nctId":16047,"briefTitle":16048,"status":103,"phases":16049,"enrollment":3270,"conditions":16050,"interventions":16051},"NCT00002128","Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients",[86],[15],[5145],{"nctId":16053,"briefTitle":16054,"status":103,"phases":16055,"enrollment":1256,"conditions":16056,"interventions":16057},"NCT00002206","A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV Drugs",[86],[15],[5145],{"nctId":16059,"briefTitle":16060,"status":103,"phases":16061,"enrollment":1862,"conditions":16062,"interventions":16063},"NCT00002346","The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients",[86],[15],[5145],{"trials":16065,"activeCount":97},[16066,16073,16077,16083,16087,16091,16095],{"nctId":16067,"briefTitle":16068,"status":103,"phases":16069,"primaryCompletion":16070,"completion":16070,"start":2323,"enrollment":4178,"conditions":16071,"interventions":16072},"NCT00645294","Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV",[86,87],"2003-08",[2334],[5145,7341,7341],{"nctId":7313,"briefTitle":7314,"status":103,"phases":16074,"enrollment":1075,"conditions":16075,"interventions":16076},[87],[15],[7318,7319,5145,5152,2395,2394],{"nctId":16078,"briefTitle":16079,"status":103,"phases":16080,"primaryCompletion":4852,"completion":4852,"start":4888,"enrollment":134,"conditions":16081,"interventions":16082},"NCT00644761","PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients",[87],[2334],[7341],{"nctId":5138,"briefTitle":5139,"status":103,"phases":16084,"enrollment":4605,"conditions":16085,"interventions":16086},[87],[15],[5143,5144,5129,5145],{"nctId":7321,"briefTitle":7322,"status":103,"phases":16088,"enrollment":1470,"conditions":16089,"interventions":16090},[87],[15],[7326,7319,5145,7327,5152,2395,2394],{"nctId":5147,"briefTitle":5148,"status":103,"phases":16092,"enrollment":4605,"conditions":16093,"interventions":16094},[87],[15],[5129,5145,5152,5153],{"nctId":11285,"briefTitle":11286,"status":11287,"phases":16096,"enrollment":1862,"conditions":16097,"interventions":16098},[87],[15],[7326,7319,5145],{"trials":16100,"activeCount":97},[16101],{"nctId":7335,"briefTitle":7336,"status":103,"phases":16102,"primaryCompletion":5041,"completion":563,"start":7027,"enrollment":7338,"conditions":16103,"interventions":16104},[88],[24],[7341,5152],{"trials":16106,"activeCount":97},[],{"trials":16108,"activeCount":97},[16109,16115,16122,16128],{"nctId":16110,"briefTitle":16111,"status":15498,"phases":16112,"conditions":16113,"interventions":16114},"NCT00042393","An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options",[],[24],[7341],{"nctId":16116,"briefTitle":16117,"status":103,"phases":16118,"enrollment":16119,"conditions":16120,"interventions":16121},"NCT00002426","A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients",[90],390,[15],[5145],{"nctId":16123,"briefTitle":16124,"status":103,"phases":16125,"enrollment":1297,"conditions":16126,"interventions":16127},"NCT00002161","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200\u002Fmm3",[90],[15],[5145],{"nctId":16129,"briefTitle":16130,"status":103,"phases":16131,"conditions":16132,"interventions":16133},"NCT00002398","Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations",[90],[15],[7319,5145],{"intervention":1049,"totalTrials":11024,"cells":16135},{"EARLY_PHASE1":16136,"PHASE1":16138,"PHASE2":16148,"PHASE3":16182,"PHASE4":16196,"NA":16198},{"trials":16137,"activeCount":97},[],{"trials":16139,"activeCount":97},[16140,16144],{"nctId":3414,"briefTitle":3415,"status":103,"phases":16141,"primaryCompletion":3417,"completion":3417,"start":3418,"enrollment":3419,"conditions":16142,"interventions":16143},[86],[3421],[1049,1088],{"nctId":6650,"briefTitle":6651,"status":653,"phases":16145,"primaryCompletion":2090,"completion":2090,"start":6653,"enrollment":6654,"conditions":16146,"interventions":16147},[86],[6656],[1049,6643],{"trials":16149,"activeCount":97},[16150,16154,16158,16162,16166,16170,16174,16178],{"nctId":1283,"briefTitle":1284,"status":653,"phases":16151,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":1008,"conditions":16152,"interventions":16153},[87],[1289],[1049,1012,991,1291,1014,1013,1089],{"nctId":1817,"briefTitle":1818,"status":653,"phases":16155,"primaryCompletion":1820,"completion":1820,"start":1821,"enrollment":535,"conditions":16156,"interventions":16157},[87],[1067],[1049,991],{"nctId":3387,"briefTitle":3388,"status":653,"phases":16159,"primaryCompletion":3390,"completion":3390,"start":3391,"enrollment":3392,"conditions":16160,"interventions":16161},[87],[3394],[1049,1453,1454,3396,1451],{"nctId":11762,"briefTitle":11763,"status":103,"phases":16163,"primaryCompletion":11765,"completion":11765,"start":11766,"enrollment":6043,"conditions":16164,"interventions":16165},[86,87],[1067,1447],[1049,11753],{"nctId":6661,"briefTitle":6662,"status":653,"phases":16167,"primaryCompletion":6664,"completion":6664,"start":442,"enrollment":4841,"conditions":16168,"interventions":16169},[87],[6666],[1049,6643,6668,6669,1541,6670,6671],{"nctId":11143,"briefTitle":11144,"status":653,"phases":16171,"primaryCompletion":11146,"completion":11146,"start":11147,"enrollment":1862,"conditions":16172,"interventions":16173},[87],[9826],[1049,11150,11151,9551,7236,11152],{"nctId":1040,"briefTitle":1041,"status":653,"phases":16175,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":1045,"conditions":16176,"interventions":16177},[87],[1047],[1049,1050,1051,57],{"nctId":1739,"briefTitle":1740,"status":653,"phases":16179,"primaryCompletion":239,"completion":239,"start":1742,"enrollment":1743,"conditions":16180,"interventions":16181},[86,87],[1745],[1049,1539,1090,1452,1747],{"trials":16183,"activeCount":97},[16184,16188,16192],{"nctId":6689,"briefTitle":6690,"status":653,"phases":16185,"primaryCompletion":6692,"completion":6692,"start":6693,"enrollment":6694,"conditions":16186,"interventions":16187},[88],[6681],[1049,6668,6643],{"nctId":6698,"briefTitle":6699,"status":653,"phases":16189,"primaryCompletion":239,"completion":239,"start":6701,"enrollment":6654,"conditions":16190,"interventions":16191},[88],[6681],[1049,6668,6643,6670,6684,6704,6705],{"nctId":6707,"briefTitle":6708,"status":653,"phases":16193,"primaryCompletion":6710,"completion":6710,"start":6711,"enrollment":6712,"conditions":16194,"interventions":16195},[88],[6714],[1049,6643],{"trials":16197,"activeCount":97},[],{"trials":16199,"activeCount":97},[16200],{"nctId":16201,"briefTitle":16202,"status":16203,"phases":16204,"conditions":16205,"interventions":16207},"NCT05627466","US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia","NO_LONGER_AVAILABLE",[],[16206],"Relapsed\u002FRefractory Acute Myeloid Leukemia",[1049],{"intervention":1539,"totalTrials":11024,"cells":16209},{"EARLY_PHASE1":16210,"PHASE1":16212,"PHASE2":16226,"PHASE3":16244,"PHASE4":16266,"NA":16268},{"trials":16211,"activeCount":97},[],{"trials":16213,"activeCount":97},[16214,16218,16222],{"nctId":7223,"briefTitle":7224,"status":103,"phases":16215,"primaryCompletion":7226,"completion":7226,"start":7227,"enrollment":7228,"conditions":16216,"interventions":16217},[86],[7230,36,7231],[1538,1539,7216,7233,7234,7235,7236,7210,7237],{"nctId":1527,"briefTitle":1528,"status":1529,"phases":16219,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":97,"conditions":16220,"interventions":16221},[86],[1535,1536],[1538,1539,1540,1013,1541],{"nctId":14793,"briefTitle":14794,"status":653,"phases":16223,"primaryCompletion":14796,"completion":14796,"start":14797,"enrollment":629,"conditions":16224,"interventions":16225},[86],[14799],[14786,1539],{"trials":16227,"activeCount":97},[16228,16232,16236,16240],{"nctId":15362,"briefTitle":15363,"status":653,"phases":16229,"primaryCompletion":1605,"completion":7246,"start":15365,"enrollment":4516,"conditions":16230,"interventions":16231},[87],[15367],[1538,1539],{"nctId":15370,"briefTitle":15371,"status":653,"phases":16233,"primaryCompletion":4070,"completion":15373,"start":2352,"enrollment":8178,"conditions":16234,"interventions":16235},[87],[13578,15375],[1538,1539],{"nctId":15395,"briefTitle":15396,"status":653,"phases":16237,"primaryCompletion":4101,"completion":15398,"start":15399,"enrollment":1335,"conditions":16238,"interventions":16239},[87],[12823,13799],[1538,1539],{"nctId":1739,"briefTitle":1740,"status":653,"phases":16241,"primaryCompletion":239,"completion":239,"start":1742,"enrollment":1743,"conditions":16242,"interventions":16243},[86,87],[1745],[1049,1539,1090,1452,1747],{"trials":16245,"activeCount":97},[16246,16250,16254,16258,16262],{"nctId":7243,"briefTitle":7244,"status":653,"phases":16247,"primaryCompletion":7246,"completion":7246,"start":7247,"enrollment":7248,"conditions":16248,"interventions":16249},[88],[7250],[1538,1539,7216],{"nctId":15441,"briefTitle":15442,"status":103,"phases":16251,"primaryCompletion":1733,"completion":4071,"start":642,"enrollment":6746,"conditions":16252,"interventions":16253},[88],[36],[1538,1539],{"nctId":7253,"briefTitle":7254,"status":653,"phases":16255,"primaryCompletion":7256,"completion":7257,"start":7258,"enrollment":7259,"conditions":16256,"interventions":16257},[88],[36],[1538,7216,1539],{"nctId":7263,"briefTitle":7264,"status":103,"phases":16259,"primaryCompletion":7266,"completion":7266,"start":7267,"enrollment":1276,"conditions":16260,"interventions":16261},[88],[36],[1538,1539,7216],{"nctId":15465,"briefTitle":15466,"status":653,"phases":16263,"primaryCompletion":15468,"completion":15468,"start":15469,"enrollment":15470,"conditions":16264,"interventions":16265},[88],[7250],[1539,1538],{"trials":16267,"activeCount":97},[],{"trials":16269,"activeCount":97},[16270,16274],{"nctId":15496,"briefTitle":15497,"status":15498,"phases":16271,"conditions":16272,"interventions":16273},[],[13578],[1538,1539],{"nctId":15503,"briefTitle":15504,"status":103,"phases":16275,"primaryCompletion":15506,"completion":15506,"start":15507,"enrollment":2423,"conditions":16276,"interventions":16277},[],[9368],[1538,1539],{"intervention":9580,"totalTrials":1335,"cells":16279},{"EARLY_PHASE1":16280,"PHASE1":16282,"PHASE2":16284,"PHASE3":16318,"PHASE4":16320,"NA":16322},{"trials":16281,"activeCount":97},[],{"trials":16283,"activeCount":97},[],{"trials":16285,"activeCount":97},[16286,16290,16294,16298,16302,16306,16310,16314],{"nctId":9574,"briefTitle":9575,"status":103,"phases":16287,"primaryCompletion":532,"completion":4349,"start":561,"enrollment":3200,"conditions":16288,"interventions":16289},[87],[4116],[4294,4295,9579,9580],{"nctId":9582,"briefTitle":9583,"status":103,"phases":16291,"primaryCompletion":4082,"completion":4082,"start":4929,"enrollment":9585,"conditions":16292,"interventions":16293},[87],[4116],[4294,4295,9588,9589,9590],{"nctId":9592,"briefTitle":9593,"status":103,"phases":16295,"primaryCompletion":532,"completion":532,"start":561,"enrollment":9595,"conditions":16296,"interventions":16297},[87],[9597],[4294,4295,9579,9589],{"nctId":15847,"briefTitle":15848,"status":103,"phases":16299,"primaryCompletion":4080,"completion":4367,"start":501,"enrollment":4058,"conditions":16300,"interventions":16301},[87],[27,1025],[4118,9580],{"nctId":10394,"briefTitle":10395,"status":103,"phases":16303,"primaryCompletion":4869,"completion":4176,"start":5575,"enrollment":853,"conditions":16304,"interventions":16305},[87],[794],[10080,10399,9580],{"nctId":10074,"briefTitle":10075,"status":103,"phases":16307,"primaryCompletion":2352,"completion":4677,"start":6634,"enrollment":19,"conditions":16308,"interventions":16309},[87],[794],[10079,10080,9580,10081],{"nctId":9604,"briefTitle":9605,"status":103,"phases":16311,"primaryCompletion":4277,"completion":4462,"start":534,"enrollment":9607,"conditions":16312,"interventions":16313},[87],[4116],[4294,9610,4295,9589,4294],{"nctId":9612,"briefTitle":9613,"status":103,"phases":16315,"primaryCompletion":4462,"completion":4462,"start":4929,"enrollment":9595,"conditions":16316,"interventions":16317},[87],[4116],[4294,4295,9588,9589],{"trials":16319,"activeCount":97},[],{"trials":16321,"activeCount":97},[],{"trials":16323,"activeCount":97},[16324,16328],{"nctId":15899,"briefTitle":15900,"status":15498,"phases":16325,"conditions":16326,"interventions":16327},[],[15903],[4118,9580,15905],{"nctId":15292,"briefTitle":15293,"status":653,"phases":16329,"primaryCompletion":15295,"completion":15295,"start":15296,"enrollment":15297,"conditions":16330,"interventions":16331},[],[18],[4118,9580,797,4107,4129,15300],{"intervention":4129,"totalTrials":1335,"cells":16333},{"EARLY_PHASE1":16334,"PHASE1":16336,"PHASE2":16342,"PHASE3":16357,"PHASE4":16390,"NA":16392},{"trials":16335,"activeCount":97},[],{"trials":16337,"activeCount":97},[16338],{"nctId":10024,"briefTitle":10025,"status":103,"phases":16339,"primaryCompletion":10027,"completion":10027,"start":10028,"enrollment":3270,"conditions":16340,"interventions":16341},[86],[794],[4129,4106,10031],{"trials":16343,"activeCount":97},[16344,16348],{"nctId":4121,"briefTitle":4122,"status":103,"phases":16345,"primaryCompletion":4124,"completion":4125,"start":4126,"enrollment":108,"conditions":16346,"interventions":16347},[87],[18],[4129,513],{"nctId":16349,"briefTitle":16350,"status":653,"phases":16351,"primaryCompletion":16352,"completion":16353,"start":16354,"enrollment":657,"conditions":16355,"interventions":16356},"NCT03820258","Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir (SOF\u002FVEL\u002FVOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection",[87],"2019-12-04","2020-02-19","2019-01-28",[18],[4129],{"trials":16358,"activeCount":97},[16359,16363,16367,16375,16382,16386],{"nctId":15601,"briefTitle":15602,"status":103,"phases":16360,"primaryCompletion":15604,"completion":15605,"start":2481,"enrollment":15606,"conditions":16361,"interventions":16362},[88],[27],[4129,4107],{"nctId":15622,"briefTitle":15623,"status":103,"phases":16364,"primaryCompletion":15625,"completion":15626,"start":15627,"enrollment":15628,"conditions":16365,"interventions":16366},[88],[18],[4129,4107],{"nctId":16368,"briefTitle":16369,"status":103,"phases":16370,"primaryCompletion":16371,"completion":16371,"start":16372,"enrollment":8439,"conditions":16373,"interventions":16374},"NCT03118843","Safety And Efficacy of Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study",[88],"2018-03-19","2017-04-25",[18],[4129],{"nctId":16376,"briefTitle":16377,"status":103,"phases":16378,"primaryCompletion":15604,"completion":16379,"start":190,"enrollment":1276,"conditions":16380,"interventions":16381},"NCT02607735","Safety and Efficacy of Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy",[88],"2017-06-21",[27],[4129],{"nctId":15656,"briefTitle":15657,"status":103,"phases":16383,"primaryCompletion":15659,"completion":15659,"start":15660,"enrollment":2381,"conditions":16384,"interventions":16385},[88],[18],[4107,4129],{"nctId":15677,"briefTitle":15678,"status":103,"phases":16387,"primaryCompletion":15680,"completion":15681,"start":15627,"enrollment":6746,"conditions":16388,"interventions":16389},[88],[18],[4129,4107],{"trials":16391,"activeCount":97},[],{"trials":16393,"activeCount":97},[16394],{"nctId":15292,"briefTitle":15293,"status":653,"phases":16395,"primaryCompletion":15295,"completion":15295,"start":15296,"enrollment":15297,"conditions":16396,"interventions":16397},[],[18],[4118,9580,797,4107,4129,15300],{"intervention":6548,"totalTrials":1645,"cells":16399},{"EARLY_PHASE1":16400,"PHASE1":16402,"PHASE2":16404,"PHASE3":16416,"PHASE4":16438,"NA":16440},{"trials":16401,"activeCount":97},[],{"trials":16403,"activeCount":97},[],{"trials":16405,"activeCount":97},[16406],{"nctId":16407,"briefTitle":16408,"status":103,"phases":16409,"primaryCompletion":16410,"completion":16411,"start":16412,"enrollment":16413,"conditions":16414,"interventions":16415},"NCT04539262","Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",[86,87],"2021-02-26","2021-03-22","2020-09-14",156,[6546],[6548],{"trials":16417,"activeCount":97},[16418,16422,16430,16434],{"nctId":6538,"briefTitle":6539,"status":103,"phases":16419,"primaryCompletion":6541,"completion":6542,"start":6543,"enrollment":6544,"conditions":16420,"interventions":16421},[88],[6546],[6548,112],{"nctId":16423,"briefTitle":16424,"status":103,"phases":16425,"primaryCompletion":16426,"completion":16426,"start":16427,"enrollment":11487,"conditions":16428,"interventions":16429},"NCT04431453","Study of Remdesivir in Participants Below 18 Years Old With COVID-19",[87,88],"2023-02-10","2020-07-21",[6546],[6548],{"nctId":6550,"briefTitle":6551,"status":103,"phases":16431,"primaryCompletion":6553,"completion":6554,"start":6555,"enrollment":6556,"conditions":16432,"interventions":16433},[88],[6546],[6548,112],{"nctId":6560,"briefTitle":6561,"status":653,"phases":16435,"primaryCompletion":6563,"completion":6564,"start":6565,"enrollment":6566,"conditions":16436,"interventions":16437},[88],[6546],[6548,6569,112],{"trials":16439,"activeCount":97},[],{"trials":16441,"activeCount":97},[16442],{"nctId":16443,"briefTitle":16444,"status":15498,"phases":16445,"conditions":16446,"interventions":16448},"NCT04323761","Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)",[],[16447],"SARS-CoV2 Infection",[6548],{"intervention":16450,"totalTrials":1645,"cells":16451},"Cidofovir",{"EARLY_PHASE1":16452,"PHASE1":16454,"PHASE2":16470,"PHASE3":16480,"PHASE4":16482,"NA":16484},{"trials":16453,"activeCount":97},[],{"trials":16455,"activeCount":97},[16456,16463],{"nctId":16457,"briefTitle":16458,"status":103,"phases":16459,"enrollment":4135,"conditions":16460,"interventions":16462},"NCT00002327","The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients",[86],[15,16461],"Condyloma Acuminata",[16450],{"nctId":16464,"briefTitle":16465,"status":103,"phases":16466,"enrollment":25,"conditions":16467,"interventions":16469},"NCT00002116","A Phase I\u002FII Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS",[86],[16468,15],"Herpes Simplex",[16450],{"trials":16471,"activeCount":97},[16472],{"nctId":16473,"briefTitle":16474,"status":103,"phases":16475,"enrollment":7002,"conditions":16476,"interventions":16478},"NCT00002437","The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS",[87],[16477,15],"Cytomegalovirus Retinitis",[16450,16479],"Probenecid",{"trials":16481,"activeCount":97},[],{"trials":16483,"activeCount":97},[],{"trials":16485,"activeCount":97},[16486,16492,16498],{"nctId":16487,"briefTitle":16488,"status":103,"phases":16489,"conditions":16490,"interventions":16491},"NCT00002181","Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS",[90],[16468,15],[16450],{"nctId":16493,"briefTitle":16494,"status":11287,"phases":16495,"conditions":16496,"interventions":16497},"NCT00002384","A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS",[90],[16477,15],[16450],{"nctId":16499,"briefTitle":16500,"status":103,"phases":16501,"enrollment":1075,"conditions":16502,"interventions":16503},"NCT00002142","An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS",[90],[16477,15],[16450,16479],{"intervention":11552,"totalTrials":477,"cells":16505},{"EARLY_PHASE1":16506,"PHASE1":16508,"PHASE2":16516,"PHASE3":16526,"PHASE4":16528,"NA":16530},{"trials":16507,"activeCount":97},[],{"trials":16509,"activeCount":97},[16510],{"nctId":16511,"briefTitle":16512,"status":103,"phases":16513,"primaryCompletion":499,"completion":499,"start":532,"enrollment":880,"conditions":16514,"interventions":16515},"NCT01779505","A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults",[86],[14927],[11552],{"trials":16517,"activeCount":97},[16518,16522],{"nctId":11544,"briefTitle":11545,"status":103,"phases":16519,"primaryCompletion":11547,"completion":11548,"start":11549,"enrollment":1743,"conditions":16520,"interventions":16521},[87],[2497],[11552,11535],{"nctId":15958,"briefTitle":15959,"status":103,"phases":16523,"primaryCompletion":613,"completion":250,"start":15961,"enrollment":15962,"conditions":16524,"interventions":16525},[87],[24],[2426,11552],{"trials":16527,"activeCount":97},[],{"trials":16529,"activeCount":97},[],{"trials":16531,"activeCount":97},[16532],{"nctId":16032,"briefTitle":16033,"status":653,"phases":16533,"primaryCompletion":16035,"completion":16035,"start":16036,"enrollment":7228,"conditions":16534,"interventions":16535},[],[24],[11552,16039,2426],{"intervention":7319,"totalTrials":477,"cells":16537},{"EARLY_PHASE1":16538,"PHASE1":16540,"PHASE2":16542,"PHASE3":16556,"PHASE4":16558,"NA":16560},{"trials":16539,"activeCount":97},[],{"trials":16541,"activeCount":97},[],{"trials":16543,"activeCount":97},[16544,16548,16552],{"nctId":7313,"briefTitle":7314,"status":103,"phases":16545,"enrollment":1075,"conditions":16546,"interventions":16547},[87],[15],[7318,7319,5145,5152,2395,2394],{"nctId":7321,"briefTitle":7322,"status":103,"phases":16549,"enrollment":1470,"conditions":16550,"interventions":16551},[87],[15],[7326,7319,5145,7327,5152,2395,2394],{"nctId":11285,"briefTitle":11286,"status":11287,"phases":16553,"enrollment":1862,"conditions":16554,"interventions":16555},[87],[15],[7326,7319,5145],{"trials":16557,"activeCount":97},[],{"trials":16559,"activeCount":97},[],{"trials":16561,"activeCount":97},[16562],{"nctId":16129,"briefTitle":16130,"status":103,"phases":16563,"conditions":16564,"interventions":16565},[90],[15],[7319,5145],{"intervention":16567,"totalTrials":993,"cells":16568},"Hepsera",{"EARLY_PHASE1":16569,"PHASE1":16571,"PHASE2":16573,"PHASE3":16575,"PHASE4":16577,"NA":16579},{"trials":16570,"activeCount":97},[],{"trials":16572,"activeCount":97},[],{"trials":16574,"activeCount":97},[],{"trials":16576,"activeCount":97},[],{"trials":16578,"activeCount":97},[],{"trials":16580,"activeCount":97},[16581,16588],{"nctId":16582,"briefTitle":16583,"status":653,"phases":16584,"completion":5092,"start":16585,"enrollment":1297,"conditions":16586,"interventions":16587},"NCT00158704","Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w\u002FChronic HBV Infection.",[90],"2002-01",[2334],[16567],{"nctId":16589,"briefTitle":16590,"status":103,"phases":16591,"primaryCompletion":2422,"completion":2422,"start":4840,"enrollment":3722,"conditions":16592,"interventions":16593},"NCT00158717","Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.",[],[2334],[16567],{"intervention":16479,"totalTrials":993,"cells":16595},{"EARLY_PHASE1":16596,"PHASE1":16598,"PHASE2":16600,"PHASE3":16606,"PHASE4":16608,"NA":16610},{"trials":16597,"activeCount":97},[],{"trials":16599,"activeCount":97},[],{"trials":16601,"activeCount":97},[16602],{"nctId":16473,"briefTitle":16474,"status":103,"phases":16603,"enrollment":7002,"conditions":16604,"interventions":16605},[87],[16477,15],[16450,16479],{"trials":16607,"activeCount":97},[],{"trials":16609,"activeCount":97},[],{"trials":16611,"activeCount":97},[16612],{"nctId":16499,"briefTitle":16500,"status":103,"phases":16613,"enrollment":1075,"conditions":16614,"interventions":16615},[90],[16477,15],[16450,16479],{"intervention":16617,"totalTrials":147,"cells":16618},"Anti-HBV nucleoside\u002Fnucleotide therapy",{"EARLY_PHASE1":16619,"PHASE1":16621,"PHASE2":16623,"PHASE3":16625,"PHASE4":16627,"NA":16629},{"trials":16620,"activeCount":97},[],{"trials":16622,"activeCount":97},[],{"trials":16624,"activeCount":97},[],{"trials":16626,"activeCount":97},[],{"trials":16628,"activeCount":97},[],{"trials":16630,"activeCount":97},[16631],{"nctId":16632,"briefTitle":16633,"status":103,"phases":16634,"primaryCompletion":16635,"completion":16635,"start":16636,"enrollment":4841,"conditions":16637,"interventions":16638},"NCT01590615","Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy",[],"2017-04-04","2012-04-26",[2334],[16617],{"intervention":15905,"totalTrials":147,"cells":16640},{"EARLY_PHASE1":16641,"PHASE1":16643,"PHASE2":16645,"PHASE3":16647,"PHASE4":16649,"NA":16651},{"trials":16642,"activeCount":97},[],{"trials":16644,"activeCount":97},[],{"trials":16646,"activeCount":97},[],{"trials":16648,"activeCount":97},[],{"trials":16650,"activeCount":97},[],{"trials":16652,"activeCount":97},[16653],{"nctId":15899,"briefTitle":15900,"status":15498,"phases":16654,"conditions":16655,"interventions":16656},[],[15903],[4118,9580,15905],{"intervention":15820,"totalTrials":147,"cells":16658},{"EARLY_PHASE1":16659,"PHASE1":16661,"PHASE2":16663,"PHASE3":16665,"PHASE4":16667,"NA":16669},{"trials":16660,"activeCount":97},[],{"trials":16662,"activeCount":97},[],{"trials":16664,"activeCount":97},[],{"trials":16666,"activeCount":97},[],{"trials":16668,"activeCount":97},[],{"trials":16670,"activeCount":97},[16671],{"nctId":15812,"briefTitle":15813,"status":103,"phases":16672,"primaryCompletion":15815,"completion":15815,"start":15816,"enrollment":15817,"conditions":16673,"interventions":16674},[],[18],[506,15820],{"intervention":16676,"totalTrials":147,"cells":16677},"Sovaldi",{"EARLY_PHASE1":16678,"PHASE1":16680,"PHASE2":16682,"PHASE3":16684,"PHASE4":16686,"NA":16688},{"trials":16679,"activeCount":97},[],{"trials":16681,"activeCount":97},[],{"trials":16683,"activeCount":97},[],{"trials":16685,"activeCount":97},[],{"trials":16687,"activeCount":97},[],{"trials":16689,"activeCount":97},[16690],{"nctId":16691,"briefTitle":16692,"status":103,"phases":16693,"primaryCompletion":16694,"completion":16694,"start":16695,"enrollment":4605,"conditions":16696,"interventions":16697},"NCT02783976","Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice",[],"2018-06-20","2016-10-28",[794],[16676],{"intervention":15300,"totalTrials":147,"cells":16699},{"EARLY_PHASE1":16700,"PHASE1":16702,"PHASE2":16704,"PHASE3":16706,"PHASE4":16708,"NA":16710},{"trials":16701,"activeCount":97},[],{"trials":16703,"activeCount":97},[],{"trials":16705,"activeCount":97},[],{"trials":16707,"activeCount":97},[],{"trials":16709,"activeCount":97},[],{"trials":16711,"activeCount":97},[16712],{"nctId":15292,"briefTitle":15293,"status":653,"phases":16713,"primaryCompletion":15295,"completion":15295,"start":15296,"enrollment":15297,"conditions":16714,"interventions":16715},[],[18],[4118,9580,797,4107,4129,15300],{"intervention":15829,"totalTrials":147,"cells":16717},{"EARLY_PHASE1":16718,"PHASE1":16720,"PHASE2":16722,"PHASE3":16724,"PHASE4":16726,"NA":16728},{"trials":16719,"activeCount":97},[],{"trials":16721,"activeCount":97},[],{"trials":16723,"activeCount":97},[],{"trials":16725,"activeCount":97},[],{"trials":16727,"activeCount":97},[],{"trials":16729,"activeCount":97},[16730],{"nctId":15822,"briefTitle":15823,"status":103,"phases":16731,"primaryCompletion":285,"completion":285,"start":15825,"enrollment":15826,"conditions":16732,"interventions":16733},[],[27],[506,15829],{"intervention":16735,"totalTrials":147,"cells":16736},"Aztreonam Lysine for Inhalation",{"EARLY_PHASE1":16737,"PHASE1":16739,"PHASE2":16741,"PHASE3":16743,"PHASE4":16745,"NA":16747},{"trials":16738,"activeCount":97},[],{"trials":16740,"activeCount":97},[],{"trials":16742,"activeCount":97},[],{"trials":16744,"activeCount":97},[],{"trials":16746,"activeCount":97},[],{"trials":16748,"activeCount":97},[16749],{"nctId":16750,"briefTitle":16751,"status":15498,"phases":16752,"conditions":16753,"interventions":16755},"NCT00499720","Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection",[],[30,16754],"Pseudomonas Aeruginosa Airway Infection",[16735],{"intervention":15919,"totalTrials":147,"cells":16757},{"EARLY_PHASE1":16758,"PHASE1":16760,"PHASE2":16762,"PHASE3":16764,"PHASE4":16766,"NA":16768},{"trials":16759,"activeCount":97},[],{"trials":16761,"activeCount":97},[],{"trials":16763,"activeCount":97},[],{"trials":16765,"activeCount":97},[],{"trials":16767,"activeCount":97},[],{"trials":16769,"activeCount":97},[16770],{"nctId":15911,"briefTitle":15912,"status":653,"phases":16771,"primaryCompletion":15914,"completion":15914,"start":15915,"enrollment":15916,"conditions":16772,"interventions":16773},[],[18],[4118,15919,15920,15921],{"intervention":15920,"totalTrials":147,"cells":16775},{"EARLY_PHASE1":16776,"PHASE1":16778,"PHASE2":16780,"PHASE3":16782,"PHASE4":16784,"NA":16786},{"trials":16777,"activeCount":97},[],{"trials":16779,"activeCount":97},[],{"trials":16781,"activeCount":97},[],{"trials":16783,"activeCount":97},[],{"trials":16785,"activeCount":97},[],{"trials":16787,"activeCount":97},[16788],{"nctId":15911,"briefTitle":15912,"status":653,"phases":16789,"primaryCompletion":15914,"completion":15914,"start":15915,"enrollment":15916,"conditions":16790,"interventions":16791},[],[18],[4118,15919,15920,15921],{"intervention":15921,"totalTrials":147,"cells":16793},{"EARLY_PHASE1":16794,"PHASE1":16796,"PHASE2":16798,"PHASE3":16800,"PHASE4":16802,"NA":16804},{"trials":16795,"activeCount":97},[],{"trials":16797,"activeCount":97},[],{"trials":16799,"activeCount":97},[],{"trials":16801,"activeCount":97},[],{"trials":16803,"activeCount":97},[],{"trials":16805,"activeCount":97},[16806],{"nctId":15911,"briefTitle":15912,"status":653,"phases":16807,"primaryCompletion":15914,"completion":15914,"start":15915,"enrollment":15916,"conditions":16808,"interventions":16809},[],[18],[4118,15919,15920,15921],{"intervention":16811,"totalTrials":147,"cells":16812},"Aztreonam lysine",{"EARLY_PHASE1":16813,"PHASE1":16815,"PHASE2":16817,"PHASE3":16819,"PHASE4":16821,"NA":16823},{"trials":16814,"activeCount":97},[],{"trials":16816,"activeCount":97},[],{"trials":16818,"activeCount":97},[],{"trials":16820,"activeCount":97},[],{"trials":16822,"activeCount":97},[],{"trials":16824,"activeCount":97},[16825],{"nctId":16826,"briefTitle":16827,"status":15498,"phases":16828,"conditions":16829,"interventions":16830},"NCT00989807","Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis",[],[30,6628],[16811],{"intervention":16832,"totalTrials":147,"cells":16833},"IMMU-132",{"EARLY_PHASE1":16834,"PHASE1":16836,"PHASE2":16838,"PHASE3":16840,"PHASE4":16842,"NA":16844},{"trials":16835,"activeCount":97},[],{"trials":16837,"activeCount":97},[],{"trials":16839,"activeCount":97},[],{"trials":16841,"activeCount":97},[],{"trials":16843,"activeCount":97},[],{"trials":16845,"activeCount":97},[16846],{"nctId":16847,"briefTitle":16848,"status":15498,"phases":16849,"conditions":16850,"interventions":16852},"NCT04320693","Expanded Access for IMMU-132",[],[16851],"Metastatic Triple-Negative Breast Carcinoma",[16832],{"intervention":16039,"totalTrials":147,"cells":16854},{"EARLY_PHASE1":16855,"PHASE1":16857,"PHASE2":16859,"PHASE3":16861,"PHASE4":16863,"NA":16865},{"trials":16856,"activeCount":97},[],{"trials":16858,"activeCount":97},[],{"trials":16860,"activeCount":97},[],{"trials":16862,"activeCount":97},[],{"trials":16864,"activeCount":97},[],{"trials":16866,"activeCount":97},[16867],{"nctId":16032,"briefTitle":16033,"status":653,"phases":16868,"primaryCompletion":16035,"completion":16035,"start":16036,"enrollment":7228,"conditions":16869,"interventions":16870},[],[24],[11552,16039,2426],{"intervention":16872,"totalTrials":147,"cells":16873},"Influenza Vaccine",{"EARLY_PHASE1":16874,"PHASE1":16876,"PHASE2":16878,"PHASE3":16880,"PHASE4":16882,"NA":16884},{"trials":16875,"activeCount":97},[],{"trials":16877,"activeCount":97},[],{"trials":16879,"activeCount":97},[],{"trials":16881,"activeCount":97},[],{"trials":16883,"activeCount":97},[],{"trials":16885,"activeCount":97},[16886],{"nctId":16887,"briefTitle":16888,"status":653,"phases":16889,"primaryCompletion":16890,"completion":16890,"start":16891,"enrollment":993,"conditions":16892,"interventions":16893},"NCT03701438","Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib",[],"2019-10-09","2018-10-23",[7179],[16872],{"intervention":16895,"totalTrials":147,"cells":16896},"Harvoni",{"EARLY_PHASE1":16897,"PHASE1":16899,"PHASE2":16901,"PHASE3":16903,"PHASE4":16905,"NA":16907},{"trials":16898,"activeCount":97},[],{"trials":16900,"activeCount":97},[],{"trials":16902,"activeCount":97},[],{"trials":16904,"activeCount":97},[],{"trials":16906,"activeCount":97},[],{"trials":16908,"activeCount":97},[16909],{"nctId":16910,"briefTitle":16911,"status":103,"phases":16912,"primaryCompletion":16913,"completion":16913,"start":166,"enrollment":16914,"conditions":16915,"interventions":16916},"NCT02591277","Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection",[],"2017-11-01",3294,[27],[16895]]